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ABSTRACT 
Background: Molecular mechanisms underlying gastric and oesophageal cancer include 
alterations in growth factors, cytokines and cell adhesion molecules.  Heme oxygenase 
(HO) enzyme catalyses the degradation of heme and generates bilirubin and carbon 
monoxide that have antioxidant, anti-inflammatory and anti-apoptotic activities.  HO 
enzyme is implicated in the biology of cancer by its effects on cell growth and resistance 
to apoptosis.  The roles of HO-1 and HO-2 enzymes in cancer cell growth are poorly 
understood, with reports suggesting both anti-inflammatory, anti-tumour effects and 
tumour-protective mechanisms mediated by HO activity.  The role of HO-2 in 
inflammation and cancer is largely unexplored.  Further understanding the influence of 
the HO enzyme system may provide improved novel targets for oesophagogastric cancer 
therapy. 
Materials and Methods: The primary objective of the thesis was to characterise the role 
of the heme oxygenase pathway and modulation of HO activity in upper gastrointestinal 
cancer cell growth in vitro.  Cell culture techniques included MTT growth assay, Western 
blotting protein analysis, pharmacological modulation of HO activity and targeted 
knockdown of HO mRNA.  Apoptosis was studied with flow cytometry techniques.  
Enzymatic HO activity was measured by specific colorimetric assay.   
Results: Results showed that specific knockdown of HO-2 protein activity with induction 
of HO-1 enzyme caused a reduction in oesophageal and gastric cancer cell growth with 
cell cycle effects and an increase in apoptosis.  Treatment with downstream products of 
HO activity carbon monoxide and bilirubin and the anti-inflammatory agent N-acetyl 
cysteine had similar effects and increased the response of cancer cells to 
chemotherapeutic agents. 
Conclusion: These studies further our understanding of the role of heme oxygenase in 
cancer, providing evidence that modification of HO activity in oesophagogastric cancer 
cells leads to reduced cell proliferation.  The findings support future potential clinical 
applications of carbon monoxide therapy that require further experimental animal model 
and clinical studies in the context of oesophagogastric cancer.    
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HRM   Heme regulatory motifs  
HSP   Heat shock protein  
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CAD   Coronary artery disease 
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GTn   Guanine thymine repeats 
MTT   3-(4,5-dimethyithiazol-2-yl)-2,5-diphenyltetrazolium bromide 
UV   Ultraviolet 
NAC   N-acetyl cysteine 
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ZnPP   Zinc protoporphyrin 
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ATP   Adenosine triphosphate 
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PCR   Polymerase chain reaction 
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RNA   Ribonucleic acid 
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CHAPTER 1: INTRODUCTION 
1.1 Oesophagogastric cancer – the clinical problem 
1.1.1 Oesophageal carcinoma 
The epidemiology of oesophageal cancer in the Western world has undergone an 
impressive change over the last 30 years. Previously a rare tumour, adenocarcinoma of 
the oesophagus has the fastest increasing incidence of any cancer in the United States. 
Comparable trends are seen in Europe, with the highest reported incidence (9 per 
100,000) in the United Kingdom1.   
Oesophageal carcinoma is diagnosed in approximately half a million people worldwide 
every year.  It is the eighth leading cause of cancer death worldwide2.  The global 
incidence of oesophageal cancer has increased by 50% over the past 20 years, from 
316,000 people diagnosed in 1990 to 482,300 new cases recorded in 20083 4.  This global 
increase reflects an interesting pattern in the epidemiology of oesophageal cancer in the 
Western world.  Historically, oesophageal cancer has predominantly been of squamous 
cell pathological type with adenocarcinoma accounting for as little as 4% of the disease 
burden in the 1970s5.  There has been a rapid rise in the incidence of oesophageal 
adenocarcinoma in Western countries over the last three decades with a reported 
increase in American white males of 463% (from 1.01 per 100,000 person-years in 1975 – 
1979 to 5.69 per 100 000 person-years in 2000 – 2004)6.  A similar rapid increase has also 
been reported among white females in whom the adenocarcinoma rate increased 335% 
over the same time period7.  Although the greater part of this increase has occurred in 
white males, significant increases have also been seen in females and across racial 
categories8 9.  
These rapid increases have meant that in the United States and Northern Europe 
adenocarcinoma represents the predominant histological subtype10-12.  Adenocarcinoma 
has replaced squamous cell carcinoma as the most common oesophageal cancer in the 
Western world even though squamous cell carcinoma is still the most common 
pathological subtype of oesophageal cancer worldwide10 13.  The rate of increase in the 
incidence of oesophageal adenocarcinoma in the United States has been higher than any 
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other cancer and this development parallels the increased prevalence of both obesity and 
gastroesophageal reflux disease6.  The patterns observed may be associated with changes 
in the exposure to potential aetiological risk factors for oesophageal carcinoma such as 
smoking, alcohol consumption, overweight and obesity and inadequate dietary intake of 
fruit and vegetables14 15.  Oesophageal adenocarcinoma in particular is linked with 
excessive body mass index and long-term gastroesophageal acid reflux.   
The U.S. National Cancer Institute reported 13,900 new cases and 13,000 deaths from 
oesophageal carcinoma in 2003 and anticipated 17,460 new cases and 15,070 deaths in 
201216.  The latest cancer statistics identify oesophageal cancer as the 7th leading cause of 
cancer deaths in males in the U.S. (12, 040) and the 5th leading cause of cancer deaths in 
males aged 40 – 79 years old16.  The UK has one of the highest incidences of oesophageal 
cancer in Europe with 8,477 new cases diagnosed in 2010.  It is the 9th most common 
malignancy in the UK and the 8th most common in males with a male: female ratio of 
approximately 2:1.  It is more common with advanced age with an average of 70% of 
cases diagnosed in men and women aged 65 years and over between 2008 and 201017 18.  
Scotland has the highest rate of oesophageal carcinoma in the UK and Europe19 with only 
33% of Scottish patients being found to be suitable for curative resection20.  
Complex surgical resection in the form of radical oesophagectomy offers the best chance 
for survival for patients with locally advanced disease21.  If oesophageal cancer is deemed 
to be resectable then the only curative option is surgical resection with radical 
lymphadenectomy, usually after neoadjuvant chemotherapy or chemoradiotherapy22-24.  
Peri-operative mortality rates for oesophageal resection should be less than 5%, but the 
operation has a significant morbidity with a relatively high complication rate and impact 
on the quality of life during patient convalescence25. 
Oesophageal cancer has a relatively poor overall outlook.  This is reflected in a high 
mortality-to-incidence rate ratio of 0.83 compared to that of 0.52 in colorectal cancer26.  
Upper gastrointestinal cancers are often diagnosed at an advanced stage with improved 
survival a consistent feature of disease that presents early.  For oesophageal cancer 
confined to the mucosa the 5-year survival rate can exceed 80% after surgery.   
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Adenocarcinoma is a highly aggressive disease with a poor prognosis: reported 5-year 
survival rates are typically about 10%27.  Prognosis depends on clinical stage.  Patients 
with cancer restricted to the mucosa commonly have an 80% survival rate, which drops to 
<50% with submucosal involvement, 20% with extension to the muscularis propria, 7% 
with extension to adjacent structures, and less than 3% with distant metastases. 
Oesophagogastric cancer still carries a relatively poor prognosis with little significant 
change in overall survival in recent years28.  American Cancer Society 2009 cancer 
statistics demonstrate an overall 5-year survival of only 17% with improved survival for 
local (33.7%) or regional (16.9%) compared to distant (2.9%) disease at the time of 
diagnosis29.  Advances in the diagnosis, staging, and management of oesophageal cancer 
have led to small but significant improvements in survival for patients with resectable 
disease and a modest improvement in the overall 5-year survival rate over the last 
decade30.  Surgical resection is a fundamental approach to potentially curative therapy for 
early-stage and locally advanced oesophagogastric cancer.  In a series of patients 
undergoing resection for oesophageal cancer an improvement in the 5-year survival rate 
from 18.8% to 42.3% (P < 0.001) was demonstrated from 1980 to 200431.  Unfortunately, 
advanced disease or co-morbidities mean that only 30-40% of patients diagnosed with 
oesophageal cancer are suitable for the complex surgery required for curative resection32.  
Early diagnosis is the key to survival with a reported 5-year survival of 95 – 100% in 
patients presenting with early-stage lesions including cancer-in-situ (high-grade dysplasia) 
or T1 disease confined to the mucosa or submucosa33. 
Improvements in the outcomes from oesophageal cancer over the last 30 – 40 years are 
supported by reported data of age-standardised survival rates in adults with oesophageal 
carcinoma.  There has been a significant improvement (p < 0.05) in the 5-year relative 
survival rate in the United States between 2001 and 2007 (19%) when compared to the 
same survival rate between 1975 and 1977 (5%)34.  Similar data are available from the 
United Kingdom with a published 5-year standardised relative survival of 13.8% for adults 
diagnosed with oesophageal cancer during the period 2006 – 2010 and followed up to 
201135.  This represents an absolute increase in 5-year age-standardised relative survival 
of 10% when compared to adults diagnosed between 1971 and 197536.  The latest 
available survivorship statistics from the UK demonstrate an improvement from a 5-year 
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survival rate for adults diagnosed between 1996 and 2000 of 7.2% to an equivalent rate 
of 13.8% for patients diagnosed in the period 2006 – 201035.  These moderate 
improvements in outcome data may be associated with a conscious effort towards 
increasing specialisation in surgical services and centralisation of the management of 
oesophageal cancer in specialist units over the last 20 years37 38.  
Oesophageal adenocarcinoma is believed to develop via a sequential change in the nature 
of oesophageal epithelium from squamous to Barrett’s metaplasia and low-grade 
dysplasia and high-grade dysplasia within the Barrett’s epithelium progressing to invasive 
carcinoma.  The change from squamous epithelium to columnar epithelium with 
glandular metaplasia (Barrett’s oesophagus) is considered to be due to chronic 
gastroesophageal acid and biliary reflux.  An increased risk of adenocarcinoma is 
associated with a high dietary fat intake, overweight and obesity (body mass index above 
25) and excessive alcohol consumption39.  Recent estimates suggest that Barrett’s 
oesophagus is prevalent in 2% of the UK population although only 1 in 20 of these is 
diagnosed32.  The prevalence of Barrett’s oesophagus may be as high as 8 – 10% in 
Western countries40.  The lifetime risk of developing adenocarcinoma in patients with 
Barrett’s oesophagus has been estimated to be 12.5 – 14.5 % from a recent UK registry 
study41.  Although this represents a 10 – 30-fold increased risk over the general 
population for oesophageal adenocarcinoma most patients with Barrett’s oesophagus die 
from other causes42-44.   
Early tumour detection may improve outcome in this defined subgroup of patients. Major 
challenges in the management of Barrett’s oesophagus include the efficacy and cost-
effectiveness of endoscopic surveillance strategies, evaluation of other risk factors for 
cancer such as obesity and acid reflux, and the identification of potential biomarkers 
indicating disease progression. 
A key area of current research concerns the possibility of sensitive and specific tests that 
predict the risk of malignancy for an individual with an established diagnosis of Barrett’s 
oesophagus. During the development of oesophageal cancer there is an established 
sequential progression from specialised intestinal metaplasia to low-grade dysplasia 
through to high-grade dysplasia and adenocarcinoma. The natural history of Barrett’s 
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oesophagus is highly variable along all stages of the sequence described. Most published 
series report an incidence of dysplasia around 5%45-47.  Both low-grade and high-grade 
dysplasia can remain static, regress or progress to invasive cancer. The majority of 
patients with low-grade dysplasia do not progress to cancer in the short term47.  When 
high-grade dysplasia is evident, however, up to 50% will have a focus of invasive 
adenocarcinoma at the time of diagnosis48. 
The overall risk of adenocarcinoma has been investigated by various authors in recent 
years and was thought to be around 1% per year.  However, a recent meta-analysis of 
small positive studies suggests that this risk has been overestimated, particularly as a 
result of publication bias, and that a more reliable annual risk is nearer 0.5%48 49. 
The conversion rate of non-dysplastic Barrett’s oesophagus to high-grade dysplasia or 
invasive oesophageal adenocarcinoma has recently been estimated at 0.47 – 0.86% per 
year49 50.  There is a low rate of progression toward adenocarcinoma in Barrett’s 
oesophagus with low grade dysplasia but the conversion rate of high-grade dysplasia to 
adenocarcinoma is much higher: 16 – 60% patients have invasive carcinoma at up to 8 
years of follow up51-55.  Overall the conversion rate of Barrett’s oesophagus without 
dysplasia is 0.3 – 0.5% per person year50 56-58.  In view of the limited resources available to 
perform regular endoscopy and the lack of clear evidence to support screening protocols, 
the management of Barrett’s oesophagus varies throughout the UK59.  Current 
surveillance strategies are relatively ineffective, costly and somewhat cumbersome.  
Progression of established metaplasia to carcinoma occurs as a consequence of molecular 
events triggered by the direct action of locally produced cytokines and exposure of the 
distal oesophagus to bile acids in refluxed gastric juice. Attempts at predicting this 
transformation include studies of biomarkers detectable by immunohistochemistry. 
Tumour suppressor genes, cell adhesion molecules and genes regulating cell apoptosis 
have all been investigated60.  Expression of p53, cyclin D1, the mucins MUC1 and MUC4 
and increased staining of Ki-67 all appear to correlate with dysplasia. Reduced expression 
of E-cadherin and p16 and loss of heterozygosity of adenomatosis polyposis coli gene 
seem to be associated with neoplastic progression. Cytokines identified as having an 
important role in carcinogenesis include cyclooxygenase-2 and telomerase61. 
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Available data indicate that no single marker accurately and reliably predicts the 
malignant potential of Barrett’s oesophagus.  Further research is recommended to verify 
the application of surrogate cancer markers within the domain of clinical practice. 
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1.1.2 Gastric carcinoma 
The incidence of gastric cancer has been in steady decline in the industrialised world over 
the past five decades62.  In the United States and Europe the incidence of gastric cancer 
has been decreasing with rates 11% lower in the year 2000 compared with 199039.  
Cancer statistics from the US estimate 21,320 new diagnoses of gastric cancer in 2012 and 
anticipate 10,540 deaths due to gastric carcinoma3.  Gastric cancer was the 12th most 
commonly diagnosed cancer in the United Kingdom between 2008 and 2010 with 7,544 
cases diagnosed.  It was the 8th leading cause of cancer-related death in the UK being 
responsible for 5,056 deaths over the same time period63.  Despite now being the fourth 
most common cancer worldwide with an estimated 934,000 cases diagnosed per year, 
gastric carcinoma results in 700,000 deaths annually64.  Gastric cancer remains the 2nd 
leading cause of cancer mortality worldwide62 65-67.  There is a marked geographical 
variation in incidence with particularly high-risk areas being Japan, China and Eastern 
Europe.  The disease presents a major clinical challenge with poor overall prognosis and 
limited survival for patients with advanced disease68 69. 
Overall survival from stomach cancer is limited by the fact that most patients present 
with advanced inoperable disease.  In the last 20 years survival from stomach cancer has 
improved in the United Kingdom70.  Survival in those patients who undergo potentially 
curative resection is approximately 50% at five years71-73.  The risk of cancer recurrence 
and survival prognosis is determined by several clinic-pathological features including 
involvement of resection margins, tumour stage and status of resected lymph nodes74-76. 
The majority of gastric cancer is of the adenocarcinoma histological subtype.  The 
pathogenesis of gastric cancer is multifactorial and complex with potential predisposing 
conditions including chronic atrophic gastritis, gastric epithelial intestinal metaplasia and 
dysplasia, gastric polyps and chronic peptic ulcer.  Lauren’s classification of gastric cancer 
describes intestinal type with glandular structures (53%), diffuse carcinoma without 
structure that secrete mucin (33%) and mixed-type tumours (14%)77.  Intestinal-type 
gastric cancer is strongly linked to environmental factors such as nitrate ingestion.  The 
Correa hypothesis describes the pathway for malignant transformation of gastric 
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epithelium including the influence of socio-economic factors, dietary influences and 
exposure to carcinogens that are especially relevant for intestinal-type cancer78-80. 
Chronic atrophic gastritis can be caused by Helicobacter pylori infection, duodenal reflux, 
ingested chemicals or autoimmune-mediated damage in pernicious anaemia.  Atrophic 
gastritis can be present in up to 40% of normal patients over the age of 60 years80-82.  
There is an established link between H. pylori infection and consequent inflammatory 
damage with particular strains including cagA (cytotoxin-associated gene A), vacA and 
iceA.  The International Agency for Cancer Research has classified Helicobacter pylori as a 
group I carcinogen for gastric cancer.  Environmental and host response factors are 
important in the pathogenesis of malignant transformation from atrophic gastritis to 
intestinal-type gastric adenocarcinoma83-85.   
Hereditary diffuse gastric cancer (HDGC) is a syndrome of familial gastric cancer that is 
associated with an inactivating germ-line mutation in the E-cadherin tumour suppressor 
gene (CDH-1) in 30 – 40% of affected families.  The remaining 60 – 70% of HDGC families 
may have other susceptibility genes that have yet to be identified, including those coding 
for cell adhesion molecules β-catenin and γ-catenin.  Carriers of the CDH1 mutation have 
a 70% or more lifetime risk of developing diffuse gastric cancer with its attendant poor 
long-term survival.  Counselling of individuals from HDGC families raises difficult 
questions as to the most appropriate management options that are essentially either 
prophylactic total gastrectomy or endoscopic surveillance86-89. 
The location of the primary tumour in gastric cancer has changed in tandem with the 
observed changes in histological subtype for oesophageal carcinoma.  Distal oesophageal 
cancer and proximal gastric cancer are now the dominant sites of disease in the western 
world10 13.  Over the past 20 years there has been an annual increase in incidence of 
adenocarcinoma of the oesophagogastric junction in the UK39.  The incidence of 
adenocarcinoma of the oesophagogastric junction has been increasing at 5–10% annually 
since the mid-1970s and represents the most rapidly increasing cancer in many Western 
countries90.  There have been parallel increases in adenocarcinoma of the gastric cardia, 
which now accounts for up to 50% of all gastric cancers39.  Both oesophageal and gastric 
cancer accounted for 7.4% of all cancer deaths in the European Union in 2006 ranking 
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joint third with breast cancer91.  The close relationship between adenocarcinoma tumours 
involving the gastric cardia, oesophagogastric junction and distal oesophagus has led 
some authors to suggest an equivalent approach to their diagnosis, staging and 
treatment92 93. 
There is a persistent demand on the disciplines of basic science research to evaluate 
novel therapeutic options in oesophagogastric cancer.  Development of tumour 
chemoresistance or the unpredictable responses to chemotherapy and radiotherapy 
present a challenge to the clinical effectiveness of treatment strategies.  Alternative 
targeted therapies are required to augment chemoresponsiveness or overcome 
chemoresistance as well as providing improved options for situations in which curative 
surgical resection is contra-indicated for clinical reasons94-97.  A central aim of the studies 
included in this thesis is the evaluation of the heme oxygenase system and oxidative 
stress responses affecting the growth of oesophagogastric cancer cells.  These 
investigations may provide valuable information for future clinical applications.   
1.2 The Heme Oxygenase System 
1.2.1 The physiological role of heme oxygenase 
The primary physiological role of heme oxygenase (HO) is the degradation of heme, a 
prosthetic group of various types of proteins including hemoglobin, myoglobin and 
respiratory cytochromes.  Heme is essential for diverse biological processes such as 
oxygen transport, electron transfer and energy production, but unbound heme is highly 
toxic to cellular structures.  Heme synthesis and breakdown is tightly regulated by 
feedback mechanisms that maintain intracellular heme at a precise level.   
Microsomal heme oxygenase is the rate-limiting enzyme of heme catabolism.  It catalyses 
the oxygen-dependent cleavage of the tetrapyrrole heme ring to generate biliverdin, with 
the concurrent release of equimolar amounts of carbon monoxide (CO) and free iron 
(Fe2+).  Biliverdin is then reduced to bilirubin by the action of cytosolic biliverdin 
reductase.  Bilirubin is poorly soluble and transported in the circulation bound to albumin.  
It is subsequently conjugated with glucuronic acid in the liver to form pigments that are 
excreted into the bile.  Ferrous iron produced from heme breakdown rapidly up regulates 
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the synthesis of both ferritin and a transporter protein that removes Fe2+ from the cell98.  
Ferritin is a high-capacity iron-chelating protein that binds most intracellular iron and 
limits the generation of free radicals.  Under normal conditions, the amount of free iron 
that can lead to the generation of reactive oxygen species (ROS) is kept at very minute 
levels, and ferritin is an efficient indicator of intracellular iron levels99. 
The HO system has a vital role in iron homeostasis.  It is responsible for the recycling of 
iron from senescent red blood cells and cells of the reticuloendothelial system, and HO 
has a high basal activity in spleen and bone marrow tissues.  It is estimated that 80% of 
the total body iron in humans is in the form of heme bound to proteins, with the rest 
bound to ferritin.  Up to 85% of the bilirubin formed in vivo is derived from hemoglobin 
released from damaged or aging erythrocytes100. 
1.2.2 Iron, Heme and Ferritin 
A Brief Overview of Iron Chemistry 
Iron exists in three primary forms in nature: firstly in its elemental form with no net 
charge (Fe) and the other two as ferrous and ferric ionic compounds depending on the 
valence state of the Fe atom.  Loss of two electrons leaves the iron atom in a charged 
state as ferrous ion (Fe2+) and loss of a further electron a ferric ion (Fe3+).  Ferrous and 
ferric compounds involving iron in a charged state are physiologically important in human 
health and disease.  A prime example is the iron carried in the blood that must be in the 
ferrous form Fe2+ in order to bind to oxygen and carry the oxygen to the body tissues.  
Transport and delivery of oxygen is a vital physiological function of human blood.  If the 
iron in the blood is changed to the Fe3+ state the bonds to oxygen are broken and 
oxygenated hemoglobin becomes deoxyhemoglobin. 
Oxidation formally refers to the process of losing electrons, increasing the positive charge 
state of an ion or ionic compound.  A typical example of oxidation is the change of iron 
from the Fe2+ state (ferrous) to the Fe3+ (ferric) state.  Common oxidizing agents include 
the hydroxyl radical, ozone, peroxides and bleaches, and natural oxidisers exist within the 
human body.  Oxidative stress refers to the process whereby oxidation produces free 
radicals that are highly reactive molecules capable of wreaking havoc within cell 
29 
 
homeostatic systems.  The structure of molecules and atoms contains two electrons 
spinning in opposite directions in the outermost orbit.  Free radicals are molecules or 
molecular fragments containing one or more unpaired electrons in their outermost 
orbital.  The unpaired electron of a free radical is unstable and highly reactive.  They are 
represented in nomenclature by a superscript dot (R·).  Important biological free radicals 
include the hydroxyl radical (OH·), the superoxide anion (O2
−), peroxide (O2
2−) and nitric 
oxide (NO·).   
Molecular oxygen (O2) is stable as each oxygen atom shares two of the electrons in the 
outermost orbit.  A single oxygen atom (singlet oxygen) is unstable and highly reactive as 
a strong oxidising agent but does not have unpaired electrons in its outer orbit and is 
therefore by definition not a free radical.  There are two forms of bonding between atoms 
that occur in conventional chemistry: ionic and covalent bonding.  Ionic bonding means 
that electrons are transferred from one atom to another.  Covalent bonding means that 
the electrons are shared between atoms with symmetrical forces applied to the shared 
electrons, as in molecular oxygen.  Polar covalent bonding is a variation of covalent 
bonding when different types of atoms join together producing an asymmetry of forces 
between shared electrons, e.g. two hydrogen atoms and one oxygen atom, H2O
101 102.   
The change in oxidation state of iron from the Fe2+ state (ferrous) to the Fe3+ (ferric) state 
in sufficient numbers within the blood can be detrimental to human health.  Fenton's 
reaction involves the combination of iron in the Fe2+ state (ferrous sulfate) and hydrogen 
peroxide101:  
Fe2+ + H2O2 → Fe
3+ + OH· + OH− 
Note that the combination of iron in the ferrous state with hydrogen peroxide produces 
three things: iron ions in the ferric state (Fe3+), the highly reactive free radical hydroxyl 
radical (OH·) and the hydroxide radical (OH−).  Hydroxyl radical is the strongest oxidizing 
agent known.   
These products can trigger cellular stress and sensitise a variety of cell types to undergo 
apoptosis (programmed cell death) in response to inflammatory agonists.   
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Heme 
Heme is a ubiquitous molecule in aerobic cells and is essentially a prosthetic group 
composed of a ferrous iron ion contained in the centre of a large organic heterocyclic ring 
called a porphyrin.  Porphyrins are aromatic compounds consisting of four modified 
pyrrole subunits joined at their α-carbon atoms via methine bridges.  The majority of 
metalloproteins containing a porphyrin ring have heme as their prosthetic group and 
contain iron in the oxidised Fe2+ state surrounded by four nitrogen atoms bound with 
coordinated covalent bonds.  These heme proteins or hemoproteins enable the protein to 
carry out a function that it cannot do alone via the ability of ferrous iron to react with 
various molecules.  Heme (iron-protoporphyrin IX complex) is a regulatory molecule that 
affects transcription and translation depending on its intracellular localisation and 
concentration103.  Heme is a critical component of heme proteins that include 
cytochromes for mitochondrial respiratory chain electron transfer, oxidases and 
peroxidases, catalases and synthases such as nitric oxide synthase104 105.  Heme 
biosynthesis occurs in all cells, especially erythroid cells and hepatocytes104 106.   
The majority of iron in the body is present in the form of heme as hemoglobin, myoglobin 
and cytochromes while up to two-thirds of Western dietary iron intake is derived from 
dietary heme107 108.  Gaseous molecules including oxygen (O2), carbon monoxide (CO), 
nitric oxide (NO) and hydrogen sulfide (H2S) readily bind to the Fe
2+ ion in heme proteins.  
The structure and activity of the heme protein is modulated by the binding of reactive 
molecules to the prosthetic heme group with resulting changes in cellular signal 
transduction pathways. 
The structural and functional characteristics of heme proteins are well studied due to 
their diverse range of biological functions.  The Heme Protein Database 
[http://hemeprotein.info/heme.php] provides a global web resource uniting data from 
studies of the relationships between heme protein structure and function.  The heme 
proteins hemoglobin and myoglobin have a high affinity to oxygen that enables reversible 
binding and transport of oxygen in humans.  The heme prosthetic moiety functions as an 
essential electron donator in oxidation – reduction cycles and is thereby of cardinal 
significance for electron transfer reactions.  Important proteins involved in aerobic 
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metabolism such as respiratory chain cytochromes and numerous cytochrome P450 
isoenzymes are tightly bound to heme groups that serve as the catalytic site in protein 
activity109.  The heme molecule functions as a prosthesis for proteins involved in vital 
biological oxidation reactions in cellular homeostasis including signal transduction 
pathways, mitochondrial respiration, steroid biosynthesis, oxygen transport and 
cytoprotective antioxidant mechanisms105 110.  In mammals the majority of heme is 
utilised for the oxygen transport protein hemoglobin.  Hemoglobin heme is synthesised in 
erythrocytes and ultimately degraded in the reticuloendothelial system where it accounts 
for 80% of bilirubin production in humans111 112.   
Heme is present in large amounts in many cells but is also inherently cytotoxic especially 
when it escapes from intracellular sites as it readily enters the hydrophobic domain of 
biological plasma membranes.  Unbound heme is highly reactive due to the ability of the 
Fe2+ ion contained within its protoporphyrin IX ring to undergo the Fenton reaction and 
catalyse the rapid and exponential production of free radicals.  The reactivity of heme is 
controlled by insertion of the prosthetic group into the heme pockets of heme proteins to 
maintain cellular homeostasis113.  Free cellular heme derived from heme proteins acts as 
a potentially cytotoxic pro-oxidant via the production of free radicals from the Fenton 
reaction114.   
Oxidative reactions catalysed by intracellular iron are particularly potent and important 
damaging events.  Generation of free radicals derived from oxygen can be driven by free 
iron and cause damage to cellular components by oxidation of proteins, carbohydrates, 
nucleic acids and lipoproteins as well as initiation of chain-propagating lipid peroxidation.  
Oxidative damage to vital cellular components may have deleterious effects at cellular 
and tissue levels leading to programmed cell death, tissue necrosis and degenerative 
diseases or cell phenotype changes causing neoplasia.  Molecules with the ability to 
sequester iron may play a crucial role in the cellular antioxidant strategy115.  
Intracellular levels of free heme are vanishingly small and tightly regulated in most cells 
and tissues.  Under conditions of oxidative stress some heme proteins can release their 
heme prosthetic groups with the consequent generation of reactive oxygen and nitrogen 
species including the superoxide anion, hydroxyl radical and nitric oxide free radicals and 
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other oxidising agents like hydrogen peroxide.  These reactive species cause damage to 
living systems by reacting with several biomolecules including lipids, proteins and nucleic 
acids.  Oxidation of polyunsaturated fatty acids in the plasma cell membrane and the 
mitochondrial membrane causes direct cellular damage by altering membrane 
permeability and indirect damage via the production of toxic products and initiation of a 
chain reaction to produce other hydroperoxy free radicals.  Loss of the mitochondrial 
membrane potential causes programmed cell death (apoptosis) in eukaryotic cells.  
Oxidation of the —SH groups of proteins by free radicals changes the biological function 
of the protein throughout physiological systems.  Direct damage to nucleic acids by free 
radicals can caused DNA mutations that can be carcinogenic116.  The hydroxyl radical is 
the most toxic reactive oxygen species targeting protein and nucleic acids.  The reaction 
of hydroxyl radicals with the nucleic acid base 8-hydroxyguanine (8-OHG) is highly 
correlated with teratogenic and carcinogenic consequences of oxidative stress.   
A variety of cell types undergo apoptosis when exposed to pro-inflammatory agonists.  
This adverse effect is believed to play an important role in the pathogenesis of certain 
inflammatory diseases such as malaria117.   
In addition to the regulation of intracellular iron levels heme has a variety of roles in other 
fundamental cellular processes including ion-channel functions, circadian rhythm and the 
regulation of microRNA processing118-120.  Heme is also capable of inducing cell 
differentiation in mammalian adipose, neuronal and erythroid cells via the promotion of 
specific gene expression patterns103 121-124.  Free heme is lipophilic and potentially 
cytotoxic due to the promotion of lipid peroxidation and the production of ROS resulting 
in membrane damage and cell apoptosis125 126.  Therefore to facilitate the regulatory 
functions of heme while avoiding its toxicity the intracellular levels of free heme must be 
tightly controlled and are estimated at less than 0.1 μM127.   
Tight control of intracellular free heme levels is a feature of homeostasis.  Regulation of 
heme biosynthesis is achieved through the modulation of δ-aminolevulinic acid synthase 
(ALA synthase) activity105.  Enzymatic heme degradation is controlled by microsomal 
heme oxygenase isoenzymes that catalyse the initial rate limiting step in heme 
catabolism128 129. 
33 
 
Heme oxygenase catalyses the oxidative cleavage of the α-mesocarbon bridge of heme 
molecules to yield equimolar quantities of biliverdin-IXα and carbon monoxide with the 
concurrent release of divalent ferrous iron.  Cellular levels of free heme regulate the 
activities of both ALA synthase and heme oxygenase130.  Heme degradation appears to be 
a highly conserved evolutionary cytoprotective response to oxidative stress.  The stress-
responsive heme oxygenase-1 isoenzyme (HO-1) is rapidly induced in cells exposed to free 
radicals and other stressful stimuli.  The increase in heme oxygenase activity enables an 
exponential capability of the cells to degrade heme and thereby avoid the deleterious 
effects of free heme.   
Ferritin  
Recent studies have suggested a protective role for the iron storage protein ferritin 
against the toxic effects of iron overload in cells.  Ferritin has also been demonstrated to 
protect endothelial cells from oxidised low-density lipoprotein (LDL) and from oxidative 
stress induced by UV light exposure131 132.  Ferritin has cytoprotective antioxidant activity 
in endothelial cells due to antiapoptotic effects133-135.  Increased transcription of ferritin 
mRNA has been shown in the nuclei of cells harvested from the livers of rats intoxicated 
with iron as compared with control animal nuclei136.  In vitro studies demonstrate a dose-
dependent cytoprotective antioxidant effect of ferritin in endothelial cells loaded with 
iron133.  There is a dichotomous time-dependent effect of heme exposure in endothelial 
cells.  Brief heme exposure of up to 2 hours causes an increase in oxidative stress and 
oxidant-mediated cytotoxicity.  By contrast, prolonged heme exposure of 16 hours causes 
significant cellular resistance to oxidative damage in endothelial cells.  This time lag effect 
observed correlates with the endothelial response to heme by induction of heme 
oxygenase and the concurrent rapid synthesis of the iron-binding protein ferritin.  Cells 
respond to oxidant stimuli by increasing heme oxygenase activity and the concomitant 
production of large amounts of ferritin.  Studies demonstrate an inversely proportional 
relationship between ferritin content of endothelial cells and their susceptibility to 
oxidant stress damage under a wide range of experimental conditions125 133 137.  
Some reports suggest that heme oxygenase activity does not directly correlate with 
cytoprotection but functions mainly to provide free intracellular ferrous iron released 
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from heme breakdown.  This increase in intracellular iron up regulates an iron-transporter 
pump to remove intracellular Fe2+ but also induces ferritin expression.  Synthesis of 
ferritin protein is promoted thereby generating a primary protectant against oxidant 
damage.  As intracellular chelatable iron levels increase the synthesis of the iron-
sequestering protein ferritin is up-regulated by a post-transcriptional mechanism138.  The 
potential for Fe2+-driven catalysis of oxidative reactions is thereby limited by the 
sequestration of intracellular iron by ferritin139.  Ferritin synthesis may be directly 
enhanced by heme itself via an increase in RNA translation140.  Further studies 
demonstrate that over-expression of heavy-chain ferritin protein protects cultured 
endothelial cells from undergoing apoptosis and protects against the ischemia-
reperfusion injury associated with liver transplantation135.   
Ferritin binds free intracellular Fe2+ that would otherwise rapidly participate in the Fenton 
reaction to promote the generation of ROS.  The oxidative stress created by intracellular 
Fe2+ is particularly relevant to mitochondrial dysfunction and is limited by up-regulation of 
ferritin106 141.  A direct link between HO-1 induction and ferritin synthesis is not universally 
established.  Recent studies have demonstrated equivalent levels of ferritin in cells 
overexpressing HO-1 and in HO-1−/− cells98.  A similar recent study noted a lack of ferritin 
synthesis despite induction of HO-1 protein when cultured cell lines were exposed to 
oxidising reagents.  Ferritin synthesis was however demonstrably increased in these cells 
after treatment with extracellular heme142.  These findings suggest that the known level 
of endogenous intracellular heme may be so low as to be insufficient as a substrate for 
HO-1 enzyme.  Under conditions of oxidative stress all available iron may be shunted 
directly to the mitochondria for biosynthesis of heme to increase the availability of 
antioxidant heme proteins without a concurrent increase in ferritin synthesis.  
Studies have demonstrated that heme also functions as an important substrate for heme 
oxygenase activity to produce end products with beneficial antioxidant properties. Many 
organisms deliberately dispose of free intracellular heme by enzymatic breakdown.  It has 
been shown that a notable proportion of newly-synthesised heme is rapidly broken down 
to biliverdin in cultured rat hepatocytes to generate bilirubin143.  There are numerous 
published observations of bile pigment antioxidant activity in vitro144-149.  These studies 
support the idea that a central physiological function of enzymatic heme breakdown by 
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HO enzyme is to produce the bile pigments biliverdin and its metabolite bilirubin 
specifically to exploit the intrinsic antioxidant properties of these species at a cellular 
level150.  
1.2.3 Characterisation of the Heme Oxygenase Enzyme 
1.2.3.1 The catabolism of heme 
Initial studies by Nakajima and colleagues obtained an enzyme from liver and kidney 
homogenate that converted heme to a possible precursor of biliverdin.  This soluble 
enzyme system was partially purified and characterised as heme α-methenyl oxygenase, 
requiring NADPH, ferrous iron, and a liver cell nucleus extract as activating co-factors151.  
The system was unusually substrate-specific for pyridine hemochromogen, hemoglobin-
haptoglobin complex and myoglobin with no activity using hematin, oxyhemoglobin or 
methemoglobin152.  Furthermore, tissues presumed to be active in hemoglobin 
degradation such as spleen and bone marrow were almost devoid of enzyme activity.  
Subsequent work failed to confirm the existence of this soluble heme α-methenyl 
oxygenase system, attributing the previous findings to a heat-stable factor of low 
molecular weight functioning as a reducing agent153 154.  
Studies of heme catabolism suggest that both the heme group bound to hemoglobin and 
unbound hemin are degraded by the same mechanism, especially as when oxidised, the 
prosthetic heme group of hemoglobin is easily detached from the native globin.  Labelled 
hemoglobin or hemin administered to rats is converted to bile largely in the liver, with 
both injected hemin and endogenous hemin formed in the liver being concentrated in the 
hepatic microsomal fraction155 156.   
Tenhunen and colleagues reported an enzymatic reaction that catalysed the oxidative 
cleavage of heme at the α-methene bridge of the ferriprotoporphyrin IX ring to yield 
biliverdin IXα which is then converted to bilirubin in the presence of nicotinamide adenine 
dinucleotide phosphate (NADPH)-dependent biliverdin reductase.  The iron atom 
contained within the centre of the heme porphyrin ring is released as the free ferrous 
iron Fe2+.  The reaction product formed under the specified conditions of incubation was 
identified as bilirubin by chemical, chromatographic and spectrophotometric methods.  
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The action of biliverdin reductase was not identified as a rate-limiting step within the 
complete enzyme system.  Important characteristics of the reaction include its heat-labile 
nature, its absolute requirement for NADPH and its inhibition by carbon monoxide in the 
presence of oxygen.  This enzymatic conversion of the heme moiety to bilirubin was 
localised specifically to endoplasmic reticulum microsomes concentrated and separated 
from cellular debris by differential centrifugation128 157.   
The tissue distribution and kinetics of the microsomal heme oxygenase system were 
characterised in 1969, suggesting a major physiological role for heme oxygenase in the 
breakdown of heme and hemoproteins to bile pigment.  Cleavage of the 
ferriprotoporphyrin ring at the α-methene bridge results in the formation of the α-
configuration linear tetrapyrrole biliverdin IXα, converted to bilirubin IXα by biliverdin 
reductase and identified as the product reaction by all analytical criteria employed by 
Tenhunen and co-workers.  Bilirubin IXα is the only physiological isomeric form of 
bilirubin129. 
Microsomal heme oxygenase has an absolute and stoichiometric requirement for 
molecular oxygen and NADPH and generates carbon monoxide in equimolar amounts to 
bilirubin.  Three moles of oxygen are consumed per mole of bilirubin formed.  The 
enzyme system is capable of catalysing the oxidative cleavage of the heme moiety of the 
α and β chains of hemoglobin and other hemoproteins including methemoglobin, 
methemalbumin, protohemin IX and the hemoglobin-haptoglobin complex.  Unbound 
heme also provides a substrate for the enzyme; heme easily dissociates from its native 
globin as well as from altered or denatured proteins.  Hemoproteins that are not acted 
upon by the enzyme include oxyhemoglobin, carboxyhemoglobin, myoglobin and free 
porphyrins158.  
Heme oxygenase enzyme is strongly inhibited by carbon monoxide.  Heme oxygenase 
activity was measured by specific colorimetric assay to quantify bilirubin production from 
hemin substrate in spleen microsomes.  The assay was performed under specific 
conditions with cuvettes gassed for 2 minutes before and during the assay with 50% 
carbon monoxide, 46% nitrogen and 4% oxygen.  These conditions inhibited enzymatic 
heme oxygenase activity129.   
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CO can activate soluble guanylyl cyclase (sGC) with the resultant production of cyclic GMP 
and also modulates mitogen-activated protein kinase (MAPK) signalling pathways159.  
Carbon monoxide has a high affinity for reversible binding to hemoglobin to form 
carboxyhemoglobin.  CO can also form complexes with reduced forms of metalloproteins 
including cytochrome P-450, cytochrome-c oxidase, inducible nitric oxide synthase and 
other heme proteins and metabolic oxidases.  CO is a small gaseous ligand that can bind 
to heme oxygenase and to the heme oxygenase-heme complex160-162.  The interaction of 
CO with cytochrome P-450 or cytochrome-c oxidase has been demonstrated to cause 
inhibition of enzymatic activity163 164.  The findings of Tenhunen and colleagues suggest 
that cytochrome P-450 is involved in the oxidative cleavage of the ferriprotoporphyrin 
ring and has an essential role in the enzymatic degradation of heme157.   
Heme oxygenase enzyme is inhibited by sodium dodecyl sulfate, trypsin, sodium azide, 
potassium cyanide, lipase and phospholipase.  The rate-limiting step in heme degradation 
is the oxidation of heme at the α-methene bridge catalysed by microsomal heme 
oxygenase enzyme.  The enzyme requires mixed function oxidation with cytochrome P450 
as the terminal oxidase165, converting heme to biliverdin with subsequent reduction of 
biliverdin to bilirubin by soluble biliverdin reductase in the cytosol166.  
Heme oxygenase enzyme activity measured in experimental rat models correlates with 
the physiological sequestration and breakdown of red blood cells.  Enzyme activity is 
highest in the spleen, liver and bone marrow tissues responsible for this important 
function.  The heme oxygenase system is capable of a regulatory adaptive response to 
substrate alterations, with increased hepatic heme oxygenase activity observed following 
splenectomy or induced haemolysis.    
Landaw and colleagues studied the production of bilirubin and carbon monoxide (CO) 
from the heme oxygenase enzyme reaction.  The carbon atom at the α-methene bridge of 
the ferriprotoporphyrin ring is oxidised to carbon monoxide as the ring is cleaved at this 
site.  For each mole of heme degraded, 1 mole of CO and 1 mole of bilirubin are formed, 
providing the source of endogenous CO production.   
The production of bilirubin and CO from hepatic heme catabolism can be measured by an 
indirect approach in experimental animal models by controlled intravenous 
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administration of isotopically labelled hematin.  The rate of formation of radioactive 
bilirubin and CO is subsequently measured and compared to the total amount of isotopic 
tracer excreted in the bile.  Heme compounds can also be pulse-labelled with glycine-2-
14C to produce labelled bilirubin and CO and isotopic bile pigment from hepatic heme 
degradation.  In the experiments reported by Landaw et al167 concurrent production of 
bilirubin-14C and 14CO was determined in 16 rat subjects of whom 8 were injected with 
glycine-2-14C, 5 with hematin-14C prepared from glycine-2-14C, 2 with bilirubin-14C, and 1 
with glycine-1-14C.  The results demonstrated an equimolar relationship between heme 
breakdown and reaction product production, with virtually equivalent quantities of 
isotopic bilirubin and CO measurable from rats given an infusion of hematin-14C.  
Although heme catabolism pathways exist that result in alternative end products, in these 
studies only a minor fraction of labelled hematin was metabolised to compounds other 
than bilirubin and carbon monoxide.  Chemical modification of the heme molecule or a 
change in metabolic conditions may encourage these alternate pathways of heme 
turnover.  Treatment with the porphyrogenic drug allylisopropylacetamide (AIA) 
enhanced the production of non-bilirubin pyrrolic derivatives and shifted the ratio of 
CO:bilirubin production in favour of carbon monoxide.  Pre-treatment with phenobarbital 
to enhance liver metabolism of heme resulted in a proportional increase in the 
production of CO and bilirubin without altering the equimolar relationship.  These 
findings suggest that the physiological pathway of heme breakdown is decided by the 
nature of the initial attack on the heme moiety tetrapyrrole ring.  Microsomal heme 
oxygenase enzyme catalyses the cleavage of the ferriprotoporphyrin ring at the α-
methene bridge producing equimolar amounts of CO and bilirubin.  If the tetrapyrrole 
ring is opened by a different mechanism then alternative pathways produce other 
metabolites without endogenous CO production. 
Studies reported by Pimstone et al168-170 provide direct evidence that alveolar and 
peritoneal macrophages derived from monocyte precursors have the potential for heme 
oxygenase (HO) enzyme activity.  Although native macrophages have very low HO activity, 
exposing these cells to heme pigments in vivo stimulates enzyme activity.  This 
demonstrates that heme triggers the activity of its own breakdown pathway in 
macrophages that are not physiologically responsible for hemoglobin degradation.  Cells 
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of the reticuloendothelial system including splenic macrophages and the Kupffer cells of 
the liver have equivalent heme oxygenase enzyme apparatus that performs at a high 
physiological activity to remove old and damaged red blood cells from the circulation170. 
The characteristic colour change observed over time in subcutaneous bruises provides a 
useful picture of the successive steps in enzymatic hemoglobin breakdown.  Extravasated 
blood stimulates movement of local tissue macrophages to the site of injury and 
phagocytosis (digestion) of red blood cells trapped in the tissue.  The initial appearance of 
the bruise is dark red due to ingested hemoglobin.  Hemosiderin deposits in tissue 
macrophages give a dark brown appearance.  The process of phagocytosis includes 
induction of lysosomal and cellular microsomal enzymes including heme oxygenase.  
Activity of heme oxygenase breaks down the hemoglobin into bilirubin, ferrous iron and 
amino acids that are gradually released into the interstitial fluid.  As the breakdown 
products appear the bruise changes colour in sequence to dark brown (methemoglobin or 
hematin), green-blue (biliverdin) and eventually to yellow (bilirubin). 
By contrast, the dark purple or black colour of subungual haematomas (bleeding 
underneath a toenail or fingernail) or intraepidermal blood blisters can persist for several 
weeks.  This can be explained by the fact that these tissue injuries do not elicit much in 
the way of a cellular response.  There is not a major process of phagocytosis by 
macrophages and the extravasated hemoglobin-heme complex remains intact and 
essentially unchanged until the protective layer of skin or nail above the trapped blood is 
shed.   
1.2.4 Heme oxygenase isoenzymes 
Heme oxygenase activity has been observed in all systemic organs.  Two recognised 
isoforms of the heme oxygenase enzyme have been isolated and characterised in 
humans.  HO-1 has a molecular mass of 32 kilo Daltons (kDa) and is inducible by a variety 
of stimuli including oxidative stress, tissue injury and nitric oxide (NO).   
The two isoforms of HO share approximately 40% of amino acid sequence homology171 
172.  HO-1 is the product of one transcript whereas HO-2 is encoded by two transcripts of 
the single gene which differ in the use of the polyadenylation signal173.  HO-2 is a 
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constitutively synthesised protein with molecular weight 36 kDa, responsible for 
providing basal HO activity for cell homeostasis174.  There is wide variability in the tissue 
distribution of HO isoforms and the basal levels of constitutively expressed HO-2 protein 
with the highest levels of HO-2 detectable in the brain.  HO-2 is also expressed at lower 
levels in testes, endothelial cells, distal nephron segments, liver, and gut myenteric 
plexus175-177.  HO-1 seems to be constitutively expressed in some unique types of cells 
including liver Kupffer cells, renal medullary cells, and CD4+ regulatory T-cells178-180.  The 
basal level of HO-1 is rather weak in mammalian tissues apart from the liver and spleen 
where the gene is strongly expressed181.  
HO-1 can be readily and strongly up-regulated in many tissues in response to cellular 
stress caused by a wide spectrum of stimuli including heme, heavy metals, UV irradiation, 
ROS, nitric oxide (NO), inflammatory cytokines, heat shock, ethanol, and 
prostaglandins182-188.  The expression of a third isoform, HO-3, has been demonstrated at 
mRNA level in the rat brain but this has negligible heme breakdown activity and its 
presence has not been established in human tissues189.  The isoform described in rats 
termed HO-3 is more likely to reflect a processed pseudogene derived from an HO-2 
transcript190.  
HO-1 and HO-2 enzymes have the same mechanism of heme oxidation, with equivalent 
co-factor and substrate specificity and susceptibility to inhibition by metalloporphyrins.  
Heme oxygenase isoforms HO-1 and HO-2 have the same enzymatic activity catalysing the 
breakdown of heme into carbon monoxide (CO), ferrous iron (Fe2+) and biliverdin128.  Both 
isoenzymes require molecular oxygen (O2) and NADPH (nicotinamide adenine 
dinucleotide phosphate) as cofactors for effective function189.  HO-1 and HO-2 proteins 
have distinct immunological characteristics, dissimilar molecular weights and substantial 
differences in their regulation and expression pattern191.  Their structure differs in terms 
of available heme and cysteine binding-sites, and their postulated function is different.  
While constitutive HO-2 is believed to be responsible for basal HO activity contributing to 
cell homeostasis, inducible HO-1 expression is relatively low in most tissues and it has 
functional significance only in response to injurious stimuli191-195.   
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The significant increases in heme oxygenase enzymatic activity observed in models of 
inflammatory and oxidative stress are mediated by an increase in HO-1 gene transcription 
rates179 196 197.  Constitutive HO-2 protein does not appear to be inducible by stressful 
stimuli although the HO-2 gene promoter contains a glucocorticoid response element and 
administration of glucocorticoids stimulates HO-2 transcriptional activity in neuronal 
cells198.  Distinct genes encode the HO isoforms located on chromosomes 22q12 (HMOX1) 
and 16q13.3 (HMOX2) in the human genome199 200.  Expression of HO-2 protein is found in 
various tissues under physiological conditions especially the testis and the brain.  
Constitutive expression of HO-1 isoform is relatively low with the exception of the 
spleen201 202.   
The constitutively expressed HO-2 enzyme isoform is not yet as widely researched as HO-
1.  HO-2 activity is believed to be essential for normal cellular function both in 
maintaining intracellular levels of the pro-oxidant heme moiety and in the tonal 
production of biliverdin and CO that contribute to endogenous cellular antioxidant 
capacity and regulation of signalling pathways.  Although the role of HO-2 in inflammation 
is largely unexplored, the enzyme has an equal ability to produce CO and bilirubin and so 
should be equally capable of exerting anti-inflammatory and antioxidant effects as HO-1.  
The relatively constant expression levels of HO-2 protein may be suitable for its 
regulatory role in heme homeostasis.  The enzymatic activity of HO-2 may be dynamically 
regulated via posttranslational mechanisms that involve phosphorylation of cellular 
proteins203.   
The HO-2 isoform molecule contains three cysteine residues each of which can function 
as the heme-binding site204.  HO-2 protein may thereby play an important regulatory role 
by sequestering heme to maintain the intracellular heme level204.  Some reports suggest 
that HO-2 functions as an oxygen sensor205 206.  Studies in HO-2 knockout mice have 
demonstrated several important cellular functions of the HO-2 enzyme particularly in the 
regulation of endothelial cell homeostasis.  Endothelial cells from HO-2−/− mice display 
active inflammation and increased levels of oxidative stress207.  Deficiency of HO-2 protein 
leads to an exaggerated inflammatory response after antigen-induced peritonitis with an 
impaired acute inflammatory and reparative response to epithelial injury174.  HO-2−/− mice 
are not able to compensate for the loss of HO-2 by increasing HO-1 expression as the 
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induction of HO-1 protein is impaired by HO-2 deficiency, suggesting that HO-2 protein 
may be critical for HO-1 expression208.   
Inducible HO-1 is widely expressed in response to stimuli in organs and tissues such as 
liver, spleen, pancreas, intestine, kidney, heart, retina, prostate, lung, skin, brain, spinal 
cord, vascular smooth muscle cells and endothelial cells.  HO-2 is expressed at high levels 
and is the predominant form of HO protein expressed in the brain and testis of mammals 
where it is suggested to have a vital neuroprotective function177 209 210.  In a rat model of 
ischaemic stroke, neural damage following middle cerebral artery occlusion and 
reperfusion was significantly worsened in HO-2 knockout mice177 210.  HO-2 is reported to 
be critical for protection of cerebral microvascular endothelial cells against apoptotic 
changes induced by oxidative stress and cytokine-mediated inflammation209. 
A characteristic feature of HO-1 expression appears to be its rapid induction in response 
to increased cellular oxidative stress and then subsequent regression to low levels.  The 
HO-2 isoform is by contrast constitutively expressed in all cells.  The HO-2 gene promoter 
responds solely to glucocorticoids to cause up-regulation of HO-2 protein109.   
A unique function for HO-2 protein is suggested by the presence of heme-binding Heme 
Regulatory Motifs (HRMs) on the N-terminus of the HO-2 molecule.  These ancient HRMs 
consist of short amino acid sequences and function as heme – oxygen sensors in bacteria, 
yeast and mammals and suggest a role for HO-2 as an intracellular sink, binding and 
regulating the heme gaseous ligands nitric oxide, carbon monoxide and molecular 
oxygen117 211-213.  This role is supported by the finding that HO-2 co-localises with nitric 
oxide synthase and binds the vasodilator nitric oxide (NO) with high affinity214.   
Recent studies have indicated a potential role for HO-2 as an oxygen sensor.  HO-2 
protein binds to the potential vasodilator carbon monoxide (CO) and oxygen (O2) with less 
affinity than it binds to NO.  The interaction with CO and the increased proximal 
production of CO from heme breakdown mediated by increased HO-2 activity stimulates 
the calcium-sensitive potassium channels that mediate the excitatory responses of the 
carotid body to hypoxia215.  Studies in HO-2 knockout mice show that HO-2-/- mice have 
mild hypoxemia.  Although the carotid bodies of HO-2-/- mice are enlarged the 
chemoreceptors respond normally to acute hypoxia and the mice have only partially 
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impaired acute ventilatory responses216 217.  The HO-2 knockout mice phenotype had an 
increased susceptibility to the lethal effects of hyperoxia.  The principal drawback in the 
interpretation of studies arises from the observation of a higher total lung HO enzymatic 
activity and increased HO-1 protein levels in mice with the HO-2-/- genotype and HO-2 
protein deficiency.  Therefore it is not clear if the observed sensitivity to hyperoxia was 
directly related to HO-2 deficiency or a combination of HO-2 deficiency and increased HO-
1 activity.   
The acute response of central and peripheral chemoreceptors to hypoxia may be 
regulated by alternative mechanisms other than HO-2 to cause inhibition of membrane 
ion channels218.  Changes in CO signalling in HO-2-/- mice may be responsible for possible 
chronic pulmonary ventilation – perfusion mismatches206.  Furthermore, the up regulation 
of HO-1 demonstrated in the pulmonary epithelium of HO-2-/- mice perhaps functions as 
an alternative compensatory source of CO production116 219.  
In a murine model of antigen-induced peritonitis, HO-2-null mice exhibited a phenotype 
of exaggerated inflammation and reduced neutrophil function.  Using a well-characterised 
model of the reparative response to epithelial injury, HO-2-null mice demonstrated an 
acute inflammatory response that failed to resolve, evolving into augmented and 
uncontrolled inflammation with impaired wound closure and neovascularisation.  These 
findings suggest a crucial role for HO-2 in providing an ordered and reparative 
inflammatory response to cellular injury174. 
1.3 The consequences of heme breakdown 
1.3.1 Heme oxygenase enzyme products 
Heme oxygenase enzyme catalyses the rate-limiting step in the breakdown of heme, a 
reaction that produces biliverdin IXα, carbon monoxide (CO), and ferrous iron (Fe2+), at 
the expense of molecular oxygen and NADPH.  The cytosolic enzyme biliverdin reductase 
then rapidly reduces biliverdin IXα to the hydrophobic pigment bilirubin IXα220.  
Circulating bilirubin-IXα is bound to albumin and has antioxidant activity at physiological 
concentrations144 221.  Accumulated serum bilirubin is conjugated to water-soluble 
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glucuronide derivatives by hepatic microsomal glucuronyl transferase enzymes and 
secreted into the bile with subsequent elimination via the faecal routes222.   
The heme oxygenase system has generated substantial scientific interest over the last 
decade with numerous studies of human physiology.  The role of the HO pathway and the 
products of heme breakdown in diabetes, inflammation, heart disease, hypertension, 
transplantation, and pulmonary disease are all areas of recent research.  Research has 
included investigation of several genetic and metabolic processes that are mediated by 
HO activity and heme metabolism.  It has become increasingly recognized that inducible 
HO-1 has cytoprotective activities including antioxidant, anti-inflammatory, anti-apoptotic 
and pro-angiogenic properties201.  The reaction catalysed by heme oxygenase enzyme 
(Figure 1.3.1) has significant cellular and physiological consequences.  The HO system 
interacts with cell signalling mechanisms and participates in the cell response to injury.  
Heme oxygenase enzyme has kinase and transcription factor activities as well as its vital 
function for the intracellular transport of Fe2+ and heme.  Biliverdin reductase has 
recently been identified as a key regulator of HO-1 expression223-225.  
By generating bilirubin and carbon monoxide, HO has antioxidant, anti-inflammatory and 
anti-apoptotic activities.  The simple degradation of heme is an important component of 
anti-oxidant activity as heme itself is an effective catalyst for the formation of ROS226.  
Although free iron is produced from heme breakdown, heme oxygenase also facilitates 
cellular storage and export of free iron by up-regulating synthesis of ferritin and iron-
transport proteins227.  Biliverdin and bilirubin are both reducing molecules that have been 
demonstrated to possess potent antioxidant activities228.  Numerous studies have 
demonstrated that bilirubin at intracellular physiological (nanomolar) concentrations is a 
potent antioxidant able to protect cells from up to a 10,000-fold excess of H2O2
210 221 229 
230.  Bilirubin is able to scavenge hydroxyl radicals, singlet oxygen and superoxide anions.  
In providing this antioxidant activity bilirubin is oxidised back to biliverdin which is then 
recycled back to the reducing agent bilirubin via the action of cellular signalling pathways 
that activate biliverdin reductase enzyme229 231 232.  In neuronal cells this reaction depends 
upon the substrate biliverdin being supplied by HO-2 isoform rather than HO-1 enzyme177 
210 233.  The water-soluble glutathione system is a major intracellular antioxidant that 
protects water-soluble proteins from targeted damage by ROS.  Recent studies indicate 
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that bilirubin similarly protects lipophilic proteins in plasma cell membranes from 
oxidative damage230.   
The cytoprotective activity of biliverdin and bilirubin is largely based on inhibition of lipid 
and protein peroxidation229.  Bilirubin is also capable of anti-inflammatory activity.  It 
reduces leucocyte adhesion and rolling and inhibits the complement cascade234 235.  
Carbon monoxide (CO) functions as an important cellular signal molecule236 in a number 
of pathways.  CO stimulates cyclic GMP to affect vascular tone and neurotransmission, 
binds to potassium channels to produce vasodilatation, increases angiogenesis and has 
anti-inflammatory and anti-apoptotic activity237.   
While the removal of free intracellular heme by heme oxygenase is certainly an important 
aspect of cellular survival the products of HO enzymatic activity are the more likely 
mechanisms underlying the cytoprotective effects mediated by HO protein.  
Administration of biliverdin or bilirubin or delivery of exogenous carbon monoxide either 
directly as a gas or via carbon monoxide-releasing molecules mediates the majority of 
protective functions ascribed to HO activity238.  Exogenous treatments with bile pigments 
and/or carbon monoxide are similarly beneficial for cell survival as isolated induction of 
HO-1 enzyme and this strategy can substitute for the lack of HO-1 activity in cell and 
animal models239 240.  The potentially toxic effects of iron, carbon monoxide and bile 
pigments in human physiology are likely to limit their beneficial actions to a narrow 
threshold of overexpression241 242.   
Up-regulation of HO-1 and increased HO activity may produce both pro- and anti-oxidant 
effects as part of the cellular response to stress.  Available evidence to date suggests that 
that HO-1 is neither exclusively cytoprotective nor exclusively cytotoxic.  Published 
reports suggest that induction of HO-1 could be harmful to the cell under certain 
circumstances224.  The release of ferrous iron previously chelated with heme provides a 
potential for the production of Fe2+-driven free radicals such as the hydroxyl radical via 
the Fenton reaction to cause subsequent cell damage.  An increase in HO-1 activity will 
have an overall benefit provided the released iron is either sequestered by storage within 
ferritin or exported out of the cell by the plasma membrane exporter protein243 244.   
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There is a large body of literature that supports a seminal role for the HO system in 
protecting cells from oxidative stress, in particular the inducible HO-1 enzyme.  The 
cytoprotective effects of HO activity depend upon limited heme degradation and 
preservation of cellular heme available for the continued production and function of 
other critical cell heme proteins.  Published evidence indicates that HO-1 activity exerts 
an important anti-inflammatory action and regulates inflammation in vivo.  Characteristic 
features of a progressive chronic inflammation are displayed in HO-1 knockout mice as 
compared to wild-type mice with a higher peripheral blood leucocyte count, 
inflammatory cell adherence and infiltration in hepatic endothelium, splenomegaly due to 
follicular hyperplasia and high splenic and lymph node CD4+:CD8+ T-cell ratios with 
numerous activated CD4+ T-cells245 246.  Peritoneal macrophages from HO-1-knockout 
mice also exhibit distinctly increased pro-inflammatory cytokines such as MCP-1 
(monocyte chemotactic protein-1) and interleukin-6 (IL-6)247.   
Administration of exogenous carbon monoxide or induction of HO-1 protein inhibits the 
production of LPS (lipopolysaccharide)-induced pro-inflammatory cytokines such as TNF 
(tumour necrosis factor)-α, interleukin-1 (IL-1) and macrophage inflammatory proteins248 
249.  Expression of the anti-inflammatory cytokine IL-10 induced by bacterial LPS was 
increased by HO-1 induction249.   
HO-1 is considered to have a valuable role in vascular biology due to its cardioprotective 
effects250-253.  HO-1 activity has been shown to limit endothelial dysfunction by reducing 
the production of pro-inflammatory cytokines such as macrophage colony-stimulating 
factor254.  The interaction between capillary endothelial cells and leucocyte adhesion is 
diminished by induction of HO-1 via the activity of bilirubin product234.  Up-regulation of 
HO-1 enzyme can inhibit the production of E-selectin and VCAM-1 vascular cell adhesion 
molecules mediated by the pro-inflammatory cytokine TNF-α254 255.   
The importance of HO-1 protein in protection against cardiovascular disease has been 
evaluated by numerous in vivo models.  Increased HO-1 expression in human carotid 
endarterectomy specimens have been shown to be associated with reduced plaque 
vulnerability256.  The effects of altered HO enzymatic activity in the cardiovascular system 
can be related to the levels of bile pigment products generated by heme breakdown.  
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High bilirubin levels have been shown to be associated with reduced prevalence and 
incidence of coronary artery disease and ischaemic stroke257 258.  Low bilirubin levels 
meanwhile can be associated with endothelial dysfunction indicated by flow-mediated 
dilatation and an increase in carotid intima-media thickness259.   
Features of human iron overload syndrome such as splenomegaly, tissue iron deposition, 
hepatomegaly, hepatic fibrosis, growth retardation and premature death are 
demonstrated in HO-1 knockout mice245 246.  Mice with a phenotype deficient in both HO-
1 and ApoE (apolipoprotein E) have increased atherosclerosis and vein graft stenosis 
compared with mice not lacking in HO-1 protein suggesting a specific role of HO-1 in 
protection against atherosclerosis260.  Cultured endothelial cells deficient in HO-1 protein 
demonstrate impaired angiogenesis in vitro261.  HO-1 knockout mice have diminished 
angiogenesis in vivo and worse neovascularization during tissue healing as compared with 
their wild-type counterparts in a cutaneous wound injury model.  Skin-specific 
overexpression of HO-1 produced an enhanced process of neovascularization during 
wound healing in transgenic mice261 262.  If the observed differences in HO-1 knockout 
mice can be assumed to be exclusively due to the absence of HO-1 protein these studies 
indicate a critical role for HO-1 activity in angiogenesis.   
The activity of HO-1 is of central importance for effective reutilisation of iron in both 
rodents and humans even under physiological conditions.  Deficiency of HO-1 protein has 
been shown to result in iron deposition and cause harmful inflammatory sequelae 
secondary to impaired iron recycling245 246 263.  The first reported case of human HO-1 
deficiency described a case of a 6-year-old boy with severe growth retardation 
characterised by marked intravascular haemolysis and hyperlipidaemia.  Extensive 
endothelial injury was evident on electron microscopy of the renal glomeruli with cell 
swelling and detachment and subendothelial deposition of iron.  Atherosclerotic fatty 
streaks and fibrous plaques were present in the aorta at post mortem examination263 264.  
Production of bilirubin was impaired in this patient, perhaps reducing the bilirubin-
mediated capacity to reduce the oxidation of LDL low-density lipoprotein and leading to 
oxidative vascular endothelial injury149 221 265.   
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The notion that HO-1 enzyme has a fundamental physiological purpose is supported by 
the fact that both the enzyme and its heme substrate are highly conserved and 
ubiquitous across evolutional life forms189 266.  The molecular processes and mechanisms 
by which HO-1 activity provides cellular and tissue protection remain only partially 
understood.  The majority of studies investigating HO-1 or CO-dependent cytoprotection 
suggest the involvement of inflammatory response mechanisms including down-
regulation of pro-inflammatory cytokines as well as HO-1-mediated regulation of 
apoptosis and cell proliferation201 267-271.   
A number of cell signaling molecules and transcription factors have been identified to be 
involved in regulating HO-1 expression including mitogen-activated protein kinases 
(MAPKs), nuclear factor-κB (NF-κB), biliverdin reductase, activating transcription factors, 
nuclear factor E2-related factor 2 (Nrf2), phosphatidyl inositol 3-kinase / Akt and protein 
kinase C.  Expression of HO-1 protein is most likely to result from complex coordinated 
interactions between these various molecules266 272.   
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Figure 1.3.1: The consequences of heme breakdown 
 
 
1.3.2 Heme oxygenase and inflammation 
Heme oxygenase (HO) is present as two functionally active isoforms in humans that are 
encoded by specific genes: HO-1 and HO-2.  A pseudo gene variant of HO-2 isoform 
termed HO-3 has been described in the rat brain.  Heme oxygenase isoforms share the 
function of heme degradation but otherwise have dissimilar molecular and biochemical 
properties109 190 273-275.   
HO-1 enzyme is a highly inducible heat shock protein up-regulated by a variety of 
stimulants including hypoxia or hyperoxia, depletion of intracellular glutathione, 
endotoxin, inflammatory cytokines, hyperthermia, ultraviolet irradiation, increased heme 
levels, and various heavy metals including sodium arsenite, cobalt and selenium.  HO-1 is 
known to be activated by a greater number of stimuli than that of any other gene with 
the cellular response depending on the cell type109 273.  HO-1 is induced by oxidative stress 
and reactive species including H2O2 and nitric oxide (NO) and its up-regulation in response 
to heat shock conferred its alternative name of heat shock protein (HSP) 32.   
Several in vitro studies have suggested that heme oxygenase activity may potentiate 
rather than attenuate oxidant toxicity under certain conditions276 277.  Treating epithelial 
cells with the competitive inhibitor of heme oxygenase enzyme zinc protoporphyrin IXa 
reduced the cytotoxic effects of H2O2 treatment at 24 hours
276.  Similar studies showed 
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that co-incubation of cultured astroglial cells with metalloporphyrin inhibitors of heme 
oxygenase activity protected against the cytotoxic effects of H2O2 treatment
277.  Studies 
using transfection models of heme oxygenase-1 (HO-1) expression suggest that HO-1 is 
capable of both pro- and anti-oxidant activity.  Rabbit endothelial cells that over-
expressed HO-1 were resistant to heme toxicity278.  Up-regulation of HO-1 in human 
pulmonary epithelial cells caused growth arrest and increased cellular tolerance to 
hyperoxia279.  Protection against hyperoxia-mediated apoptosis, protein oxidation and 
lipid peroxidation was afforded by overexpression of HO-1 in rat foetal pulmonary 
epithelial cells, whereas HO-1 overexpression during hyperoxia increased glutathione 
depletion and plasma membrane damage241 280.  
Increased enzyme activity confers protection against oxidative stress conditions in vitro 
and in vivo through anti-oxidative, anti-apoptotic and anti-inflammatory actions.  These 
include inhibition of inflammatory adhesion molecules and leucocyte recruitment and 
suppression of cytokine and chemokine expression.  When cells are exposed to non-heme 
insults, it is assumed that the cellular stress response also promotes release of sufficient 
amounts of substrate for the induced HO-1 enzyme.  A study of heme catabolism found 
that a noticeable proportion of newly-synthesized heme was converted rapidly and 
directly to biliverdin without incorporation into hemoproteins, suggesting that heme 
substrate is synthesized purely for the products of its breakdown by heme oxygenase143.   
It is apparent that an increase in HO activity is a positive cellular response to potentially 
damaging stimuli, with anti-inflammatory and immunosuppressive effects.  HO activity 
augments the endogenous cellular antioxidant reserve and its effects are achieved by 
influencing redox-sensitive signal transduction pathways and cell to cell interactions such 
as leukocyte migration and inflammatory cytokine production.  Moreover, evidence 
suggests that HO-1 activity is essential for the survival of organisms.  In murine models of 
HO-1 deficiency, mice lacking the gene are at increased risk of adverse consequences of 
oxidative stress and show poor overall survival, commonly dying in utero or within 1 year 
of birth.  HO-1-/-  adult mice generate increased amounts of pro-inflammatory cytokines 
including interferon-γ (IFN-γ) and interleukin-6 (IL-6) and develop progressive 
inflammatory disease characterised by hepatic and renal inflammation, splenomegaly, 
lymphadenopathy and leukocytosis281 282.  Young adult HO-1-/- mice exposed to endotoxin 
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were vulnerable to hepatic necrosis and had an increased mortality when compared to 
their HO-1+/+ counterparts246.   
The first human case report of HO enzyme deficiency was reported in 1999 describing a 6-
year-old boy diagnosed with HO-1 deficiency263.  He suffered from growth failure, 
anaemia, tissue iron deposition, lymphadenopathy, leucocytosis and increased sensitivity 
to oxidant injury.  The enzyme deficiency ultimately led to his premature death189 264.  The 
same phenotype is observed in HO-1-/- mice and emphasises the importance of HO-1 for 
cellular homeostasis246.  There has been only one further case of HO-1 deficiency in 
humans reported to date so the expression of HO-1 protein seems to be an indispensable 
component of human physiology283.  
The principal functions of HO-1 in cellular homeostasis include regulation of the oxidative 
load, anti-inflammatory activities and modulation of the cell cycle and programmed cell 
death284.  The widespread effects on cell function encompass the beneficial effects of HO-
1 and the products of heme breakdown observed in inflammatory responses including 
septic shock, ischemia-reperfusion injury, angiogenesis, carcinogenesis and degenerative 
diseases201.  HO-1 activity has a role in many pathophysiological conditions, including 
ischaemic stroke and potential graft failure following organ transplantation.  Abnormal 
HO activity has been demonstrated in angiogenesis and in stress-induced 
neurodegenerative disorders such as Alzheimer’s disease.  HO-1 expression has a potent 
cytoprotective effect in experimental models of cardiac ischemia and reperfusion injury, 
pulmonary inflammation and hypertension285-287.   
The mechanisms that mediate the anti-inflammatory effects of the HO have not been 
fully elucidated.  The major contribution may be from CO-mediated signalling, with the 
antioxidant properties of biliverdin/bilirubin and the sequestration of iron by ferritin 
combined towards cell protective effects of heme oxygenase activity248 288-291.  Carbon 
monoxide is reported to have important anti-inflammatory effects in models of tissue 
injury.  In lipopolysaccharide (LPS)-stimulated macrophages, CO caused a significant 
reduction in the generation of inducible nitric oxide synthase (iNOS)-derived NO and 
production of pro-inflammatory tumour necrosis factor (TNF) and IL-6249 292.  Under the 
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same conditions, CO increased production of the anti-inflammatory cytokine, interleukin-
10 (IL-10).   
HO-1 expression has been demonstrated to reduce vascular constriction and prevent 
excessive vascular smooth muscle cell proliferation in mouse and pig models of arterial 
injury293.  Increased HO-1 activity produces CO that readily diffuses into adjacent smooth 
muscle cells and activates soluble guanylyl cyclase (sGC).  This results in elevated 
intracellular levels of cyclic GMP (cGMP), leading to smooth muscle relaxation and 
vasodilatation.  HO-1 expression inhibits the proliferation of vascular smooth muscle cells 
in vitro and in vivo by causing up-regulation of p21 gene and cell cycle G1/S growth arrest.  
This effect is most likely mediated by cyclic GMP-dependent transcriptional regulation of 
p21 subsequent to cGMP activation by CO.  HO-1-/- mice subjected to arterial wire injury 
demonstrated greater intimal hyperplasia and smooth muscle cell proliferation compared 
to HO-1+/+ controls on examination of the injured arteries after two weeks293.  These 
findings indicate protective effects of HO-1 in arterial trauma that are relevant to vascular 
diseases in which vasoconstriction and cell proliferation are a pathological feature, 
including atherosclerosis and graft failure. 
Biliverdin and bilirubin inhibit nuclear factor-κB (NF-κB) activation in leucocytes, causing 
reduced expression of various adhesion molecules such as E-selectin and vascular cell 
adhesion molecule-1 (VCAM-1), thereby reducing cell adhesion to vascular endothelium 
and inhibiting a recognised component of acute inflammation234.  Biliverdin and bilirubin 
have also been demonstrated to reduce the chemotactic response when monocytes are 
exposed to oxidized low-density lipoprotein (LDL) 294.  
The role of HO-1 in inflammation appears to be of particular importance in the lungs. In 
rodent lung models of hyperoxia- and endotoxin-mediated acute lung injury, researchers 
have found that HO-1 expression and levels of activity increase after such injury and that 
HO-1 inhibition results in increased susceptibility to lung injury279 295-297.  This suggests 
that HO-1 has a protective role against these forms of injury298.  In acute and chronic lung 
transplant rejection, increased expression of HO-1 in alveolar macrophages has been 
found in human transplanted lungs, whilst HO-1 has been shown to induce cytokine 
expression following transplantation in rat allograft lung models299 300. Several groups 
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have also found that HO-1 overexpression protects against ischaemia-reperfusion injury, 
which commonly causes graft failure286 301-303. A recent study found that HO-1 induction is 
protective against pancreatic microcirculatory derangements following ischaemia-
reperfusion injury301.  
Published studies of the functional roles of HO-1 and HO-2 in vivo indicate that 
deficiencies of either HO-1 or HO-2 influence oxidant sensitivity and cause disruption in 
the homeostatic flow of intra and extracellular iron102 106 141 220 304.  Cellular oxidative 
stress causes modification of cell proteins by ROS to make the proteins more susceptible 
to proteolytic degradation.  Increased breakdown of heme proteins may result in a 
transient increase in free intracellular endogenous heme levels.  Oxidative stress 
conditions also temporarily decrease the cellular content of the reduced form of 
glutathione.  Up-regulation of inducible HO-1 protein is triggered by both a rise in 
intracellular free heme and a disruption of intracellular thiol equilibrium.  The increase in 
HO-1 activity compensates for the brief rise in intracellular free heme by removing the 
heme from the cell in exchange for free ferrous iron.  The free Fe2+ stimulates ferritin 
protein synthesis with consequent iron sequestration restoring the cellular iron 
equilibrium.  Increased ferritin synthesis depends upon the intracellular accumulation of 
free reactive Fe2+ that becomes temporarily available as a catalyst for harmful oxidative 
reactions via Fenton chemistry.  An initial competition therefore arises between iron 
sequestration and reutilization pathways and reactions with Fe2+ to generate free 
radicals102 106 141 220 304.  Once the iron equilibrates to the ferritin pool it is transiently 
sequestered in an inert oxidised form with a restricted reactivity.  This sequestered iron 
may still however be available for catalysis of oxidative reactions under conditions that 
promote its release.   
The cytoprotective antioxidant effects of heme oxygenase only occur when both the free 
intracellular heme has been degraded and the free intracellular Fe2+ has been either 
completely sequestered in the ferritin pool or transported out of the cell cytoplasm.  
Enzymatic HO activity can therefore be regarded as an intermediate in cell antioxidant 
defence102.  The protection of cells against oxidative stress cannot be exclusively 
attributed to the enzymatic function of HO-1.  HO-1 protein may be additionally involved 
in cellular signalling and regulation of gene transcription to activate cell protective 
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pathways involving up-regulation of catalase and glutathione peroxidase expression and 
an increase in glutathione content305.  The multifunctional nature of heme oxygenase in 
the regulation of cell proliferation, differentiation, oxidative status and apoptosis renders 
its significance much greater than simply elimination of cellular heme.  Beneficial effects 
of heme oxygenase activity have been demonstrated via the inhibition of inflammatory, 
apoptotic and proliferative processes in lung inflammation, lung and vascular 
transplantation, sepsis, and pulmonary hypertension models. 
Numerous studies indicate a protective role for HO-1 during microbial sepsis.  HO-1-
deficient mice had an increased level of free circulating heme and suffered higher 
mortality rates after caecal ligation and puncture to induce peritonitis as compared to 
HO-1-sufficient mice306-309.  Administration of exogenous carbon monoxide (CO) at low 
doses with associated HO-1 expression selectively inhibited the expression of pro-
inflammatory cytokines TNFα and IL-1β caused by a concomitant sublethal dose of 
bacterial lipopolysaccharide (LPS) in mice and cell culture models181 249 297.  The p38 
mitogen-activated protein kinase (MAPK) pathway was demonstrated to be important for 
the CO-mediated effect observed in cultured macrophages249 297.   
Overexpression of HO-1 and low-dose administration of CO have been shown to afford 
protection against hyperoxic lung injury and increased cell survival from hyperoxia-
related stress in both rodent models and cultured epithelial cells279 295.  Animal models of 
ventilator-induced lung injury collectively support a potential role for low-dose CO 
administration with mechanical ventilation to protect from lung injury.  Rodent models of 
lung ischaemia and reperfusion injury describe a therapeutic potential for HO-1-derived 
carbon monoxide.  Homozygous HO-1 knockout mice (HMOX1−/−) were more sensitive to 
the lethal effects of lung ischaemia/reperfusion injury than their wild-type counterparts, 
with an increased survival phenotype achieved by inhalation of exogenous CO to 
compensate for the HO-1 deficiency287.   
Recent evidence suggests an additional mechanism mediated by heme oxygenase 
activity: the regulation of cellular autophagy and the preservation of mitochondrial 
homeostasis.  The autophagy process is a regulated cellular pathway targeting cytosolic 
material such as damaged organelles or denatured proteins.  This material is engulfed by 
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double-membrane vesicles that fuse with lysosomes to facilitate its enzymatic 
degradation.  Important precursor molecules including amino acids and fatty acids are 
thereby regenerated for use in anabolic pathways and ATP production310-317.  This aspect 
of the autophagy mechanism may help to prolong cellular survival during starvation.  
Autophagy assists in the immune response to infection by augmenting the intracellular 
degradation of pathogenic microorganisms and may also contribute to adaptive immune 
mechanisms316.   
The role of autophagy in human diseases is complex with both protective and deleterious 
effects in response to various stimuli.  Autophagy contributes to the stress response by 
reducing the activation of potentially lethal signal transduction cascades, enabling the 
elimination of cytotoxic protein aggregates and maintaining crucial levels of ATP to 
facilitate protein synthesis.  Cellular sensitivity to cell cycle-dependent toxins may be 
influenced by autophagy since progression of the cell cycle is affected by the induction of 
the process318 319.  Cell death via an autophagy process may occur during development 
and the neonatal period to maintain cellular energy homeostasis and cell survival and also 
during homeostasis in adulthood but there is no conclusive evidence for the existence of 
a specific mechanism for cell death via autophagy313.   
Translocation of HO-1 protein to the mitochondria has been observed in human alveolar 
and bronchial epithelial cells after treatment with hemin and exposure to LPS and 
cigarette smoke320.  The HO-1 response causes down regulation of apoptosis and 
autophagy signalling pathways to confer cytoprotection and reduce the cellular stress 
caused by cigarette smoke321.  Up-regulation of HO-1 occurs in the liver in response to 
sepsis and LPS exposure and is associated with induction of HO-1-dependent autophagy 
signalling pathways that lead to reduced hepatocellular injury and increased protection 
against cell death322.  Anti-inflammatory effects produced by HO-1-dependent autophagy 
signalling have also been demonstrated by a reduction in cytokine production in 
macrophages stimulated by LPS323.   
Conversely, induction of autophagy signalling by HO-1 activity has been demonstrated to 
increase cell death, with activation of mitochondrial autophagy by HO-1 up-regulation 
producing characteristic iron-laden cytoplasmic inclusions in Alzheimer’s and Parkinson’s 
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diseases324.  Limited available evidence suggests that the role of HO-1 in the regulation of 
autophagy is variable and specific to the cell type and stimulus applied.  Both HO-1 
induction and the process of autophagy represent an adaptive cellular response to stress 
with a key aim to restore cellular homeostasis325-327.  Apoptosis and autophagy may share 
a common regulatory pathway and while the two processes can occur simultaneously the 
phenomenon of autophagy only seems to occur in cells that cannot die by conventional 
apoptotic mechanisms328.  The detailed interaction between autophagy and apoptosis 
pathways requires further investigation.   
1.3.3 Heme oxygenase and cancer 
There are a host of molecular mechanisms underlying gastric and oesophageal cancer 
including alterations in growth factors, cytokines and cell adhesion molecules which 
contribute to the activation of complex signalling pathways leading to cell cycle 
modulation.  Abnormalities of oncogenes, tumour suppressor genes and genetic 
instability influence the development of carcinoma.  Understanding of the molecular 
pathways that characterize cell growth, cell cycle kinetics, apoptosis, angiogenesis and 
invasive biology may provide improved novel targets for cancer therapy. 
There is a recognised link between inflammation and carcinogenesis, but the precise role 
of inflammation in tumourigenesis is not fully understood.  Leucocyte infiltration into 
tumour tissue is recognised as a negative prognostic indicator of clinical outcomes329.  
Tumours are infiltrated by many types of leucocytes that have conflicting influences on 
cell proliferation and survival, angiogenesis and tumour migration.  Macrophages can 
promote tumour growth by producing angiogenic factors such as interleukin-8, vascular 
endothelial growth factor (VEGF) and epidermal growth factor (EGF) 330.  Macrophages 
can also promote tumour cell migration by the release of proteolytic enzymes that 
breakdown the extracellular matrix.  At the same time, an important role of macrophages 
is the ability to destroy tumour cells directly by releasing lysosomal enzymes, TNF or 
macrophage-activating factor (MAF)331.  They also function as antigen-presenting cells 
and activate T lymphocytes which release inflammatory cytokines.  These lymphocyte-
derived cytokines are primarily responsible for the anti-tumour effects of leucocyte 
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infiltration into tumour tissue332.  The anti-inflammatory action of heme oxygenase may 
influence tumour progression and could have a potential clinical benefit. 
The reported cytoprotective effects of heme oxygenase activity may be relevant to cancer 
cells.  An increasing body of literature suggests that HO-1 expression and activity may 
modulate tumour induction and influence tumour growth and metastasis. HO-1 activity 
may affect various aspects of tumour progression including cell growth, resistance to 
apoptosis and angiogenesis333.  The level of HO-1 protein expression has been 
demonstrated to be elevated in various tumour tissues including prostate cancer, 
pancreatic cancer, hepatoma, malignant melanoma, glioblastoma and various sub-types 
of adenocarcinoma334-341.  Within the tumour tissues expressing HO-1 the protein can be 
localised to the malignant epithelial cells or found in infiltrating leucocytes, particularly 
macrophages335 340.  Expression of HO-1 has been shown to be up-regulated further by 
anti-cancer therapy as a response to increased oxidative stress334 342.   
The cytoprotective, anti-inflammatory and anti-apoptotic properties of HO-1 activity may 
confer a clinical disadvantage in cancer therapy.  HO-1 has an established role in the 
regulation of cell growth and angiogenesis in studies of inflammation.  Numerous studies 
indicate an important role for HO-1 activity in angiogenesis343-345.  Specific targeted 
knockdown of HO-1 protein in murine fibroblasts and human keratinocytes lowered the 
basal synthesis of VEGF, an important inducer of angiogenesis343.  Angiogenesis in human 
capillary endothelial cells is promoted by carbon monoxide (CO) signalling via an 
increased production of endogenous CO from heme oxygenase enzymatic activity344 346-
348.  
The propensity of tumours to metastasise may be enhanced by the pro-angiogenic 
activity of HO-1349.  Angiogenesis is necessary for the continued growth, invasion, and 
metastasis of cancer cells.  Tumours with a volume greater than 1–2 mm3 require 
expansion of the vasculature to facilitate metastatic spread via the bloodstream350.  HO-1 
activity has been demonstrated to accelerate tumour angiogenesis in a mouse model of 
human pancreatic carcinoma.  Increased expression of human HO-1 protein accelerated 
tumour growth, stimulated the early stages of angiogenesis and increased the occurrence 
of lung metastasis351.  
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Studies in a human colonic adenocarcinoma cell line report an increase in resistance to 
apoptosis after induction of HO-1 protein and increased production of bile pigment 
products bilirubin and biliverdin.  Induction of HO-1 activated Akt signalling and reduced 
the levels of p21 expression causing the modification of the apoptotic protein Bcl-2/Bax 
ratio toward cell survival352.  Increased levels of HO-1 may thereby promote tumour 
resistance to stress in conditions of limited nutrient supply.   
On the other hand, inhibition of HO activity has been shown to improve control of 
angiogenesis and reduce both the growth and spread of certain tumours353 354.  
Administration of the competitive heme oxygenase enzyme inhibitor zinc protoporphyrin 
IX has been demonstrated to suppress cancer cell growth in lung, sarcoma and hepatoma 
cancer models.  Inhibition of total heme oxygenase enzymatic activity by zinc 
protoporphyrin IX significantly reduced tumour growth in a rat model355-358.  Significant 
reductions of tumour growth in vivo have been reported after administration of zinc 
protoporphyrin that causes HO-1 inhibition and reduced production of bile pigment 
products with a consequent impairment in cellular antioxidative function359.   
Targeted knockdown of the HO-1 gene caused reduced HO-1 protein expression leading 
to significant reduction in the growth of pancreatic cancer cells.  Tumour tissues with 
reduced HO-1 expression became significantly more sensitive to anti-cancer radiotherapy 
and chemotherapy334.  Inhibition of heme oxygenase activity may be a useful adjunct in 
anti-cancer chemotherapeutic intervention to prevent the promotion of angiogenesis and 
cancer cell resistance to apoptosis associated with HO-1 activity356 357 360 361. 
Studies of the effects of modification of heme oxygenase activity on cancer cell 
proliferation have produced contradictory results.  Induction of HO-1 enzyme in rat and 
human breast cancer cell lines caused HO-mediated inhibition of a proliferative enzyme 
indoleamine dioxygenase and caused an overall reduction in cell growth362.  Studies in 
human pancreatic cancer cell lines and murine or rodent models of lung cancer, 
hepatoma and Kaposi’s sarcoma have demonstrated an increase in tumour cell 
proliferation associated with activation of HO-1 protein351 363.  Some reports indicate that 
the antioxidant properties of heme oxygenase pathway activation appear to protect 
cancer cells from oxidative damage.  Up-regulation of the HO-1 isoform in particular has 
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been demonstrated when tumour cells are exposed to oxidative stress, hypoxia, serum 
deprivation, or toxic compounds including chemotherapeutic agents334 337 355 357.   
HO-1 is implicated in the biology and pathogenesis of cancer by its effects on cell growth, 
resistance to apoptosis and angiogenesis.  Increased expression or activity of HO-1 has 
been demonstrated to correlate with cellular proliferation in tumour tissues including 
prostate cancer and renal cell carcinoma339 341.  HO-1 expression may represent the 
cellular response to an acute inflammatory precancerous condition.  Initially this may 
serve as a protective mechanism to limit the extent of inflammation and oxidative stress.  
Anti-proliferative effects of HO-1 may limit neoplastic cell proliferation and progression, 
but if neoplastic cells become established the increased HO-1 activity may serve to 
protect the cancerous cells, promoting tumour growth by allowing apoptotic escapes.  CO 
produced at increased levels with HO-1 up-regulation can readily diffuse through cell 
membranes and reduce inflammatory cytokine release from infiltrating leucocytes.  The 
biliverdin/bilirubin system could protect tumour cells from oxidative stress mediators 
generated by activated neutrophils.  Bilirubin and CO production can improve the 
antioxidant capacity of tumour cells, conferring tumour resistance to chemotherapies 
whose effect relies on intracellular oxidative stress333.  HO-1 enzyme is demonstrably up 
regulated when tumour cells are exposed to oxidative stress, hypoxia, serum deprivation, 
or toxic compounds including chemotherapeutic agents337.  This response may contribute 
to tumour chemoresistance.  Cancer cell phenotype may be altered by constitutive 
expression, induction or inhibition of HO-1.  Studies in cultured human gastric cancer cell 
lines demonstrated that up-regulation of HO-1 caused markedly increased expression of 
p21.  Cells with elevated p21 levels were significantly resistant to apoptotic stimuli.  The 
resistance to apoptosis was achieved via a p38 mitogen-activated protein kinase-
dependent pathway, with decreased caspase-3 activity demonstrated364.  Evidence 
supporting a role of the HO-1 system as an endogenous influence on cancer growth is 
further provided by reports of HO inhibitors causing reduced tumour cell proliferation 
and restoration of apoptosis355. 
HO-1 is recognised as an important regulator of cell proliferation and angiogenesis.  
Angiogenesis is required for the sustained growth, invasion and metastasis of tumours.  
Increased HO activity in human endothelial cells promotes prolactin-mediated cell 
60 
 
proliferation and angiogenesis via CO-signalling pathways344 353.  HO-1 has been shown to 
accelerate tumour angiogenesis in human pancreatic cancer351. 
HO-1 enzyme has been investigated as a potential target for chemotherapy with varying 
success.  Increased HO-1 expression is a characteristic feature of only certain tumours, 
with considerable individual variability within one particular cancer.  Up-regulation of HO-
1 enzyme has been shown to inhibit the growth of rat and human breast cancer cell lines 
by inhibiting a pro-proliferative enzyme, indoleamine dioxygenase, to give an overall 
antiproliferative effect362. 
Fang and colleagues demonstrated that inhibition of HO activity by zinc protoporphyrin 
(ZnPP) significantly reduced tumour growth in an orthotopic mouse model of sarcoma.  
Mice were treated with polyethylene glycol-conjugated ZnPP (pegylated zinc, PEG-ZnPP) 
that is water-soluble and accumulates in tumour tissue after intravenous administration.  
The PEG-ZnPP treatment caused tumour-selective suppression of HO activity and 
induction of apoptosis with suppression of implanted sarcoma tumour growth without 
apparent side effects.  In vitro studies using cultured SW480 human colon 
adenocarcinoma that express HO-1 showed an increase in apoptotic death via induced 
oxidative stress in cells treated with pegylated zinc protoporphyrin356-358.   
Increased expression of HO-1 mRNA and HO-1 protein has been demonstrated in human 
pancreatic cancer as compared to normal pancreatic tissue334.  HO-1-mediated effects on 
angiogenesis, tumour progression and metastasis have been studied by HO-1 gene 
manipulation in mouse models of pancreatic adenocarcinoma.  Up-regulation of HO-1 
protein caused an increase in tumour growth with accelerated angiogenesis and 
increased occurrence of lung metastasis, whereas inhibition of HO activity with tin 
mesoporphyrin (SnMP) had beneficial limiting effects on both tumour growth and 
metastasis351.  Targeted knockdown of HO-1 protein mediated by short interfering RNA 
transfection caused a significantly reduced proliferation rate in cultured pancreatic cancer 
cell lines, with a demonstrated reduction in bilirubin levels in transfected cells.  Cell lines 
with an inhibited HO-1 activity were significantly sensitised to treatment with both 
gemcitabine chemotherapy and γ-radiation (20 Gy)334.   
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A study reported by Busserolles et al showed anti-apoptotic effects of HO-1 in the human 
colon adenocarcinoma cell line Caco-2, with HO-1 induction resulting in resistance to 
apoptosis mediated by formation of biliverdin and bilirubin and activation of the protein 
kinase Akt pathway352.  Several studies of the human lung adenocarcinoma cell line A549 
have described the cytoprotective effect of HO-1 expression.  Constitutive over-
expression of HO-1 and its associated transcription factor Nrf2 may be primarily 
responsible for enhancing chemoresistance in these cells.  Silencing of the basal HO-1 
gene caused significantly increased up-regulation of the proapoptotic tumour suppressor 
p53 and its downstream p21 and Bax, thereby increasing cellular vulnerability to 
apoptosis365.   
There is limited knowledge of the role of HO-1 in tumour-associated inflammation.  
Studies of murine melanoma show that HO-1 overexpression inhibits inflammation and 
reduces the leucocytic tumour infiltrate.  In tumour-bearing mice with subcutaneous 
growing melanomas, reduced neutrophil activation improved the angiogenic potential of 
tumour cells.  HO-1 induction increased tumour cell viability and proliferation and 
decreased survival in affected mice.   Mice bearing melanoma cells with a high level of 
HO-1 had lower concentrations of tumour necrosis factor (TNF) and higher levels of 
soluble TNF-receptor-1 in the blood and tumour tissues, reducing TNF availability which 
could contribute to the observed inhibition of the inflammatory response and promote 
tumour angiogenesis366. 
The expression of HO-1 protein in gastrointestinal cancers is not well studied with one 
published report to date investigating HO-1 expression in ex-vivo samples of human 
colorectal cancer and colonic adenoma367.  HO-1 expression was demonstrable in 41.8% 
(23/55) of patients with colorectal cancer and in 36.8% (7/19) of colonic adenoma 
samples.  There was a significantly reduced rate of lymphatic tumour invasion, fewer 
lymph node metastases and a significantly improved overall survival in colorectal cancer 
patients with tumours expressing HO-1 protein367.  These findings suggest an overall 
beneficial anti-cancer effect of HO activity that may be mediated via anti-angiogenic and 
anti-proliferative pathways.  Consistent and definitive effects of heme oxygenase enzyme 
are yet to be established in studies of cancer cell biology and clinical outcomes. 
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Up-regulation of HO-1 enzyme has been demonstrated in human colorectal cancer cells 
after treatment with chemotherapeutic agents and may be induced in response to 
radiotherapy and photodynamic therapy350 368.  The cytoprotective effects of HO activity 
may be mediated via decreased levels of free intracellular pro-oxidant heme and 
increased levels of antioxidant bilirubin and carbon monoxide355.   
A dominant role for HO enzyme in the context of malignancy is yet to be established, with 
variable effects on apoptosis, angiogenesis and tumour progression reported in published 
studies to date.  The properties of HO activity have implications for tumour proliferation 
and cell death, differentiation, angiogenesis and metastasis and tumour-related 
inflammation.   
Increased HO-1 activity has been shown to confer resistance to apoptosis in human 
gastric cancer cells.  The anti-apoptotic effects were independent of p53 expression and 
mediated via p38 MAP kinase pathways to cause reduced caspase-3 activation364.  
Inhibition of HO-1 activity by a flavonoid Vitex fruit extract caused an increase in 
apoptosis in cultured gastric signet ring adenocarcinoma cells369.  By contrast, treating 
cells derived from human colonic adenocarcinoma with the flavonoid Vitex fruit extract 
caused induction of HO-1 enzyme and was associated with an increase in cellular 
apoptosis368.  Induction of HO-1 enzyme in alternative human colonic cancer cell lines 
(Caco-2) resulted in increased cell resistance to apoptosis with effects mediated via Akt 
signalling pathways and independent of p38 expression352 370.  Treatment with a potent 
competitive heme oxygenase inhibitor (pegylated zinc protoporphyrin) caused induction 
of apoptosis in human colon carcinoma SW480 cells when administered in vitro and 
reduced the growth of murine colon carcinoma in vivo357.   
Angiogenesis is a critical feature of cancer biology for tumour growth and metastasis.  The 
pro-angiogenic properties of heme oxygenase enzyme may thereby facilitate tumour 
progression333 371.  Vascular endothelial growth factor (VEGF) has been shown to induce 
prolonged HO-1 expression and increased enzymatic activity in human endothelial cells.  
Angiogenesis driven by VEGF activity was prevented by inhibition of HO-1 protein349. 
Overexpression of HO-1 protein is associated with an increased occurrence of metastasis 
in pancreatic cancer cells and melanoma cells with effective prevention of metastasis 
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achievable via inhibition of HO activity351 366.  Studies in a mouse model of colonic 
carcinoma found conflicting evidence of HO-1-related effects with no effect on lung 
metastases and an increased frequency of liver metastases associated with inhibition of 
HO enzyme by zinc deuteroporphyrin372.  Ex-vivo samples of colonic adenocarcinoma that 
expressed HO-1 protein demonstrated a significantly lower rate of lymphatic invasion367. 
The overall influence of the HO enzyme pathway on the growth, invasion and metastatic 
potential of malignant cells may depend on the specific type of cancer or other 
contributory factors yet to be defined.   
1.3.4 HO gene promoter polymorphism 
HO-1 deficiency is extremely rare within the human population but the level of HO-1 
expression can be variable due to the polymorphism associated with the promoter of the 
HMOX1 gene.  HO-1 generation is chiefly regulated at the transcriptional level and the 
length of the GT repeat in the HO-1 promoter is a much more common determinant of 
the variation of HO-1 activity in humans373.  The human HO-1 gene promoter contains a 
stretch of microsatellite DNA with GT repeats ranging from 11 to 40 located within the 
regulatory sequence approximately 250 base-pairs upstream of the transcription 
initiation site374.  Published studies indicate that longer (GT)n sequences are associated 
with a reduction in HO-1 protein expression374-379.  
It is thought that shorter GT repeats have higher HO-1 transcriptional activity and 
expression compared with longer GT repeats.  A recent study showed that variations in 
HO-1 expression and activity modulated by the number of GT repeats influenced various 
functions in human endothelial cells.  The endothelial cells with short dinucleotide 
sequences (n <25) displayed a phenotype with a beneficial intracellular glutathione ratio, 
increased resistance to oxidative stress, reduced synthesis of pro-inflammatory cytokines 
and enhanced proliferation in response to VEGF treatment375.   
Allelic variants of the HO-1 gene promoter may affect HO-1 protein expression and 
enzymatic activity especially in response to oxidative stress.  The variability in HO-1 
activity mediated by HMOX1 gene promoter polymorphism may be of clinical relevance 
with some studies suggesting a protective role against atherosclerosis of short, more 
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active alleles of the HMOX1 promoter251.  Short (GT)n repeats have been shown to be 
associated with low levels of inflammatory markers while long dinucleotide repeats were 
associated with increased lipid peroxidation in serum378 380 381.  
A protective role of HO-1 in cardiovascular disease is supported by several human studies 
demonstrating an association between shorter (GT)n repeats and a reduced risk of 
coronary artery disease and myocardial ischaemia382 383.  Some studies show that longer 
GT repeats are associated with a significantly higher risk of developing restenosis after 
coronary stenting377 whereas other studies have failed to find an association between GT 
repeat length and either coronary restenosis or CAD384 385.   
Studies examining the relationship between the genotype of (GT)n sequences and graft 
survival after renal and heart transplantation are contradictory.  Reported studies indicate 
that transplanted organs with short (GT)n repeats survive better and are less susceptible 
to tissue injury386 387.  These findings are not universal, however, with a recent study 
demonstrating no influence of HMOX1 genotype and the presence of (GT)n sequences on 
kidney survival after transplantation, although a significant effect was observed when 
comparing normal and impaired graft function388 389.  The significance of (GT)n 
polymorphism may be related to patient ethnicity or other individual factors or may be 
relevant only in specific clinical conditions.   
Although HO-1 may facilitate the progression of established tumours it may also protect 
against potential carcinogens and reduce the probability of tumour initiation.  Variation of 
HO-1 activity associated with the HMOX1 gene promoter polymorphism may contribute 
to cancer risk in individuals.  Patients with a lower level of HO-1 activity due to a relative 
lack of short (GT)n sequences but an increased proportion of longer (GT)n sequences are 
considered to be at an increased risk of tumour development333 390.  Published studies 
indicate that longer (GT)n sequences in the HO-1 gene promoter region are associated 
with a lower HMOX-1 transcriptional activity and a reduction in HO-1 protein 
expression374-379.  If one accepts that the dominant role of HO-1 activity in malignancy is 
to protect against carcinogenesis and tumour progression then it is feasible to consider 
individuals with a lower HO-1 transcriptional activity to be more susceptible to 
malignancy.   
65 
 
The dual effect of HO-1 on protection against carcinogenesis and promotion in different 
stages of tumour progression may indeed be related to HO-1 genetic polymorphism.  
Humans differ quantitatively in their ability to mount an HO-1 response, modulated by 
functional microsatellite polymorphisms in the HO-1 gene promoter region.  The human 
HO-1 gene has been mapped to chromosome 22q12, and a (GT)n  dinucleotide repeat has 
been identified as a functional polymorphism in the proximal promoter region, 
modulating the transcriptional activity of the gene.  The length of the (GT) repeat can be 
classified into short, medium and long component alleles.  Short (<25 GT) repeats are 
associated with an increased HO-1 up-regulation after stimulation, and longer (GT)n 
repeats have been shown to exhibit lower HO-1 transcriptional activity.  Association of 
the HO-1 promoter polymorphisms has been evaluated in pulmonary disease (including 
the development of lung adenocarcinoma), cardiovascular disease, renal transplantation, 
recurrent miscarriage, and neurological disorders including Alzheimer’s and Parkinson’s 
disease374.  Long (GT)n repeats are associated with increased severity of cardiovascular 
and pulmonary inflammatory disorders suggesting important clinical roles for HO-1 
expression as an anti-inflammatory mediator. 
A recent study reported that the homozygous short allele with <25 (GT)n repeats was 
found more frequently in patients with malignant melanoma when compared to a healthy 
control population.  In addition, the short (GT)n genotype was significantly associated 
with a deeper Breslow thickness of primary tumours as compared to L-allele (>25 repeats) 
carriers391.  It is possible that increased HO-1 expression confers resistance to apoptosis 
during the initial malignant transformation of malignant melanoma, allowing further 
subsequent mutations during disease progression that promote proliferation, invasion, 
and tumour cell migration. 
By contrast, a recent study in gastric cancer suggests a higher frequency of gastric 
adenocarcinoma associated with the long (GT)n repeat HO-1 gene promoter 
polymorphism, with a lower frequency of lymphovascular invasion of gastric tumours 
associated with the medium (GT)n repeat allele392.  A study in a Japanese population 
found that the long (GT)n repeat in the HO-1 gene promoter may also be associated with 
the development of lung adenocarcinoma (but not squamous carcinoma) amongst male 
smokers393.  These polymorphisms reduce HO-1 protein expression, suggesting a 
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protective influence of HO-1 in preventing gastric and lung cancer.  This supports an anti-
inflammatory, anti-tumour role of HO-1 in carcinogenesis rather than a tumour-protective 
mechanism facilitating disease progression. 
The presence of a long HMOX1 allele is recognized to be related to the increased risk of 
oral squamous cell carcinoma in patients chewing areca nuts394.  The risk of developing 
lung cancer amongst male smokers has been shown to be increased for the long allele 
HMOX1 genotype when compared to a non-long allele genotype393.  The incidence of long 
(GT)n repeats was increased in a group of patients with lung adenocarcinoma when 
compared to a control group.  This positive correlation is not demonstrated in other 
tumours, with a microsatellite polymorphism promoter associated with a modification in 
the relative risk for malignant melanoma391.  HMOX1 genotypes of short (GT)n sequences 
were found to be more frequent in patients with malignant melanoma tumours 
compared to healthy subjects.  There was a higher risk for malignant melanoma with 
higher levels of HO-1 protein and a higher likelihood of drug resistance with an increased 
tendency for the melanoma to be resistant to apoptosis391.   
Lymphoblastoid cell lines from patients with short allele (GT)n repeats (less than 27) have 
been found to display more resistance to oxidant-induced apoptosis than those cells 
obtained from patients with longer (GT)n repeats (more than 33) and therefore reduced 
HO-1 expression395.  This finding concurs with the observed effects of HO-1 activity on 
development of malignant melanoma in an animal model.  The viability, proliferation and 
angiogenic potential of malignant melanoma cells were increased by overexpression of 
HO-1 protein with increased metastasis and decreased survival in tumour-bearing 
mice366.  Increased activity of HO-1 enzyme was associated with a detrimental outcome in 
this murine model of melanoma.  Therefore the association of the HMOX1 promoter 
polymorphism with an increased risk of cancer development appears to be dependent 
upon the specific tumour type.   
Recent studies of the relationship between the HO-1 gene promoter polymorphism and 
the risk of gastric cancer suggest that the long (GT)n repeat HMOX1 genotype is 
associated with a higher incidence of gastric adenocarcinoma.  The medium (GT)n repeat 
genotype may confer some protection against gastric adenocarcinoma with a reduced 
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frequency of lymphovascular tumour invasion396 397.  Similar studies in gastrointestinal 
stromal tumours (GIST) indicate a significant association between the short (GT)n HMOX1 
allele and the incidence of high-risk tumours, higher tumour recurrence rates and 
metastatic spread.  A significantly reduced disease-free survival and overall survival was 
observed in patients with GIST tumours carrying the short (GT)n HMOX1 allele398.   
The focus of published studies to date has suggested a role for HO-1 enzyme in cancer 
regulation.  HO-1 expression is a characteristic feature of only certain types of cancer, and 
the anti-tumour activity of experimental HO inhibitors may be limited to cancer cells that 
constitutively over-express HO-1.  In the studies by Ding and colleagues399 400 of the 
expression profiles of HO isoforms in eight human cancer cell lines, HO-1 mRNA and 
protein was detected in five cell types.  By contrast, HO-2 mRNA and protein was evident 
in all eight cell lines.  In an immunohistochemical study of biopsy specimens from patients 
with oesophageal squamous cell carcinoma, HO-1 expression was detected in 7 out of 13 
patients.  There was no correlation between HO-1 expression and tumour size, stage or 
histological grade.  The presence of HO-1 expression did however predict tumour 
sensitivity to radiotherapy treatment in this small clinical sample401.   
Constitutively expressed HO-2 may also play important roles in cancer cell proliferation.  
The potential benefits of HO inhibitors may also be applicable to cells lacking HO-1 
expression.  Tonic HO-2 activity is increasingly recognised to be important for cellular 
function presumably via basal heme breakdown and generation of HO enzyme products.  
HO-1 enzyme may provide an additional dynamic level of HO activity as an appropriate 
response to stressful situations.   
1.3.5 The role of the HO pathway in cancer cell biology 
The process of carcinogenesis requires eight hallmark capabilities and two facilitating 
characteristics to establish complete tumour formation and progression.  The initial eight 
capabilities include the maintenance of proliferative signalling, evasion of growth 
suppressors, favourable reprogramming of energy metabolism, cell death resistance, 
promotion of replicative immortality, evasion from immune destruction, induction of 
angiogenesis and activation of cell invasion and metastasis.  The accompanying 
characteristics that facilitate the process are genome instability and inflammation402 403.  
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There is various published evidence supporting an association of HO-1 activity with the 
majority of these features333 350.  The cytoprotective properties of HO-1 activity could tip 
the endogenous balance between apoptosis and proliferation towards an anti-apoptotic 
and pro-proliferative state404.   
The overall effects in the context of neoplasia are especially relevant to oncogenesis, 
maintenance of malignant cell growth, resistance to apoptosis and resistance to 
chemotherapy.  Various reports suggest that over-expression of HO-1 protein in some 
human cancers provides an important contribution to resistance to chemotherapeutic 
agents including cisplatin, doxorubicin and gemcitabine405-407.  A potential role for HO 
activity in carcinogenesis has been suggested by clinical studies of the HO-1 gene 
promoter polymorphism.  The presence of less active HMOX1 allelic variants correlates 
with an increased incidence of lung cancer in smokers and of squamous cell carcinoma in 
areca nut chewers393 394 408.   
These findings indicate a possible protective role for HO-1 activity in the induction of 
neoplasia.  To date, only one study has investigated this possibility under controlled 
experimental conditions examining the effect of HO-1 on the induction of squamous cell 
carcinoma in mice exposed to a two-step model of chemical carcinogenesis409.  Topical 
application of 7,12-Dimethylbenz[a]anthracene (DMBA) followed by phorbol 12-myristate 
13-acetate (PMA) was used as a chemical carcinogenesis model in mice of different HO-1 
genotypes.  Treatment of mice with DMBA and PMA led to the development of skin 
lesions resembling papilloma with gradual progression to squamous cell carcinoma.  
Measurement of cytoprotective genes in treated mouse livers demonstrated evidence of 
systemic oxidative stress in all HO-1 genotype mice.   
The first carcinogen-induced skin lesions appeared 2 weeks earlier in HO-1−/− and HO-1+/− 
genotype mice than in their wild-type counterparts.  The tumours contained significantly 
higher local concentrations of vascular endothelial growth factor and lower levels of 
tumour necrosis factor-α.  The volume of nodules in the wild-type subjects increased at a 
much slower rate than tumours in the other genotype mice and remained small even at 
the last week of experiments.  In HO-1+/− mice there were low levels of HO-1 expression 
that produced more numerous but relatively small skin nodules.  In HO-1 knockout mice 
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(HO-1−/−) the absence of HO-1 activity led to the development of fewer often solitary 
tumours of increased volume that grew much larger than in the other experimental 
groups.  Histopathological analysis of tumour specimens demonstrated that the large 
lesions on HO-1−/− mice displayed features of benign papilloma.  By contrast, even low 
levels of HO-1 in HO-1+/− animals generated skin lesions with a higher grade of 
malignancy.  Significantly more tumours displayed dysplastic features and progressed to 
invasive carcinoma in genotypes expressing HO-1 protein.  Foci of dysplasia or typical 
features of infiltrating squamous cell carcinoma were found in 8 out of 9 HO-1+/− subjects 
and in all 10 HO-1+/+ individuals.  The large tumours developed by HO-1−/− mice remained 
benign papillomas409.   
The complete absence of HO-1 expression in HO-1−/− mice was associated with the 
highest mortality and the smallest body weight gain over the experimental time course.  
Overall survival rate at the end of the experiment was 82% in HO-1+/+ mice, 69.2% in HO-
1+/− animals and only 41.7% in HO-1−/− individuals409.  These findings indicate a level of 
protection against DMBA/PMA-induced skin injury and development of lesions associated 
with HO-1 expression but an increase in the malignant transformation of already growing 
tumours exposed to continued HO-1 activity.  Healthy tissues may thus be protected 
against carcinogen-induced injury by HO-1 activity whereas malignant progression of 
established tumours is facilitated by HO-1 expression.  It is not clear what mechanisms 
are responsible for the apparent facilitation of clonal promotion despite the protection 
against carcinogenesis associated with HO-1 activity.  A deficiency of HO-1 protein may 
result in an increased apoptotic rate of affected cells exposed to carcinogens and thereby 
lead to a reduced rate of cancer initiation.  Once the affected cells have transformed into 
malignant cells the reduced HO-1 activity may facilitate cell proliferation.  The variable 
effects of HO-1 activity observed in cancer studies reflect the tissue-specific influence of 
HO-1 on the cell cycle333 390.  
Tauber and colleagues recently performed a transcriptome analysis of potential target 
genes associated with HO-1 expression in human cancers410.  They first undertook 
genome-wide expression profiling of HO-1 expressing versus HO-1 silenced human 
choriocarcinoma cells to identify putative target genes of HO-1 protein.  A subsequent 
comparative meta-profiling of a pre-existing expression database was performed to 
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include gene expression analysis of 190 individual tumours from 14 types of human 
cancer.  This research led to the identification of 14 genes whose expression correlated 
strongly and universally with that of HO-1 protein from choriocarcinoma cells.  The genes 
identified to be up-regulated downstream of HO-1 protein included moderators of cell 
adhesion, signalling and transport and other critical functions of malignant cells410.  The 
overall findings demonstrated a distinct molecular signature identifiable in malignant cells 
that was determined by HO-1 expression and promoted tumour cell growth and 
metastatic spread.   
Recent published studies have examined the expression of HO-1 in human head and neck 
squamous cell carcinoma and its correlation with clinical and pathological features411-414.  
A recent study by Gandini and co-workers investigated the expression of HO-1 using 
immunohistochemistry in tissue microarrays in a large collection of human primary head 
and neck squamous cell carcinomas with correlation to clinical parameters415.  Real-time 
quantitative PCR was performed on selected oral tissue tumour samples to further 
validate HO-1 expression.  Results indicated a significantly increased HO-1 expression in 
tumour tissues as compared to healthy samples.  Localisation of HO-1 protein to the cell 
nucleus was associated with malignant progression in human and murine models of 
squamous cell carcinoma415. 
A body of evidence suggests that HO-1 activity exerts potent and comprehensive pro-
tumour effects in established tumours.  Up-regulation of HO-1 improves the survival of 
various cancer cell lines exposed to stressful stimuli both in vitro and in vivo337 352 358 361 364 
366 416 417.  Overexpression of HO-1 protein in murine and human melanoma models 
caused an increase in cell proliferation366.  Knockdown of HO-1 protein mediated via 
siRNA transfection was associated with a statistically significant inhibition of cell growth 
in human pancreatic cancer cell studies334.  The effects of altered HO-1 expression on cell 
proliferation appear to be markedly dependent upon the cell type.  Down-regulation of 
HO-1 protein inhibits the growth of pancreatic carcinoma cell lines whereas up-regulation 
of HO-1 significantly increased the proliferation of human melanoma cells.  Alternatively 
increased HO-1 activity was associated with significant anti-proliferative responses in 
human and rodent breast cancer cell lines362.   
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Promotion of angiogenesis and tumour metastasis due to increased HO-1 activity has 
been demonstrated in various human and animal models340 361 363 366 418.  Up-regulation of 
vascular endothelial growth factor (VEGF) is promoted by HO-1 in many in vitro cultured 
cell types251.  Increased VEGF activity can mediate the pro-angiogenic activities of HO-1 in 
selected cancers and promote tumour growth and metastasis340 351 366 418. 
Pharmacological inhibition or genetically-mediated knockdown of enzyme activity 
resulted in reduced cell proliferation in studies of malignant mast cells, hepatocellular 
carcinoma, prostate carcinoma and urothelial cancer cell lines419-422.  Conversely an 
antiproliferative effect of HO-1 activity has been demonstrated in experimental models of 
prostate cancer, lung adenocarcinoma and breast cancer.  Treatment with the HO 
inhibitor tin protoporphyrin IX (SnPP IX) caused a reversal in the growth arrest observed 
in human lung adenocarcinoma cells that overexpressed HO-1 protein279.  A small but 
significant increase in the proliferation of rat and human breast cancer cell lines was 
observed after administration of SnPP IX whereas HO-1 induction with heme substrate or 
cobalt protoporphyrin IX resulted in a marked reduction of cell growth362.  Prostate 
carcinoma cells that overexpressed HO-1 protein either constitutively or in response to 
hemin treatment displayed a significant decrease in cell proliferation423.   
The majority of in vivo studies report a permissive role of HO-1 activity in tumour growth 
with increased cell proliferation evident in the larger volumes of nodules or increased 
numbers of cancer cells observed363 366.  Reduced expression of HO-1 enzyme caused 
inhibition of cancer cell growth in hepatocellular carcinoma, lung adenocarcinoma, 
pancreatic cancer, sarcoma, angioma and selected prostate cancer cell lines334 337 351 361 363 
419 422.  Experiments performed in various tumour cell lines including colonic 
adenocarcinoma, gastric adenocarcinoma, malignant melanoma and thyroid carcinoma 
indicate that HO-1 plays an important cytoprotective and anti-apoptotic role in the 
response of cancer cells to various therapeutic strategies with an overall improvement in 
cancer cell survival342 352 358 364 416.   
Under certain conditions up-regulation of HO-1 protein can promote the accumulation of 
ROS within the mitochondria and other intracellular compartments419.  Induction of HO-1 
enzyme does not consistently protect cancer cells from oxidative damage.  Up-regulation 
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of HO-1 in breast carcinoma cells did not prevent an increase in apoptosis induced by 
chemotherapeutic agents424.  Over-expression of HO-1 protein in some experiments 
compounded mitochondrial oxidative damage and generated increased apoptosis in 
breast cancer cells and vascular smooth muscle cells424 425.   
Heme oxygenase activity can facilitate angiogenesis and thereby promote the growth of 
primary and secondary tumours.  Tumour progression may be further supported by HO-1 
activity via moderation of inflammatory cell function and suppression of the immune 
response350.  A significantly increased frequency of metastatic lung nodules was observed 
in mice with melanoma or pancreatic cancer cells engineered to over-express HO-1 
protein as compared to their wild-type counterparts.  Pharmacological inhibition of HO 
activity achieved complete prevention of lung metastasis351 366.  Over-expression of HO-1 
caused a significant reduction in cell proliferation and migration observed in prostate 
cancer cells, with a corresponding increase in cell growth and invasion after small 
interfering RNA-mediated silencing of HO-1 expression423.   
Inhibition of HO enzymatic activity via knockdown of HO-1 mRNA in human prostate 
carcinoma cells decreased activation of the p38-mitogen-activated protein kinase / 
extracellular signal-regulated kinase pathway with reduced cellular oxidative stress 
observed.  Cells displayed concurrent reductions in cell proliferation, invasion and cell 
viability in vitro.  Equivalent in vivo mouse experiments produced marked inhibition of 
primary prostate tumour growth and fewer lymph node and lung metastases419. 
An increased level of HO-1 expression has been shown to be associated with a higher 
frequency of lymph node metastases in patients with oral squamous cell carcinoma due 
to chewing areca nut and betel leaves412.  A recent study reported alternative findings 
with reduced levels of HO-1 expression in squamous cell carcinoma of the tongue and a 
correlation of low HO-1 expression levels with increased frequency of cervical lymph node 
metastases414. 
The majority of investigations indicate a marked increase in HO-1 protein expression in a 
variety of tumours, particularly in response to anticancer therapy such as chemotherapy, 
radiotherapy or photodynamic therapy.  The mechanism of HO-1 up-regulation may serve 
to protect cancer cells against therapeutic interventions.  Increased HO-1 expression in 
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pancreatic cancer cell lines was associated with increased chemoresistance to 
gemcitabine407.  A significantly shorter recovery from photodynamic therapy was 
observed in a mouse model of adenocarcinoma with tumours that up-regulated HO-1 
expression342. 
1.3.6 Heme oxygenase and anti-cancer therapy  
Pharmacological inhibition of enzymatic HO activity has been investigated as a novel 
therapeutic strategy with the potential to increase tumour sensitivity to chemotherapy, 
radiotherapy or photodynamic therapy in a range of cancers including urothelial cancer, 
lung carcinoma, melanoma, chronic myeloid leukaemia, hepatoma, pancreatic cancer and 
colonic adenocarcinoma334 342 366 420 421 426 427.  Administration of the potent HO inhibitor 
zinc protoporphyrin IX has been able to reduce tumour growth in murine models of 
hepatoma, sarcoma, B-cell lymphoma and lung carcinoma337 356 359 361 427.  Furthermore, 
administration of pegylated zinc protoporphyrin IX to mice with chronic myeloid 
leukaemia enabled the cancer cells to overcome chemoresistance to imatinib therapy417. 
A major drawback to interpreting the results using pharmacological HO inhibitors and 
exploiting their therapeutic potential is the exertion of significant HO-independent effects 
associated with these molecules345 428.  Zinc protoporphyrin IX can be demonstrated to 
reduce tumour blood flow in rat models and cause an accumulation of ROS in sarcoma, 
colonic carcinoma and lung cancer models355-357 360 429-432.  Reported HO-1-independent 
effects mediated by protoporphyrin HO inhibitors include the reduction of cyclin-D1 
expression in colonic adenocarcinoma with consequent inhibition of cell proliferation and 
increases in cellular apoptosis427 431.   
A more specific approach to modulation of the HO pathway involves the targeted 
knockdown of the HMOX1 gene achieved by siRNA transfection.  This approach has been 
shown to cause reduced cell proliferation and inhibit tumour growth and angiogenesis in 
orthotopic hepatocellular tumours with induction of apoptosis demonstrable in cultured 
colonic adenocarcinoma and leukaemia cells352 356 422 433 434.  Knockdown of HO-1 mRNA in 
human prostate carcinoma cells reduced cell proliferation, invasion and cell viability in 
vitro and growth inhibition of both primary and secondary prostate tumours in vivo419.  
Reduced HO activity mediated by siRNA HMOX1 knockdown increased apoptosis and 
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enabled the chemosensitisation of lung cancer cells toward cisplatin therapy405 432.  
Similarly, siRNA-mediated HO-1 gene silencing was able to potentiate the anticancer 
effectiveness of gemcitabine chemotherapy or γ-radiation against pancreatic 
carcinoma334.   
Pharmacological inhibition of enzymatic HO activity or siRNA-mediated HO-1 knockdown 
has the ability to increase the chemosensitivity of cells in pancreatic and lung carcinoma 
and acute myeloid leukaemia405 407 435.  Not all experiments produce consistent results.  
HO inhibition by zinc protoporphyrin IX was unable to potentiate the antitumour effects 
of 5-fluorouracil, cisplatin or doxorubicin chemotherapy in three different tumour models 
including orthotopic in vivo melanoma431.  The detailed mechanism of chemosensitisation 
associated with suppression of HO-1 activity is yet to be fully elucidated.  Pharmacological 
inhibition of HO-1 by zinc protoporphyrin has been shown to produce significant 
increases in the formation of ROS334 362 431.   
Recent studies of possible chemoresistance include the exposure of human hepatocellular 
carcinoma (HepG2) cells to the environmental pollutant crotonaldehyde436.  
Crotonaldehyde is a highly reactive aldehyde that occurs naturally in many foods and can 
be generated from lipid peroxidation437 438.  High levels of crotonaldehyde have been 
measured in cigarette smoke439.  
Treating HepG2 cells with crotonaldehyde caused a significant increase in the nuclear 
translocation of Nuclear factor erythroid 2-related factor 2 (Nrf2) and induced expression 
of HO-1 protein via p38 MAPK-Nrf2 pathways.  The overall observed effect was a 
reduction in apoptosis.  Inhibition of HO activity by zinc protoporphyrin IX or HO-1 
knockdown via siRNA transfection produced an increase in the G0/G1 phase of the cell 
cycle in crotonaldehyde-stimulated HepG2 cells436.  These studies provide a mechanism 
by which induction of HO-1 expression may promote tumour resistance to oxidative 
stress and a survival advantage for carcinoma cells when exposed to environmental 
pollutants.   
Kongpetch and colleagues recently investigated the role of HO-1 enzyme in 
cytoprotection against gemcitabine and doxorubicin chemotherapeutic agents in human 
cholangiocarcinoma (CCA) cell lines440.  Cell lines were treated with gemcitabine (0.001 – 
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0.1 mM) in the presence of zinc protoporphyrin (0.01 and 0.1 mM) for 24 hours.  A clear 
downward shift in the dose-response curves of both gemcitabine and doxorubicin was 
observed in the presence of pharmacological HO inhibition with zinc protoporphyrin (zinc 
PP).  Cell lines became highly susceptible to cytotoxic effects of chemotherapy with 
significantly increased inhibition of cell growth and induction of apoptosis after co-
incubation with either doxorubicin or gemcitabine and zinc PP.  A slight cytotoxicity was 
inherent in the effects of zinc PP alone at the concentrations used in these experiments.   
The generation of reactive oxygen species (ROS) was shown to be essential for the 
observed chemosensitisation effect as scavenging of ROS effectively prevented any 
sensitisation with zinc PP treatment.  Inhibition of HO-1 activity may increase cellular 
oxidative stress and produce ROS derived from cell metabolism201 404.   
Co-incubation of cells with gemcitabine and zinc PP caused a significantly increased 
induction of p21Cip/WAF1 protein which is a p53-dependent downstream gene product 
and a potent cyclin-dependent kinase inhibitor up-regulated by mitochondrial 
dysfunction441.  Treating cells with gemcitabine or zinc PP alone did not produce any 
significant changes in the levels of p21 protein440.  A reduction in active HO-1 protein 
levels by specific siRNA-mediated knockdown of HO-1 mRNA exerted a similar sensitising 
effect with transfected cholangiocarcinoma cells rendered highly susceptible to 
gemcitabine cytotoxicity440.  Induction of HO-1 protein by tin (II) chloride (SnCl2) was 
associated with a 2-fold increase in cholangiocarcinoma cell viability and reduced 
apoptotic and necrotic cell death after gemcitabine or doxorubicin treatment.  The drug 
resistant effects of HO-1 induction by SnCl2 were observed regardless of the basal HO-1 
expression levels in the cell lines studied440.   
These studies indicate that HO-1 plays a substantial role in the resistance of human 
cholangiocarcinoma cells to chemotherapeutic agents regardless of constitutive levels of 
HO-1 protein expression.  Treatment with anticancer agents caused a marked up-
regulation of HO-1 protein in cells with very low basal levels of HO-1 expression 
suggesting an adaptive cellular response to chemotherapy-induced stress.   
Therapeutic inhibition of HO-1 enzyme is able to overcome intrinsic resistance to 
chemotherapy in cancer cells that constitutively over-express HO-1 and also the acquired 
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resistance to anticancer agents in tumours that rapidly up-regulate HO-1 protein in 
response to treatment.   
Inhibition of HO activity either as an independent therapeutic approach or as a chemo or 
radio-sensitisation strategy should ideally be specifically targeted to the cancer cells given 
that HO activity can exert beneficial effects and protect healthy tissues against 
carcinogenesis350.   
1.3.7 Mechanisms of heme oxygenase activity in cancer 
The precise cellular mechanisms responsible for producing the cytoprotective effects of 
HO-1 activity observed in tumour cells are yet to be elucidated.  One potentially 
important pathway is the reduction of intracellular levels of free heme, a pro-oxidant and 
substantial mediator of signal transduction124.  Heme can be released from heme proteins 
and may directly catalyse free radical reactions together with the released Fe2+ via the 
Fenton reaction and can interact with nitric oxide to enhance heme uptake442.  Heme 
induces neutrophil activation and increases the expression of endothelial cell adhesion 
molecules causing the subsequent initiation of robust inflammatory reactions443-445.  
Heme-binding proteins including albumin and haptoglobin block the cellular uptake of 
heme and prevent the resulting increase in cellular susceptibility to oxidative damage156 
446 447.  Although free heme can be harmful to cells it can simultaneously directly regulate 
the activity of Nrf2 and Bach1 transcription factors448 449.  Heme rapidly induces the 
expression not only of HO-1 protein but also a selection of genes with cytoprotective and 
detoxifying activity450 451.   
There is evidence for the importance of the Nrf2 transcription factor in the cytoprotective 
activity of HO-1 enzyme433 452.  Up-regulation of HO-1 and the resultant cytoprotection 
was mediated by Nrf2 signalling in neuronal cells exposed to nitric oxide and in 
monocytes treated with epigallocatechin 3-gallate, a polyphenol compound with anti-
carcinogenic properties found in green tea365 453 454.  Induction of HO-1 and prevention of 
oxidative damage in response to nitric oxide exposure was dependent upon Nrf2 
signalling activity in colonic carcinoma cells451.  Nrf2 is an upstream transcription factor 
causing HO-1 induction and can also be up-regulated in response to increased HO-1 
activity creating a positive feedback loop to promote HO-1-mediated cytoprotection455. 
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The major source of endogenous carbon monoxide (CO) in mammalian cells is provided 
via the enzymatic degradation of heme.  CO is recognised as a gaseous mediator that 
plays important roles in neurotransmission and vascular smooth muscle relaxation.  CO 
derived from HO-1 activity produces vasodilatation via a cyclic-GMP-dependent pathway 
and via cyclic-GMP-independent activation of voltage-gated potassium channels456.  
Inhibition of platelet aggregation, reduced leucocyte adhesion, and decreased endothelial 
cell apoptosis is mediated by CO via induction of soluble guanylyl cyclase (sGC)326 457.  
Increased activation of both sGC and p38-MAP-kinase signalling pathways mediated by 
HO-1-derived CO can produce cytoprotective and anti-inflammatory responses268 358 458.  
Increased CO levels are associated with a decreased production of pro-inflammatory 
cytokines such as tumour necrosis factor (TNF) and interleukin-1β (IL-1β) with the 
concomitant up-regulation of anti-inflammatory cytokine IL-10249.  CO has been 
demonstrated both to inhibit the release of mitochondrial cytochrome c (thereby 
preventing induction of apoptosis) and to reduce the expression of pro-apoptotic p53 
protein357.   
Administration of exogenous CO has been shown to increase the viability of cultured cell 
lines including pancreatic β-cells, hepatocytes and endothelial cells and can also reduce 
doxorubicin-induced apoptosis in cardiomyocytes267 459-462.  The effects of exogenous CO 
may be specific to the cell type studied given that no cytoprotection was afforded by CO 
exposure in gastric cancer or colonic adenocarcinoma cells352 417.   
Bile pigment products of heme breakdown are acknowledged as potent antioxidants and 
inhibitors of the inflammatory complement cascade.  The anti-apoptotic effects mediated 
by HO activity may be due to increased intracellular levels of biliverdin and bilirubin.  
Biliverdin and bilirubin have been shown to inhibit hepatocyte cell apoptosis both in vitro 
and in vivo463 464.  Unconjugated bilirubin is capable of scavenging the singlet oxygen 
molecule and can act as a reducing agent for certain peroxidases including horseradish 
peroxidase235.   
Ferrous iron (Fe2+) is potentially harmful to cells by virtue of its propensity to generate 
toxic hydroxyl radicals via the Fenton reaction as described above.  Hydroxyl radicals 
cause lipid peroxidation and direct damage to cellular proteins and DNA.  Intracellular 
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Fe2+ can be rapidly sequestered by ferritin or removed by ATP-dependent iron exporter 
pumps to prevent oxidative stress465.  Ferritin can contribute to the cytoprotective actions 
of heme oxygenase and shares common induction stimuli with HO-1 protein.  Increased 
cellular levels of heavy-chain ferritin protein produced a marked resistance to cytotoxicity 
mediated by pro-oxidant hydrogen peroxide (H2O2) in breast and colon cancer cells
466.  
Increased HO-1 activity improved cell viability in malignant oral keratinocytes exposed to 
nitric oxide by up-regulation of iron regulatory proteins (IRP1 and IRP2), transferrin 
receptor (TfR), and ferritin protein467.   
1.3.8 Inflammation and cancer  
Acute inflammation is an important physiological response to injury and infection that 
aims to rapidly restore cellular homeostasis and repair damaged tissue.  The process of 
acute inflammation is characterised by vasodilatation and increased capillary permeability 
with infiltration of leucocytes into the site of infection to eliminate invading pathogens.  
Inadequate resolution of inflammation and uncontrolled inflammatory reactions can 
evoke produce a state of chronic inflammation with potentially pathological 
consequences468 469.  A variety of biochemical processes that are modified during chronic 
inflammation are implicated in carcinogenesis470.  There is increasing evidence of a 
central aetiological role for inflammation in the initiation, promotion and progression of 
cancer471-473.   
Inflammation can contribute to carcinogenesis via a number of mechanisms including: 
induction of chromosomal instability; stimulation of cell proliferation, metastasis and 
angiogenesis; alterations in epigenetic events with subsequent inappropriate gene 
expression; increased DNA damage; a shift in the cellular redox balance towards 
increased oxidative stress472 474-476.  A range of diverse pro-inflammatory mediators such 
as cytokines, chemokines, prostaglandins, cyclooxygenase-2 (COX-2), inducible nitric 
oxide synthase (iNOS) and nitric oxide (NO) are over-expressed or abnormally activated to 
play a fundamental role in the malignant conversion of cells in a chronic inflammatory 
environment.  The primary molecular event connecting inflammation and cancer is the 
inappropriate transcription of genes encoding inflammatory mediators, survival factors, 
and angiogenic and metastatic proteins.   
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A variety of intracellular signalling pathways are inappropriately activated during chronic 
inflammation to cause disordered function of cell surface receptors, transcription factors, 
cytosol scaffold proteins and mitogen-activated protein (MAP) kinases.  Activation of 
protein kinases causes propagation of disproportionate growth signals and abnormal 
expression of pro-inflammatory genes that allow the cells to acquire a malignant 
phenotype.  The downstream activation of several transcription factors including nuclear-
factor-κB, hypoxia inducible factor-1α (HIF-1α), signal transducer and activator of 
transcription (STAT) and activator protein-1 (AP-1) has been implicated in tumour growth, 
angiogenesis and metastasis468 472.  Inflammation can drive carcinogenesis intrinsically as 
well as via the extrinsic release of pro-inflammatory mediators within the tumour 
microenvironment.  The transcription of genes involved in cell proliferation, resistance to 
apoptosis, angiogenesis and metastasis is thereby enhanced.   
Exposure to environmental toxins or disordered cellular redox regulation causes oxidative 
or nitrosative stress resulting in local tissue inflammation.  Oxidative stress can activate 
transcription factors to cause deregulated protein expression and lead to 
carcinogenesis477.  The generation of excessive ROS such as superoxide anion, hydroxyl 
radical and hydrogen peroxide causes DNA damage and can contribute to carcinogenesis 
by activating oncogenes and inactivating tumour suppressor genes478.  The sustained 
accumulation of reactive oxygen and nitrogen species enables covalent modifications of 
cellular proteins such as cysteine thiol modification and protein adduct formation that are 
associated with promotion of inflammation and an increased risk of malignant 
transformation.  Increased oxidative stress leads to the accumulation of reactive 
aldehydes as a product of cellular lipid peroxidation.  These reactive aldehydes can cause 
further damage via covalent modification of various proteins479 480.  
Nitric oxide plays a dominant role in carcinogenesis associated with oxidative or 
nitrosative stress by direct modification of DNA and inactivation of DNA repair 
enzymes481.  The nitric oxide radical captures superoxide anion to form a powerful 
oxidant peroxynitrite that is capable of causing direct DNA damage by forming 8-
nitroguanine, a useful biomarker of cancers associated with inflammation482-484.   
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The cellular adaptive response to excessive oxidative stress is the up-regulation of a panel 
of endogenous antioxidant enzymes including superoxide dismutase and heme 
oxygenase-1.  The antioxidant-response element (ARE) is a consensus sequence located at 
the promoter regions of genes encoding various cytoprotective enzymes.  The redox-
sensitive transcription factor Nrf2 binds to the ARE region in response to mild oxidative 
stress to cause up-regulation of HO-1 protein485.  The protective role of Nrf2 against 
inflammation and oxidative stress may be exploited as a potential target for 
chemoprevention486 487.  Loss of Nrf2 function via gene knockdown or blockade of the 
Nrf2 activation pathway renders healthy cells vulnerable to inflammatory damage 
induced by oxidative stress and subsequent malignant transformation.  Recent studies 
indicate however that the activation of Nrf2 can facilitate growth in established tumour 
cells and encourage chemoresistance488 489.  The increased activity of Nrf2-regulated 
antioxidant proteins such as HO-1 may provide an overall survival benefit to malignant 
tumour cells.   
The link between inflammation and cancer is especially relevant in oesophagogastric 
cancer with both chronic gastric inflammation and chronic acid reflux damage to the 
oesophagus predisposing to malignant disease472 480.  The induction of genomic instability 
in cells subjected to chronic inflammation can be demonstrated in the progression of 
Barrett’s oesophagus to invasive adenocarcinoma490.  Analysis of tissue samples in 
patients with Barrett’s oesophagus and adenocarcinoma arising in a background of 
Barrett’s oesophagus demonstrated a 64% alteration in chromosome 11 and a 43% 
change in chromosome 12.  These chromosomal instabilities were found in non-dysplastic 
Barrett’s epithelium that maintained a normal expression of tumour suppressor protein 
p53490.  Therefore the genomic instability associated with persistent tissue inflammation 
is induced before the inactivation of tumour suppressor genes in patients with Barrett’s 
metaplasia that progresses to dysplasia and invasive adenocarcinoma.   
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1.4 Study Aims and Objectives 
1.4.1 Hypotheses of study 
Oxidative stress plays an important role in the development and progression of 
oesophagogastric cancer.  The heme oxygenase system has a critical role in the adaptive 
cellular responses to oxidative stress and chronic inflammation.  Alterations in HO activity 
may have an important role in the cell biology of upper gastrointestinal tract cancer.  
Modifications in the heme oxygenase pathway may influence cellular signalling pathways 
with the ability to regulate cell proliferation and apoptotic activity.  Changes in heme 
oxygenase activity and the production of its downstream products can affect the 
proliferation of oesophagogastric cancer cells. 
1.4.2 Aims of study 
1. To characterise constitutive and inducible HO protein expression in malignant and 
benign oesophagogastric cell lines.   
2. To explore the mechanisms of HO activation and the influence of pro-
inflammatory and antioxidant mediators on HO expression. 
3. To investigate the role of oxidative stress in the regulation of epithelial cell cycle 
kinetics, apoptosis and proliferation. 
4. To investigate the effects of modified HO protein expression and enzymatic 
activity on epithelial cell cycle kinetics, apoptosis and proliferation. 
5. To examine the specific effects of downstream products of heme oxygenase 
activity and their potential regulatory roles in the HO pathway and influence on 
cancer cell proliferation.   
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell Culture Experiments 
2.1.1 Cell Culture Techniques 
The role of the heme oxygenase system was investigated by experiments carried out on 
the following commercially obtained human cell lines: OE-33 oesophageal 
adenocarcinoma; HET-1A normal oesophageal squamous epithelium; AGS gastric 
adenocarcinoma; and HGC-27 metastatic gastric adenocarcinoma.  OE-33, AGS and HGC-
27 were purchased from the European Collection of Cell Cultures (ECACC) and HET-1A 
obtained from the American Type Culture Collection (ATCC).   
The OE-33 cell line was established from a poorly-differentiated adenocarcinoma of the 
lower oesophagus of a 73 year old female patient.  These cells are known to be 
tumourigenic in nude mice.  The culture medium used was RPMI 1640 with 2 mM L-
Glutamine and 10% foetal bovine serum as recommended, with added antibiotics 100 
mgmL-1 streptomycin and 100 IUmL-1 penicillin.  The AGS cell line is derived from an 
adenocarcinoma of the stomach of a 54 year old Caucasian female with no prior anti-
cancer treatment.  The culture medium used was Ham's nutrient mixture F12 with 2 mM 
L-Glutamine and 10% foetal bovine serum (FBS) with added penicillin and streptomycin at 
1% concentration.  The HGC-27 cell line originates from a metastatic lymph node deposit 
of a patient with undifferentiated mucin-producing gastric adenocarcinoma.  The 
recommended culture medium is Dulbecco’s Modified Eagle’s Medium (DMEM) with 2 
mM L-Glutamine and 10% foetal bovine serum.  RPMI, Ham and DMEM culture mediums 
were purchased from Sigma-Aldrich as were all antibiotic solutions, glutamine and FBS.   
The HET-1A cell line is derived from oesophageal autopsy tissue of a 25 year old male and 
has been shown to be non-tumourigenic in athymic, nude mice for more than 12 months.  
The growth of these cells is inhibited by foetal bovine serum, and the culture medium 
used was bronchial epithelial basal medium (BEBM) plus additives including growth 
supplements as provided (BEGM SingleQuots, Cambrex Bioscience, UK).  The HET-1A cells 
were grown in flasks precoated with a mixture of 0.01 mgmL-1 fibronectin, 0.03 mgmL-1 
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bovine collagen type I (PureCol) and 0.01 mgmL-1 bovine serum albumin dissolved in 
culture medium.   
Cells were grown in adherent cultures using tissue culture flasks with a surface area of 75 
cm2 and a hydrophobic filter cap (T75 Nunc Easyflasks, Thermo Fisher Scientific).  All 
culture vessels were kept in a humidified incubator maintained at 5% CO2 and 37°C.  All 
manipulations of the cultured cells were carried out in a Class II biosafety hood using a 
sterile technique.  All surfaces were cleaned with a 70% industrial ethanol solution.  All 
solutions and growth media were warmed to 37°C prior to use.  Growth medium was 
renewed every 48-72 hours for all cell lines, using a volume of 12-15 mL per flask.  Cells 
were assessed by light microscopy and subcultured when 70-80% confluent to avoid 
possible senescence associated with a higher cell density.   
For passaging cells, after discarding the spent medium the cell layer was briefly rinsed 
with warm phosphate-buffered saline to remove all traces of serum to avoid inhibition of 
trypsin enzyme.  The monolayer was then treated with 3 mL of a mixture of 0.25% 
(weight/volume) trypsin and 0.1% EDTA (ethylenediaminetetraacetic acid) and left in the 
incubator for up to 10 minutes, until dispersion of the cell layer was observed using the 
inverted microscope.  A further 3 mL of complete growth medium was then added to 
quench the trypsin reaction and the cells aspirated by gentle pipetting, transferring the 
suspension into a 15 mL conical centrifuge tube.  The cell suspensions were centrifuged at 
300 x g for 6 minutes, the resulting cell pellet resuspended in medium and appropriate 
aliquots of the new cell suspension added to the desired culture vessels, maintaining a 
subcultivation ratio of 1:3.  For the HET-1A cells grown in serum-free medium, the trypsin-
EDTA solution contained 0.5% polyvinylpyrrolidone (PVP) added.  Once the cells were 
detached from the flask the trypsin was neutralised with 0.1% soybean trypsin inhibitor.  
The cells were resuspended and centrifuged as above and dispensed into coated flasks or 
plates. 
Cells were stored as a 1 mL frozen suspension in cryovials at -70°C.  Cells were preserved 
by resuspending the cell pellet in 90% complete growth medium with 10% dimethyl 
sulfoxide (DMSO) solvent.  The HET-1A cells needed a separate freeze medium consisting 
of Leibovitz's L-15 medium with 2 mM L-glutamine and 10 mM HEPES (4-(2-hydroxyethyl)-
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1-piperazineethanesulfonic acid) buffer supplemented with 1% PVP, 10% foetal bovine 
serum and 7.5% DMSO.  When taking cells out of storage, the frozen suspension was 
thawed quickly at 37°C and added to 5 mL of complete growth medium.  This volume was 
centrifuged and the cell pellet resuspended in fresh medium to extract the DMSO solvent.   
2.1.2 Cell seeding and cell counting technique 
To achieve correct cell seeding, a flask of cells was passaged and the resulting cell pellet 
resuspended to a volume of 1 mL.  A 10 μL volume of this well-mixed suspension was 
added to an equal volume of 0.4% trypan blue solution (Sigma-Aldrich) and made up to a 
100 μL with medium, being allowed to stand for up to 5 min at room temperature.  
Trypan blue is a diazo dye that crosses the cell membrane of dead cells but is not taken up 
by viable cells with an intact membrane.  After mixing thoroughly again with gentle 
pipetting to ensure a representative sample, 10 μL was placed on a haemocytometer and 
the slide examined under the microscope.  The number of viable cells was counted as the 
average of cells in 4 large squares (area = 1 mm2) on the haemocytometer grid.  The 
number of cells per mL can then be calculated with the following equation: 
Cells per mL = [average cells in one large grid square] x 104 x dilution factor 
An appropriate dilution of the cell suspension was chosen with regard to the number of 
cells likely to be counted.  Under-dilution of the sample would make the cells crowded 
and difficult to count, while a sample size that is too dilute does not contain enough cells 
to adequately represent the concentration in the original mixture.  For seeding out cells 
from a 70-80% confluent T75 flask, the cell suspension of 1 mL will contain an adequate 
number of cells to allow a dilution factor of 10 (10 μL into 100 μL).  However when 
counting cells per well for a 24-well plate, the number of cells was anticipated not to be 
sufficient for a volume of 1 mL.  In this situation, after first discarding the well medium 
and rinsing briefly with warm PBS, 125 µL of trypsin-EDTA solution was added to the well.  
An equal volume of 125 μL was then added and the well gently scraped with a cell 
scraper.  The sample volume of 250 μL was aspirated by pipette and transferred into an 
eppendorf tube.  From this sample, 10 µL was placed on the haemocytometer and the 
cells counted as above.  Because the original volume is 250 μL the cells per well is 
calculated as the average number of cells in one large grid square multiplied by 104 and 
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divided by 4.  Similarly, when counting cells per well for a 96-well plate, 31.25 μL of 
trypsin-EDTA is added to the well to be followed by 31.25 µL of trypan blue to give a total 
volume of 62.5 μL and the cells per well is calculated by the average number of cells in 
one large grid square multiplied by 104 and divided by 16. 
2.1.3 Measurement of cell growth: Cell counts and MTT assay technique 
In addition to cell counts, cell growth was studied by the use of Thiazolyl Blue Tetrazolium 
Bromide (MTT) assay.  MTT [3-(4,5-dimethyithiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] is a yellow solution that is reduced to water-insoluble purple formazan by 
mitochondrial dehydrogenases of living cells. The crystals are solubilised with acidified 
isopropanol and the intensity measured with standard colorimetric assay at a wavelength 
between 500 and 600 nm.  The quantified absorbance should be directly related to the 
number of viable cells.  MTT was prepared to a concentration of 0.25 mg per mL in 
complete medium and sterilized through a 0.2 micron pore size filter (Sartorius Minisart).  
For 96-well plates, a volume of 100 µL was added and for 24-well plates, 250 µL was 
added to the well once the well medium was discarded.  The plate was then left for 2 
hours to allow formation of purple formazan crystals.  After a 2-hour incubation period 
the MTT reaction medium was discarded and the purplish-blue MTT formazan crystals 
dissolved by adding 0.04 molL-1 HCl-Isopropanol.  An equal volume of solubilisation buffer 
was added, mixed by careful pipetting and incubated for 30 min to dissolve the crystals.  
The solubilisation buffer consisted of 5 g Triton X-100 detergent and 430 µL hydrochloric 
acid made up to 50 mL with isopropanol.  From each well, 200 µL of the dissolved 
coloured solution was transferred to a 96-well plate and the absorbance measured by 
spectrophotometer (Multiskan EX, Thermo labsystems) at 562 nm wavelength. 
To evaluate the relationship between MTT optical density and number of viable cells, cell 
seeding experiments were performed with all cell lines seeded in 24-well and 96-well 
plates at a known number.  Cells were seeded at 1000, 5000, 10000, 20000, 40000, 
60000, 10000 and 150000 cells per well in a 24-well plate.  Cell counts using trypan blue 
exclusion and MTT assay were performed at 24, 48 and 72 hours.   
The number of viable cells counted from each well showed a strong correlation with the 
number of cells seeded in the well (Pearson correlation 0.992; p < 0.001).  The number of 
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dead cells counted was far fewer and was not related to the number of cells seeded.  The 
results are displayed in Appendix II.  Absorbance measured by MTT assay demonstrated a 
strong positive correlation to the number of cells seeded per well (Pearson correlation 
0.967; p < 0.001).  This relationship was evident for both AGS and HGC-27 cell lines 
seeded into 24-well plates and for AGS cells seeded into 96-well plates (Figures II.1b & 
II.2, Appendix II). 
The results support the MTT and cell counting techniques as a valid measure of cell 
proliferation for cells seeded in a 24-well or a 96-well plate. 
2.1.4 Obtaining growth curves for cell lines under different conditions 
To investigate growth of the four available cell lines under various conditions, cells were 
seeded at the same number and grown using recommended culture media with or 
without serum.  Cell counts and MTT assay were performed at 24, 48 and 72 hours to 
obtain growth curves for each cell line.     
Growth curves generated by both cell counting and MTT assay demonstrate exponential 
growth for all cell lines under the specified conditions.  Standard curves generated by 
MTT assay for all cell lines studies are displayed in Appendix III.  There was significantly 
increased growth observed in malignant cell lines studied compared to benign epithelial 
oesophageal cell line HET-1A (Figures III.1 – 5, Appendix III). 
2.2. Investigating Protein Expression with Western Blotting 
Expression of heme oxygenase proteins in each cell line was assessed under basal and 
experimental conditions using protein electrophoresis and Western blotting techniques. 
2.2.1 Protein Assay 
The protein content in cell lysates was measured against a known standard 
concentration.  Cell lysates were collected by adding 50 µL of lysis buffer to each well, 
collecting 3 wells together with a further 50 µL lysis buffer to wash the wells.  The lysis 
buffer was made up as sodium docedyl sulfate (SDS) dissolved in phosphate-buffered 
saline to make a 1% solution.  To inhibit proteolytic activity in the cell lysates, one 
complete protease inhibitor tablet (Roche) was added per 10 mL of 1% SDS solution.  Cell 
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lysates were stored at -20°C for future use.  A solution of bovine serum albumin (BSA) was 
diluted with 1% SDS with protease inhibitor (lysis buffer) solution to make concentrations 
of 0.4 – 1.6 mgmL-1 for the protein standard.  The first step was to decide what 
concentration of cell lysate to use to ensure that the sample fell within the range of the 
protein standard.  Initial assay was performed on neat samples and those diluted with 
lysis buffer at a ratio of 1:1, 1:2 and 1:4.  Protein assay was performed using a 
bicinchoninic acid (BCA)-based assay kit (Pierce BCA Protein Assay, Thermo Scientific).  
Samples were assayed in duplicate, with 10 µL of sample and 100 µL of working reagent 
per well, in a 96-well plate.  Visual assessment of colour change was made with the initial 
samples to choose a concentration of lysate sample whose colour was within the range of 
the BSA standard.  For the formal protein assay of the chosen concentration, the plate 
was read by spectrophotometer at 562 nm wavelength.  The absorbance value was 
plotted against the BSA concentration to produce a standard curve using Microsoft Excel.  
A curvilinear regression was applied using a 2-parameter polynomial equation calculated 
by the spreadsheet program.  This equation was then used to determine the protein 
concentration of the samples with known absorbance value, accounting for any dilution 
factor used.  Once the µg per µL concentration is known for the sample, then an 
appropriate volume for 30, 20 or 10 µg of protein can be calculated.   
2.2.2 Gel electrophoresis 
Protein electrophoresis was performed using the NuPage Bis-Tris gel system.  These are 
polyacrylamide gels that are buffered to a pH of 6.4, with a separating gel that operates 
at pH 7.0.  The protein samples are loaded onto the less dense stacking matrix of the gel.  
With the use of SDS running buffers and a sample reducing agent, the proteins are 
unfolded and denatured with breaking of the disulfide cysteine bonds between 
polypeptide chains.  The tertiary globular protein is broken down to its single-stranded 
primary structure, and coated in SDS detergent with an overall negative charge in 
proportion to its mass.  A positive charge at the distal end of the gel pulls the protein 
down through the denser resolving matrix of the gel, in which the proteins are separated 
according to their molecular weight.  The separated proteins are then transferred onto a 
nitrocellulose membrane for immunoassay.  At a neutral pH the protein structure is more 
stable and proteins are kept denatured, whereas at a higher pH cysteine bonds can re-
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form between protein chains.  Furthermore, at a higher pH proteins are potentially 
subjected to chemical modifications such as deamination and alkylation that may reduce 
band sharpness and alter the efficiency of transfer onto the membrane.  The included 
reducing agents move into the gel ahead of the protein stack to maintain a reducing 
environment. 
During preparation of the samples to load onto the gel, the volume of lysate containing 
an equal amount of protein (at least 15 µg) was calculated for each experiment sample 
and made up to a total volume of 15.5 µL with 1% SDS solution.  The maximum 
recommended load volume was 25 µL per well.  A volume of 5.5 µL 1% SDS was added to 
10 µL of full-range rainbow molecular weight marker (GE Healthcare) to run with each gel.  
Sample buffer (6.25 µL) and ultrapure water (0.75 µL) was added to each sample.  The 
NuPage sample buffer uses lithium dodecyl sulfate (LDS) that stays in solution better than 
in the sodium form SDS.  The hydrophobic dodecyl group interacts with hydrophobic 
amino acids in the core of proteins, disrupting their 3-D structure and transforming 
globular proteins into linear molecules now coated with negatively charged lithium 
groups.  The sample buffer contains glycerol to increase the density of the sample to be 
loaded and hence maintain the sample at the bottom of the well, restricting overflow and 
uneven gel loading.  To enable visualization of the migration of proteins Coomassie G250 
and Phenol Red are included in the sample buffer as tracking dyes.  These are small, 
anionic molecules that migrate faster than any component in the mixture to be separated 
and provide sharp viewing of the migration front to monitor the separation progress.  
Reducing agent was added to each sample (2.5 µL) and mixed by vortexing just prior to 
heating at 70°C for 10 minutes.  The reducing agent contains 0.5M dithiothreitol (DTT) 
that reduces the disulfide bridges to break up quaternary protein structure and also 
prevents cysteine residue binding, working effectively under the denaturing conditions 
described.  The samples were vortexed again after heating and centrifuged with pulse 
spin at 300 x g for 5 – 10 seconds prior to loading onto the gel.   
The NuPage gels were assembled using the XCell SureLock mini-cell system (Invitrogen) 
according to manufacturer instructions.  Normally 2 gel cassettes were run together.  If 
only one gel was run, a buffer dam was placed between the buffer core and the tension 
wedge.  The inner buffer chamber was filled with 200 mL of 1x NuPage MOPS (3-N-
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morpholino-propane sulfonic acid) SDS running buffer with 500 µL antioxidant added to 
prevent re-oxidisation of the reduced proteins as the gel runs.  The reducing agent DTT 
does not migrate with the sample through the gel in the neutral pH environment of the 
NuPage gels, tending instead to remain at the top of the gel.  Although disulfide bonds are 
more stable at neutral pH and less likely to reoxidize than in a gel with a higher pH, 
antioxidant is required to avoid potential reoxidation resulting in slightly diffuse bands.  
NuPage antioxidant (a proprietary reagent) migrates with the proteins during 
electrophoresis maintaining their reduced state, and also protects sensitive amino acids 
such as tryptophan and methionine from oxidizing.  After making sure there were no 
leaks from the buffer core, the outer chamber was filled with 600 mL of 1x MOPS running 
buffer.  The prepared 25 µL volume samples were then loaded carefully into the wells 
using a fine pipette.  The gels were then run at a constant voltage of 200 V for 1 hour, 
with an expected starting current of 100-115 mA per gel.   
2.2.3 Western Blotting Gel Transfer 
The separated proteins were transferred onto a Hybond ECL Nitrocellulose membrane 
(GE Healthcare) using the XCell II Blot module (Invitrogen) system.  Transfer buffer was 
made up containing methanol 80 mL, 20x NuPage Transfer Buffer 20 mL to maintain the 
neutral pH environment, 400 µL of NuPage antioxidant to maintain the reduced protein 
state and ultrapure water to a total volume of 400 mL.  Transfer buffer with 20% 
methanol was used for transferring two gels within a single blot module and 10% 
methanol for a single gel.  The nitrocellulose membrane was soaked in the transfer buffer 
for several minutes prior to use.  The gels were removed from the cassettes and placed 
between pre-soaked filter paper and the prepared membrane.  The proteins within the 
gel have a negative electrical charge conferred by the SDS and are induced to travel 
towards the positively-charged electrode of the applied electrical field.  The gel and 
nitrocellulose membrane are tightly sandwiched between blotting pads and filter paper 
with careful arrangement of the gel and membrane ensuring no air bubbles are trapped 
between them.  The moving proteins are stopped by the nitrocellulose membrane and 
bound to its surface, thereby blotting the proteins from the gel.   
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The blot module was secured in the XCell SureLock system, making sure that the gel-
membrane sandwich was covered in transfer buffer and filling the outer chamber with 
deionised water to act as a heat sink during the transfer run.  The lid was secured and 
connected to electricity to run at a constant voltage of 30 V for 1 hour, with an expected 
starting current of 170 mA per gel.  After the transfer run was complete, the stack was 
disassembled by reversing the assembly order and carefully peeling the membrane off 
the gel.  The membrane was immediately placed in a blocking solution made up of 
phosphate buffered saline (PBS) with 0.1% added Tween detergent and 5% skimmed milk.  
The membrane was left in blocking solution for at least 1 hour at room temperature or 
overnight at 4°C with gentle agitation.  The milk proteins bind to all the available sites on 
the nitrocellulose membrane where the target proteins from the gel transfer have not 
attached, thereby preventing non-specific binding of the probing antibodies to places 
other than the specific binding sites of the target protein.  In addition, any unbound 
proteins are washed off into the blocking buffer.  The nitrocellulose membrane has a high 
affinity for binding protein, so blocking is required to eliminate false positives in the final 
product of the blot and to produce clearer results. 
Figure 2.2.1: Arrangement of the gel-membrane sandwich for transfer of 2 gels 
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2.2.4 Probing the membrane and generating a signal 
The nitrocellulose membrane was probed for heme oxygenase proteins using specific 
monoclonal antibodies targeted against HO-1 (BD Biosciences) and HO-2 (Santa Cruz).  
Antibodies bound to protein were detected by a secondary anti-mouse antibody 
covalently conjugated to horseradish peroxidise (DAKO). The membrane was incubated 
with the antibodies in blocking buffer (PBS + 0.1% Tween with 5% low-fat milk) for 1 hour 
at room temperature.  After incubation the membranes were washed with PBS + 0.1% 
Tween in cycles of 3x 5 mins and 1x 15 mins to wash away all unbound antibody.  Primary 
monoclonal mouse anti-HO-1 antibody was diluted to a 1 in 500 concentration, the 
primary anti-HO-2 antibody to 1 in 100 and the secondary anti-mouse antibody used at 1 
in 3000 dilution.  Membranes were also probed for β-tubulin protein to check for equal 
protein loading across the wells using monoclonal anti-β-tubulin antibody produced in 
mouse (Sigma) at a 1 in 1000 dilution.   
A signal was generated using the ECL Plus chemiluminescent reagents (GE Healthcare) 
with oxidation of the luminol substrate producing a sustained light emission detected on 
radiography film (Hyperfilm, GE Healthcare).  Autoradiographs were developed through 
an MI-5 X-ray film processor (Jencons).  HO-1 has a molecular weight of 32 kilo Daltons 
(kDa), HO-2 has a molecular weight of 36 kDa while that of β-tubulin is 55 kDa.   
2.3 Oxidative Stress Experiments 
Hydrogen peroxide (H2O2) is a powerful oxidant that denatures proteins by reacting with 
available thiol groups and methionine residues491 492.  The oxidative properties of H2O2 
have enabled its use as an antiseptic and antimicrobial agent for many years.  It is a 
relatively stable reactive oxygen species that is capable of diffusing across cellular 
membranes.  By interaction with free ferrous iron (Fe2+), H2O2 is readily converted to the 
highly reactive hydroxyl free radical (OH·) capable of indiscriminate oxidative damage.  
There is recent evidence to suggest a physiological role of H2O2 at lower concentrations in 
cell signalling pathways involved with acute inflammation.  In smooth muscle cells and 
vascular endothelial cells, hydrogen peroxide has been shown to activate intracellular 
NADPH oxidase resulting in the production of superoxide anion free radical and 
consequential oxidative damage.  In vitro cellular studies examining the potential 
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pathological effects of H2O2 commonly employ the oxidant in the concentration range of 
20 – 250 µM.   
N-acetylcysteine (NAC) is a well-known pharmacological agent with clinical indications 
including adjuvant mucolytic therapy for certain respiratory conditions, emergency 
treatment of paracetamol overdose, and to prevent the onset of acute renal failure with 
administration of intravenous radiographic contrast in patients with renal impairment493-
497.  N-acetylcysteine is derived from the amino acid cysteine, and is a substrate for 
intracellular glutathione produced in vivo.  Antioxidant properties are conferred by 
available thiol groups that break disulfide bonds linking protein chains and bind directly to 
free radicals. 
The aim of the experiments was first of all to establish the basal expression of heme 
oxygenase enzyme isoforms in cultured cell lines.  The influence of modulating oxidative 
stress on the proliferation of gastro-oesophageal cancer cells and their expression of 
heme oxygenase isoenzymes was investigated. 
Oxidative stress was simulated by treating the cultured cells with hydrogen peroxide for 
24 hours, at concentrations of 0.2 – 200 µM.  Hydrogen peroxide was available as a 
solution at 10 Molar (M) concentration.  This solution was diluted in Ham culture medium 
for a working stock at 2 mM concentration, and appropriate serial dilution was performed 
to give stocks of 2, 20, 100, 200, 500 µM and 1 and 2 mM at sufficient volumes.   
The influence of antioxidant N-acetylcysteine on cell growth and heme oxygenase 
expression was studied by exposing cells to concentrations of 0.1 – 20 mM over 24 hours.  
NAC was obtained as a water-soluble white powder with molecular weight 163.2g.  To 
make a stock solution at 200 mM concentration 0.163g was weighed and dissolved in 5 
mL of medium.  The stock was sterile filtered and protected from the light.  Serial dilution 
of this solution gave further stocks at 1, 2.5, 5, 10, 50 and 100 mM.   
Cell lines were seeded into 24-well plates such that the wells were 50% confluent at the 
time of adding reagents.  The medium in each well was replaced with 450 µL of serum-
complete medium warmed to 37°C.  A volume of 50 µL stock reagent was added to the 
corresponding well.  For the control wells, 50 µL of medium was added at the same time 
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as adding the reagents.  Cells were thereby treated with H2O2 at doses of 0.2, 2, 10, 20, 
50, 100 and 200 µM and NAC at doses of 0.1, 0.25, 0.5, 1, 5, 10 and 20 mM including 
triplicate wells for each experiment dose.  After 24 hours the reagent medium was 
washed out and replaced with 250 µL of MTT medium, performing MTT assay to assess 
cell growth.   
Experiments were extended to 72 hours and to 168 hours (7 days) with AGS and OE-33 
cell lines to further assess observed effects with selected reagent doses.  Expression of 
heme oxygenase proteins HO-1 and HO-2 was determined by Western blotting and heme 
oxygenase activity assay performed on representative experiment samples.  Apoptosis 
studies were performed to evaluate possible mechanisms of the observed reductions in 
cell growth using flow cytometry techniques and caspase activity assay.   
2.4 Pharmacological modulation of Heme Oxygenase activity 
Cell lines were treated with Hemin, an iron-containing porphyrin used as a substrate 
analogue to increase heme oxygenase activity125 165.  Cells were treated with Zinc 
Protoporphyrin-IX (ZnPP), a normal metabolite that is formed in trace amounts during 
heme biosynthesis which is a competitive inhibitor of all isoforms of the heme oxygenase 
enzyme498-500.  Hemin powder was obtained from Sigma chemicals and zinc 
protoporphyrin purchased from Frontier Scientific.  These compounds were found to have 
limited solubility in dimethyl sulfoxide (DMSO) but were readily soluble in sodium 
hydroxide (NaOH) at 1 mM concentration.  To evaluate the effects of the chosen vehicle 
for hemin and zinc, an experimental plate was first set up to include NaOH at 1 mM 
concentration at time points of 24, 48 and 72 hours.  Cells were then exposed to hemin at 
concentrations of 2 – 200 µM and treated with zinc PP at concentrations of 0.1 – 40 µM. 
Hemin powder has a molecular weight of 651.94g.  A stock solution of 2 mM 
concentration was made with hemin at 0.0013 gmL-1.  The powder was first dissolved in a 
certain volume of 1M NaOH and further diluted with culture medium such that the hemin 
content was 0.0013 gmL-1 and the concentration of NaOH 10 mM.  The stock was sterile 
filtered and protected from light.  Serial dilution of the stock was performed to create 
stocks at 10x the desired concentration in the well.  A volume of 50 µL stock reagent was 
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added to 450 µL in the corresponding well.  Thus the maximum final concentration of 
NaOH in the wells was 1 mM.   
Zinc powder has a molecular weight of 626.03g.  A stock solution of 4 mM concentration 
was made with zinc at 0.0025 gmL-1.  The initial stock was dissolved in NaOH and filtered 
as above, with subsequent serial dilution to obtain the appropriate stock concentrations 
for the experiment plate. 
2.5 Chemotherapy studies 
2.5.1 Cisplatin  
The chemotherapeutic agent cis-diamminedichloroplatinum(II), cis-DDP, or cisplatin is 
one of the most effective chemotherapeutic agents used in the management of a variety 
of human cancers501.  Cisplatin is a key component of treatment regimens for carcinoma 
of the oesophagus.  Response rates of up to 40% can be achieved using single-agent 
cisplatin in patients with advanced disease while administration of cisplatin with 
continuous intravenous infusion of fluorouracil (5-FU) doubled the response rate 
reported in the EORTC trial (19% versus 35%)502-504.  
Cisplatin is also the mainstay of combination therapy regimens for gastric cancer.  The 
cisplatin-based combination ECF (epirubicin, cisplatin and 5-FU) demonstrated a 
significant survival benefit at 5-years (36% for perioperative chemotherapy versus 23% in 
surgery alone)505.   
2.5.2 Fluorouracil 
Fluorouracil (5-FU) is an anti-metabolite chemotherapeutic agent that is a pyrimidine 
analogue.  Fluorouracil remains one of the most potent chemotherapeutic agents for 
solid tumours even at limited response rates of between 10 – 30%506 507.   
2.5.3 Chemotherapy study protocol 
Initial chemotherapy experiments were performed to establish the median lethal dose 
(LD50) with cytotoxicity assays using Trypan blue exclusion and the equivalent half 
maximal inhibitory concentration (IC50) with MTT assay to measure cell proliferation.  
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Dose response growth curves were obtained to obtain the IC50 concentration of 
chemotherapeutic agent causing 50% inhibition of cell growth.  For the cytotoxicity assay 
cells were seeded at optimal density in serum-complete media into 12-well plates and 
returned to the incubator for 24 hours to establish monolayer cell adherence.  Media 
supplemented with a range of concentrations of the chemotherapeutic agents cisplatin 
and 5-FU were then added to the plate and the plate returned to the incubator for either 
48 hours or 72 hours.  Cells were harvested from three control wells prior to adding the 
reagents and counted using Trypan blue exclusion to assess cell viability at time = 0.  
Further wells were similarly harvested and counted at appropriate time to obtain cell 
viability at 48 and 72 hours with various reagent concentrations.  All subsequent cell 
experiments were based on the IC10 and IC50 concentrations of the chemotherapy agents 
representing the cytotoxic dose resulting in a 10% and 50% decrease in viable cell 
numbers respectively at 48 hours so that time was the only variable.  Cell proliferation 
curves were obtained using equivalent ranges of reagent doses in 24-well plates and 
performing MTT assay after 24 hours for control wells (t = 0) and 48 and 72 hours for 
treated wells. 
Cytotoxicity and cell growth assays were repeated to determine the influence of the 
heme oxygenase pathway and oxidative stress response.  Cells were treated with a range 
of Cisplatin doses between 0.5 – 30 µM (0.15 µgmL-1 – 9 µgmL-1) and 5-FU doses between 
1 – 50 µM (0.13 µgmL-1 – 6.5 µgmL-1) in the presence or absence of NAC 10 mM to 
determine the effect of the antioxidant on IC10 and IC50 chemotherapeutic concentrations.   
Growth curves were extended to 144 hours to determine the latent toxicity of the 
chemotherapeutic agents with and without NAC exposure.  Cells were plated in 24-well 
plates and treated for 48 hours with IC10 and IC50 doses of each chemotherapy agent 
alone and in combination with NAC.  Media was then removed and the cells washed with 
warm PBS (37°C) to remove any traces of residual chemotherapy.  Fresh serum-complete 
media was then added to each well and the plates returned to the incubator.  MTT assays 
were performed at 24, 48, 72, 96, 120 and 144 hours to determine any recovery of cell 
growth after exposure to chemotherapy and evaluate the influence of heme oxygenase 
reagents.  Spent media was changed to fresh serum-complete media after every 48 hours 
to encourage cell growth.  Each experiment was repeated in triplicate with six replicate 
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wells for each experiment reagent and time point with the total time for each experiment 
extending to 192 hours (8 days). 
Previous studies on AGS cell lines using the same chemotherapeutic agents provided a 
suitable range for establishing IC10 and IC50 doses.  Published IC10 and IC50 doses for 
cisplatin are 0.156 and 5 – 10 µgmL-1 and those for 5-FU 0.156 and 10 – 20 µgmL-1 
respectively508 509.   
2.5.4 Preparation of reagents 
Cisplatin was supplied by Sigma Aldrich as cis-Diammineplatinum(II) dichloride crystalline 
powder with molecular weight 298.029g.  A stock solution was prepared by dissolving 
cisplatin powder in 0.9% Normal Saline solution to a 10 mM concentration of 3 mgmL-1.  
Stock solution was stored at 2°C protected from light to avoid precipitation.  A range of 
concentrations was prepared by serial dilution so that the final concentration in 
experiment wells was between 0.15 – 15 μgmL-1 [0.5 – 50 μM] per well509.   
Cisplatin [FINAL] 50 μM = 15 μgmL-1 30 μM = 9 μgmL-1 10 μM = 3 μgmL-1 
5 μM = 1.5 μgmL-1 1 μM = 0.3 μgmL-1 0.5 μM = 0.15 μgmL-1  
Fluorouracil (5-FU) was supplied by Sigma Aldrich as a white powder with molecular 
weight 130g.  Stock solution of 100 mM was prepared by dissolving supplied dry power in 
DMSO to a concentration of 13 mgmL-1.  Stock solution was stored at 2°C protected from 
light with the solution expected to be stable for at least 4 months under these conditions.  
An initial range of concentrations was prepared by serial dilution so that the final 
concentration in experiment wells was between 0.13 – 78 μgmL-1 [1 – 600 μM] per 
well509.  The final DMSO concentration per well was always less than 0.1%. 
5-FU [FINAL]  600 μM = 78 μgmL-1 200 μM = 26 μgmL-1  
100 μM = 13 μgmL-1 50 μM = 6.5 μgmL-1  
25 μM = 3.25 μgmL-1 5 μM = 0.15 μgmL-1  1 µM = 0.13 µgmL-1  
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2.6 Targeted knockdown of HO mRNA  
2.6.1 Short Interfering RNA Technology 
Small interfering or short interfering RNA (siRNA), are double-stranded RNA molecules of 
20-25 nucleotides in length that interfere with the expression of a specific gene.  Small 
interfering RNA strands have complementary antisense nucleotide sequences to the 
targeted cellular messenger RNA strand.  When introduced into a cell or organism, the 
siRNA strand is recognized as exogenous genetic material and activates the RNA 
interference (RNAi) pathway.  The RNA interference pathway is a naturally occurring 
mechanism of post-transcriptional gene silencing that inhibits the translation of specific 
gene expression.  The Nobel Prize in Physiology or Medicine was won by Fire and Mello in 
2006 for their discovery of RNA interference510 511. 
In this process the antisense strand of the siRNA duplex becomes integrated with several 
proteins to form a nuclease complex known as the RNA-induced silencing complex (RISC).  
The active components of an RNA-induced silencing complex are endonucleases called 
argonaute proteins.  The siRNA duplex unwinds and then pairs by means of its antisense 
strand to target messenger RNAs (mRNAs) that carry a high degree of nucleotide 
sequence complementary to the siRNA.  Endonucleases within the RISC then proceed to 
cleave the associated mRNA at sites not bound by the siRNA.  The mRNA is broken down 
into smaller portions that can no longer be used as a template for translation into protein.  
This inactivated mRNA releases the RISC and is further degraded by cellular nuclease 
enzymes.  The guiding antisense strand is protected from degradation and can direct the 
cleavage of multiple mRNA molecules.  Inhibition of the translation process ultimately 
results in a loss of targeted protein expression.   
RNAi has a unique degree of sequence specificity: introduction of a single nucleotide base 
mismatch in the siRNA structure nullifies the RNA interference effect.   
Chemically synthesized siRNAs can be introduced into mammalian cell cytoplasm by 
distorting the integrity of the cell membrane.  Lipofectamine transfection creates 
reparable pores in the cell membrane which facilitate gentle siRNA uptake.  Transfection 
of an exogenous siRNA can be problematic because the gene knockdown effect is only 
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transient, particularly in rapidly dividing cells.  Other problems include off-target effects 
that occur when the siRNA sense strand has a complementary base sequence to 
untargeted mRNA and becomes incorporated into a RISC complex and activates the RNAi 
pathway.  SiRNAs can also be degraded over time with exposure to cellular nucleases.  
Furthermore, certain siRNAs can induce non-specific cellular stress response pathways 
including the interferon response that can alter the cellular phenotype. 
2.6.2 siRNA transfection 
The mode of delivering the siRNA into the cells involved using a positively-charged lipid 
transfection reagent, Lipofectamine (Invitrogen).  The siRNA nucleic acid strand is 
encapsulated into liposomes with the resulting positive surface charge enabling 
interaction with the negatively charged cell membrane.  The liposome-nucleic acid 
complex enters the cell by a process of endocytosis and diffuses through the cytoplasm.  
The Lipofectamine™ RNAiMAX reagent was chosen as it is specially designed and 
manufactured for delivery of siRNA double-stranded molecules.  All experiments used 
Opti-MEM reduced serum medium to dilute siRNA duplexes and Lipofectamine prior to 
forming a transfection complex, in accordance with manufacturer recommendations.  
Antibiotics were not added to cell culture media during transfection as this may cause cell 
death.  A forward transfection protocol was employed for all siRNA experiments, with 
cells being plated in the wells and the transfection mix prepared and added the next day. 
2.6.3 siRNA and Negative Universal Control 
To ensure that any observed results are due to effects mediated by the targeted RNAi 
molecules and not an artefact of the delivery method, a negative control needs to be 
included in the siRNA experiment.   
For targeted knockdown of HO-2 gene expression, three pairs of Human Stealth™ Select 
HO-2 siRNA (HMOX2) were obtained from Invitrogen.  Stealth™ RNAi uses proprietary 
chemical modifications to provide higher specificity and increased stability in cell culture, 
reducing off-target effects with a reduced potential to activate cellular stress response 
pathways.  HMOX2 was obtained as RNA duplexes of 25 base pairs with low GC content.  
The recommended predesigned negative universal control (NUC) for experiments using 
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Stealth™ RNAi was obtained from Invitrogen, featuring the same base pair length and low 
GC content to match that of the experimental siRNA.  The NUC sequence is not 
homologous with any known vertebrate gene, and does not induce non-specific cellular 
stress responses according to information from the supplier.   
2.6.4 RNA purification 
Purification of total RNA was performed using the RNeasy mini-kit supplied by QIAGEN.  
This uses a column-based solid phase extraction method to quickly purify nucleic acids, 
and relies on the fact that nucleic acid binds by adsorption to the solid phase (silica) 
depending on the pH and the salt content of the buffer.  The selective binding properties 
of a silica-based membrane are combined with the speed of microspin centrifugation.  A 
high-salt buffer system allows up to 100 µg of RNA longer than 200 bases to bind to the 
RNeasy silica membrane. 
Initially, 10 µL of Beta-Mercaptoethanol (β-ME) was added to every 1 mL of RNeasy lysis 
buffer (RLT buffer).  Medium was removed from the experiment well and a volume of 350 
µL RLT buffer/β-ME was added to lyse the cell monolayer.  This was mixed well by 
pipetting to homogenise the sample and transferred to an eppendorf.  These samples 
were frozen at -20°C for future use.  The RLT buffer contains guanidine thiocyanate that is 
highly denaturing, immediately inactivating RNases to ensure purification of intact RNA.   
Defrosted samples were processed according to QIAGEN protocol to yield total RNA.  
Ethanol was added to the defrosted lysate sample to provide appropriate binding 
conditions, and the sample then applied to the RNeasy silica membrane in a spin column.  
Total RNA binds to the membrane and contaminants are efficiently washed away by 
treatment with wash buffer and repeated centrifugation.  High-quality RNA was then 
eluted in 60-100 µL of RNAse-free water. 
Isolated RNA was treated with Turbo DNase enzyme (Ambion Applied Biosystems) to 
digest contaminating DNA.  Purified RNA was checked for DNA contamination using the 
polymerase chain reaction with GAPDH primers. 
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2.6.5 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is a technique widely used in molecular biology to 
amplify specific regions of a DNA strand (the DNA target) by enzymatic replication in vitro.  
The heat-stable DNA polymerase, such as Taq polymerase, assembles a new DNA strand 
from nucleotide DNA building blocks, using single-stranded DNA as a template and DNA 
oligonucleotides (DNA primers) required for initiation of DNA synthesis.  As PCR 
progresses, the DNA thus generated is itself used as template for replication, setting in 
motion a chain reaction in which the DNA template is exponentially amplified.  
Components of the PCR reaction and reagents required include: the DNA template that 
contains the DNA region (target) to be amplified; two primers that have a complementary 
sequence to the DNA at the 5' (five prime) or 3' (three prime) ends of the DNA target 
region; Taq polymerase with an optimum temperature at approximately 70°C; 
Deoxynucleoside triphosphates (dNTPs), the building blocks from which the DNA 
polymerase synthesizes a new DNA strand; divalent magnesium cations (Mg2+), 
monovalent potassium cations (K+) and a buffer solution, all to provide the suitable 
chemical environment for optimum stability and activity of the DNA polymerase enzyme.   
In order to assess the purified total RNA for possible DNA contamination, PCR for the 
GAPDH gene sequence was performed with the GAPDH sense primer 5'-
TGAAGGTCGGTGTCAACGGATTTGGC-3' and antisense primer 5'-
CATGTAGGCCATGAGGTCCACCAC-3'.  A negative control PCR reaction was set up to 
ensure no reagent contamination using 1 µL of RNase-free water as a substitute for 1 µL 
of sample RNA. 
PCR was carried out using small reaction volumes in a thermal cycler. The thermal cycler 
heats and cools the reaction tubes to achieve the temperatures required at each step of 
the reaction, with a heated lid to prevent condensation at the top of the reaction tube. 
The PCR consisted of a series of 40 repeated temperature changes called cycles, and each 
cycle had 3 discrete temperature steps: 
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Denaturing step: heating the reaction to 94°C for 60 seconds causes denaturing of the 
DNA template and primers by disrupting the hydrogen bonds between complementary 
bases of the DNA strands, yielding single strands of DNA. 
Anneal primers: the temperature is lowered to 55°C for one minute – this allows the 
forward and reverse primers to anneal (base pair) to their complementary sequences.  
Typically the annealing temperature is about 3-5 degrees Celsius below the melting 
temperature of the primers used.  Stable DNA-DNA hydrogen bonds are only formed 
when the primer sequence very closely matches the template sequence.  Upstream and 
downstream primers are designed to bracket the DNA region to be amplified. 
Extend primers: the temperature is raised to 72°C for one minute, allowing Taq 
polymerase to attach at each priming site and extend (synthesize) a new DNA strand.  The 
DNA polymerase synthesizes a new DNA strand complementary to the DNA template 
strand by adding dNTPs that are complementary to the template in 5' to 3' direction. 
At its optimum temperature, the DNA polymerase is capable of polymerizing a thousand 
bases per minute.  If there are no other limitations such as lack of substrates or reagents, 
at each extension step the amount of DNA target is doubled, leading to exponential 
amplification of the specific DNA fragment.  After 2 complete cycles, 4 DNA copies are 
produced.  When the strands are then denatured during the first step of the 3rd cycle, the 
DNA fragments of desired length are denoted and 2 copies made after primer binding 
sites are extended.  The region of interest is then replicated geometrically such that by 
the end of 20 cycles the PCR products include 1,048,576 DNA copies and 1,048,536 target 
sequence copies.  This is the exponential amplification stage of the PCR process.  As the 
DNA polymerase loses activity and consumption of substrate and reagent (including 
dNTPs and primers) becomes a limiting factor, the enzymatic reaction slows.  The 
efficiency of amplification is decreased because of contaminants (inhibitors), competitive 
reactions, inactivation of the polymerase and target re-annealing.  As the number of 
cycles increases, the amplification efficiency decreases.  Finally, a plateau phase is 
reached when there is no more accumulation of product due to exhaustion of reagents 
and enzyme. 
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The PCR method is extremely sensitive, requiring only a few DNA molecules in a single 
reaction for amplification across several orders of magnitude. Therefore, adequate 
measures to avoid contamination from any DNA present in the laboratory environment 
were required. 
2.6.6 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was employed for size separation of the PCR products in 
order to assess whether the PCR generated the anticipated DNA fragment.  Negatively 
charged nucleic acid molecules are moved through an agarose matrix with 
electrophoresis applied, and molecules are separated according to length with shorter 
molecules migrating further.   
Gels were prepared by dissolving 1.8g agarose per 100 mL 1x Tris-Borate EDTA buffer 
(TBE Buffer).  The solution was brought to the boil carefully in a microwave to dissolve the 
agarose, and kept at 65°C in an incubator.  Then 50 µL of 1mgmL-1 ethidium bromide 
solution was added per 100 mL of 1.8% agarose solution, to give a final concentration of 5 
µgmL-1.  Ethidium bromide is an intercalating agent that interacts in between base pairs 
of double-stranded DNA, inducing local structural changes to the DNA molecule.  These 
structural modifications result in altered DNA function, hindering transcription and DNA 
repair processes and thereby increasing the frequency of DNA mutations.  By this 
mechanism, ethidium bromide is widely assumed to be carcinogenic.  Ethidium bromide is 
useful as a nucleic acid stain because when exposed to ultraviolet light it fluoresces with 
an orange colour, intensifying 20-fold when intercalated into DNA.  By running samples 
through a gel treated with ethidium bromide, any band containing more than 20 ng of 
DNA becomes distinctly visible under UV light. 
The warm solution containing ethidium bromide was poured into a gel rack with a comb 
in one end and allowed to cool and solidify.  PCR samples were loaded into the gel wells 
with a negatively charged loading buffer (Orange G) that also marked the progress of DNA 
fragments through the agarose matrix.  A DNA ladder containing DNA fragments between 
100 and 1,500 base pairs in length was loaded to run alongside the PCR products on the 
gel.  This enabled the size of the PCR products to be determined by direct comparison 
with a molecular weight marker.   
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The gels were run with 1x TBE running buffer at a constant 100 V for 30 minutes.  The gel 
was then transferred to the UV illuminator and the presence or absence of bright PCR 
product bands was recorded. 
2.6.7 Reverse Transcriptase Polymerase Chain Reaction 
The PCR technique described above is only applicable to DNA strands.  However, PCR 
analysis of RNA molecules is made possible by first using reverse transcription to convert 
RNA to complementary DNA.  The double-stranded DNA transcribed thus can be used in a 
standard polymerase chain reaction using primers targeted for analysis of the original 
single-stranded RNA.  With this reverse transcriptase PCR (RT-PCR) method it is possible 
to isolate, amplify and identify a known sequence from total cellular RNA.  For these 
experiments this technique was employed to assess the efficacy of siRNA-mediated 
knockdown of the HO-2 gene by qualitative analysis of the gene transcript in total cellular 
RNA samples. 
Complementary DNA (cDNA) is synthesized from messenger RNA (mRNA) template in a 
reaction catalysed by reverse transcriptase enzyme.  This enzyme operates on a single 
strand of mRNA, generating the cDNA sequence according to the pairing of RNA base 
pairs adenine (A), uracil (U), guanine (G) and cytosine (C), to their DNA complements 
thymine (T), adenine (A), cytosine (C) and guanine (G) respectively.   
cDNA was synthesized from purified total RNA with the Improm-II reverse transcriptase 
system (Promega).  The first step was a brief heat denaturation of the RNA template prior 
to reverse transcriptase, recommended to improve sensitivity.  A poly-T oligonucleotide 
primer was combined with the RNA template and RNase-free water and incubated for 5 
minutes at 72°C.  This disrupts any secondary structures formed in the RNA and makes a 
more linear arrangement allowing for more effective binding by the primer.  Cooling to 
4°C for 5 minutes allows the poly-T oligo primer to hybridise onto the poly-A tail of the 
mRNA template by means of base pairing.  Reverse transcriptase requires this double-
stranded segment as a primer to start its operation.  An alternative is to add random 
hexamer primers that contain every possible 6 base single strand of DNA and can thereby 
hybridise anywhere along the RNA template with complementary base pair sequence.   
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The next step was to add reverse transcriptase, along with deoxynucleoside triphosphates 
(dNTPs) substrate (A, T, G, C) and reaction buffer, magnesium chloride, RNase-free water 
and ribonuclease inhibitor to protect the RNA.  This mixture was incubated at 25°C for 5 
mins to ensure annealing of the oligo (dT) primer.  This also enables the reverse 
transcriptase to extend the oligo (dT) primer and allows the primer to remain hybridised 
at higher temperatures.  The mixture was then heated to 45°C for 60 minutes for the first-
strand cDNA synthesis reaction, when the reverse transcriptase generates the cDNA 
sequence according to RNA base pairs using the dNTPs as substrate.  A full length of cDNA 
is synthesized and includes all gene transcripts included in the available RNA template.  
This enables subsequent priming of different gene sequences from the same cDNA 
sample.   
The final stage was inactivation of the reverse transcriptase by heating to 70°C for 15 
minutes.  The resulting cDNA product required no clean-up or dilution prior to being 
added to amplification reactions, and was suitable for storage at -20°C for future use. 
The cDNA provided the necessary template for the heat stable Taq polymerase to amplify 
regions of interest in a standard PCR process. 
2.6.8 Semi-quantitative RT-PCR 
To investigate HO-2 gene knockdown in the RNA samples, standard PCR was performed 
using cDNA and specific HO-2 primers (sense primer 5'-CAAGGAAGGGACCAAGGAAG-3' 
and antisense primer 5'-CTCCTCCCAGTTTTCACCAA-3').  The PCR reaction included 40 
cycles of 94°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute.  To assess the 
efficiency of amplification, PCR was also carried out with cDNA and an internal control 
GAPDH primer pair (sense primer 5'-TGAAGGTCGGTGTCAACGGATTTGGC-3' and antisense 
primer 5'-CATGTAGGCCATGAGGTCCACCAC-3').  The GAPDH gene was expected to have 
constant expression levels throughout all the experimental conditions compared.  
Amplification of the GAPDH gene verifies acceptable quantity and quality of the target 
nucleic acid and reaction components.  The pair of RT-PCR series was also used to semi-
quantitate the levels of HO-2 mRNA present against GAPDH mRNA levels, allowing 
comparison between experiment samples.  However, differences in amplification 
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efficiencies between the GAPDH and HO-2 transcript due to variations in PCR product size 
or primer annealing efficiency may still have occurred. 
Possible contamination with extraneous DNA was assessed with a negative control in 
every PCR reaction. This control reaction was performed alongside the experimental 
sample PCRs with the same reagents but without template cDNA added. 
Assessment of RT-PCR-derived products was again performed using ethidium-treated 
agarose gel TBE electrophoresis with a DNA ladder for reference. 
2.7 Real-Time Quantitative Polymerase Chain Reaction 
2.7.1 Introduction 
Real-time Polymerase Chain Reaction (PCR) is the ability to measure DNA amplification 
during PCR as it occurs.  Data is collected throughout the PCR process as amplified 
product is measured at each PCR cycle rather than at the end of the PCR, changing the 
approach to PCR-based quantitation of DNA and RNA.  During real-time PCR a fluorescent 
signal is generated that is directly proportional to the amount of accumulating PCR 
product.  This signal is detected, calibrated and used to provide a measure of initial target 
gene abundance and calculate relative gene expression in experiment samples.  Real-time 
PCR monitors the point in time during cycling when amplification of a target is first 
detected rather than the amount of target accumulated after a fixed number of cycles.  
The higher the starting copy number of the nucleic acid target, the sooner the fluorescent 
signal increases above a statistically significant threshold.   
In traditional PCR, an endpoint assay measures the amount of accumulated PCR product 
after the reaction is complete, making it impossible to determine the starting 
concentration of nucleic acid and introducing variability in results due to changes in 
reaction kinetics.   
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2.7.2 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) method allows exponential amplification of short 
DNA sequences (up to 600 bases) within a longer double stranded DNA molecule.   
PCR uses a pair of primers that are complementary to a defined target sequence on each 
of the two strands of the DNA molecule.  These primers, each approximately 20 
nucleotides in length, are designed to bracket the region that is targeted for 
amplification.  The primers are extended by a DNA polymerase thereby making a copy of 
the designated sequence.  This copy can then be used as a template for further copies 
using the same primers, leading to exponential amplification.   
Double-stranded DNA must be denatured by heating to more than 90° Celsius to expose 
two single strands for each PCR cycle.  The isolation of a DNA polymerase (Taq 
polymerase) from Thermus aquaticus, a bacterium that grows in hot pools, was significant 
progress for the PCR method.  Researchers demonstrated that Taq DNA polymerase had 
5’ to 3’ exonuclease activity at high temperatures, avoiding the need to add new 
polymerase for every cycle of amplification512.   
2.7.2.1 PCR Reaction Cycles 
To quantify mRNA within a sample, the mRNA is first copied to cDNA by reverse 
transcriptase using an oligo dT primer and random hexamers.  The reverse transcriptase 
has endoglycosidase H activity that digests the mRNA strand template prior to real-time 
PCR allowing the second strand of DNA to be formed.  The PCR experiment set up mix 
includes Taq polymerase, specific primers for the gene of interest, deoxynucleotides and 
a suitable buffer.  The steps involved in the reaction are as follows: 
2.7.2.2 PCR Cycle 1 
Denaturation: The sample is heated to 94-96°C for several minutes to separate double 
stranded DNA into single strands.   
Anneal Primers: The sample temperature is lowered to 50-65°C for one to several 
minutes.  This allows specific primers to base-pair (anneal) to their complementary 
sequences on each strand.  Primers are designed to bracket the region that is targeted for 
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amplification.  The primers sites may be up to 600 bases apart but there is often about 
100 bases between upstream and downstream primer sites.   
Extend primers: The temperature is raised to 72°C for one to several minutes.  At 
this higher temperature the heat-stable Taq polymerase attaches to each primer site and 
adds nucleotides to synthesise a new DNA strand. 
2.7.2.3 PCR Cycle 2 
Denaturation: The sample is again heated to 94-96°C for several minutes to separate 
double stranded DNA into single strands. 
Anneal Primers: The temperature is lowered to 50-65°C for one to several minutes 
to allow primers to anneal. 
Extend primers: The sample is heated to 72°C again for one to several minutes.  Taq 
polymerase binds to each primer and extends from the primer to the end of the new 
cDNA strand.   
2.7.2.4 PCR Repeated cycles 
The steps of denaturation, annealing and extension are repeated, doubling the number of 
target sequence copies at every cycle (2, 4, 8, 16, 32 etc.).  The PCR reaction generates an 
exponential number of smaller double stranded cDNA molecules that are the size of the 
distance between the two primers.  After 3 cycles this target sequence defined by the 
primers begins to accumulate so that by the 5th cycle 24 of 32 strands (75%) are the same 
size.  After 30 cycles up to 1 billion copies of the target sequence or amplicon are 
produced from a single starting double-stranded DNA molecule.  The strands of larger size 
only increase arithmetically and are soon a small proportion of the total number of 
molecules. 
Analysis of PCR products on an agarose gel can be performed when product is abundant 
enough to be detected with the rather insensitive ethidium bromide stain.  Ethidium 
bromide dye binds to double stranded DNA by interpolation (intercalation) between the 
base pairs.  When irradiated in the UV part of the spectrum the dye is fluorescent.  
Detectable bands can provide a qualitative tool for detecting the presence or absence of a 
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particular DNA.  The amount of end-product of PCR may not however be related to the 
amount of input DNA template as the exponential stage of amplification is over.  The 
addition of the reverse transcriptase step makes standard PCR even less accurate to 
quantify relative mRNA levels in different samples.   
2.7.3 Principles of Real-Time PCR 
Real-time PCR technologies include the use of dual-labelled oligonucleotide fluorogenic 
probes such as TaqMan® assay probes.  A labelled oligonucleotide probe specifically 
designed to hybridise within the target sequence is introduced into the PCR assay.  The 
probe is labelled with a reporter fluorescent dye at its 5’ end and a quencher dye at its 3’ 
terminus, and anneals to PCR product strands to generate a substrate suitable for 
exonuclease activity.  Cleavage of the target probe during PCR by the 5’ to 3’ exonuclease 
activity of Taq polymerase only occurs if the target sequence is being amplified, and the 
fluorescence signal emitted on cleavage of the probe can be used to detect amplification 
of the amplified product.   
While the probe is still intact, the close proximity of the quencher dye significantly 
decreases the fluorescence emitted by the reporter dye by permitting fluorescence 
resonance energy transfer (FRET).  Following denaturation, the primer anneals to the 
cDNA strand if the target sequence is present and the fluorogenic probe anneals 
downstream from one of the primer sites.  During this initial annealing stage both primers 
and probe base-pair bind to the complementary DNA target sequence.  Polymerisation of 
a new DNA strand is extended from the primers.  When the polymerase reaches the 
downstream probe the 5’ to 3’ exonuclease activity degrades the probe, physically 
separating the fluorescent reporter dye from the quencher dye.  The unquenched 
reporter dye fluorescence can be detected after excitation with a laser.    
Cleavage removes the probe from the target cDNA strand, allowing primer extension to 
continue to the end of the template strand.  Thus, inclusion of the probe does not inhibit 
the exponential accumulation of PCR product.  Additional reporter dye molecules are 
cleaved from their respective probes with each PCR cycle.  When the product targeted by 
the reporter probe increases at each PCR cycle, breakdown of the probe and consequent 
release of the reporter signal causes a proportional increase in fluorescence.  The 
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increase in fluorescence intensity is directly proportional to the amount of amplicon 
produced during the exponential phase of PCR513 514.  
2.7.4 PCR Chemistry 
The introduction of fluorogenic-labelled oligonucleotide probes that use the 5´ nuclease 
activity of Taq DNA polymerase into real-time PCR experiments enables the detection of 
only specific amplification products.  This is because specific hybridization between probe 
and target is required to generate fluorescent signal.  The assay utilises the 5’ nuclease 
activity of DNA polymerase to hydrolyse the hybridisation probe bound to its target 
amplicon.  Probes can also be labelled with different, discernible reporter dyes that allow 
amplification and detection of two distinct sequences in one reaction tube.  Furthermore, 
this development eliminates the post-PCR processing step previously required to analyse 
probe degradation by polymerase.   
2.7.4.1 TaqMan® Probes 
TaqMan® technology (Applied Biosystems, California, USA) uses hydrolysis probe 
chemistry with assay efficiency chiefly dependent on 5’ to 3’ exonuclease activity of Taq 
polymerase enzyme.  The oligonucleotide probe has a covalently bonded fluorescent 
reporter dye at the 5’ end and quencher dye at the 3’ end.  Reporter dyes commonly in 
use include 6-carboxyfluorescein (FAM), tetrachloro-6-carboxyfluorescein (TET), 
hexachloro-6-carboxyfluorescein (HEX) and VIC.  A commonly used quencher dye is 6-
carboxytetramethylrhodamine (TAMRA).  For real-time PCR experiments a forward and 
reverse primer are used in addition to the labelled oligonucleotide probe.   
2.7.4.2 Assay Design 
TaqMan® assays require both the usual pair of PCR primers with a sequence-specific 
fluorescently labelled probe that is flanked by the primers.  The primers and probe should 
be contained within a target amplicon of between 50 – 150 base pairs in length, 
preferably straddling an exon-exon junction.  Amplicons that are small in length promote 
high-efficiency assays and are more tolerant of variable reaction conditions.  The melting 
temperature Tm of the two primers should be within 1°C of each other and between 58 
111 
 
and 60°C.  The Tm of the TaqMan® probe should be 10°C greater than that of the primers 
to ensure that the probe is fully hybridised during primer extension.   
Nucleic acid techniques are highly sensitive and susceptible to small changes in assay 
conditions, being thereby prone to variability in results.  Assays with the design, synthesis 
and optimisation of concentrations of probe and primers and determined amplification 
efficiencies prior to use are commercially available.  Using a standardised validated 
biological assay can help to control variations in results and reduce the potential for error.   
Pre-optimised TaqMan® assays for human heme oxygenase 1 (Hs00157965_m1) and 
heme oxygenase 2 (Hs00157969_m1) were performed for the real-time PCR experiments.  
These assays are designed to detect all splice variants of the heme oxygenase gene.  
Assays used TaqMan® probes with FAM as the gene of interest reporter dye and TAMRA™ 
as the quencher dye515.   
2.7.5 PCR Kinetics 
Under ideal experimental conditions, the amount of DNA product doubles during each 
cycle of the PCR reaction.  After 2 cycles the amount of product is 2 x 2 the initial amount, 
after 3 cycles 2 x 2 x 2 (23) and after 4 cycles 24 the starting amount.  This can be defined 
by the equation N = N02
n where N is the number of amplified molecules, N0 is the initial 
number of molecules and n is the number of PCR cycles.  The exponential nature of PCR 
amplification only applies to the early phases of the reaction.  The reaction cannot go on 
indefinitely and as it progresses the reagents involved are depleted and become limiting.  
A plateau effect can be observed as the rate of product amplification slows and 
eventually stops.  Factors that can contribute to the plateau effect include: accumulation 
of DNA product to a concentration at which re-association competes with primer 
annealing and extension; components necessary for the reaction become limiting; 
inhibitors of polymerase enzyme activity accumulate such as pyrophosphates; the molar 
ratio of polymerase to template falls below a critical value and enzyme activity is 
impaired. 
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As the efficiency of the PCR reaction becomes increasingly impaired, PCR product 
amplification is reduced.  In real-time PCR analysis all phases of the PCR is revealed for 
every sample, enabling quantification of the product early during the exponential phase.   
PCR kinetics can be displayed by plotting DNA product copies against cycle number.  Using 
a regular scale gives an exponential graph: 
Figure 2.7.1: DNA copies per PCR cycle regular scale 
 
 
There is a linear relationship between DNA copies and cycle number using a logarithmic 
scale: 
Figure 2.7.2: DNA copies per PCR cycle log scale 
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The kinetic approach used in real-time PCR involves looking at the reaction in the early 
stages when amplification is exponential and linear on a logarithmic scale.  PCR machines 
contain a highly sensitive camera that monitors the fluorescence in each well of a 96-well 
plate at frequent intervals during the reaction.  The ABI Prism 7700 systems used for 
these experiments collects a fluorescent signal from each reaction every 7 seconds.  Over 
the course of a 40-cycle PCR lasting 1 hour and 56 minutes a total of 994 measurements 
are made for each reaction.  The kinetics of fluorescence accumulation is displayed in real 
time when the data are plotted against time.  Detection of fluorescence signal is directly 
proportional to product amplification.  The PCR reaction can be described in three 
phases: 
Exponential  
The early phase of PCR when all necessary reagents are fresh and available and the 
reaction is precise and very specific.  When PCR efficiency is assumed to be 100%, 
amplicon is doubled at every cycle.  During the exponential phase, the increase in signal 
detection corresponds directly to an increase in PCR product and is dependent on the 
amount of starting material. 
Linear (High Variability)  
Reagents are consumed as a result of amplification as the reaction progresses.  PCR 
efficiency is impaired, reactions slow down and amplicon is no longer doubled with every 
cycle. 
Plateau (End-Point) 
The PCR reaction has stopped.  DNA copies are no longer being made and the PCR 
products will begin to degrade if left long enough.  Each experiment sample has 
potentially different reaction kinetics and will reach the plateau phase at a different point 
in time.  Traditional agarose gel-based analysis of PCR products measures the amount of 
product at the plateau phase.  This method will detect misleading variations in end-
product amounts even when the starting amount of DNA template is identical between 
samples.  In contrast, real-time PCR uses the exponential phase to provide accurate and 
precise data for quantitation of PCR product.  This is in the early stages of the reaction, at 
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the very beginning of the upturn of the curve and not in the linear region of the curve on 
a standard scale. 
Figure 2.7.3: Phases of PCR   
 
 
2.7.6 The threshold cycle  
A fundamental measurement in real-time PCR is the threshold cycle (CT).  The CT is the 
cycle at which fluorescence generated by the accumulating PCR product exceeds a fixed 
threshold.   
At the start of PCR reporter fluorescent signal is beneath a baseline detection level 
defined as the PCR cycles during which signal is accumulating but is below instrument 
detection levels.  PCR cycles 3 to 15 are set as the default baseline and the arbitrary 
threshold level calculated as ten times the standard deviation of the average signal of the 
baseline fluorescent signal between cycles 3 to 15.  A fluorescent signal detected above 
threshold can be considered a true signal used to define the sample threshold cycle (CT).  
The threshold cycle can be defined as the fractional PCR cycle number at which reporter 
fluorescent intensity during the reaction is recorded as statistically significant above 
background.  The CT thereby indicates the number of cycles required to detect 
appearance of PCR product above the minimal detection threshold level.  The higher the 
abundance of target cDNA in the starting sample, the sooner the threshold fluorescence 
level is reached and the lower the CT
516.   
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The threshold line and CT values are always calculated during exponential phase cycles of 
PCR target amplification when none of the reaction components are limiting.  The CT 
value is proportional to the log concentration of the template cDNA (and target RNA).  
The amount of template cDNA and target RNA in experiment samples can be accurately 
determined by comparing the CT values of these samples against a series of standards 
with log transformation and calibration of the CT value.  The observed CT is not an 
absolute measure of target abundance as its value will vary depending on where the 
threshold line is set.  The CT value is dependent on the starting template copy number, 
the efficiency of amplification, the PCR system and the type of chemistry used.  
Comparison of the absolute CT value is only valid when comparing experiments using 
exactly the same reaction conditions including assay design, reaction volumes, reagents, 
primers and probes and PCR instruments.   
The CT value 
CT (threshold cycle) is the intersection between an amplification curve and a threshold 
line (Figure 2.7.4). It is a relative measure of the concentration of target in the PCR 
reaction. 
Figure 2.7.4: The CT threshold cycle value 
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2.7.7 PCR Efficiency 
Target PCR product abundance recorded at any time during a reaction is influenced by 
the amount of initial starting template, the efficiency of PCR and by the number of PCR 
cycles performed. 
PCR efficiency can be described by the equation Xn = X0 (1 + E)
n where n is the number of 
cycles performed, Xn is the amount of PCR product at cycle n, X0 is the initial amount of 
target mRNA or DNA and E is the amplification efficiency.  As the nature of the PCR 
reaction is exponential, very small changes in amplification efficiency can yield dramatic 
differences in the amount of product Xn even if the initial number of target molecules X0 is 
the same.   
PCR reaction efficiency can clearly affect the threshold cycle.  Two identical samples 
amplified under low and high experimental efficiency conditions produce different CT 
values for the same target template abundance.  Although the high efficiency condition 
results in a later CT at high concentrations, it has a better sensitivity at low target 
concentrations.  
Experimental factors that may affect the efficiency of amplification include impurities in 
the sample, the nature and length of the sequence being amplified, the sequence of the 
forward and reverse primers and the performance of other master mix components used 
in the reaction that affect the solution pH and salt concentration.  Efficiency between 90 
and 110% is generally considered acceptable.  
The purpose of the PCR is to copy a specific DNA fragment corresponding to the size 
predicted from the position of the primers on the cDNA (if looking at mRNA) or the 
genomic or plasmid DNA according to the nature of the target DNA.  Primer-dimer 
artifacts arise when primers anneal to themselves and create additional small templates 
for PCR amplification.  Mispriming describes the process whereby primers anneal to 
complementary or partially complementary sequences on DNA strands that are not part 
of the target sequence516.   
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2.7.8 Quantitation Assay 
A quantitation assay measures the amount of a nucleic acid target during each 
amplification cycle of the PCR.  The nucleic acid target may be DNA, cDNA or RNA using 
reverse transcription polymerase chain reaction (RT-PCR).  The aim of the assay is to 
calculate from the final PCR product abundance either the initial number of target 
molecules or the relative starting levels of target molecules among several samples.   
Absolute quantitation assays calculate the quantity of target nucleic acid in experiment 
samples from a standard curve.  Absolute quantitation is the appropriate method if 
researchers need to know the exact copy number of the target DNA or RNA in a given 
sample.  A common example is the correlation of viral copy numbers in biological samples 
to monitor the progress of disease in Human Immunodeficiency Virus infection. 
Relative quantitation assays calculate target RNA or DNA abundance in a given sample 
relative to another reference sample or control group.  The calculation methods used to 
perform relative quantitation with data from the ABI PRISM®7700 Sequence Detection 
System are the standard curve method or the comparative CT method. 
2.7.8.1 Standard Curve Method 
Standard curves are generated using accurate serial dilutions of stock DNA or RNA 
containing the appropriate target.  Three independent serial dilutions of the nucleic acid 
standard are assayed in duplicate together with positive and negative control reactions.  
The dilutions are made over the range of target copy numbers that include the amount of 
target nucleic acid expected in the experimental samples. 
Target abundance is expressed relative to an untreated control or reference calibrator 
sample.  Quantity of target nucleic acid in experimental sample is determined from the 
standard curve and divided by the target quantity of the control, expressed as n-fold 
difference relative to the control.  Relative target quantities can be determined across 
multiple plates by using identical stock DNA or RNA to prepare standard curves.   
The CT value is inversely proportional to the log of the initial copy number, so to generate 
a standard curve the CT values (with 95% confidence intervals) are plotted against the 
118 
 
logarithm of the initial target DNA or RNA copy numbers.  The copy numbers of 
experimental samples can be calculated after real-time amplification from the linear 
regression of the standard curve517.  
Quantitation can be normalised to an endogenous control using standard curves prepared 
for both the target nucleic acid and the endogenous reference.  The quantity of target 
and endogenous control is calculated from the appropriate standard curve for each 
experiment sample, dividing the target by the reference amount to obtain a normalised 
value.  Each of the normalised values can be expressed relative to a reference calibrator 
sample.   
2.7.8.2 Comparative CT method 
The comparative CT method was one of the first methods to be used to calculate real-
time PCR results.  It is an approximation method that permits comparison of expression of 
a gene of interest among different samples.  The expression level of the gene of interest is 
normalised to an endogenous control gene to normalise for variation in the amount and 
quality of RNA between samples.  It is similar to the standard curve method but uses the 
arithmetic formula 2-ΔΔCT to achieve the same result for relative quantitation
518. 
Expression of target mRNA abundance in experimental samples is normalised to an 
internal standard such as 18S ribosomal RNA and related to the expression level in a 
control sample (e.g. normal or untreated cells).  The difference between the CT value of 
the target mRNA and that of the internal standard is represented as CT(target mRNA) - 
CT(internal standard) = ΔCT.  The expression of the target gene in the test sample relative 
to the control sample is therefore given as ΔCT(test) - ΔCT(control) = ΔΔCT.   
Where the efficiency of PCR is close to 100% (i.e. close to a doubling of product per cycle) 
the relative abundance of the target RNA between the two samples becomes 2-
(ΔC
T
EXPERIMENT – ΔC
T
CONTROL) or 2-ΔΔCT.  This applies to all amplicons designed and optimised 
according to Applied Biosystems guidelines.  The formula 2-ΔΔCT represents the normalised 
expression of the target gene in the unknown sample relative to the normalised 
expression of the calibrator sample.  The advantage of the comparative CT method is that 
standard curves do not need to be constructed to achieve the same outcome.  
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Throughput is increased because wells no longer need to be used for the standard curve 
samples.  Adverse effects of any dilution errors made in creating the standard curve 
samples are also eliminated. 
The PCR efficiency has a major impact on the fluorescence profile and the accuracy of the 
calculated expression result when the ΔΔCT method is used.  For reliable comparison 
between samples there needs to be constant amplification efficiency in all samples being 
compared.  The 2-ΔΔCT equation assumes that target and standard efficiencies are both 
100%.   
The PCR efficiency must be demonstrated for both the target gene and the internal 
standard assay and is assessed by observing how CT varies with template dilution.  If the 
graph plot of template versus CT is close to zero, it implies that the amplification 
efficiencies of the housekeeping and target genes are very similar.  When efficiencies for 
each PCR are equal, the ΔCT value will be the same no matter what the dilution (standard 
curves have similar slope).   
Before using the comparative CT (ΔΔCT) method for quantitation a validation experiment 
must be performed to demonstrate that efficiencies of target and endogenous control 
amplifications are approximately equal and that the assumptions of the method are 
reasonably correct.  A sensitive method for assessing if two amplicons have the same 
efficiency is to look at how ΔCT varies with template dilution.  A graph is plotted of log 
input cDNA amount versus ΔCT values [ΔCT = CT(target mRNA) - CT(internal standard)].  
The absolute value of the slope is calculated by linear regression.  Applied Biosystems 
stipulate that only when this ΔCT plot gradient is less than 0.1 can the comparative CT 
calculation be reliably used for the relative quantitation of target without running 
standard curves on the same plate.  For situations in which the efficiencies of the two 
systems are not equal quantitation should be performed using the standard curve 
method.  Alternatively the validation experiment can be repeated using new primers 
designed and synthesised for the less efficient system to try and optimise efficiency519 520.   
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2.7.9 Endogenous Control 
Minor differences in the abundance of template RNA, variable RNA quality or disparities 
in the efficiency of cDNA synthesis and PCR amplification all introduce specific errors into 
real-time quantitative PCR experiments.  Amplification of an endogenous cellular control 
may be performed for the quantitation of gene expression in experiment samples to 
minimise these errors and correct for inter-sample variation.  Commonly used controls 
include β-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ribosomal RNA 
(rRNA).  The endogenous standard sequence is simultaneously amplified with the target 
gene using a second pair of gene-specific primers.  The ratios of the amount of PCR 
products generated by target and endogenous standard sequences in all experiment 
samples are then determined and compared.  An active reference has its own specific pair 
of primers and probe to generate an active signal as a result of PCR amplification.  Using a 
DNA or RNA that is present in each experiment sample as an active reference enables 
normalisation of target messenger RNA for differences in the amount of total RNA in each 
sample.  An alternative is to use an exogenous control which is a characterised RNA or 
DNA added or “spiked” into each experiment sample at a known concentration.  This can 
be used as an internal positive control to distinguish true target negatives from PCR 
inhibition.  An exogenous reference can also be used to normalise for variations in sample 
extraction efficiency or complementary DNA (cDNA) synthesis by reverse transcriptase 
PCR.   
The main advantage of using expression of an endogenous sequence as an internal 
standard is that the reference mRNA and the target mRNA are usually processed together 
for the entire duration of the experiment from RNA extraction through to PCR 
amplification.  This minimises differences in RNA yield between samples.  Using oligo(dT) 
primers and random hexamers converts the entire population of mRNA to cDNA in an 
attempt to normalise the overall efficiency of cDNA synthesis.   
Regardless of the use of an active reference, a passive reference is always used to provide 
an internal reference to which the reporter dye signal can be normalised during data 
analysis.  This correction is required to account for any non-PCR-related fluctuations in 
fluorescence signal caused by changes in concentration or volume.   
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Choosing a suitable internal control for normalisation of the target mRNA is of crucial 
importance.  The principal challenge of normalisation is to identify one or more 
endogenous control gene which evaluates RNA quality and quantity and takes into 
account factors influencing the various steps of PCR.  Characteristics required for a 
suitable control gene include: stable cellular expression in all experimental samples 
analysed with expression unaffected by reagent treatment in the experiment; equivalent 
stability to the target gene transcript so that any impaired amplification is mirrored by a 
corresponding reduction in target gene transcript quantity; PCR amplification that reflects 
variations in RNA quality, quantity or the efficiency of cDNA synthesis; no association with 
pseudogenes to avoid genomic DNA amplification and a level of expression that is neither 
too low (CT > 30) or too high (CT < 15) since the applied correction should be more 
accurate with a medium copy number.  Most importantly, expression of the internal 
control must be unaffected by the target mRNA.  Commonly used standards include the 
cytoskeletal protein β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a 
glycolytic enzyme.  Reported drawbacks of using GAPDH are that expression levels are 
altered by glucose, insulin, heat shock and cellular proliferation.  Levels of β-actin may 
also be modified by experimental treatments.  Alternative common control genes include 
MHC I (major histocompatibility complex I), cyclophilin and 28S or 18S ribosomal RNAs.  
For 18S ribosomal RNA all cells present in the sample under investigation will contribute 
to the resulting signal.  Ribosomal RNA (rRNA) is expressed at a much higher level than 
mRNA and therefore may not always be a good representative of total mRNA abundance 
in a cell.  One advantage of using rRNA is the relatively stable expression it provides under 
conditions affecting mRNA transcription.  
Since it may be said that the perfect standard does not exist, some researchers advocate 
the use of a minimum of three and five independent housekeeping genes in a single 
experiment.  The mean expression of these multiple genes can then be used for 
normalisation521-523.   
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2.7.10 Multiplex PCR 
A Multiplex PCR method can be used in relative quantitation when one primer pair 
amplifies the target gene of interest sequence and another primer pair amplifies the 
endogenous control simultaneously in the same reaction tube.  A multiplex reaction can 
be performed for both the standard curve and the comparative method by colour-coding 
the independent reactions using TaqMan probes labelled with different fluorescent 
dyes524.  There are multiple reporter dyes available for TaqMan® probes including 6-FAM, 
TET, and JOE that are distinguishable from one another due to their different emission 
wavelength maxima: 
6-FAM, λmax = 518 nm TET, λmax = 538 nm  JOE, λmax = 554 nm 
In addition the quencher dye TAMRA (λmax = 582 nm), and the passive reference dye 
ROX (λmax = 610 nm) are currently recommended for use in the TaqMan system.  The ABI 
PRISM 7700 Sequence Detection System software features a mathematical algorithm 
called multicomponenting that uses pure dye reference spectra to calculate the 
contribution of each dye to a complex reaction spectrum.  This process can thereby 
detect independent amplification of the relevant target sequences within the same 
experiment.  Multicomponenting does introduce a degree of error into the accuracy of 
fluorescent signal quantitation due to the experimental variation of measuring more than 
one spectrum.  The magnitude of this error can be minimised by maximising the spectral 
resolution between the various dyes used in the reaction.  This can be achieved using 
reporter dyes with a large difference in emission maximum – e.g. 6-FAM and JOE.   
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2.7.11 Limiting Primer Concept 
Common reagents are shared by PCR amplification reactions of multiple target 
sequences.  If one target segment has larger initial copy numbers this may use up the 
shared reagents to a degree that impairs amplification of the less abundant target gene.  
This will lead to a disproportionate amplicon and inaccurate quantitation.  To avoid this 
competition in amplification reactions the concentration of primers used can be limited 
to control the size of fluorescent signal generated.   
Limiting primer concentrations are defined by running a series of forward and reverse 
primer concentrations.  The limiting concentration is defined as the concentration that 
forces the fluorescent signal generated by PCR to plateau at a lower copy number without 
affecting the cycle threshold value.  Soon after obtaining accurate CT values the primers 
become exhausted and the reaction is halted.  In this way, amplification of the more 
abundant target species is stopped before it can limit the common reagents available for 
amplification of the minority species. 
The relative abundance of target and endogenous target sequences to be amplified must 
be taken into consideration when applying the limiting primer concept.  For these 
experiments ribosomal RNA (18S) was used as an endogenous reference.  The 
concentration of rRNA in total RNA is always greater than the concentration of any target 
mRNA.  Therefore, in a multiplex reaction amplifying both target mRNA and rRNA we 
need only limit the concentrations of the rRNA primers525.   
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2.7.12 Experimental protocol for mRNA quantitation using TaqMan® Hydrolysis probes 
1. RNA isolation 
RNA was prepared using the purpose-made RNeasy kit (Qiagen, Crawley, UK) for RNA 
extraction.  RNA is thermolabile and susceptible to rapid degradation by 
endoribonucleases (RNases) released as the intracellular matrix breaks down.  During 
RNA extraction samples are disrupted and homogenised in a buffer containing 
guanidinium salts which simultaneously lyses cells and inactivates endogenous RNases.  
Ethanol is added to the sample lysate.  Passing this solution through a silica-based filter 
allows other cellular components to pass through while the RNA binds to the filter.  The 
final step is to wash the filter to remove contaminants and the RNA is eluted. 
2. Primer design and optimisation 
A standardised validated biological TaqMan® assay was used for heme oxygenase (gene 
of interest) and internal control gene assays.  The design, synthesis and pre-optimised 
probe and primer concentrations have passed Applied Biosystem bioinformatics design 
criteria.  A validated assay was used to minimise the potential errors arising from 
experimental variation.  The reporter dye FAM was used for the gene of interest and the 
dye VIC to report the endogenous control 18S rRNA with TAMRA used as a quencher dye 
in the PCR reaction. 
3. RNA quantification  
The most common method of measuring RNA concentration is ultraviolet (UV) absorption 
spectroscopy which is quick and relatively simple but comparatively insensitive and 
typically requires minimum nucleic acid concentrations of 1μg per mL in order to obtain 
reliable measurements.  RiboGreen RNA quantification reagent is a superior alternative 
(Molecular Probes Europe BV, Leiden, The Netherlands Cat No. R11490).  RiboGreen is an 
RNA-binding dye that exceeds the sensitivity of UV absorbance spectrophotometry by 
1000-fold and ethidium-bromide-based assays by 200-fold518 526.   
Conventionally RiboGreen reagent is used with a fluorescence microplate reader, 
standard spectrofluorometer or filter fluorometer.  The reagent may also be used on any 
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real-time PCR instrument by selecting the SYBR dye layer (SYBR Green I) and deselecting 
other dye options – the reporter dye is changed from FAM to SYBR and the quencher dye 
TAMRA is deselected, also deselecting ROX as a reference dye.  RiboGreen assay is linear 
between 10 and 500ng per mL when performed on ABI Prism 7700 in a 200 μL per well 
reaction volume with RiboGreen reagent at a final dilution of 1 in 400.  RiboGreen reagent 
is stored at -80°C with a working 1X solution stored at -20°C.  The reagent is light-sensitive 
and the working solution is protected from light using foil wrapping as required.   
RNA samples were measured in triplicate for accurate quantification.  RiboGreen 
standards across the range of concentrations 0.013 – 0.526 ng per μL were used to 
construct a standard curve, with 100 μL reaction volume and 100 μL of Tris-EDTA buffer 
used for blank samples. 
Ribonucleases (RNases) are very active and stable enzymes that do not generally need 
cofactors to function.  RNase contamination of plasticware or glassware must be 
eliminated prior to use as RNases are difficult to inactivate and only tiny amounts are 
sufficient to destroy RNA.  To create and maintain an RNase-free environment, disposable 
RNase-free polypropylene tubes were used throughout RNA experiments.  Clean 
disposable gloves were worn during handling and preparation of all materials and 
solutions.   
Diethylpyrocarbonate (DEPC) is a strong inhibitor of RNase enzymes causing inactivation 
of RNases in water by the covalent modification of histidine residues.  DEPC-treated water 
was used in RNA handling and to create RNase-free solutions in order to minimise the 
inadvertent introduction of RNases into the RNA sample during or after the isolation 
procedure.  Water was treated with 0.1 mL diethylpyrocarbonate added to 100 mL (0.1% 
v/v) and the mixture vortexed to bring the DEPC into solution.  The solution was 
incubated for 12 hours at 37°C then autoclaved to 100°C for 15 minutes to inactivate any 
trace of DEPC.  Inactivation of DEPC in this manner yields carbon dioxide, water and 
ethanol.   
Purified RNA was stored at –20°C or –70°C in RNase-free water.  Under these conditions, 
no degradation of RNA is detectable after 1 year527. 
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4. Reverse Transcription 
Reverse transcription (RT) of RNA is necessary because RNA cannot act as a template for 
PCR.  Two-tube RT-PCR generates a stock of stable cDNA that is more suitable for long-
term storage.   
Using random hexamers and oligo dT as primers will allow amplification of the whole 
mRNA population.  If only use oligo dT primers then ribosomal transcripts (e.g. 18S) will 
not be represented in the cDNA since the oligo dT lack a poly-A tail.  Use of random 
hexamers is recommended.   
Gene-specific primers analyse a single gene specified by the initial RT primer.   
PCR mix is prepared at room temperature because the DNA polymerase is inactivated 
either by chemical modification or by an antibody.   
Mastermix used – contains buffer, MgCl2, dNTPs, enzyme 
Optimal probe concentration 50 – 200nM & optimal primer concentration 100 – 900nM 
Total volume 50 μL  
Negative controls – water – allow identification of contamination of reaction mix.  An RT 
sample is prepared in which reverse transcriptase has been omitted.   
Positive PCR controls can be used as a calibrator e.g. a cell line dilution 
5. Amplify cDNA 
The cDNA was amplified using TaqMan® Assays and TaqMan® master mix.  These 
purchased products (Applied Biosystems, Foster City, CA, USA) contain all of the enzymes, 
buffers, primers and probe necessary to perform TaqMan® real-time PCR for accurate 
nucleic acid quantitation.   
The ABI Prism 7700 instrument (Perkin-Elmer–Applied Biosystems, Foster City, CA, USA) is 
capable of combining amplification, detection and quantification of real-time PCR 
products using fluorescent signal techniques.  The instrument contains a built-in thermal 
cycler with 96-well positions able to detect fluorescence between 500nm and 660nm.  
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The cycle starts at 50°C for 2 minutes, heating to 95°C for 10 minutes to activate the Taq 
polymerase enzyme.  The instrument then runs through 40 thermal cycles of 95°C for 15 
seconds to denature DNA strands and allow unwinding followed by 60°C for 1 minute to 
allow primer and probe binding to the template strands.   
Amplification is performed in closed thin-walled optical tubes of the 96-well microplate 
within the combined thermal cycler/detector.  Laser light is distributed to each of the 96 
sample wells via a multiplexed array of optical fibres.  Each well is irradiated sequentially 
thereby inducing fluorescence.  The resulting fluorescence emission data for each sample 
are collected once every few seconds via the optical fibres and directed to a spectrograph 
as PCR products are being generated.  The spectrograph has a charge-coupled device 
(CCD) camera enabling spectral resolution of the fluorescent light.  Spectral analysis 
allows the simultaneous use of more than one spectrally distinct fluorescent probe as 
described above.  The initial starting copy number is determined by monitoring when PCR 
product is first detected at the threshold cycle.  The higher the starting copy number of 
the target, the sooner a significant increase in fluorescence is observed and the lower the 
threshold cycle.  These data are fed to a computer, which analyses and displays the 
results, eliminating the need for post-PCR processing. 
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2.7.13 RNA Quantification 
Detection and quantification of small amounts of RNA in molecular biology procedures 
can be achieved via numerous methods.  The most common traditional technique for 
measuring nucleic acid concentration is the determination of ultraviolet (UV) absorbance 
at 260 nm (A260) and at 280 nm (A280) using a spectrophotometer.  The Beer-Lambert law 
predicts a linear change in absorbance with concentration with an A260 of 1 unit 
corresponding to approximately 40 μg per mL of RNA in solution.  Absorbance readings 
should be greater than 0.15 to ensure significance.  The linear relationship between 
absorbance and concentration is based on an extinction coefficient calculated for RNA in 
water, so this method is only valid for RNA samples diluted in water. 
RNA has its absorption maximum at 260 nm and while the OD at 260 nm is used to 
determine the RNA concentration in a solution, the ratio of the absorbance at 260 and 
280 nm can be used to assess the RNA purity of an RNA preparation.  The A260:A280 ratio 
(A260/A280) can indicate contamination with solutes that absorb in the UV including 
proteins.  The pH of the sample also has a marked influence on the A260:A280 ratio, with 
lower pH producing a lower A260:A280 ratio and reduced sensitivity to protein 
contamination.  Measuring the purity of RNA samples in water can introduce variation in 
results as water is not buffered and the pH is not constant.  The most accurate value can 
be obtained by measuring the absorbance ratio in 10 mM Tris-Chloride buffer at pH 7.5, 
in which solution pure RNA has an A260:A280 ratio of 1.9 – 2.1.  Many protocols accept a 
value of 1.8 – 2.1 to indicate a pure RNA sample, depending on how the measurement is 
performed and the source of potential contaminants.   
For all the RNA samples eluted for real-time PCR analysis, an estimation of purity and RNA 
concentration was first performed using UV absorbance measurement with a 
spectrophotometer.  The solution volume measured in 1 mL cuvettes was 150 μL with 10 
μL of RNA sample diluted with 140 μL of RNase-free distilled water giving a dilution factor 
of 15.  The absorbance was measured at 260 and 280 nm.  The concentration of the RNA 
sample was calculated according to the following formula: 
Concentration of RNA sample = 40 x A260 x dilution factor = 40 x A260 x 15 μg per mL OR ng 
per μL 
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2.7.13.1 RiboGreen RNA Quantification 
The principal drawbacks of the UV absorbance-based technique include the relative 
insensitivity of the assay, the relatively large contribution of free nucleotides and proteins 
to the absorbance signal and interference by contaminants often present in nucleic acid 
preparations.  The use of sensitive fluorescent nucleic acid stains solves many of these 
issues.  To provide accurate RNA quantitation prior to reverse transcriptase PCR and real-
time RNA analysis a sensitive RNA-binding stain was used called Quant-iT™ RiboGreen® 
RNA reagent (Invitrogen, catalogue number R11490).  The Quant-iT™ RiboGreen® RNA 
reagent enables quantitation of as little as 1 ng per mL RNA using fluorescein excitation 
and emission wavelengths and was supplied with concentrated assay buffer and 
ribosomal RNA standards.  The sensitivity of the RiboGreen assay exceeds that achieved 
with ultraviolet absorbance determination by 1,000-fold, with as little as 200 pg RNA 
detectable in a 200 μL sample volume528 529.  The RiboGreen reagent accurately measures 
the amount of intact RNA polymers in potentially degraded samples and unlike UV 
absorbance the reagent does not detect significant sample contamination by free 
nucleotides528.   
The RiboGreen reagent also binds to DNA, and sample contamination by DNA generates 
fluorescence using the assay.  Although no currently available purification method can 
guarantee that RNA is completely free of DNA, DNase digestion of the purified RNA with 
RNase-free DNase was performed in an effort to ensure that the entire sample 
fluorescence generated was due to RiboGreen dye bound to RNA530 531.   
Tris-EDTA buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) was used to dilute the Quant-iT™ 
RiboGreen® reagent and for diluting the RNA samples.  The 20X Tris-EDTA buffer included 
in the Quant-iT™ RiboGreen® RNA Assay Kit is nuclease-free and nucleic acid–free.  A 1X 
Tris-EDTA working solution was prepared by diluting the concentrated buffer 20-fold with 
nuclease-free water.  
For the experimental RNA quantification assay, RiboGreen reagent was diluted to 1:400 in 
Tris-EDTA buffer and added to DNase-treated RNA in Tris-EDTA buffer.  The DNase-
treated RNA was diluted 100-fold in Tris-EDTA buffer and 100 μL added to 100 μL of dilute 
RiboGreen reagent per well.  This reaction was left at room temperature for 10 minutes in 
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a 96-well microplate and read on the ABI Prism 7700 plate reader.  The SYBR green dye 
filter on the ABI Prism 7700 was selected for the unknown dye, deselecting TAMRA as the 
quencher dye and ROX as the reference dye.  This is because the excitation and emission 
spectra for RiboGreen and SYBR green dyes are very similar: the SYBR green binds DNA 
while RiboGreen binds RNA.   
2.7.13.2 RNA Standard Curves  
For the construction of a standard curve 16S and 23S ribosomal purified RNA preparations 
were used.  In preparation of the standard curve, the RNA solution used was treated in 
the same manner as the experimental samples and estimated to contain similar levels of 
RNA and other possible contaminants. 
The ribosomal RNA standard was provided at 100 μg per mL in the RiboGreen® Assay kit 
and diluted 50-fold in Tris-EDTA buffer to make a working solution of 2 μg per mL.  This 2 
μgmL-1 solution was further diluted in Tris-EDTA buffer to give a range of final RNA 
concentrations used in the assay between 13 and 526 ng per mL.  Tris-EDTA buffer was 
used for blank samples in 6 wells of the 96-well microplate.  The reaction volume for all 
RiboGreen assays was 200 μL per well, with 100 μL diluted RNA sample added to 100 μL 
of RiboGreen reagent diluted 400-fold.  The plate was sealed and left in the dark at room 
temperature for 10 minutes before reading on the ABI Prism 7700.  The mean 
fluorescence value of the reagent blank was subtracted from the fluorescence value of 
each of the standard samples.  These corrected data were used to generate a standard 
curve and formula of fluorescence versus RNA concentration.   
All RNA samples eluted from siRNA experiments were initially quantified using UV 
absorbance as described above.  This provided a quality control measure to ensure purity 
of RNA samples with A260:A280 ratio between 1.9 and 2.1.  Accurate RNA concentrations 
were then obtained using RiboGreen assay.  A total of 40 ng RNA was used for cDNA 
synthesis for each sample.  The cDNA samples were diluted to 1 ngmL-1 with pure water 
and a total of 10 ng used in each PCR amplification reaction.   
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2.8 Heme Oxygenase Enzymatic Activity Assay 
The method used to measure the activity of heme oxygenase enzyme was performed as 
described by Motterlini et al532 533.  The assay measures the total heme oxygenase activity 
present in the cell suspension sample, i.e. the summation of HO-1 and HO-2 enzymatic 
activity.  It is not designed to determine the activity of individual HO enzyme isoforms.   
All experiments were completed with the kind supervision of Motterlini and colleagues at 
the Northwick Park Institute for Medical Research.  The validated technique described 
originally by Tenhunen et al and modified by Balla and co-workers has been 
demonstrated to produce the same results as the more refined mRNA assay133 137 165.   
2.8.1 Cell sample preparation 
Cells were cultured in 175 cm3 flasks (Nunc, Thermo Scientific, Denmark) to facilitate 
careful cell scraping during harvest.  Cells were cultured to achieve the desired confluency 
depending on the reagents used and the cell line under investigation.  A working volume 
of 48 mL was used for the flasks with a culture area of 175 cm2.  Oesophageal cell lines 
HET-1A and OE-33 were seeded at 3.2 x 106 cells in 48 mL for reagent experiments and at 
2.4 x 106 cells in 48 mL for siRNA transfection experiments.  Gastric adenocarcinoma cell 
lines AGS and HGC-27 were seeded at 2.4 x 106 cells in 48 mL for reagent experiments and 
at 1.44 x 106 cells in 48 mL for siRNA transfection experiments.  This strategy was 
consistent with corresponding experiments using 6-well, 24-well or 96-well plates, 
seeding at equivalent cells per mL to achieve cells that were 30 – 50% confluent at the 
time of siRNA transfection and 50 – 75% confluent prior to addition of experimental 
reagents.  Preparation of reagents and siRNA transfection protocols were carried out as 
previously described.  Cells were exposed to experimental conditions for the required 
predetermined duration.   
At the end of the experiment cells were washed twice with cold sterile phosphate-
buffered saline (PBS) at pH 7.4.  The adherent monolayer cells were then gently scraped 
in 10 mL of PBS using a cell scraper (Sarstedt, Germany) with a further 5 mL portion of 
cold PBS to wash any remaining cells anchored to the flask culture area.  The aspirated 15 
mL cell suspension was placed on ice in polypropylene Falcon tubes (BD Biosciences, 
132 
 
USA).  The cell suspension was finally centrifuged at 1,000 x g for 10 minutes at 4°C.  
Remaining supernatant was discarded and the cell pellet re-suspended in 550 μL MgCl2 (2 
mM) phosphate (100 mM) buffer at pH 7.4 with adequate vortex.  This cell suspension 
was suitable for short-term storage at -70°C until required for enzyme assay.   
2.8.2 Heme Oxygenase Assay 
Cell suspensions were subjected to three freeze / thaw cycles at -70°C for 10 minutes 
immediately followed by placement in a water bath at 37°C for 5 minutes to disrupt cell 
membranes before a final vortex on ice for 30 seconds to complete cell lysis.  The 
resulting cellular suspension was then divided into 400 μL for enzyme activity assay with 
100 μL transferred to an eppendorf tube and kept at 4°C for subsequent sample protein 
assay as detailed below.   
A reaction mixture was prepared for each HO activity assay sample containing:  
300 μL PBS with 2 mM MgCl2  
90 – 120 μL rat liver cytosol containing ≈3 mg per mL of protein prepared from 
supernatant fraction centrifuged at 105,000 x g as a source of bilverdin reductase 
(prepared according to Tenhunen, Marver, and Schmid165) 
25 μL hemin at 20 μM final concentration from a freshly prepared 2 mM hemin stock 
solution (see reagent preparation details previously described above) 
50 μL glucose-6-phosphate at 2 mM final concentration 
15 μL glucose-6-phosphate dehydrogenase at 0.5 IU per mL final concentration 
The remaining 400 μL cell suspension for each experiment sample was added to the 
corresponding labelled tube containing the reaction mixture.  A positive control was 
included using liver microsomal fraction from a rat treated with hemin for 24 hours.  
When all tubes were ready, 25 μL nicotinamide adenine dinucleotide phosphate (NADPH) 
at 0.8 mM final concentration was added to each tube to start the reaction.  All tubes 
were vortexed well, wrapped in aluminium foil and incubated in a 37°C waterbath.  The 
reaction was conducted for 1 h at 37°C in the dark as NADPH is light-sensitive.  The 
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reaction was terminated by the addition of 1 mL of chloroform to achieve a 1:1 ratio of 
reaction solution to chloroform.   
All tubes were then centrifuged at 1,000 x g for 5 minutes at room temperature.  Three 
layers were then expected to appear to form a top aqueous layer, a middle solid layer of 
cell material and lipids and a clear organic layer at the bottom.  All samples were vortexed 
briefly to disturb the bottom layer and then spun repeatedly at 1,000 x g until three layers 
were well defined.  This ensured extraction of all the bilirubin into the chloroform.   
The extracted bilirubin was calculated by measuring the difference in absorption between 
464 and 530 nm of the lower chloroform layer isolated by careful pipette aspiration.  The 
pipette tip was advanced through the overlying solid layer creating a smooth puncture to 
avoid any solid debris appearing in the aspirated chloroform layer.  A quartz cuvette was 
used with pure chloroform as a blank sample using the extinction coefficient 40 mM-1 cm-
1 for bilirubin. 
Heme oxygenase activity was expressed as picomoles of bilirubin formed per milligram of 
cell protein per hour.  The formula for calculation of heme oxygenase activity is as 
follows: 
1. Bilirubin concentration in chloroform: 
 
OD464 – OD530 nm [extinction coefficient ε = 40 mM
-1 cm-1 for bilirubin] 
         40 
 
2. Bilirubin is extracted with 1 mL chloroform for each sample reaction.  1 mL chloroform 
contains: 
 
   ΔOD  mmoles of bilirubin formed over 1 hour by one cell suspension 
40 x 103 
 
3. Heme oxygenase activity as pmol bilirubin formed / mg cell protein / hour 
 
 OD464 –OD530   x 10
6   pmol   
         40 x (protein content)        mg / hour 
 
The protein content of confluent cultured cells per experiment sample was measured by 
Bio-Rad DC protein assay method (Bio-Rad Laboratories Inc, Calif. USA) using bovine 
serum albumin as a standard534-536.  The protocols for preparation of rat liver cytosol as a 
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source of biliverdin reductase and rat liver microsomal fractions for a positive control 
both of which were required for the heme oxygenase enzyme activity assay were kindly 
performed by colleagues at the Northwick Park Institute for Medical Research. 
2.8.3 Preparation of rat liver cytosol as a source of biliverdin reductase 
Male Sprague-Dawley rats weighing between 200 – 250 grams were housed under 
laboratory conditions for at least 3 days prior to use.  They were fed with commercial rat 
chow and water ad libitum.  Animals were anaesthetised with intravenous ketamine and 
the liver perfused in situ with ice-cold 1.15 % (w/v) potassium chloride solution (KCl) via 
the portal vein.  The liver was quickly harvested and kept on ice bathed in KCl solution.  
All remaining procedures were performed at 0 – 4°C.  The liver was finely minced and 
homogenised in 2 – 3 volumes of cold 1.15 % KCl – 20 mM Tris Buffer (pH 7.4).  Each 
homogenate was transferred to polycarbonate tubes and centrifuged at 5,000 x g for 20 
minutes.  The supernatant fraction was collected and centrifuged at 105,000 x g for 60 
minutes.  Following each centrifugation the turbid lipid layer was removed with a Pasteur 
pipette.  After the final centrifugation the cytosol was removed taking care not to disturb 
the microsomal pellet.  The liver cytosol was divided into aliquots and kept at -80°C until 
required for use as a source of biliverdin reductase.    
2.8.4 Preparation of rat liver microsomal fractions for heme oxygenase positive control 
Male Sprague-Dawley rats housed in experimental conditions as above were treated with 
hemin at a final concentration of 20 – 30 μM for 24 hours.  At the end of the experimental 
protocol animals were euthanised by inhalation with isoflurane for 30 – 40 seconds or 
sacrificed by decapitation.  The liver was perfused in situ with cold 0.9 % sodium chloride 
solution (NaCl) via the portal vein for 2 – 3 minutes until the liver parenchyma became 
blanched.  The liver was then quickly harvested and homogenised in 5 volumes of 0.25 M 
sucrose with 0.05 M Tris-Hydrochloric Acid (HCl) buffer (pH 7.4).  The liver tissue 
homogenates were centrifuged at 27,000 x g for 20 minutes.  The remaining supernatant 
was then centrifuged at 105,000 x g for 90 minutes to yield the microsomal pellet.  The 
microsomal fraction was suspended in 1mL 0.1 M PBS – 2mM MgCl2 (pH 7.4) and kept at -
80°C until required for use as a positive control for heme oxygenase activity assay.   
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2.8.5 Protein Assay 
Several reported methods are available to analyse protein content within a particular 
sample, and each has advantages and limitations.  The method of choice depends upon 
the analysis required – qualitative analysis to determine purity or quantitative analysis to 
provide protein concentrations.  The most accurate method of determining protein 
concentration is probably acid hydrolysis followed by amino acid analysis that can 
calculate amino acid composition from primary analytical data and provides precise and 
sensitive quantitative and qualitative information.  Spectrophotometric techniques are 
available to characterise protein samples and measure protein concentration by 
measuring the absorbance of the aromatic amino acids in a sample at difference 
wavelengths.  Fluorescence spectroscopy provides a highly sensitive and more qualitative 
evaluation of amino acid composition.   
Colorimetric procedures can conveniently and reliably quantify the amount of protein 
contained within a sample solution.  A chemical reagent is added to the sample solution 
producing a visible colour change that is quantitated with a spectrophotometer or 
microplate reader.  The measured absorbance from the sample solution is compared 
against a standard curve of known concentrations of protein.  This determines the total 
quantity of protein in an unknown sample via interpolation from the standard curve.  The 
Bradford and the Lowry methods are the most frequently used colorimetric techniques.  
Both methods are sensitive to the amino acid composition of the protein, and absolute 
concentrations cannot be obtained537.  The technique of protein assay employed may 
depend on the type of protein, or the amount of protein likely to be available for assay.  
The choice of assay may also depend on experimental factors such as the chemical 
components contained in the buffer, the filters available for the laboratory 
spectrophotometer or the settings available on the microplate reader. 
2.8.6 The Lowry Method for Protein Quantitation 
The Lowry technique was reported in 1951534-538 and the method was developed and 
adapted from earlier work of Wu539 advocating the use of the Folin phenol reagent for the 
determination of protein concentration.  The method is based on both the Biuret reaction 
and its subsequent amplification by reaction with the Folin phenol reagent (Folin–
136 
 
Ciocalteu reagent540).  It quantifies the colour obtained from the reaction of Folin-
Ciocalteu phenol reagent with the tyrosyl residues of an unknown protein sample.   
The Biuret reaction is based on the complex formation of cupric ions (Cu2+) with the 
peptide bonds of proteins under alkaline conditions.  In this reaction copper sulphate is 
added to a protein solution in strong alkaline solution containing sodium potassium 
tartrate.  A purple-violet coloured chelate complex is formed between cupric ions and 
peptides containing three or more amino acid residues.  The intensity of the colour 
produced is proportional to the number of peptide bonds participating in the reaction.  
The nature of the biuret reaction with unknown sample proteins is independent of the 
composition of the protein541-544.  The name of the reaction is derived from a similar 
reaction between copper and the organic compound biuret (NH2-CO-NH-CO-NH2) that is 
a product of excess urea and heat.  Biuret forms a light blue tetradentate chelate complex 
with cupric ions545.  Although protein composition is not a factor in the reaction, both 
protein purity and association state can influence the results obtained with the biuret 
reagent537 538 542 544.   
The Folin–Ciocalteau reaction is poorly understood.  The principle depends on the 
reaction of the phenolic (R) group of tyrosine residues with colourless 
phosphomolybdotungstate ions in the presence of cupric ions.  Folin-Ciocaltaeu reagent 
contains phosphomolybdotungstate complex which is a mixture of sodium tungstate, 
sodium molybdate and phosphate.  The phenol groups within the tyrosyl of aromatic 
amino acids are oxidised in a reaction catalysed by alkaline copper sulphate.  The 
phosphomolybdotungstate complex is reduced to a blue chromogen 
heteropolymolybdenum blue.  The intensity of the blue-purple colour formed due to this 
oxidation-reduction reaction depends partly on the amount of aromatic amino acids 
tryptophan and tyrosine present in the sample.  The intensity can be estimated 
spectrophotometrically by measuring the absorbance at 650 – 750 nm wavelength.  
Adding the use of Folin-Ciocalteau reagent greatly enhances the sensitivity of the Lowry 
assay.  The method is reliably sensitive down to approximately 0.01 mg of protein per mL 
and is best used on solutions with expected concentrations in the range 0.01 – 1.0 mg per 
mL of protein.   
137 
 
Various substances can interfere with the Lowry reaction, including many nitrogen-
containing buffers535 536 538.  There are two principle disadvantages of the Lowry protein 
assay method, namely that the amount of colour development is not strictly proportional 
to protein concentration and that this amount is variable depending on protein 
composition534.  The variation in colour development with different proteins reflects the 
pivotal contributions of specific amino acids tyrosine and tryptophan to the reaction546 547.  
Studies by Viner et al observed that oxidative inactivation of tyrosine and tryptophan 
decreased protein reactivity in the Lowry reaction548.  Protein variability can be minimised 
by performing the assay at an appropriate wavelength549 550.  Overall, the Lowry method 
sensitivity to amino acid composition is fairly constant from protein to protein.  The 
method has been so widely used that Lowry protein estimations are an acceptable 
alternative to rigorous absolute determinations of protein content for various 
experimental approaches.  Applicable circumstances include the measurement of mixed 
tissue protein, highly diluted protein samples or analysis of large numbers of similar 
protein samples such as antigen-antibody precipitates.  
2.8.7 Protein Assay for HO activity assay 
DC Protein Assay (Bio-Rad Laboratories Inc, Calif. USA) 
The Bio-Rad DC (detergent compatible) protein assay is a colorimetric assay for protein 
concentration following solubilisation of any detergent contained in the samples to be 
analysed.  If the test samples contain detergent, 20 μL of surfactant reagent is added to 
each ml of copper tartrate reagent needed for the assay.  The DC protein assay technique 
was used to quantify protein in cell suspensions tested for heme oxygenase activity.  The 
reaction is similar to the Lowry assay but has been modified to reach 95 % of its maximum 
colour development within 15 minutes of incubation and to have stable absorbance for at 
least 2 hours with a colour change of less than 5 % within 1 hour.  It is based on the initial 
reaction between protein and copper at alkaline pH coupled with the subsequent 
reduction of Folin-Ciocalteu reagent by the copper-treated protein.  Proteins reduce the 
Folin-Ciocalteu reagent by the loss of 1, 2, or 3 oxygen atoms yielding several possible 
reduced species that have a characteristic blue colour with a maximum absorbance at 750 
nm and minimum absorbance at 405 nm.  The intensity of the colour development 
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depends on the contribution of the amino acids tyrosine and tryptophan and to a lesser 
extent cysteine, cystine and histidine present in the sample proteins analysed.   
The experimental protocol used 100 μL of protein sample with 100 μL of PBS as a blank 
sample.  The Bio-Rad kit included an alkaline copper tartrate / carbonate (CTC) solution 
(reagent A) and a dilute Folin-Ciocalteu reagent at 20% (v/v) concentration (reagent B).  
For the protein assay, 500 μL of reagent A was added to the 100 μL test sample and 
vortexed to mix well.  Then 4 mL of reagent B was added and vortexed followed by 
incubation at room temperature for 30 minutes.  The absorbance was measured using 
standard disposable polystyrene cuvettes with the spectrophotometer at 750 nm within 1 
hour.  The spectrophotometer was equipped with a constant temperature cuvette 
chamber.  Bovine serum albumin was used as a protein standard.  The DC protein assay 
shows little difference in colour development between bovine serum albumin and bovine 
gamma globulin.  A standard curve was prepared over a range of BSA concentrations from 
0.125 – 1.5 mg/mL with a final volume 100μL.  The BSA standard was prepared in the 
same buffer as the cell suspension test samples to minimise any interference effects.  The 
dilutions for the standard curve were prepared according to the table below: 
Final concentration (mg/ml) Volume of a 2mg/ml standard (μl) Volume of water or 
dilution buffer (μl) 
0 (blank)    0      100 
0.2     10      90 
0.4     20      80 
0.6     30      70 
0.8     40      60 
1.0     50     50 
1.5     75      25 
Table 2.8.1: Standard dilutions for preparation of a calibration curve 
The standard curve fit is quadratic of the form y = ax2 + bx + c. 
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2.9 Flow cytometry 
Measurement of DNA content for cell cycle analysis and characteristics of labelled probes 
for studies of apoptosis was performed using flow cytometry techniques.   
2.9.1 Flow Cytometry Sample Preparation 
When preparing a sample of cells for flow cytometry analysis the aims are to produce a 
suspension of single cells with minimal cell aggregation, minimal cell debris and the 
lowest possible number of dead cells.  Cell clumps can cause disruption of fluid flow 
through the cytometer or block the flow channels within the instrument.  Care must be 
taken during sample preparation especially when using cells in monolayer.  Various 
enzyme techniques can alter cell-surface antigens and affect cell viability that introduces 
bias into the results obtained by cytometry analysis.  In all flow cytometry experiments 
conducted, cells were filtered through a 70 μM nylon mesh immediately prior to analysis 
through the cytometers in order to prevent cell clumping. 
2.9.2 Cyan ADP Flow Cytometer (Beckman Coulter) 
The instrument used for all flow analysis was the CyAn ADP (three laser) 9-colour flow 
cytometer produced by Beckman Coulter.  It has eleven parameters (forward scatter, side 
scatter and fluorescent channels FL-1 to Fl-9) and is equipped with 488 nm, 405 nm, and 
642 nm solid-state lasers.  The CyAn ADP is capable of flow rates up to 150 µL per minute.  
The instrument includes sophisticated optics and utilises high performance electronics 
with pulse processing speed up to 70,000 events per second complementing a high 
acquisition and analysis capability of up to 1 x 108 event data files.  Summit software 
version 4.3 (Dako) was used for all data analysis applications.   
2.9.3 Cell preparation and staining protocol 
Measurement of DNA content for cell cycle analysis was achieved using propidium iodide 
(PI) staining of cell samples.  Cells were prepared using ethanol to fix and permeabilise 
the plasma membrane to enable DNA staining of intact cells.  Binding of propidium iodide 
to DNA is not covalent and is reversible, essentially following the law of mass action.  
Equilibrium exists in solution between available intracellular DNA binding sites and the 
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concentration of free fluorochrome.  For diploid cells in G1 phase of the cell cycle there 
are 3 x 109 DNA base pairs per cell but some nucleosomal DNA within the cell is 
inaccessible to intercalating dyes and only a fraction of the potential binding sites (10-
70%) are actually available for staining551.  If cell samples include an increased population 
of tetraploid cells arrested at the G2/M phase then the higher DNA content of the sample 
causes a shift in equilibrium towards reduced concentration of free dye that consequently 
reduces the ability to stain DNA binding sites and altered fluorescence552.  
Recommended standard conditions include using a fluorochrome ligand at 100 µM 
concentration to stain 1 x 106 cells in a volume of 500 µL – 1 mL.  Under these conditions 
there is an excess of available dye ligand per available DNA binding site meaning that an 
increase in cell number from 1 to 2 million (changing the concentration of free dye by 1%) 
should not be reflected by any change in DNA staining greater than 1%.  Nevertheless it 
remains critically important to keep the ratio of dye:cells relatively constant especially 
when comparing DNA content histograms between cell samples of a specific experiment.  
For this reason every cell sample prepared was counted using a haemocytometer prior to 
staining with PI553 554.   
Cell lines were seeded into experiment wells at an appropriate number to achieve 60 – 
70% density at the time of adding reagents 24 hours after seeding.  For OE-33 and HET-1A 
cell lines cells were seeded into 6-well plates at 165,000 cells per well in 2.5 mL and into 
24-well plates at 33,000 cells per well in 0.5 mL from a cell suspension of 1 x 106 cells in 
15 mL.  For AGS and HGC-27 cell lines comparatively fewer cells were required to achieve 
the equivalent density after 24 hours.  AGS and HGC-27 cells were seeded into 6-well 
plates at 125,000 cells per well in 2.5 mL and into 24-well plates at 25,000 cells per well in 
0.5 mL from a cell suspension of 0.75 x 106 cells in 15 mL.   
Cell collection was performed at the appropriate time point with every step carried out 
on ice.  Floating cells were first harvested into a 15 mL Falcon tube.  Attached monolayer 
cells were then harvested by incubating with 4 mM EDTA PBS at 37°C for 5 minutes 
followed by aspiration into the corresponding Falcon tube.  Cell suspensions were 
pelleted by centrifugation at 300 x g for 6 minutes and re-suspended in 1 mL of cold PBS 
in the falcon tube to count the cells using a haemocytometer.  Cell suspensions were then 
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aliquoted to use at approximately 1 x 106 cells per mL, washed with 10 mL PBS and 
resuspended in 250 µL cold PBS in the falcon tube.  Cells were fixed and permeabilised by 
adding 1 mL of ice-cold 70% ethanol drop by drop with constant slow vortex to shake the 
tube.  Cells were thoroughly re-suspended prior to adding the 70% ethanol to achieve a 
single cell suspension as fixation of cells that are in aggregates while suspended in PBS 
stabilises the aggregates which are then impossible to disaggregate.  The fixed 
permeabilised cell suspension was incubated overnight at 4°C.  Cells suspended in ethanol 
can be stored at 0 – 4°C for several months to a year. 
The following day 10 mL of PBS was added to the ethanol-fixed cells, the suspensions 
centrifuged at 300 x g for 6 minutes and the ethanol carefully decanted.  The resulting cell 
pellet was re-suspended in 5 mL of binding buffer and left for 1 minute prior to repeat 
centrifugation at 300 x g for 6 minutes.  Finally the cell pellet was suspended in 500 µL of 
PI staining solution (50 µgml-1 PI and 50 µgml-1 RNase A in PBS).  Stained cells were 
incubated at room temperature protected from light for 30 minutes prior to transferring 
the samples to the FACS laboratory for flow cytometry analysis.  Cell cycle distribution 
was assessed counting 10,000 cells for each experiment sample.   
2.9.4 Cell staining reagents  
EDTA (Ethylenediaminetetraacetic acid) has a molecular weight of 380.2 so 0.38g powder 
was weighed and dissolved in 10 mL PBS to achieve a 100 mM stock solution.  Stock 
solution was diluted further in PBS to produce a 4 mM solution to add to the cell 
monolayer for cell detachment. 
Binding buffer was prepared as a 10x concentrated calcium chloride and sodium chloride 
buffer at pH 7.5 using 100 mM HEPES, 1.4 M NaCl and 25 mM CaCl2.  Sodium chloride 
(NaCl) was prepared to a 1.4 M solution by dissolving 8.18g in 100 mL ddH2O (1M = 
58.44g in 1000 mL).  Calcium chloride was prepared to a 25 mM solution by dissolving 
0.3675g in 100 mL ddH2O (1 M = 147.0g in 1000 mL). 
Ribonuclease A (RNase A) is an endoribonuclease that cleaves single stranded RNA.  The 
enzyme attacks pyrimidine nucleotides at the 3'-phosphate group and cleaves the 5'-
phosphate linkage to the adjacent nucleotide. RNase A works in the absence of cofactors 
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and divalent cations and although active under a wide range of reaction conditions it can 
be inhibited by RNase inhibitor that occurs naturally in cell cytosol.  At sodium chloride 
concentrations of 0.3 M or higher RNase A specifically cleaves single-stranded RNA555.   
For this application DNase-free ribonuclease A from bovine pancreas (Sigma-Aldrich 
R4642) was supplied as a solution in 50% glycerol containing 10 mM Tris-HCl buffer at pH 
8.0 and diluted in PBS to a stock solution of 5mg per mL.  The supplied preparation did 
not require the traditional boiling of RNase A solution to inactivate DNase and remained 
active for at least 2 years under recommended storage conditions at −20°C. 
Propidium iodide (BD Biosciences) was provided in a PBS buffered pH 7.4 stock solution at 
a concentration of 1 mg per mL.  A PI staining solution was prepared containing 50 μg per 
mL PI and 50 μg per mL RNase A in PBS.  The PI solution contained 18.8 mL PBS, 1 mL PI 
stock at 1 mg per mL and 200 µL of RNase A stock at 5 mg per mL and was stable at 4°C 
for up to 3 months.  Cell pellets of 1 x 106 cells were suspended in 500 µL of staining 
solution containing 25 µg PI and 25 µg RNase A.   
2.9.5 Cell Cycle Analysis 
Cell growth and proliferation in eukaryotic cells is characterised by five distinct phases of 
development that constitute the cell cycle.  Cell division represents a highly conserved 
and ordered process involving a tightly controlled series of molecular events.  The 
sequence of events can be described as follows: an initial quiescent or resting state (G0 
phase) followed by cell growth with RNA and protein synthesis as the cell prepares for 
chromosomal replication (G1 phase); DNA synthesis as chromosomes are replicated (S 
phase); preparations for cell division and repair of duplicated chromosomes (G2 phase); 
mitosis and cytokinesis of parent cells (M phase) to give two daughter cells that 
immediately enter G0 phase to continue the cycle.  The three gap phases G0, G1 and G2 
and DNA replication during S phase are collectively referred to as interphase or between 
mitoses.   
The DNA content within cells varies as the cells progress through the cell cycle.  The DNA 
content of cells can be measured rapidly and conveniently by flow cytometry techniques.  
DNA content measurements are based on the properties of fluorescent nuclear dyes such 
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as propidium iodide that selectively bind DNA under appropriate staining conditions.  
Cells stained with nuclear dyes emit fluorescence after excitation with ultraviolet or 488 
nm laser light in direct proportion to their DNA content with flow cytometers able to 
simultaneously measure cell volume parameters.  Cells in the G0/G1 phases of the cell 
cycle are diploid, cells in the G2/M phases are tetraploid and S phase cells are somewhere 
in between.  Staining of the DNA of apoptotic cells is a simple method to quantify 
apoptosis within a sample.  Apoptotic cells are sub-diploid (less than 2n) and the 
fragmented DNA strands result in a typical sub-G0 peak on the histogram.  The size of this 
peak can be used as an approximate indicator of the number of apoptotic cells. 
2.9.6 Cell Cycle Data Analysis 
Acquisition settings for measurement of DNA content using flow cytometry included 
limiting the event rate below a maximum of 200 counts per second and obtaining 
histogram plots of events versus PE Texas Red fluorescence.  Initial histograms of pulse 
width versus forward scatter detected cell doublets.  A polygon gate was drawn to 
exclude the doublets and applied to area versus linear plots and the gating process 
repeated for linear side scatter versus linear forward scatter histograms to correct for the 
size and granularity of cells.   
At cell concentration below 1 x 106 per mL the flow rate of the sample through the 
cytometers has to be increased which can degrade the value of the coefficient of 
variation.  Alternatively if the concentration is too high there may be insufficient dye to 
stoichiometrically stain the DNA present in the sample.   
The histogram plots obtained were checked systematically to satisfy the following criteria:  
the number of channels in the histogram should be at least 512; the flow rate should be 
kept low in order to obtain the best CV (coefficient of variation); the linearity of the plot 
should produce a tight and short distance G1 peak with a CV of less than 8%; the ratio 
between G1 and G2 peaks should be between 1.95 – 2.05 and the cell debris measured 
should be up to a maximum of 30%.  A polygon gate was drawn around cell debris on a 
single-parameter count rate versus PE Texas Red histogram and if greater than 30% then 
the threshold Texas Red fluorescence was altered accordingly.   
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2.10 Apoptosis studies: Plasma membrane changes 
2.10.1 FITC-Annexin V and PI Staining for Apoptosis 
Sequential changes occur in the plasma membrane during apoptosis.  An early and unique 
event in the apoptotic sequence is the exposure of membrane phospholipids as the 
maintenance of plasma membrane asymmetry is impaired556 557.  Changes in the lipid 
composition of the plasma membrane and its permeability to small cations have been 
documented as relatively early signs of the apoptotic cascade558 559.  Membrane 
alterations usually follow the loss of mitochondrial membrane potential and caspase 
activation and appear before nuclear DNA fragmentation and DNA laddering560.   
An asymmetrical phospholipid distribution is sustained by cell membrane proteins 
including aminophospholipid translocase that facilitate the translocation of lipid 
molecules from one leaflet to the other in a magnesium/ATP-dependent process561 562.  
The activity of membrane proteins not only keeps phosphatidyl serine (PS) on the inner 
surface but also provides cells with the ability to translocate PS to the outer plasma 
membrane leaflet when required.  Phosphatidyl serine generally constitutes less than 
10% of the total membrane phospholipid composition.  During apoptosis the function of 
aminophospholipid translocase is reduced and activity of the enzyme phospholipid 
scramblase is relatively increased.  Translocation of phosphatidyl serine to the outer 
leaflet is thereby achieved with exposure of PS residues on the cell surface563 564.  The 
exposed PS on the cell surface has an important function as a marker for specific 
recognition by macrophages with PS receptors565 566.  The macrophages are recruited to 
perform phagocytosis of apoptotic cells and apoptotic bodies.  Expression of PS residues 
at the outer plasma membrane leaflet has been demonstrated to occur early during 
apoptosis before loss of plasma membrane integrity559.  
Flow cytometry techniques were used to detect binding of Annexin-V conjugated with 
FITC (fluorescein isothiocyanate) to exposed phosphatidyl serine (PS) residues in the 
plasma cell membrane as an indicator of early apoptosis.  Annexin-V is a 35 – 36 kDa 
anticoagulant protein with a higher affinity for phosphatidyl serine (PS) than most other 
phospholipids.  Annexin V is not able to bind to normal living cells since the molecule 
cannot penetrate the phospholipid bilayer of the plasma membrane.  The FITC-Annexin V 
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conjugate reversibly binds to exposed PS residues in the presence of defined millimolar 
concentrations of salt and calcium ions (Ca2+).  Annexin V conjugated to fluorochromes 
with different absorption and emission wavelengths can be detected by flow cytometry 
and fluorescence microscopy560 567.  Cationic vital dyes such as propidium iodide (PI) or 7-
amino-actinomycin (7-AAD) stain cellular DNA but are only able to infiltrate the cell after 
plasma membrane breakdown.  Cells that are live or going through early apoptosis are 
still able to exclude the cationic dyes.  As secondary necrosis occurs the plasma 
membrane loses the ability to exclude the dyes568.  Therefore annexin-V assays can be 
used in conjunction with plasma membrane permeability marker and analysed by flow 
cytometry.   
2.10.2 Cell Seeding 
Experiments for flow cytometry analysis of apoptosis were conducted using 6-well plates 
and 25 cm2 growth area culture flasks (Nunc).  The growth area of each well in a 6-well 
plate is 9.6 cm2.  For cell seeding purposes, AGS and HGC-27 cells were seeded at 125,000 
cells per well of a 6-well plate in a well volume of 2.5 mL.  OE-33 and HET-1A cells were 
seeded at 165,000 cells per well of a 6-well plate in 2.5 mL.  For the T25 culture flasks AGS 
and HGC-27 cells were seeded at 350,000 cells per flask while OE-33 and HET-1A cells 
were seeded at 420,000 cells per flask, both in a volume of 7 mL per flask.   
Individual flasks or triplicate wells were used as negative controls to set up flow 
compensation and dot plot quadrants for cytometry analysis.  Controls included: 
1. Unstained cells 
2. Cells stained with FITC-Annexin V alone (no PI) 
3. Cells stained with PI alone (no FITC-Annexin V) 
4. Untreated experimental control cells stained with FITC-Annexin V conjugate and PI 
solution 
Experimental reagents were added across various time points for a kinetic study aiming to 
demonstrate the progression of cells through viable cells to early apoptosis to secondary 
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necrosis.  Time points chosen were 6 hours, 12 hours and 24 hours as standard with 
extension to 48 hours when indicated.   
As a positive control cells were exposed to 1 µg per mL staurosporine for 3 hours.   
2.10.3 Reagents 
Binding Buffer  
A buffer to promote annexin V binding to exposed PS residue sites was prepared to 
include 100mM HEPES buffer, 1.4 M sodium chloride (NaCl), 25 mM calcium chloride 
(CaCl2) adjusted with 1M NaOH to a final pH 7.5.  Sodium chloride solution at 1.4 M was 
prepared by dissolving 8.18g in 100 mL sterile water.  Calcium chloride solution at 25 mM 
was prepared by dissolving 0.3675g in 100 mL sterile water.  The binding buffer thus 
prepared was at 10X concentration to provide a final concentration (1X) of calcium ions at 
2.5 mM required for binding of annexin V to phosphatidyl serine.   
Annexin V and Propidium Iodide 
Annexin V conjugated with FITC fluorochrome was purchased from Sigma-Aldrich 
(catalogue number A9210).  The annexin V-FITC reagent contained approximately 50 µg 
per mL 50 mM Tris-HCl buffer at pH 7.5 and containing 100 mM NaCl.  Propidium Iodide 
solution was also supplied by Sigma (catalogue number P2667) containing 100 µg per mL 
in 10 mM potassium phosphate buffer at pH 7.4 and containing 150 mM NaCl.  
Fluorescence-labelled annexin V needs to be stored refrigerated at 2–8°C and loses 
biological activity due to dimerisation if stored frozen.   
Staurosporine  
The p21 cell cycle inhibitor staurosporine (Sigma-Aldrich, catalogue number S5921) was 
dissolved in DMSO universal solvent to a concentration of 100 µg per mL.  A working stock 
solution was prepared for storage at 1 mM and further diluted to 10 μM stock to give a 
final concentration of 1 µg per mL when added to experiment wells or culture flasks.   
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2.10.4 Cell collection 
Cell morphology was documented for each experiment condition with attention to 
obvious rounding or detachment of cells to indicate apoptosis.  The culture supernatant 
was collected into 15 mL Falcon tubes to include detached cells in the analysis.  Cells were 
washed twice with sterile PBS.  For experiments using 6-well plates adherent cells were 
detached by the addition of 2 mL 4 mM EDTA [0.15%] in PBS and incubation for 3-4 
minutes.  EDTA solution (EDTA MW = 380.2) was prepared by dissolving 0.380g in 10 mL 
PBS to obtain 100 mM stock solution that was diluted further with PBS to a 4 mM 
solution.  Cells were then gently scraped and collected into corresponding Falcon tubes 
with addition of 2 mL serum complete medium to facilitate cell collection.   
For experiments using T25 culture flasks a technique of labelling the cells prior to 
harvesting was used569.  The cell monolayers were washed twice with PBS before adding 
FITC-Annexin V and PI reagents in 1x binding buffer.  Flasks were incubated in the dark at 
room temperature for 10 minutes.  After labelling all flasks were washed twice in 1x 
binding buffer to remove excess staining reagent and detached using EDTA and cell 
scraping as described above.   
Falcon tube cell suspensions were centrifuged at 400 x g for 6 minutes and cell pellets 
resuspended in 1x binding buffer at a concentration of approximately 1 x 106 cells per mL.  
Unstained cell suspensions from 6-well plates were labelled by the addition of 5 mL FITC-
Annexin V conjugate and 10 mL Propidium Iodide solution to each cell suspension.  Tubes 
were incubated at room temperature for 10 minutes and protected from light.  Cells were 
then analysed by flow cytometry using 30,000 cells for each experiment sample. 
2.10.5 Flow Cytometry Analysis 
FITC-Annexin V was detected as a green fluorescence with a maximum emission of 528 
nm.  This was measured in the standard FITC Channel on a flow cytometer (FL1).  
Propidium iodide was detected as a red fluorescence with a maximum emission of 620 
nm.  This was measured on the PE Texas Red short channel on a flow cytometer (FL2 or 
FL3). 
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Initial analysis of unstained control cells was performed to establish the correct 
instrument settings.  Pulse width and forward scatter was first analysed on a linear scale 
to discard cell doublets or cell clumps and the associated false positive results.  Applying a 
gate below 64 pulse width on the histogram included only single file cell interrogations.  
The histogram of FITC versus Texas Red provided analysis of annexin V and PI staining and 
fluorescence emission.  The FITC and Texas Red populations were brought on scale and 
instrument voltages adjusted to gate the population so that most were in the first log 
decade.   
Control cells untreated by experiment reagents were then analysed to apply appropriate 
compensation with single staining of annexin V-FITC and PI and stained with both annexin 
V-FITC and PI.  A positive control double-stained sample of cells treated with the 
apoptosis-inducing staurosporine was used to establish correct placement of quadrant 
regions.  Cells that are early in the apoptotic process stain with the annexin V-FITC 
conjugate alone.  Necrotic cells stain with both the propidium iodide solution and annexin 
V-FITC conjugate.  It is not possible to have cells that are PI positive without the cells also 
being positive for annexin V binding as the PI staining reflects compromise of the plasma 
membrane.  As the plasma membrane is disrupted, annexin V can also enter the cell and 
bind to PS residue sites on the internal cell membrane surface.  If cells appear to be PI 
positive but annexin V negative then the FITC channel histogram gating is adjusted to 
include annexin V staining for all PI positive cells.  Viable cells show no staining by either 
annexin V-FITC or PI solution (Figure 2.12.2).  
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Figure 2.10.1: Quadrants applied for analysis of Annexin V-FITC and Propidium Iodide 
fluorescent staining 
 
The cells identified in each of the four quadrants can provide quantitative analysis of the 
cell populations studied in the experiment (Figure 2.12.3) 
 
Figure 2.10.2: Quantitative analysis of apoptosis in cell samples by Annexin V-FITC and 
Propidium Iodide staining 
 
  
150 
 
2.11 Apoptosis studies: DNA Fragmentation Assay  
Fragmentation of the genomic DNA is an irreversible event that commits the cell to death 
and is a biochemical hallmark of apoptosis.  DNA degradation is able to occur via several 
pathways but in many systems it results from activation of a group of endogenous Ca2+ 
and Mg2+-dependent nuclear endonuclease enzymes termed DNases.  Caspase-activated 
DNase (CAD) is the best characterised enzyme that is activated by cleavage of its inhibitor 
by initiation of caspase-3 and caspase-7570.  Caspase-activated DNase then translocates to 
the cell nucleus where its activity causes characteristic DNA fragmentation571.   
One of the hallmarks of late stage apoptosis is the fragmentation of nuclear chromatin 
resulting in an abundance of DNA strand breaks572-574.  Cleavage of nuclear DNA can 
generate double-stranded low molecular weight DNA fragments (mono- and 
oligonucleosomal fragments) as well as single strand breaks or nicks in high molecular 
weight DNA.  DNA fragmentation can be detected at a single-cell level.  Assays can 
demonstrate specific DNA breaks by labelling the ends of the nucleosomal fragments with 
subsequent colorimetric or fluorescent detection using flow cytometry or microscopy575.  
A common method to identify apoptotic cells involves the in situ labelling of DNA strand 
breaks generated in the cell nucleus with either absorption dyes or fluorochromes576-580. 
The free 3’-hyroxyl termini of DNA strand breaks can be labelled with fluorochromes by 
the attachment of modified nucleotides.  A direct approach is the use of fluorochrome-
labelled triphosphodeoxynucleotides (e.g. fluorescein-deoxyuridine triphosphate) in a 
reaction catalysed preferably by exogenous terminal deoxynucleotidyl transferase 
enzyme579 581.  Terminal Deoxynucleotidyl Transferase (TdT) enables detection of DNA 
strand breaks when used with a fluorescent marker.  TdT enzyme has the ability to label 
blunt 3’-OH ends of double-stranded DNA breaks independent of a template.  It 
preferentially catalyses the repetitive addition of deoxyribonucleotide triphosphates 
(dNTPs) to the exposed 3´-OH group of a DNA fragment.  To label the end of the fragment 
fluorescently conjugated deoxyuridine triphosphate nucleotides (dUTPs) are used as a 
template for exogenous terminal deoxynucleotidyl transferase activity.  An alternative 
labelling enzyme for DNA nick translation is DNA polymerase.  The end-labelling 
technique is generally termed the TUNEL (TdT-mediated dUTP nick end labelling) assay582.  
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The TUNEL acronym is something of a misnomer since double strand DNA breaks are 
labelled as opposed to single strand nicks, and nucleotide analogues other than dUTPS 
are commonly used for this approach579 581.  Labelling DNA strand breaks with 
fluorochromes enables rapid analysis of cells by flow or laser scanning cytometry.  Dual 
staining techniques allow the concurrent measurement of DNA content and analysis of 
the cell cycle phase position of apoptotic cells576 577 583.   
The TUNEL assay is the most widely used in situ method for detecting apoptotic 
programmed cell death584.  Originally described in 1992, TUNEL relies on the presence of 
breaks in DNA that can be identified by terminal deoxynucleotidyl transferase enzyme575.  
The TdT enzyme promotes the template-independent addition of dUTPs to the exposed 
3’-hydroxyl ends of double-stranded or single-stranded DNA breaks.  The nucleotides 
incorporated by TdT enzyme activity form a polymeric tail composed of unlabelled 
nucleotides and chemically modified nucleotides or nucleotide analogues in a random 
sequence.   
Chemical modifications of the nucleotide templates enable labelling of the oligomer 
molecule formed from their addition to DNA strand breaks.  Labelling with fluorochromes 
enables direct detection of modified nucleotides such as fluorescein-dUTP.  Indirect 
approaches use alternative haptens such as biotin (biotin-dUTP detected with 
streptavidin protein) or bromine (BrdUTP detected with fluorescein-labelled anti-BrdU 
monoclonal antibody).  Cells are treated in the assay system so that the plasma 
membrane is permeable to all reagents and enzymes required to label the DNA 
fragments.  Fluorometric detection is applicable with fluorochrome-labelled DNA 
fragments incorporating fluorescein-dUTP.  Addition of biotinylated nucleotides to 
exposed 3’-OH sites is detectable using streptavidin-conjugated horseradish peroxidase.   
2.11.1 Apo-BrdU in situ DNA Fragmentation Assay 
A suitable substrate for terminal deoxynucleotidyl transferase enzyme is the 
deoxythymidine analogue 5-bromo-2'-deoxyuridine 5'-triphosphate (BrdUTP).  This is a 
brominated nucleotide analogue that labels the DNA strand breaks by incorporation into 
the DNA oligomer.  The 3′-OH termini of the fragmented DNA serve as primers for the 
reaction catalysed by exogenous TdT.  Exposed primer sites are only present at a 
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detectable level in cells undergoing apoptosis585.  Incorporated BrdUTP can be identified 
by anti-BrdU monoclonal antibody labelled with fluorescein isothiocyanate (FITC).  The 
FITC-conjugated anti-BrdU reagent is commonly used in studies of cell proliferation to 
detect BrdU incorporated during DNA replication586 587.  Bromo-deoxyuridine replaces 
thymidine in dividing DNA and can be detected by antibodies to BrdU to measure new 
DNA synthesis.  Of all the available deoxynucleotides BrdUTP is considered to be the most 
advantageous to label DNA strand breaks with a highly sensitive, simple and low cost 
assay.  The BrdUTP nucleotide is more readily incorporated into DNA strand breaks than 
alternative ligands of larger size such as fluorescein or biotin585.  The greater 
incorporation generates a brighter signal when BrdUTP sites are identified by FITC-
conjugated anti-BrdU antibodies.   
Cell fixation and membrane permeabilisation are essential steps for successful labelling of 
DNA strand breaks.  Cells are treated briefly with paraformaldehyde that cross-links small 
low molecular weight DNA fragments to other cell constituents.  This fixation prevents 
the extraction of fragmented nuclear DNA that would otherwise occur during repeated 
centrifugation and cell sample rinsing.  After fixation cells are permeabilised by 
suspension in ethanol.   
The relatively complex procedure of DNA strand break labelling involves multiple reagents 
and is technically demanding.  A negative result may reflect technical or methodological 
problems such as loss of TdT enzyme activity or degradation of BrdUTP substrate rather 
than the absence of apoptotic DNA strand breaks.  The inclusion of positive and negative 
cell controls is required for every assay.   
Extensive DNA degradation is considered to be a hallmark event of late apoptosis with the 
presence of DNA strand breaks highly specific for an apoptotic process.  The abundance of 
strand breaks in apoptotic cells generates intense labelling in the TUNEL assay enough to 
ensure their positive identification.  False-negative results from the TUNEL procedure may 
arise in late apoptosis when prior shedding of apoptotic bodies leaves cells with reduced 
DNA content or when such extensive DNA fragmentation occurs that small DNA 
fragments cannot be retained in the cell after fixation with paraformaldehyde.  False-
negative results may also result from atypical apoptosis when internucleosomal DNA 
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degradation does not occur keeping the number of DNA strand breaks in apoptotic cells 
below a significantly detectable threshold level by the TUNEL method. 
Distinctive features of apoptosis include specific DNA fragmentation and chromatin 
condensation with preservation of the plasma cell membrane integrity that is lost in the 
process of necrosis.  In some circumstances necrosis causes extensive DNA fragmentation 
and these cells can be indistinguishable from apoptotic cells using TUNEL assay despite 
having morphological hallmarks of necrosis588-590.   
Additional false-positive TUNEL results arise from some developmental processes such as 
spermatid maturation that involve chromatin condensation and a degree of transient 
DNA strand fragmentation591.  
It is generally recommended to validate TUNEL staining results using additional 
alternative criteria for identification of apoptosis such as analysis of morphological 
features or changes in the plasma cell membrane. 
2.11.2 Apo-BrdU in situ DNA Fragmentation Assay Protocol 
A DNA fragmentation assay was performed using the Apo-BrdU assay kit purchased from 
MBL International (Watertown, MA, USA).  The assay kit includes brominated 
deoxyuridine triphosphate nucleotide (BrdUTP) that is incorporated into the 3’-hydroxyl 
termini of double and single-stranded DNA.  These sites are identified with flow 
cytometry by staining the cells with fluorescein-labelled anti-BrdU monoclonal antibody.  
Components of the Apo-BrdU assay kit included: 
One 120 mL bottle of wash buffer and one 120 mL bottle of rinse buffer (both containing 
0.05% sodium azide); one 0.6 mL vial of reaction buffer containing cacodylic acid 
(dimethylarsenic); one 0.3 mL vial of FITC-labelled Anti-BrdU mouse monoclonal antibody 
(1 µg per test); one 30 mL bottle of Propidium Iodide/RNase A staining solution (PI 5 
µgmL-1, RNase 200 µgmL-1).  The kit also provided one 45 µL bottle of TdT (terminal 
deoxynucleotidyl transferase) enzyme (200 µgmL-1 in 50% glycerol solution) and one 0.48 
mL bottle of BrdUTP nucleotide (54.7 µgmL-1) both of which require storage at -20°C.   
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After observing cell morphology with light microscopy experiment cells were collected 
with the supernatant and centrifuged to a pellet of 1 – 5 x 106 cells.  Cell pellets were 
resuspended in PBS and fixed by adding 1% (w/v) paraformaldehyde and placing on ice 
for at least 15 minutes.  To prepare a 1% paraformaldehyde solution 1g 
paraformaldehyde was weighed in a fume hood and 100 mL PBS added.  The 
paraformaldehyde was dissolved by heating in a water bath at 65°C for 2 hours.  This 
solution is stable for at least 2 weeks stored at 4°C.   
Fixed cells were then centrifuged at 300 x g for 5 minutes and washed twice with PBS to 
remove excess paraformaldehyde solution.  Cell pellets were re-suspended in PBS and 
added to 5 mL of ice-cold 70% (v/v) ethanol solution for membrane permeabilisation and 
stored at -20°C overnight or up to several days prior to analysis.  Fixed and permeabilised 
cells were resuspended and centrifuged at 300 x g for 5 minutes with the ethanol 
removed from the pellet by careful aspiration.  Pellets were resuspended in wash buffer 
at approximately 1 x 106 cells per mL and centrifuged as above.  The washing step was 
repeated once.  The cell pellet was then resuspended in 50 µL of the DNA labelling 
solution.  The DNA labelling solution was prepared for 10 assays with the following 
reagents supplied in the assay kit: TdT enzymes 7.5 μL and BrdUTP nucleotides 80 μL 
(both stored frozen) and TdT reaction buffer 100 μL (stored chilled at 4°C).  The labelling 
solution was made up to 510 μL with 322.5 μL double-distilled H2O.  Cells were incubated 
in the DNA labelling solution at 37°C for 60 minutes.  Each falcon tube was shaken every 
15 minutes to ensure the cells were well suspended in solution.   
The cell solutions were rinsed with the addition of 1 mL rinse buffer provided in the kit 
followed by centrifuge at 300 x g for 5 minutes and repeating the process once.  
Fluorescein-labelled antibody was then added by resuspending the cell pellet in 100 µL of 
antibody solution.  The antibody solution was prepared for 10 assays using 50 µL of the 
Anti-BrdU-FITC antibody provided and making up to 1 mL with 950 µL of rinse buffer 
(both stored at 4°C).  Cells were incubated with the antibody solution at room 
temperature in the dark for 30 minutes.  Finally 0.5 mL of propidium iodide and RNase 
staining buffer was added to the cells and suspensions incubated for a further 30 minutes 
in the dark at room temperature.  Cells were analysed by flow cytometry within 3 hours 
of staining to count 20,000 cells for each experiment sample.   
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2.12 Apoptosis studies: Measurement of changes in Δψm 
Collapse of the electrochemical gradient across the mitochondrial membrane as 
measured by the change in the mitochondrial transmembrane potential (Δψm) has been 
observed to occur during the early phases of apoptosis.  Mitochondrial alterations often 
occur long before any identifiable morphological hallmarks of apoptosis592-594.  
Dissipation of mitochondrial transmembrane potential is frequently associated with the 
insertion and oligomerisation of pro-apoptotic proteins including Bax, Bak and Bad that 
are believed to create pores in the outer mitochondrial membrane.  The activation and 
assembly of pro-apoptotic Bcl-2 family proteins in the mitochondria creates pores in the 
membrane and enables the release into the cell cytoplasm of various apoptosis-
modulating small proteins normally enclosed in the intermembrane space of the 
organelle595-601.  These proteins include cytochrome c that is essential for activation of 
pro-caspase-9.  Pores created in the mitochondrial membrane causes a coincidental loss 
of transmembrane potential.  Although dissipation of Δψm has been thought to be a 
prerequisite for release of cytochrome c and therefore for caspase activation, there are 
reported examples where loss of Δψm precedes, accompanies or follows permeabilisation 
of the outer mitochondrial membrane594 602.   
Loss of mitochondrial inner transmembrane potential may not represent an irreversible 
point of no return for cell commitment to apoptosis.  Fluorometric or flow cytometric 
detection of Δψm loss can be a sensitive marker of events in early apoptosis
603 604.  
Detection procedures are based on lipophilic cationic probes that are readily taken up by 
viable cells and accumulate in mitochondria according to the Nernst equation.  Lipophilic 
cationic probe dyes accumulate within the mitochondria of healthy eukaryotic cells 
because the electrochemical gradient across the mitochondrial membranes is larger than 
the Δψ across the cytoplasmic plasma cell membranes605 606.  
To signal the loss of the mitochondrial membrane potential in experiment cells the Apo-
Logix JC-1 Assay Kit was purchased (Bachem, San Carlos, CA, USA).  The kit uses a unique 
cationic fluorochrome 5,5′,6,6′-tetrachloro-1,1′, 3,3′-tetraethylbenzimidazolcarbocyanine 
iodide (JC-1)607 608.  In healthy cells, energised mitochondria with an intact membrane 
establish and maintain a negative charge in the mitochondrial matrix that facilitates 
156 
 
uptake of the lipophilic JC-1 dye bearing a delocalised positive charge.  The dye 
accumulates in the mitochondrial matrix and forms aggregates once a critical threshold 
concentration is exceeded.  These J-aggregates emit a bright orange/red fluorescence.  In 
apoptotic cells, collapse of the mitochondrial membrane potential leads to dissociation of 
the J-aggregates and transition to monomeric form.  The JC-1 cannot accumulate within 
the mitochondrial matrix and remains in the cytoplasm in its monomeric form that 
exhibits green fluorescence. 
With flow cytometry analysis the green monomeric form of JC-1 has absorption and 
emission maxima of 510 and 527 nm when excited with a 488 nm wavelength laser.  The 
red JC-1 aggregates formed at higher concentration have absorption and emission 
maxima of 585 and 590 nm609.  Therefore, cells with a high mitochondrial Δψm display 
orange-red fluorescence while cells with low mitochondrial Δψm emit green fluorescence.  
The extent of JC-1 dye uptake and formation of aggregates is proportional to Δψm status 
and can be directly measured by the intensity of cellular fluorescence.  Apoptotic cells 
show primarily green fluorescence and can be easily differentiated from healthy cells that 
show red and green fluorescence610. 
2.12.1 Apo-Logix JC-1 Assay Kit Protocol 
Assay kit components included lyophilised JC-1 reagent and 10X assay buffer both stored 
at 2 – 8°C.  Assay buffer was diluted to 1X with double distilled water (1 mL of 10X assay 
buffer added to 9 mL dd H2O).  The lyophilised vial of JC-1 reagent was resuspended with 
500 µL DMSO to obtain a 100X stock solution.  Reagent crystals were completely 
dissolved in the solvent by gentle vortex and inverting the vial at room temperature.  The 
reconstituted JC-1 reagent was aliquoted in small amounts sufficient for one session of 
experimental work and stored at -20°C in amber vials protected from light and moisture.  
The shelf life of resuspended JC-1 is six months if stored frozen at or below minus 20°C.   
Immediately prior to use one vial of 100X JC-1 stock was defrosted in a water bath and 
diluted to 1X using warm serum-free culture medium or 1X assay buffer.  Using small 
aliquots of frozen 10X JC-1 stock avoided the need for multiple freeze-thaw cycles of 
stock solution.  If any undissolved particles remained in the diluted JC-1 solution, this was 
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centrifuged at 13,000 x g for 1 minute with careful transfer of the supernatant into a fresh 
tube by pipette aspiration excluding the pelleted debris.   
Experiment cells were harvested and collected together with their supernatant.  Cells 
were analysed at concentrations not exceeding 1 x 106 cells per mL.  Cell suspensions 
were centrifuged at 300 x g for 5 minutes at room temperature and the supernatant 
removed by careful aspiration.  Cell pellets were resuspended in 0.5 mL 1X JC-1 reagent 
solution as prepared above.  The cell suspension was incubated at 37°C in a 5% CO2 
incubator for 15 minutes.  Cell suspensions were again centrifuged at 300 x g for 5 
minutes at room temperature, the supernatant removed and the pellet resuspended with 
2 mL 1X assay buffer before centrifugation at 300 x g.  The wash step with 2 mL assay 
buffer was repeated one time.  The resulting cell pellets were resuspended in 0.5 mL fresh 
serum-free culture medium or 1X assay buffer ready for flow cytometry analysis. 
Cells were analysed immediately by flow cytometry and fluorometry.  Red JC-1 aggregates 
in the mitochondria of healthy cells were detected in the FL-2 fluorescence channel and 
green monomers in apoptotic cells were detected in the FITC (FL-1) fluorescence channel.  
The untreated control sample was used first to generate log FITC (x-axis) versus log PE 
Texas Red (y-axis) dual parameter dot plots with gating regions dependent on the peak 
population of control cells.  Induced samples were then analysed with gated dot plots 
with a cell population appearing in the gated region due to a loss of red fluorescence 
corresponding to the loss of mitochondrial membrane potential in treated cells.  The dot 
plot of red versus green fluorescence with red - % green compensation resolved live cells 
with intact Δψm from apoptotic and dead cells with lost mitochondrial membrane 
potential.   
Additional analysis was performed on a FLUOstar Optima plate reader (BMG Labtech, 
Aylesbury, UK) with the filters set to 485 nm excitation and 520 nm emission (green) and 
544 nm excitation and 590 nm emission (red).  Data were presented as the ratio of red to 
green signals generated (590 nm/520 nm).  Viable cells were expected to generate a 
higher 590 nm/520 nm ratio than cell samples undergoing apoptosis.   
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2.13 Apoptosis studies: Caspase Activity 
A family of cysteine proteases that cleave a variety of intracellular target proteins are 
fundamental participants in apoptotic pathways.  The enzyme family is termed caspases 
(from cysteinyl aspartate-specific proteases).  Biological caspase substrates include poly-
(ADP ribose) polymerase (PARP), protein kinase C (PKC) delta, DNA-dependent protein 
kinase (DNA-PK), topoisomerases and sterol regulatory element binding proteins 
(SREBP)611-614.  In mammalian cells there are probably at least 14 protein caspases that 
form a closely related family of cysteine proteases.  Caspases are the central mediators of 
the proteolytic cascade leading to elimination of cells selected for apoptosis.  Caspase 
function is tightly regulated both transcriptionally and by endogenous anti-apoptotic 
polypeptides that can block caspase activation and prevent the proteolytic cascade615.  
While specific functions can be identified for individual caspases some degree of overlap 
exists between them with occasional redundancy of function observed616.   
Currently there are 8 caspases identified as participants in the apoptotic pathway: 
caspase-2, caspase-3, caspase-12 and caspases-6 to -10 inclusive617 618.  Caspase enzymes 
also have crucial roles in cell signalling pathways and demonstrate specialised functions 
consistent with their role in apoptosis such as inflammatory responses and cytokine 
processing.  Mammalian cysteine proteases can be divided into initiator and effector 
caspases and these are especially useful targets for the detection of cellular apoptosis.   
Under normal physiological conditions caspase enzymes are constitutively expressed in all 
cells and exist in the cytoplasm as zymogen precursors with very low intrinsic activity.  
Zymogens are activated by cleavage to form a single heterotetramer with two active 
enzymatic sites in a head-to-tail configuration619.  
Activation of caspases can result from a variety of stimuli including exposure to radiation 
or chemotherapeutic agents, withdrawal of growth factors or initiation of the intrinsic 
apoptotic pathway.  The active heterotetramers drive apoptotic events in a concerted 
effort with a proteolytic cascade causing self-amplification and cleavage of vital 
intracellular substrates.  Cell homeostatic and repair enzymes are disabled and the cell 
structure is systematically disassembled.  Apoptosis is the end result616 618 619.  
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Assays designed to directly measure the activity of endogenous caspases can provide 
valuable information about the mechanism of death in dying cells.  Fluorescent and 
luminescent substrates for specific caspases have enabled homogeneous assays to detect 
their activity to be developed.  Specific antibodies that recognize the products of caspase 
cleavage or the activated caspase enzyme rather than its zymogen can also be used to 
detect cellular apoptosis.  Fluorescently conjugated caspase inhibitors can specifically 
label individual active caspases within cells.  This is achieved through binding to a caspase 
recognition element made up of a four amino-acid peptide.  The most common 
recognition element contains the valine – alanine – aspartic acid residue sequence (VAD) 
that facilitates binding to activated caspases.  
An alternative approach for measuring caspase activity involves the use of caspase 
substrates that generate fluorescent products upon cleavage by active caspases.  The 
Apo-ONE® Homogeneous Caspase-3/7 Assay (Promega, Madison, WI, USA) enables fast 
and sensitive measurement of caspase-3 and caspase-7 activity.  These caspase family 
members have central effector roles in the apoptotic process in mammalian cells620-623.  
Numerous homologues of CED-3, a proapoptotic gene of C. elegans and caspase family 
member have been identified in mammalian cells624 625.  Caspase-3-like proteases display 
specificity for cleavage at the C-terminal side of the aspartate residue of the sequence 
DEVD (Aspartate – Glutamine – Valine – Aspartate).  The caspase-3-like proteases are 
inhibited by the tetrapeptide inhibitor Ac-DEVD-CHO621.   
The purchased Apo-ONE® Homogeneous Caspase-3/7 Assay Kit provides all the necessary 
reagents for caspase-3/7 activity assays.  These include a profluorescent substrate 
together with a dual-purpose buffer optimised for both cell lysis and caspase activity.  The 
proprietary buffer rapidly lyses and permeabilises cultured mammalian cells and supports 
optimal caspase-3/7 enzymatic activity.  The assay uses a caspase-3/7 substrate that 
exists as a profluorescent substrate prior to the assay.  The profluorescent substrate is 
rhodamine 110, bis-(N-CBZL-aspartyl-L-glutamyl-L-valyl-L-aspartic acid amide; Z-DEVD-
R110).  After the buffer and substrate are mixed and added to experiment cell samples, 
sequential cleavage and removal of the DEVD peptide sequence by caspase-3/7 activity 
leaves the rhodamine 110 group.  The rhodamine 110 emits an intense green 
fluorescence with excitation and emission maxima of 499 and 521 nm wavelengths.  The 
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amount of fluorescent product generated is proportional to the amount of caspase-3/7 
cleavage activity present in the sample analysed by a fluorescent plate reader.   
The assay using the Z-DEVD-R110 substrate is sensitive over short incubation times and 
can be scaled to suit the required sample number provided that a 1:1 ratio of assay 
reagent volume to sample volume is maintained.  Multiple assays on the same 
experiment plate can be performed to provide valuable internal control data.  Specific 
inhibition of caspase-3/7 activity may be achieved using the addition of the caspase 
inhibitor Ac-DEVD-CHO (Promega).  
2.13.1 Apo-ONE® Homogeneous Caspase-3/7 Assay Protocol 
The components of the assay kit included 100 μL Caspase Substrate Z-DEVD-R110 (at 
100X concentration) and 10 mL Apo-ONE® Homogeneous Caspase-3/7 Buffer (1X).  The 
complete system supplied contained sufficient reagents to make 10 mL of Apo-ONE® 
Caspase-3/7 Reagent suitable for 100 assays of 100 μL per well in a 96-well plate.  96-well 
opaque black plates (Nunc International Brand) suitable for cell culture and fluorescent 
plate reader analysis were used for experiment purposes.  A fluorescent plate reader with 
FLUOstar Optima software was used for analysis with a plate shaker function to mix the 
reagents in each experiment well.   
The buffer and concentrated 100X substrate were thawed to room temperature and 
mixed by vortexing.  The substrate was diluted 1:100 by addition of 100 µL of 100X 
substrate to 9,900 µL buffer.  The assay reagent thus prepared was stored protected from 
light at 4°C for up to 24 hours prior to use.   
The following controls were included in triplicate: 
Blank wells containing complete cell culture medium without cells + Apo-ONE Caspase-
3/7 reagent; Control wells containing untreated cell culture + Apo-ONE Caspase-3/7 
reagent; Negative control wells containing vehicle-treated cell culture + Apo-ONE 
Caspase-3/7 reagent.  The vehicle was the appropriate solvent or carrier used to deliver 
the reagent of interest.  Blank controls provided a measure of background fluorescence 
associated with culture samples and the assay reagent and were subtracted from 
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experimental values.  Untreated control cell sample reactions determined the basal 
caspase activity of the experimental cell culture system. 
100 µL of Apo-ONE® Caspase-3/7 Reagent was added to each well of the black 96-well 
plate containing 100 µL of blank medium, controls or experiment cell samples.  Gentle 
mixing of reagent and samples was performed using a plate shaker at 400 RPM for 30 
seconds.  Pipetting was not used to avoid creating bubbles that interfere with 
fluorescence readings or the cross-contamination of samples.  96-well plates were 
incubated at 37°C protected from light for 1 hour prior to measuring fluorescence of each 
well using a plate reader.  Data were collected on the plate reader over 4 hours.  A time 
course of experiments was performed to assess caspase activity associated with 
experimental reagents after 6 hours, 12 hours, 24 hours and 48 hours.   
The FLUOstar Optima plate reader (BMG Labtech, Aylesbury, UK) was used to measure 
fluorescence generated by caspase-3/7 activity.  The microplate reader is capable of 
measuring time-resolved fluorescence intensity using a high-energy xenon flash lamp 
with an excitation and emission spectral range of 240 – 740 nm wavelengths.  The 
manufacturer’s protocol for the Apo-ONE caspase assay was developed using a 
spectrofluorometer configured to detect caspase-3/7 activity at an excitation wavelength 
range of 485 ± 20 nm and an emission wavelength range of 530 ± 25 nm.  Researchers 
have reported the optimal excitation wavelength for detection to be 499 nm with 
emission maximum at a wavelength of 521 nm624.  
A caspase protocol was set up using the instrument software.  This included microplate 
readings over 250 cycles with a reading time of 60 seconds and 20 lamp flashes per cycle 
at 37°C temperature.  Excitation filters were set at 485 nm and emission filter at 520 nm.  
Maximum absorbance was measured at 65000 units of absorbance.  A gain adjustment 
well was selected prior to each test run choosing a well of greatest intensity and adjusting 
reading such that 90% was the required value for endpoint readings and 30% of 
maximum activity was the required value in test run kinetic readings.  The full spectrum of 
kinetic absorbance data was collected to generate signal curves over 250 cycles.  A line 
graph from the raw data was obtained and the X-Y scatter analysed to identify a linear 
portion of the graph indicating a steep part of the signal curve for all signals generated.  
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This identified a particular time point or cycle number for all values.  These values were 
then chosen for absorbance measurement and normalised to MTT assay to obtain the 
relative caspase activity per 1000 cells.  Cell proliferation MTT assay was performed 
concurrently using clear 96-well plates under the exact experimental conditions as the 96-
well opaque black plates used for caspase activity assay.  Cell numbers per well were 
calculated from an MTT standard curve assay as previously described.  The measured 
absorbance value for each well was divided by the cell number per well and multiplied by 
1000 to give caspase fluorescence per 1000 cells.   
2.14 Methods for Detecting Apoptosis 
Events in apoptosis provide the opportunity to examine the process with a quantitative 
approach.  Structural and biochemical features used to identify apoptosis include the loss 
of plasma membrane phospholipid asymmetry, nuclear DNA fragmentation and the 
mitochondrial permeability transition pore.  The complex signalling cascade of apoptosis 
and its multiple regulation points allows evaluation of the activity of the various proteins 
involved.   
The array of apoptotic quantifiable markers for apoptosis may vary according to the cell 
type, the level of stress or stimulus applied to the cell and the unique cellular 
microenvironment that modulates the cellular response.  For example, markers including 
oligonucleosomal DNA fragments may be undetectable in cells challenged with variant 
stimuli such as inflammatory cytokines or growth factor deprivation.  It is therefore 
recommended to always study several parameters at a time to provide a 
multidimensional aspect of apoptotic progress.   
2.15 Timing of Apoptosis Assays 
Apoptosis is a dynamic process with variable induction and execution kinetics. There is a 
short time-window during which apoptotic cells may display their characteristic features.  
The induction and progress of apoptosis can vary widely depending on the type of cell 
investigated.  Different cell lines treated with an identical apoptotic stimulus may 
undergo apoptosis across an interval of between 2 hours and more than 24 hours.  The 
interval between induction and execution of apoptosis also varies depending on the initial 
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stimulus applied626.  Cells of haemotopoietic lineage tend to have a much shorter 
apoptotic induction time when compared to cells of solid tumour lineage.  The length of 
the apoptotic process from initiation to complete cell disintegration also depends on the 
cell type investigated.  Apoptotic cells can remain detectable in cell culture systems for an 
extended time period due to the lack of clearance of apoptotic bodies by phagocytosis 
that occurs in vivo.   
When identification of apoptotic cells relies on a specific marker that is detectable at 
variable time intervals, clear knowledge of the relevant time-windows for appearance of 
the marker is required.  To determine if apoptosis is the primary mechanism of cell death, 
the duration of exposure to the cytotoxic reagent, the concentration of the test reagent 
and the choice of assay endpoint are critical for the experimental system.  Different 
methods to measure apoptosis can produce different results depending on the timing of 
the assay and the process of apoptosis627.   
Loss of the mitochondrial transmembrane potential has been observed to be an initial 
transient event followed by later permanent collapse during the apoptotic cascade as 
depolarization of the mitochondrial membrane is followed by release of cytochrome c 
and caspase activation602.   
In the early stages of apoptosis terminal deoxynucleotidyl transferase can be positive for 
DNA breaks (TUNEL assay) but negative for the fractional DNA content (sub-G1 peak) as 
DNA fragments are still maintained in the nucleus.  DNA laddering will not be observed on 
agarose gel electrophoresis until DNA fragments become isolated later in the process628.   
Extensive DNA fragmentation is considered to be a specific marker of apoptosis.  The 
intensity of TUNEL assay labelling due to the large number of DNA strand breaks in 
apoptotic cells enables their discrimination from primary necrotic cells.  Apoptotic or 
apoptotic-like cell death processes may however occur without extensive 
internucleosomal DNA degradation629.  If this occurs the intensity of cell labelling with 
TUNEL assay will be inadequate to positively identify apoptotic cells.  
The plasma cell membrane can expose phosphatidyl serine residues that stain Annexin-V 
positive in early phases of apoptosis.  Changes in plasma membrane integrity with the 
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appearance of blebs and the morphological hallmarks of apoptotic bodies can be 
identified at a later stage in apoptosis.  It may often be difficult to distinguish late 
apoptotic cells (secondary necrotic cells) from the primary necrotic cells that have 
undergone accidental cell death.  In both instances the cells cannot exclude cationic dyes 
such as propidium iodide or Trypan blue as the integrity of plasma membrane is lost583.   
2.16 Carbon Monoxide Releasing Molecules  
For all experiments investigating the influence of CO on the cell lines studied, CORM-3 
tricarbonylchoro(glycinato)-ruthenium(II) was used exclusively with the kind collaboration 
of Dr Roberto Motterlini and colleagues at the Northwick Park Institute for Medical 
Research.  The CORM-3 was obtained as a material transfer agreement between Imperial 
College and Hemocorm limited company, the manufacturer and owner of intellectual 
property rights of the CORM compounds.   
2.16.1 CORMS Preparation and Administration Protocol 
CORM-3 was supplied as an off-white powder stable stored at -20°C.  The compound is 
mostly present as an hydrochloric acid adduct with an effective molecular weight of 310 
and chemical formula Ru(CO)3Cl (NH2CH2CO2).  The powder forms a low-pH solution in 
water that remains stable for several hours.  The half-life of CORM-3 is approximately 24 
hours when the powder is dissolved in double-distilled water (ddH2O).  Dissolving 310g in 
1000 mL or 0.31g in 1 mL gives a solution at 1M concentration.  A workable stock solution 
at 10 mM concentration was obtained by dissolving 3 mL ddH2O to 0.0093g powder.  This 
stock solution was aliquoted into small volumes and frozen at -70°C for use within one 
month thereby avoiding multiple freeze-thaw cycles and minimising half-life impact.  The 
stock was defrosted quickly for each experiment and a serial dilution performed 
immediately prior to adding the final solution to experiment wells.  One mL of the 10 mM 
stock was added to 9 mL of serum-free medium to give a 1 mM stock solution.  A volume 
of 600 µL 1 mM stock was then added to 2400 µL serum-free medium to give a final stock 
solution of 200 µM concentration.  The appropriate volume of 200 µM solution was 
added to experiment wells to give the final dose of CORM-3.  A negative control was 
prepared by dissolving an equivalent quantity of CORM-3 powder in equivalent volumes 
of sterile phosphate-buffered saline and leaving the solution at room temperature for 48 
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hours.  The solution was bubbled with nitrogen gas in a fume hood using a Pasteur 
pipette after 48 hours and was then serially diluted as described above.  This gave an 
inactive form of the CORM-3 termed iCORM-3.  Universal precautions were followed for 
preparation of all CORM-3 reagents as the recommendation is to assume the compound 
to be toxic630.    
2.17 Bilirubin studies 
2.17.1 Bilirubin reagent preparation  
Bilirubin was purchased from Porphyrin Products (Frontier Scientific, Logan, UT, USA) and 
supplied as a 99% pure bilirubin-α crystalline powder with molecular weight 584.7 g.  
Initial experiments were performed with mixed-isomer bilirubin obtained from Sigma 
Aldrich but subsequent doubts emerged regarding the trace impurities in β- and γ-
isomers of this product.  Therefore all results were rejected and experiments repeated 
using 99% pure free unconjugated α-isomer bilirubin available from Porphyrin Products.  
Bilirubin solution was prepared by dissolving powder in 0.01 M sodium hydroxide alkali 
(NaOH) to a concentration of 1 mg per mL.  Once dissolved the solution was diluted with 
an appropriate volume of sodium phosphate buffer and adjusted with 1 M hydrochloric 
acid (HCl) to pH 7.4 – 7.6.  The diluted solution was sterile filtered through a 0.2 µm pore 
size filter (Sartorius) to obtain a working stock solution at 500 µM concentration.  The 1 
mgmL-1 solution (1.71 mM) was stored at -20°C and defrosted to make up a 500 µM stock 
solution fresh for each experiment.  All bilirubin solutions were stored protected from 
light and all experiments carried out avoiding direct light. 
Sodium phosphate buffer was prepared using 50 mM Na2 HPO4
2- (3.45 g dissolved in 500 
mL ddH2O) and 50 mM Na H2PO4
2- (3.549 g dissolved in 500 mL ddH2O).  Each solution 
was prepared separately, sterile filtered and combined to prepare the buffer stored at 
2°C.   
2.17.2 Bilirubin Experiment Protocol 
Cells were seeded at optimum density into 24-well plates such that cells were 40 – 50% 
confluent at the time of adding reagents.  After 24 hours incubation media was changed 
and supplemented with bilirubin reagent at the following concentrations: 0.1 µM, 1 µM, 5 
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µM, 10 µM, 20 µM and 50 µM (0.06 µgml-1 – 30 µgml-1).  These concentrations were 
chosen to provide include a spread across the physiological range.  Experiment plates also 
included a control set of wells to which only medium was added and a vehicle set of wells 
to which the reagent vehicle solution was added.  The vehicle solution was prepared with 
equivalent 0.01 M NaOH and sodium phosphate buffer solution and pH adjusted with HCl 
to pH 7.4 – 7.6.  
Effects of prolonged exposures to bilirubin over 24 – 72 hours were compared to the 
effects of 24 hour treatment with bilirubin.  The reagent medium was replaced with 
serum-complete medium after 24 hours and modified MTT assay performed at 24, 48 and 
72 hours as described below.   
2.17.3 Cell proliferation assay 
Cell counts and cell viability MTT assays were performed at 24, 48 and 72 hours to assess 
the influence of 24-hour and extended bilirubin treatment.  Cell counts were performed 
using Trypan blue exclusion using a standard haemocytometer having disaggregated cell 
clumps by passing the cell suspension through a 21G needle.  Cell proliferation was 
determined with an indirect 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide 
(MTT) to assay mitochondrial activity.   
Previous work by Ngai and colleagues has identified that application of the MTT assay 
technique to studies using bilirubin can present the problem of interference with 
colorimetric readings.  The data obtained by the formazan colour index can be affected by 
the yellow bilirubin crystal deposits in microplate wells.  The reported study 
demonstrated a significant misinterpretation of MTT readings with the apparent results 
10 – 24% higher than the actual concentrations due to bilirubin deposition.  Dissolving the 
MTT formazan crystals in 0.04 molL-1 hydrochloride-isopropanol does not disturb bilirubin 
precipitates as bilirubin is not readily soluble in acidic solvents: less than 5% of the total 
bilirubin deposits were extracted into the supernatant.  The MTT-formazan solution was 
transferred to a clean 96-well microplate for direct reading of the optical density (OD) 
with a spectrometer at 562 nm wavelength as previously described.  The OD due to 
formazan produced in control cells was taken as 100% viability and all other 
measurements were expressed as a percentage (%) of the control cell value.  This 
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modified MTT assay was adopted for all experiments using the MTT assay as it does not 
change either the peak or the absorption spectrum of the assay and produces highly 
reproducible and consistent results631.   
Studies of apoptosis were performed using flow cytometry techniques described above to 
evaluate possible mechanisms for observed proliferation effects after bilirubin treatment. 
Further experiments were performed to investigate the impact of bilirubin treatment on 
reversal or prevention of the effects of heme oxygenase competitive inhibition or gene 
knockdown.  Initial experiments identified bilirubin doses of 1, 5 and 10 µM for 24 hours 
did not cause any alteration in cell viability or mitochondrial activity assessed by MTT 
assay.  This dose range and exposure time was therefore chosen to determine bilirubin 
effects after competitive HO enzyme inhibition with zinc protoporphyrin and specific 
siRNA-mediated knockdown of HO-2 protein.  Zinc protoporphyrin reagent (ZnPP) and 
siRNA and negative control transfection reagents were prepared as previously described.  
Cells were exposed to 10 µM ZnPP for 48 hours, the reagent media discarded and 
replaced with fresh media supplemented with 1, 5 and 10 µM bilirubin.  Similarly cells 
transfected with 10 nM siRNA vectors using 6 pmole of oligonucleotide were incubated 
for 48 hours as described above prior to treatment with bilirubin.  Cell counts, cell 
viability assays, RT-PCR analysis of mRNA and Western blot analysis of protein expression 
were performed 24 hours after bilirubin addition.   
2.18 Statistics protocol 
All experiment results from cell proliferation studies are expressed as percentage of 
control for each individual experiment.  Statistical analysis used the non-parametric 
Kruskal-Wallis Independent samples test to look for significant differences between 
results of study experiments or the Mann-Whitney U test to compare 2 independent 
samples.  Analysis was based on data from experiments performed in triplicate or higher 
as indicated in the results chapter.  When histograms of continuous variable data 
demonstrated a normal distribution, one-way ANOVA or the Students t test for 2 
independent samples were used to compare means. 
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CHAPTER 3: Downstream Effectors of Heme Oxygenase Activity 
3.1 The Role of Carbon Monoxide  
3.1.1 Carbon monoxide biochemistry 
Carbon monoxide (CO) traditionally has a bad reputation as an odourless, colourless air 
pollutant and toxic gaseous molecule due to its strong affinity for hemoglobin that causes 
a significant reduction in the oxygen-carrying capacity of hemoglobin and results in tissue 
hypoxia.  Carbon monoxide also binds to myoglobin and mitochondrial cytochrome 
oxidases to cause impairment of oxygen utilisation in these molecules632.   
The physiological effects of carbon monoxide are however not all negative.  Recent 
studies demonstrate that CO has considerable influence on intracellular signalling 
processes that culminate in anti-inflammatory, anti-proliferative, and anti-apoptotic 
effects239 633.  Heme oxygenase enzyme activity produces endogenous levels of CO in the 
body.  Studies document the antioxidant and cytoprotective properties associated with 
activity of the inducible HO-1 isoform159.  Endogenous CO may be generated as an 
effector of HO-1 activity and may provide the means for a physiological protective 
response to stress237.  In experimental models looking at HO-1 in the response to stress, 
administration of CO at appropriate doses results in a comparable protective response 
even when heme oxygenase activity is totally abolished237 634. 
There are two major sources of CO in mammalian biology: production as a by-product of 
heme oxygenase enzyme activity and a heme oxygenase-independent source as a result 
of severe stress that is not achieved under normal physiological conditions.  Severe stress 
causes oxidation of organic molecules, phenols, and flavenoids and the peroxidation of 
lipids that generates CO635.  The major source of CO in mammal is via the degradation of 
heme by heme oxygenase with consequent production of CO, iron and biliverdin.  
Mammalian tissues have the ability to generate CO locally as cells express both inducible 
(HO-1) and constitutive (HO-2) heme oxygenase isoforms159 273.  Heme oxygenase 
enzymes are found in most human tissues with high abundance in the spleen (HO-1), liver 
(HO-2 and HO-1), brain (HO-2), vascular endothelial cells and smooth muscle tissues (HO-
1 and HO-2).  Rapid increases in CO levels that occur in vivo are solely due to either the 
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induction of HO-1 or constitutive HO-2 activity636.  Recent evidence supports the concept 
that carbon monoxide functions as an important cellular signalling molecule236 637.   
Endogenous CO production can be detected in exhaled breath.  Adults exhale 
approximately 6 cm3 of CO per day.  The activity of heme oxygenase accounts for about 
86% of endogenous CO production in humans.  The majority originates from the 
degradation of heme in the spleen and liver where senescent red cells are processed.  A 
variety of sources such as lipid peroxidation, bacteria and xenobiotics generate the 
remaining 14% of CO produced638.  Without external sources of CO, approximately 0.6% 
of hemoglobin is bound to CO as carboxyhemoglobin as a reservoir of body carbon 
monoxide639.  CO is a relatively stable and unreactive molecule in vivo.  The amount of CO 
converted to CO2 in mammals is very unlikely to be significant.  CO binds to heme and 
heme proteins including cytochromes in a reversible reaction.  The half-life of CO bound 
to myoglobin is approximately one minute before the carboxymyoglobin dissociates640.  
There are two isoforms of heme oxygenase enzyme characterised: the inducible HO-1 
that is up-regulated in response to a wide variety of insults that cause a threat to cell 
homeostasis and survival641-643 and the constitutive HO-2 isoform present in organs and 
tissues including brain, liver and endothelium that has regulatory functions associated 
with neurotransmission and changes in vascular tone159 641.  Various disease states cause 
a marked increase in CO production including asthma, bronchiectasis, cystic fibrosis and 
diabetes644-648.   
3.1.2 Carbon Monoxide Toxicity 
Carbon monoxide toxicity results from a combination of tissue hypoxia and direct CO-
mediated damage at a cellular level that is independent of HbCO-induced hypoxia.  
Several pathophysiological mechanisms for CO toxicity have been suggested including 
lipid peroxidation and oxidative stress and ischaemia-reperfusion injury649 650.  
Intracellular targets of CO activity such as cytochrome c oxidase contribute to the adverse 
and ultimately lethal effects of CO at HbCO levels above 20%.  Binding of CO to cellular 
cytochromes has been demonstrated to contribute to mitochondrial CO toxicity.  A 
sustained and significant inhibition of cytochrome c oxidase activity (complex IV of the 
mitochondrial respiratory chain) has been observed in acute CO poisoning of human 
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lymphocytes651.  Alonso and colleagues reported a statistically significant and progressive 
inhibition of cytochrome c oxidase activity parallel to increased concentrations of CO.  
Other enzyme complex activities did not show any significant variation in relation to the 
presence of CO652.   
Whereas CO is directly toxic to human mitochondria, carboxyhemoglobin is not.  The toxic 
effects of HbCO are due to the consequent tissue hypoxia.  Recent studies observe 
inhibition of cytochrome c oxidase activity that is dependent on oxygen concentration as 
CO directly competes with oxygen binding of the mitochondrial cytochromes653.  Tissue 
hypoxia caused by high affinity binding of CO to hemoglobin and myoglobin inhibits 
cytochrome c oxidase synergistically with CO as the reduced oxygen level enables 
competitive CO binding.  The inhibition of cytochrome c oxidase may play a role in the 
development of acute CO poisoning symptoms and in disease effects associated with 
smoking.  The significance of cytochrome c oxidase inhibition by endogenously produced 
CO is debatable.  CO binds with such high affinity to hemoglobin and myoglobin that free 
levels of cellular CO are likely to be very low653.  
3.1.3 Endogenous CO production and prognostic value 
Carbon monoxide levels measured in different animal models of oxidative stress and 
tissue injury have been demonstrated to correlate with both the degree of stress and 
with increased tissue survival.  Limited human trials report a higher production of CO in 
critically ill patients when compared to healthy controls654.  Endogenous CO production is 
higher in septic patients than in controls with an elevated level of CO measured at 24 
hours in patients with sepsis that survived the episode as opposed to non-survivors655. 
Increased serum leucocyte counts in intensive care have been found to have a significant 
correlation with HbCO levels as a marker of total body CO content656.  The increased 
white blood cell count was associated with increased severity of illness.  In paediatric 
studies significantly higher levels of exhaled CO have been observed in full term septic 
infants admitted to neonatal intensive care compared to healthy neonates657.  The 
possibility of CO as a mediator in the pathogenesis of neonatal sepsis is supported by a 
described correlation between cyclic guanosine monophosphate (cGMP) and HbCO levels 
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in preterm infants with respiratory distress syndrome658.  An increase in cGMP mediated 
by CO may contribute to systemic vasodilatation and hypotension in preterm neonates. 
Studies of mechanically ventilated intensive care adults found higher levels of 
endogenous CO production in patients with cardiac disease and those undergoing dialysis 
as compared to other critically ill patients659.  The levels of CO correlated with serum 
bilirubin and with serum creatinine reflecting the severe renal failure prevalent in these 
patients659.  Recent studies have reported a strong trend of higher levels of exhaled CO in 
critically ill patients that survived the illness without a clear correlation demonstrated 
between exhaled CO and illness severity or degree of inflammation660.  Arterial HbCO 
levels measured at low or high extremes are associated with increased mortality in 
intensive care patients suggesting an optimal range of increased CO production661.   
There are numerous questions surrounding the clinical significance of carbon monoxide 
levels.  CO levels may provide a marker of disease severity or progression and may have a 
direct role in disease pathogenesis.  Increased endogenous CO production may reflect this 
role or indicate enhanced heme oxygenase activity in response to stressful conditions.  
Protective effects of heme oxygenase induction may become detrimental at excessive 
induction levels661.  Measurement of CO levels during the early stages of acute 
pathological conditions might be crucial in understanding and predicting survival 
outcomes in intensive care.   
CO levels may provide a useful prognostic marker particularly in inflammatory disorders.  
Exhaled CO levels are elevated in patients with seasonal allergic rhinitis662 and can reflect 
the severity of pulmonary inflammation in asthmatic patients648.  Levels of exhaled CO are 
also higher measured in preterm infants with bronchopulmonary dysplasia663 and in 
patients with cystic fibrosis664.  In ulcerative colitis patients with active disease have an 
increased level of CO detectable in the colon665.  Patients with cirrhotic liver disease have 
elevated arterial HbCO levels although no correlation with disease severity has been 
reported666.  
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3.1.4 CO at lower doses 
Initial studies on lung injury in animal models found evidence to support a valuable action 
of CO in the stress response269 642.  These findings were corroborated in later studies 
examining more tissues including heart, liver, kidney, intestine and the reticulo-
endothelial system201 237.  Endogenous production of CO and inhalation of exogenous CO 
gas can produce beneficial cytoprotective outcomes provided that the oxygen-carrying 
capacity of hemoglobin is not severely compromised.  Studies suggest a threshold level of 
HbCO < 20% below which favourable responses are observed against inflammation, cell 
proliferation, apoptosis, organ injury, vasoconstriction and both systemic and pulmonary 
hypertension201 249 271.  Available evidence supports the potential use of small amounts of 
CO gas as a therapeutic agent to treat conditions of cellular stress. 
Studies on cellular and animal models indicate a complicated CO-dependent cell signalling 
network that varies in response to a specific stimulus and the type of tissue involved.   
The mechanisms and signalling pathways involved in CO-mediated activity are yet to be 
fully understood.  Carbon monoxide is likely to target guanylate cyclase activation to 
mediate vascular tone and blood pressure regulation667 668.  Various signal transduction 
pathways are implicated in the anti-apoptotic and anti-inflammatory function of CO.  
These include the mitogen-activated protein kinase cascade (MAPK), particularly the p38 
protein MAP kinases, phosphatidylinositol 3-kinases (PI3-K) and NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) signalling pathways110 237 240 249 297 669.  The 
multiplicity of CO effects and variability of CO action make its specific targets difficult to 
interpret.  The proposal of CO as a future therapeutic option is made more feasible with 
the advent of controlled methods for delivery of CO to the tissues using CO-releasing 
molecules (CORMs)238 670-672.   
3.1.5 Carbon Monoxide and Nitric Oxide 
Nitric oxide (NO) is generated by nitric-oxide synthase (NOS) enzyme that contains the 
heme moiety.  Specific effects mediated by NO can be duplicated by CO including the 
regulation of action of certain neurotransmitters and muscle relaxants.  Both CO and NO 
are active in the vascular endothelium with NO established as a powerful vasodilator.  
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While similarities exist between CO and NO gaseous monoxides there are substantial 
differences in the molecules regarding their modes of action.  Physiological stimuli tightly 
regulate NO synthesis by the constitutive NOS isoforms via intracellular release of Ca2+.  
The half-life of NO is strictly limited due to its unpaired electron (NO·) causing rapid free 
radical reactions with reactive oxygen species, sulfhydryl groups or metal ions within the 
cell.  A short-lived burst of NO production results from stimulation of the constitutively 
expressed NOS isoforms NOS1 and NOS3.  This transient rise in NO leads to a rapid and 
brief increase in local cyclic GMP levels reflecting a 100 to 400-fold activation of soluble 
guanylate cyclase (sGC).  A significant increase in sGC activity is due to NO binding with 
the prosthetic heme moiety of sGC leading to formation of a nitrosyl heme complex673 674. 
Carbon monoxide is likewise considered a vasorelaxant via stimulation of cGMP but the 
relative potency of CO much smaller compared with that of NO.  Carbon monoxide is not 
a free radical and its production by heme oxygenase activity is not so tightly regulated.  
When CO binds to the iron of the prosthetic heme group of sGC a heme complex is 
formed with only a five-fold increase in activity of the sGC enzyme675.  However, the 
potency of the CO-mediated increase in cGMP may be significantly increased by other 
mechanisms including the sensitization of sGC to CO in biological systems676 677.   
Recent evidence shows that HO-derived CO can regulate NO production by inhibition of 
NOS enzymes678.  The impact of the HO pathway in the control of cGMP levels can be 
thereby substantially augmented with recent studies demonstrating the contribution of 
CO product to hypertension and endothelial dysfunction in Dahl salt-sensitive rats679. 
Heme prosthetic moieties are commonly present in enzymes that catalyse reactions of 
single electron transfer.  CO can bind to heme and may disrupt the activity of a variety of 
heme protein enzymes other than sGC.  Published evidence supports a panel of 
susceptible enzymes including xanthine oxidase, NADPH oxidase, and prostaglandin-H-
synthase all of which underlines the significance of the HO pathway in modulation of the 
oxidative stress response680-683.   
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3.1.6 Carbon Monoxide Effects 
Up regulation of heme oxygenase and measurement of HO-1 protein levels does not 
directly equate to measurement of HO activity.  HO-1 gene expression is readily induced 
by a variety of stimuli.  Studies by Kruger and colleagues reported that increased HO-1 
protein in Zucker rats did not result in increased total HO activity.  Antioxidants and 
peroxynitrite scavengers with inducers of HO-1 restored the activity of preexisting 
inactive HO-1 to active HO-1 with a resulting increase in the levels of CO and bilirubin, 
restored endothelial NOS, decreased blood pressure, and normalised kidney function684.  
Therefore, the measurement of HO-1 protein or a description of an increase in HO-1 
protein expression does not mean an increase in HO activity and consequent increased 
production of bilirubin and CO.  The measurement of total HO enzymatic activity is 
essential. 
Carbon monoxide and bilirubin derived from HO activity lead to relaxation of vascular 
smooth muscle mediated via both cGMP-dependent and cGMP-independent pathways 
such as stimulation of specific potassium channels and an increase in adiponectin 
levels685-688.  The vasodilator effect produced by CO on the endothelium may be due to a 
CO-mediated reduction in the cytochrome P450-dependent synthesis of 
vasoconstrictors689.  Cytochrome P450 metabolises arachidonic acid to generate the very 
potent vasoconstrictor 20-Hydroxyeicosatetraenoic acid (20-HETE)690.  Activation of 
calcium-dependent potassium channels is an important mechanism for vasodilatation 
independent of cGMP691.  
Direct effects of CO can result from binding of high levels of exogenously administered CO 
to heme proteins.  Excessive CO competes with NO for prosthetic heme binding sites 
causing a transient increase in unbound NO· that will lead to the production of 
peroxynitrite anion (ONOO−) and oxidative tissue damage in the presence of reactive 
oxygen species692.  Binding of excess CO to heme proteins disrupts mitochondrial 
transport and leads to release of superoxide anions (·O2
−) that react with NO· to form the 
powerful oxidant peroxynitrite and cause tissue damage.  Administration of CO in the 
form of CO donors must therefore be carefully controlled693 694.  CO-releasing compounds 
have been shown to be effective in delivering CO and to cause induction of HO-1 
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protein695.  Treatment with CO can reverse or reduce the adverse effects of treatment 
with inhibitors of heme oxygenase enzyme, suggesting that endogenous CO contributes 
to the protective effects of HO activity.  CORMs are able to deliver CO effectively thereby 
preventing renal injury and attenuating the endothelial cell death associated with 
diabetes in vivo695 696. 
Treating endothelial cells with CO-releasing molecules restores glutathione (GSH) levels 
that are diminished when cells are treated with short interfering RNA or HO inhibitors455.  
Carbon monoxide up regulates the expression of the rate-limiting enzyme in GSH 
biosynthesis glutamate cysteine ligase via activation of the phosphatidylinositol 3-kinase 
pathway and HO-1 mediated Nrf2 transcription factor signalling455.  Cell treatment with a 
CO donor up regulated expression of the catalytic subunit of glutamate cysteine ligase 
associated with protective effects of CO against NO-induced cell death697.  
Carbon monoxide is a neurotransmitter in the autonomic peripheral nerves of the 
gastrointestinal and urogenital tract.  In many synapses CO appears to act synergistically 
with nitric oxide.  One or the other gas may be dominant at specific sites that may differ 
in different species.  A physiological function of CO as a brain neurotransmitter has been 
proposed236.  Functions attributed to CO in the central nervous system include 
neuroendocrine functions, circadian rhythm, cerebellar development, learning and 
memory, temperature control and pain perception.  CO may be the principal physiological 
regulator of cGMP levels in the brain via activation of guanylyl cyclase.  The HO-2 
isoenzyme is found closely associated with guanylyl cyclase, ALA synthase, cytochrome 
P450 reductase, and NOS in brain tissue637.  Although not yet clearly defined, the role of 
HO-2 in the brain could be the production of CO to function in cell signalling pathways. 
Evidence for the physiological functions of endogenous CO is largely indirect and often 
inconclusive.  In studies of HO knockout mice HO-1 deficiency causes adverse effects 
primarily from heme toxicity and iron recycling deficiency.  HO-1 expression is induced as 
an adaptive response to a wide variety of stresses that cause acute or chronic 
inflammatory responses.  The HO-2 deficient mouse phenotype demonstrates impaired 
intestinal mobility, pain perception and subtle behavioural defects all of which have been 
attributed to deficient CO production.  
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3.1.7 Carbon monoxide targets  
The cellular fate of CO formed during heme degradation by HO enzyme is not completely 
understood.  CO preferentially binds to and interacts with heme proteins or transition 
metal-containing proteins.  As reported for nitric oxide, CO can bind to oxyhemoglobin as 
well as to other heme proteins to affect their heme prosthetic moieties and alter 
enzymatic activity159 698.  CO has been demonstrated to inhibit apoptosis of endothelial 
and epithelial cells and to reduce proliferation of smooth muscle cells, fibroblasts and T 
lymphocytes.  CO also inhibits the production of cytokines implicated in a variety of 
disease pathologies including tumour necrosis factor (TNF), interleukins IL-1 and IL-6, and 
endothelin.  CO activity is mediated by its molecular interaction with proteins such as 
soluble guanylyl cyclase, high conductance calcium sensitive K+ channels and mitogen-
activated protein kinases (MAPK).   
CO effects may involve three broad mechanisms: activation of soluble guanylyl cyclase 
(sGC) with resultant increase in cyclic guanine monophosphate (cGMP) production, 
modulation of the MAPK pathway and binding of CO to a range of intracellular heme 
proteins with formation of metal-CO complexes and inhibition or activation of enzymes 
containing heme that generates varied biological effects.  
3.1.8 cGMP dependent pathways 
CO binding to the heme moiety of soluble guanylate cyclase activates the enzyme and 
increases cGMP levels to relax vascular smooth muscle and cause vasodilatation.  Soluble 
guanylyl cyclase is classically considered as the target to mediate CO cellular actions, but 
there is far less CO stimulation of sGC compared to NO, with CO only about 1/80th as 
effective as NO in activation of sGC.  Very high levels of CO are normally required to 
activate soluble guanylate cyclase.  Furthermore, CO can be demonstrated to effect 
vasodilatation despite concurrent administration of blockers of the cGMP pathway.  
These observations suggest the involvement of cellular mechanisms independent of sGC 
activation699 700.  Interaction of CO with the cGMP pathway may be particularly relevant in 
neuronal tissues.  The HO-2 enzyme isoform co-localises with soluble guanylate cyclase 
primarily in neural tissues including the brain.  At these sites there is therefore a close 
association between a potential source of endogenous CO and a potential target of CO 
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activity.  Heme oxygenase inhibition by false substrates or knockdown of the HO-2 gene 
can cause adverse effects to central and peripheral nervous system functions236 674 701 702.   
3.1.9 cGMP independent pathways 
3.1.9.1 Ca2+-activated K+ channels  
Published reports suggest that vasodilatation produced by CO is mediated via activation 
of calcium-dependent potassium channels.  Blockade of Ca2+-activated K+ channels 
inhibits vasodilatation associated with CO and inhibition of HO activity compromises K+ 
channel activity in smooth muscle cells691 703.  Activation of vascular 238pS and 105pS 
Ca2+-activated K+ channels render smooth muscle cells less responsive to the actions of 
vasoconstrictors704 705.  In the normal physiology of smooth muscle cells, K+ channel 
activity is regulated by a local transient increase of Ca2+ concentration in the micromolar 
range.  Activation and opening of large conductance potassium channels enables passive 
flow of K+ ions down the electrochemical gradient causing an efflux of K+ from the cell and 
plasma cell membrane hyperpolarisation.  Cell excitability is decreased and voltage-
dependent Ca2+ channel activity is reduced resulting in smooth muscle cell relaxation706.  
Endogenously generated or exogenously administered CO increases the amplitude and 
frequency of K+ channel activity dependent on micromolar changes in Ca2+ concentration.  
This may be an essential mechanism for CO-mediated vasodilatation707.  The Ca2+-
activated K+ channel has a tetrameric structure containing α-subunits that are critically 
involved in its activation process.  Each α-subunit contains a heme-binding pocket and 
binding of heme to the channel inhibits its activity708.  CO activates the K+ channel by 
binding to protein-bound prosthetic heme and altering the interaction of heme with the 
intrinsic active protein of the α-subunit resulting in an increase in sensitivity to Ca2+ 
concentration688 709 710.   
Oxygen levels can regulate calcium-sensitive potassium channel activity via a similar 
mechanism of heme binding.  Carbon monoxide derived from HO-2 activity has been 
demonstrated to be an essential component of this regulatory control of respiration by 
oxygen sensing.  Carotid body cells demonstrate inhibition of Ca2+-dependent K+ channel 
activity induced by hypoxia that is dependent on HO-2 expression and augmented by 
increased HO-2 activity215.   
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3.1.9.2 Mitogen-activated protein kinases 
Carbon monoxide has been demonstrated to regulate mitogen activated protein kinases 
(MAPK) related pathways with specific activation of p38 protein and down-regulation of 
extracellular signal-regulated kinase 1/2 (ERK1/2)237.  MAPK-regulated CO effects include 
cytoprotective, anti-inflammatory and anti-proliferative activity via cell cycle arrest.   
Production of inflammatory cytokines is suppressed by CO activity involving the c-Jun N-
terminal kinase (JNK) pathway711.  Physiological concentrations of CO inhibit the 
production of inflammatory cytokines such as interleukin-1 (IL-1), macrophage migration 
inhibitory factor (MIF) and tumour necrosis factor (TNF-α) from activated macrophages.  
The secretion of interleukin-2 (IL-2) from activated T-lymphocytes is also suppressed by 
CO via selective activation of the MAPK pathway249 633. 
The protective effect of HO-1 up regulation has been attributed to an increase in cGMP 
levels induced by CO and CO-mediated activation of the p38 MAPK pathway712.  Recent 
studies in the human lung epithelial cell line A549 demonstrate inhibition of the 
expression and activity of the matrix metalloproteinases MMP-1 and MMP-2 by carbon 
monoxide effects regulated by the MAPK system.  These findings imply a central role for 
CO in the pathophysiology of emphysema and other alveolar diseases involving a 
protease/antiprotease imbalance713.   
It has been demonstrated that different cell types and stimuli can produce variable 
effects of CO on MAPK signaling cascades.  CO inhibits the proliferation of pancreatic 
stellate cells by activating p38 MAPK714 whereas CO produces a similar reduction in 
proliferation of human airway smooth muscle cells by inhibiting ERK activation715.  The 
mechanisms by which CO modulate MAPK pathways are not fully elucidated.  CO slows 
the rate of electron transport in the mitochondria enabling electrons to accumulate at 
complex III.  This promotes the production of superoxide anion (O2
−) and its conversion to 
hydrogen peroxide (H2O2) by manganese superoxide dismutase
710.  Hydrogen peroxide 
derived from mitochondria can activate the MAPK and Akt protein kinase signalling 
pathways716.  
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3.1.9.3 Heme protein binding 
Carbon monoxide binds to the heme moiety of other hemoproteins thereby affecting 
their enzymatic activity.  Alternative targets of CO include nitric oxide synthase292 717 718, 
cytochrome oxidase and mitochondrial complexes461 719-722 and NADPH oxidase722.  There 
is published evidence to support a role for CO in stimulation of cyclooxygenase (COX) 
activity723.  Treating rat hypothalamic explants and primary cell cultures of rat 
hypothalamic astrocytes with the heme oxygenase substrate hemin increased the 
production of prostaglandin E2 via activation of COX.  Treatment with the HO inhibitor tin 
mesoporphyrin-IX reduced E2 production and adding hemoglobin as a CO scavenger 
abolished the stimulatory effect on COX activity.  Furthermore, exposure of rat 
hypothalamus samples to a CO-saturated medium caused significant increases in 
prostaglandin E2 release723-725.   
Additional evidence indicates targeting of various heme proteins such as cytochrome 
P450 and biologically relevant protein ligand systems containing transition metals713 726.  
CO can bind to iron, nickel and copper in bacteria, and copper in cytochrome c oxidase727.  
Binding of CO to cytochrome P450 and cytochrome c oxidase alters their enzymatic 
activity and provides a potential mechanism for CO effects.  Protection against 
reperfusion injury mediated by CO may be implemented via competitive binding of CO to 
cytochromes that prevents their activation by oxygen.   
The potential for iron binding is particularly interesting given that HO activity produces 
biliverdin, CO and ferrous iron (Fe2+).  The ferrous iron is not oxidised to ferric iron (Fe3+) 
in the heme oxygenase system.  Ferrous iron reacts with cysteine to give Fe(cysteinate)2 
which readily absorbs CO to produce Fe(cysteinate)2(CO)2
728.  Fe2+ binds CO much more 
readily than Fe3+ via these reactions.   
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3.1.10 Adverse CO Effects 
Pharmacological levels of CO have cytoprotective properties when added to cell cultures 
and in vivo models.  Appropriate CO levels can inhibit apoptosis, inflammation, platelet 
aggregation and proliferation of vascular smooth muscle729.  Carbon monoxide may also 
exert deleterious effects in certain organs, particularly by stimulating pro-inflammatory 
responses in the brain204.  CO activates cyclooxygenase enzyme in rat ex vivo 
hypothalamus and primary cultures of rat hypothalamic astrocyte cells resulting in the 
increased formation of pro-inflammatory prostaglandins202 204.  CO may cause oxidative 
tissue damage by increasing the formation of mitochondrial reactive oxygen species 
through CO binding to cytochromes residing in complex IV.  Intracellular levels of 
antioxidants such as glutathione can be reduced by this mechanism716.  Inhibition of 
cytochrome oxidase by endogenously produced CO is thought to be physiologically 
insignificant.  CO binds so tightly to hemoglobin and myoglobin that levels of available 
free CO are likely to be very low. 
3.2 Clinical Aspects of Carbon Monoxide 
3.2.1 CO in inflammation 
The anti-inflammatory activity of CO could have the greatest potential for future 
therapeutic applications.  Inflammation is the underlying cause of chronic diseases 
including diabetes, cardiovascular disease, cancer and obesity.  Acute inflammation 
corresponds to the constitutive systemic response to acute conditions such as microbial 
infection.   
Chronic inflammation is a pathological condition characterised by ongoing active 
inflammation, tissue loss and tissue repair processes.  Chronic inflammatory tissue 
typically includes infiltration of activated macrophages and monocytes that generate 
inflammatory mediators including nitric oxide.  Carbon monoxide has been demonstrated 
to inhibit NO production in macrophages and reduce inflammation.  Nitric oxide synthase 
contains a heme prosthetic group that provides a binding site for CO.  CO binding impairs 
the activity of NO synthase preventing the enzymatic oxidation of arginine to citrulline 
and NO730.  
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The anti-inflammatory response mediated by HO-1 activity and its products CO and 
bilirubin also impairs expression of intercellular adhesion molecule-1 (ICAM-1).  
Production of pro-inflammatory cytokines such as TNF-α is reduced while important anti-
inflammatory molecules such as interleukin-10 (IL-10) are upregulated730.  Evidence from 
several cell culture experiment models indicates that CO directly inhibits the production 
of pro-inflammatory cytokines TNF-α and IL-1β induced by lipopolysaccharide endotoxin 
(LPS) while stimulating the release of IL-10249 297 642.  Similar CO effects are documented 
from studies in animal models with induction of inflammatory responses caused by LPS, 
ischaemia–reperfusion injury and organ transplantation often involving various cytokines 
such as IL-2 and IL-6249 642 731-733.  Mice exposed to CO at 250 ppm for 1 hour before 
administration of LPS exhibited an inflammatory response with significantly lower levels 
of TNF-α and IL-1β and higher levels of IL-10 as compared to control mice subjects.   
Cytoprotective effects of pharmacological or inhalation CO therapy in animal models of 
acute lung injury and sepsis are mediated by multiple cellular and molecular mechanisms 
including vasodilatation, maintenance of mitochondrial integrity and regulation of the 
redox state by controlling the production of reaction oxygen species (ROS).  Levels of HO-
1 and CO regulate cellular autophagy by means specific to the cell type involved.   
CO has demonstrated a therapeutic benefit in experimental animal models of ventilator-
induced lung injury, oxidative and acid-induced lung injury, challenge with LPS endotoxin 
and sepsis induced by caecal ligation and puncture734 735.  A recent study describes the 
effects of timing of CO administration with respect to lung protection in animal subjects 
undergoing mechanical ventilation.  Pre-treatment with CO had no measurable impact on 
ventilator-induced lung injury.  Delaying administration of CO until 3 – 5 hours after the 
start of mechanical ventilation reduced the observed lung damage, cellular infiltrate and 
accumulation of neutrophils.  Treatment with CO for 6 hours protected against ventilator-
induced lung injury (VILI)736.  A similar study of VILI in a mouse model demonstrated 
protective effects of CO on mechanically-ventilated lung.  CO treatment prevented the 
early up regulation of early growth response-1 (Egr-1) associated with mechanical 
ventilation with decreased neutrophil infiltration and prevention of lung injury.  CO 
effects were mediated by peroxisome proliferator-activated receptor-γ and dependent on 
inhibition of Egr-1737.   
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The effects of CO inhalation on systemic inflammation have been studied during 
experimental endotoxaemia in humans.  In a double-blinded randomized controlled trial 
with a two-way crossover trial design experimental endotoxaemia was induced in healthy 
volunteers by injection of 2 ng per kg LPS endotoxin.  Inhalation of 500 ppm CO sufficient 
to increase HbCO levels was compared to inhalation of synthetic air as a placebo for 1 
hour.  No adverse effects of CO inhalation were observed despite an increase in HbCO 
levels from 1.2% to 7% in treatment subjects.  CO inhalation had no effect on the 
inflammatory response as measured by systemic production of cytokines TNF-α, IL-1β, IL-
1α, IL-6 and IL-8738.  A recent clinical feasibility study reported the administration of 
inhaled CO to human subjects with chronic obstructive pulmonary disease (COPD)739.  Ex-
smokers with stable COPD were subjected to CO inhalation at 100–125 ppm for 2 hours 
per day for 4 consecutive days.  Arterial carboxy-Hb levels increased to 4.5%.  CO 
inhalation demonstrated a trend towards reduced sputum eosinophils and an improved 
response to inhaled methacholine challenge739.   
The efficacy and potential of CO therapy in humans with inflammatory conditions remains 
relatively uninvestigated, and further controlled clinical studies in human subjects are 
required740.  A recently completed trial supported by the U.S. National Institutes of Health 
Clinical Center aims to examine how CO inhalation affects local pulmonary inflammatory 
responses in healthy volunteers subjected to bronchoscopic instillation of bacterial 
endotoxin.  Clinical trials in the recruiting phase include studies of CO therapy for severe 
pulmonary hypertension and idiopathic pulmonary fibrosis and a trial of CO inhalation to 
reduce the duration of post-operative intestinal ileus741.   
3.2.2 Potential of CO as a therapeutic agent 
Experimental models of acute lung injury including mechanisms of ischaemia, hyperoxia 
and acute respiratory distress syndrome (ARDS) have demonstrated increased expression 
of stress-induced HO-1 measured in broncho-alveolar epithelial cell and macrophage cell 
specimens269 287 742.  Administration of exogenous CO has shown promising therapeutic 
potential in animal models of acute oxidative lung injury, ventilator-induced lung injury, 
pulmonary fibrosis and lung transplantation743.  These observations suggest a 
contribution of the HO-1 pathway in protecting pulmonary function during pathological 
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conditions.  Comparatively high levels of exhaled CO have been observed in rodent 
models of acute lung injury induced by extracorporeal circulation and in experimental 
ARDS744 745.  These findings indicate that sustained levels of substrate are available to 
maintain increased heme oxygenase activity in pulmonary tissue.  
In vitro studies performed with lung epithelial cells and fibroblasts confirm that up 
regulation of HO-1 conferred resistance to ischaemic lung injury, oxidative damage and 
apoptosis mediated by TNF-α279 746 747.  Cytoprotective and anti-oxidative effects in the 
respiratory and cardiovascular system can be observed with direct exposure to exogenous 
CO gas as well as other effectors of heme oxygenase activity biliverdin and bilirubin748.  
Whereas the biliverdin and bilirubin products have direct capability to scavenge oxidants 
and prevent damage, the CO product has additional unique activity in cell signalling 
pathways.   
Beneficial properties of CO have also been documented for in vivo experimental models.  
The majority of experiments involve administering CO gas at 200 to 400 ppm in the air 
supplied for inhalation.  The first study to include CO inhalation at low concentrations as a 
therapeutic strategy observed a protective effect of CO gas against hyperoxic lung injury 
and proposed anti-inflammatory and anti-apoptotic CO activity as the likely mechanism 
responsible269.  Carbon monoxide inhibits the development of post-operative intestinal 
ileus in a mouse model and is involved in the control of gastrointestinal contractile 
activity749 750.  CO administration also reduces the inflammation associated with allergen-
induced asthma in mice734.   
In rodent models CO has been demonstrated to protect against inflammation associated 
with orthotopic lung transplantation and oxidative lung injury.  CO checks the progression 
of atherosclerotic lesions associated with chronic graft rejection and with intimal vessel 
wall injury following balloon angioplasty297 751 752.  Experiment rats exposed to 400 ppm of 
CO gas for 2 days following mouse-to-rat cardiac transplantation had graft survival 
evident at 50 days post-transplant.  Control rats exposed to air alone had no suppression 
of graft rejection and the organs survived only 5 to 7 days after transplantation634.   
Further success with rodent models has been observed with CO treatment able to reverse 
established pulmonary hypertension271.  Cytoprotective effects on the respiratory system 
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produced by CO gas exposure seem to be mediated by mitogen-activated protein kinase 
pathways (p38, MKK3)249 297 and caspase-3747 and cyclic-GMP-dependent mechanisms753.  
CO inhalation treatment may reduce the deposition of fibrin in the microvasculature 
thereby preventing a major pathophysiological contribution to ischaemic lung injury287 753.  
CO exposure has similar actions in protecting against ventilator-induced lung injury by 
reducing TNF-α production and neutrophil recruitment to the affected alveoli754.  
Evidence for the potential therapeutic benefits of CO inhalation in animal models of lung 
disease is not universal.  Clayton and colleagues report no significant benefit of CO 
treatment on acute lung injury due to hyperoxia and observed neurotoxicity at relatively 
low levels of CO exposure (200 and 500 ppm)755.   
The role of endogenous CO as a vasodilator in the cardiovascular system is associated 
with guanylate cyclase (sGC) activation and consequent increases of cGMP levels as well 
as stimulation of various potassium channels756.  In a porcine model CO exposure 
improved cardiac output and protected the heart during reperfusion after 
cardiopulmonary bypass757.  Although nitric oxide is the more important physiological 
vasodilator the role of endogenous CO may become more relevant when NO signalling 
pathways are disrupted667.  The CO-mediated responses of the vasculature may be tissue-
dependent.  Although CO treatment provokes vasodilatation in most vessels investigated 
including the aorta and cerebral vessels756 758 it has also been observed to cause 
vasoconstriction rather than dilatation in gracilis muscle arterioles759.   
3.2.3 Heme oxygenase-1 (HO-1) and stress induction  
Induction of heme oxygenase-1 (HO-1) enzyme can produce beneficial effects mediated 
via an increased production of endogenous CO.  Increased expression of HO-1 protein 
occurs in cells and tissues exposed to agents or conditions that cause an increase in 
oxidative stress641.  Enhanced HO-1 expression may contribute to the therapeutic activity 
of drugs including aspirin and statins in the cardiovascular system.  Further experiments 
are required to establish clear evidence for this relationship760 761.  
A number of compounds that occur naturally in fruits and vegetables are capable of 
potent HO-1 induction, including curcumin found in turmeric762, L-sulforaphane present in 
broccoli763, resveratrol in grape skin764 and organosulfur compounds derived from red 
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wine and garlic765.  Although again direct experimental evidence is lacking, a high intake 
of certain fruits or vegetables may exert beneficial action on the cardiovascular system via 
increased HO-1 activity and consequent increased endogenous CO production.     
3.2.4 Clinical development of CO therapy  
Initial attempts to use CO inhalation for therapy were performed for sickle cell anaemia 
and reported by Beutler in 1975766.  Carbon monoxide administration at a concentration 
of 1000 – 2000 ppm significantly prolonged the life span of chromium-labelled red blood 
cells in two patients with sickle cell disease.  Decreased sickling of red cells results from 
binding of CO to hemoglobin and an increased affinity of hemoglobin for O2 shifting the 
O2 dissociation curve to the left. 
A recent pilot study examined the effects of CO inhalation on the inflammatory response 
to experimental endotoxaemia in vivo using a randomised, double-blinded, placebo-
controlled crossover trial in healthy volunteers738.  Healthy male smokers aged 18 to 40 
years randomly inhaled either synthetic air as placebo or 500 ppm CO for 1 hour with a 
washout period of 6 weeks in between both treatments.  Carboxyhemoglobin levels were 
assessed as a safety parameter with an HbCO level greater than 10% defined as a stop 
criterion.  Immediately after inhalation all volunteers received an intravenous bolus of 
reference endotoxin E. coli lipopolysaccharide (LPS) at a dose of 2 ng per kg.  CO 
inhalation increased carboxyhemoglobin levels from 1.2% to peak values of 7.0%.  
Infusion of LPS induced transient increases in cytokines (TNF, IL-6, IL-8, IL-10), c-reactive 
protein and prothrombin fragments in serum, as well as IL-1α and IL-1β mRNA levels in 
blood cells.  Administration of inhaled CO had no significant effect on any LPS-induced 
response observed.  Increases in blood pressure, heart rate and body temperature after 
LPS treatment were not prevented by CO inhalation.  Contrasting results were reported in 
rodent models using CO inhalation at 250 ppm for 1 hour738. 
This trial was somewhat controversial as some observers considered the study to violate 
acceptable standards of ethical research.  There remains a lack of consensus regarding 
the safety threshold of CO exposure in a trial context.  Opponents of CO inhalation 
therapy studies maintain that low dose CO inhalation (e.g. 100 ppm CO for 1.5 to 2.5 
hours) has been proven to have adverse neuropsychological effects.  This opinion does 
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not consider the lack of such effects directly caused by CO in other studies and in smokers 
exposed to higher CO doses.  Circumstantial evidence exists that CO has beneficial effects 
in humans as CO inhalation in smokers may partially protect women from pre-
eclampsia767 and may provide partial protection against cell proliferation of the intimal 
vessel wall following balloon angioplasty768.   
Several CO inhalation trials are currently in progress with the aim of assessing the 
therapeutic viability of CO inhalation769-772.  The U.S. National Institutes of Health 
programme includes various phase I clinical trials that are either recently completed or 
currently recruiting to investigate trials of CO inhalation therapy in severe pulmonary 
hypertension, idiopathic pulmonary fibrosis and prevention of post-operative intestinal 
ileus741 773.   
The therapeutic use of CO gas presents several practical and clinical problems.  It has to 
be administered through the lungs as a mixture with air at a typical dose of 200 ppm.  The 
whole body is therefore exposed to it and the level of blood carboxyhemoglobin has to be 
carefully monitored.  A preferable approach would be to selectively administer the CO to 
disease tissue targets that may be achieved using a metal carbonyl solution to deliver a 
tightly controlled therapeutic local dose.   
There is recent reported interest in the targeted induction of mitochondrial biogenesis as 
a potential therapy for multiple organ failure that can be mediated by CO activity.  A 
murine model of Staphylococcus aureus sepsis was investigated using inhaled carbon 
monoxide at 250 ppm once daily for 1 hour.  CO treatment activated mitochondrial 
biogenesis via induction of HO-1 enzyme and increased mitochondrial HO activity through 
Nuclear-related factor-2 transcriptional and Akt kinase activity.  Survival of mice with S. 
aureus sepsis was significantly enhanced with CO inhalation compared to control subjects 
with demonstrable resolution of hepatic mitochondrial damage774.   
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3.3 Carbon Monoxide Releasing Molecules  
3.3.1 Development of CORMS 
Increased expression of heme oxygenase-1 (HO-1) enzyme has been demonstrated to 
provide beneficial effects in a wide variety of pathological conditions.  These findings have 
fostered interest in the therapeutic potential of heme oxygenase inducers, heme 
oxygenase gene transduction and cell permeable heme oxygenase-peptide conjugates.  
An alternative strategy is the direct application of carbon monoxide in its gaseous form, 
the end product of heme oxygenase activity.  Experimental animal disease models have 
shown beneficial effects using inhalation of gaseous CO or oral administration of 
methylene chloride, a compound that generates CO through its metabolism in the liver.   
Under pathological conditions endogenous CO production is delayed or reduced so that 
its potential for beneficial effect is not realised.  Administration of exogenous CO may 
have therapeutic potential in clinical applications but the systemic delivery of inhaled 
gaseous CO is not practical outside a hospital setting.  It requires ventilators, face masks, 
normobaric chambers or portable inhalers.  Systemic inhalation delivers CO 
indiscriminately to tissues using the same pathway that eliminates endogenously 
produced CO under normal physiological conditions.  Delivery of CO to therapeutic 
targets involves the binding and dissociation of CO with hemoglobin.  The hemoglobin 
molecule has a very high affinity for binding CO so that a relatively high loading of 
hemoglobin with CO is required to deliver a CO dose to target tissues within the 
therapeutic range.  This dose range is likely to be associated with the adverse effects of 
mild CO poisoning.  An ideal solution would be the primary delivery of therapeutic CO to 
diseased tissue targets before the gas diffused into the blood to be eliminated by 
respiration732.   
The limitations of CO inhalation therapy may be overcome by the use of a promising 
alternative pharmacological method: the development of transition metal-based carbon-
monoxide-releasing molecules (CORMs).  These compounds have been designed with the 
aim of providing safe and controlled administration of gaseous CO to a specific tissue 
target.   
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3.3.2 CORM design 
A substantial panel of organic compounds and metalloorganic complexes that generate 
CO under different conditions have been designed and synthesised by chemists.  The 
nomenclature CO-releasing molecules was introduced by CORM pioneers Roberto 
Motterlini and colleagues at the Northwick Park Institute for Medical Research and the 
University of Sheffield.  CORMs are essentially prodrugs that deliver active carbon 
monoxide without adverse effects on healthy tissues.  Selective delivery of CO to diseased 
tissue targets may be further enhanced by incorporating CORMs into macromolecular 
carriers such as cyclodextrins and liposomes with attached specific targeting devices.  The 
clinical applications of CORMs may be expanded by conjugating them with drugs such as 
aspirin to complement the therapeutic effects and potentially counteract the adverse 
effects of the drug.   
The two major classes of CORMs are organic molecules and metalloorganic complexes.  
These are similar to organic nitrates and the metalloorganic compound nitroprusside that 
have longstanding clinical applications in the delivery of nitric oxide.  There is a complex 
interaction between gaseous mediators NO and CO in human tissues with many similar 
effects on shared target proteins.  Carbon monoxide may have several advantages over 
NO as a therapeutic principle due to much lower toxicity at comparable doses, its more 
restricted target range and greater stability775.  The goal of CORM candidate development 
is to establish drugs that are stable in healthy tissues but released in diseased tissue 
targets.  Studies are ongoing in tissue culture and animal models to determine the 
kinetics of CO release under different conditions.  Optimisation of CORM designs and 
specific properties of bioavailability, tissue distribution and pharmacokinetics are yet to 
be established.   
3.3.3 Mechanism of CO release 
Carbon monoxide is known to bind strongly to transition metals in organic solvents to 
form stable carbonyl complexes776 777.  CORMs are designed as a metal carbonyl 
compound or equivalent salt and at least one appropriate carrier with pharmacologically 
acceptable properties.  Carbon monoxide becomes available for physiological effect from 
the metal carbonyl with a reversible process of CO binding via one or more of the 
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following mechanisms: dissociation of the metal carbonyl produces CO in dissolved form; 
the metal carbonyl releases CO on contact with a solvent, tissue, organ or cell; the metal 
carbonyl releases CO on irradiation.   
3.3.4 Types of CO-releasing molecules 
The first CORMs identified were transition metal carbonyl compounds Mn2CO10 
(manganesedecacarbonyl) and Ru(CO)3Cl2 dimer [tricarbonyldichlororutheium-(II)-dimer] 
that subsequently became commercially available and termed CORM-1 (Mn2CO10) and 
CORM-2 [Ru(CO)3Cl2-dimer].  When stimulated under appropriate physiological conditions 
these compounds liberated CO and promoted typical CO-mediated pharmacological 
effects such as vasodilatation and hypotension in vivo693.  CORM-1 is insoluble in water 
and releases CO by photolysis when stimulated by light, producing a marked reduction of 
coronary vasoconstriction in isolated rat hearts693 and increasing blood 
carboxyhemoglobin levels, renal blood flow, glomerular filtration rate, and urinary cGMP 
excretion778.  Both CORM-1 and CORM-2 are lipid-soluble and soluble in organic solvents 
such as dimethylsulfoxide (DMSO) commonly used as a vehicle for biological experiments.  
The pharmacological action of Mn2CO10 and Ru(CO)3Cl2 dimer has been confirmed to be 
directly linked to the CO liberated, and the CO-releasing properties of both chemicals 
have been well characterised693.   
In an effort to improve the compatibility of these compounds with biological systems 
water-soluble carbonyl complexes were designed and developed.  Another ruthenium-
based compound tricarbonylchoro(glycinato)-ruthenium (II) (CORM-3) dissolves in water 
and rapidly releases CO in physiological fluids672 779.  The chemistry of transition metal 
carbonyls is varied and highly versatile with CORM development not restricted to 
particular compounds.  Several subgroups of metal carbonyl complexes have been 
synthesised and assessed as CORM candidates including compounds containing 
manganese, iron, cobalt, molybdenum and ruthenium without restriction to transition 
metals780.  
There is substantial experimental evidence in animal disease models demonstrating the 
beneficial effects of CO administered in gaseous form or derived from CORMs.  
Therapeutic benefit has been shown in acute lung injury, liver and kidney injury, acute 
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and chronic rejection of a transplanted organ grafts and in cardiovascular disease, sepsis, 
and shock.  A major difficulty of CORMs in medical applications is the rapid diffusion of 
the small molecular weight drugs after administration with release of their CO prior to 
reaching the diseased target tissue.  Future work is directed toward developing a safe and 
efficient delivery system encompassing the design and synthesis of CORMs with 
molecular characteristics that provide appropriate absorption, distribution, metabolism, 
and excretion properties yet maintain an effective therapeutic action and low toxicity 
profile781.   
3.3.5 Water-soluble CORMs and alternative delivery mechanisms 
A central challenge is the development of water-soluble compounds that release CO 
relatively fast with half-lives of less than two hours and are non-toxic to healthy cells and 
tissues.  Slower release of CO will reduce the effective CO concentration as available CO is 
diluted in the systemic circulation and binds to hemoglobin.  The CORM compound 
concentration required to produce therapeutic doses of CO may become prohibitively 
high from an adverse effect standpoint.   
The first prototype of a water-soluble transition metal carbonyl was synthesised by co-
ordination of the amino acid glycine to a ruthenium metal centre 
[Ru(CO)3Cl(glycinate)]
782.  This CORM-3 compound is relatively stable in aqueous solutions 
but rapidly releases CO in the presence of myoglobin, other biological stimuli that interact 
directly with the ruthenium metal and after contact with cellular components.  The half-
life (t½) of CO release from CORM-3 in biological fluids conditions is typically less than 1 
minute whereas the half-life is 24 hours when the molecule is dissolved in distilled 
water782.   
The specific CO-releasing properties of CORM-3 in biological fluid can be explained by 
what is believed to be the coordination of a strong ligand such as a thiol group.  
Experiments conducted in vitro have demonstrated the prompt loss of CO from an 
aqueous solution of [Ru(CO)3Cl(glycinate)] only after addition of cysteine or pyridine.  
Both the chloride and glycinate ligands of the CORM-3 molecule are labile and readily 
replaced by stronger ligands782 783.  This binding chemistry limits a very slow release of CO 
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from aqueous solutions of [Ru(CO)3Cl(glycinate)] until the compound meets suitable 
strong ligands present in biological fluids. 
CORM-3 has been proved to effect vasodilatory and antihypertensive activity in biological 
experiments782 783.  CORM-3 protects an isolated rat heart from reperfusion injury 
following 30 minutes of ischaemia and markedly improves the survival time of mice 
following heart transplantation782.  CORM-3 administration produces demonstrable 
vasodilatation in an isolated aortic ring pre-treated with the vasoconstrictor 
phenylephrine758.  There is evidence the treatment with [Ru(CO)3Cl(glycinate)] affords 
renal protection against cisplatin-induced nephrotoxicity and improved renal and cardiac 
graft function following cold ischaemia when used during organ preservation720 732 784 785.   
Recent experimental in vitro studies of vascular and neural inflammation suggest 
important anti-inflammatory properties of CORM-3 activity with evidence of inhibition of 
platelet aggregation786-788.  CORM-3 is undoubtedly the most-studied of all the CORMs 
developed to date.  Several subsequent generations of CORMs have been synthesized and 
studied and are the subject of unpublished patent applications.  A key challenge that so 
far remains incompletely solved is the controlled delivery of therapeutic amounts of CO 
to target tissues without adverse effects of the carrier molecule or generation of 
excessive carboxyhemoglobin levels.  A consistent strategy to achieve this aim is the use 
of stable molecules that release CO only after activation by a specific stimulus779 789 790.  
Suitable mechanisms are the pH-dependent release of CO from boranocarbonate 
compound (CORM-A1) and its aminoderivates or the release of CO from transition metal 
carbonyl complexes triggered by UV-radiation694 791-793.   
The water-soluble boron-containing compound boranocarbonate can slowly liberate CO 
under physiological conditions with a t½ = 21 minutes794-796.  Boranocarbonate CORMs 
have recently been developed by Professor Alberto and collaborators at the University of 
Zurich694.  The prototype sodium boranocarbonate (CORM-A1) does not contain a 
transition metal carbonyl but a carboxylic group that is converted to CO through 
hydrolysis with a strictly controlled slow release of CO dependent on pH and 
temperature.  The gradual mild vasodilatation and hypotensive effects produced by 
194 
 
CORM-A1 can be amplified with the concomitant use of guanylate cyclase sensitizers694 
758.   
Recently, a new light-sensitive CORM has been developed that can deliver CO directly to 
target tissues without significant formation of carboxyhemoglobin and a low toxicity 
profile as compared to that of boron-containing compounds797.  This water-soluble 
CORM-S1 is based on iron and cysteamine and releases CO under irradiation with visible 
light spectrum whilst maintaining overall stability in the dark797.   
Recently developed CO-delivery systems based on aggregate micelle molecule forms of 
metal carbonyl complexes have demonstrated slowed diffusion in tissues and an 
improved ability to target specific tissue798 799.  The CO release at distal tissue drainage 
sites was slower than that achieved with equivalent CORM-3 treatment.  The LPS-induced 
NF-κβ activation of human monocytes was successfully attenuated after treatment with 
CO-releasing micelles whereas CORM-3 exposure did not elicit a beneficial response. 
A recent novel concept using iron complexes that release CO via an enzyme-catalysed 
reaction has been introduced, termed enzyme-triggered CO-releasing molecules (ET-
CORMs)800 801.  
To maximise the potential for therapeutic applications of CO the issues that require 
continued study include the development of novel CORMs with ideal delivery 
mechanisms, a greater understanding of CO release from carrier molecules, improved 
analytical techniques to monitor CO release and further investigation of the cellular 
uptake of CORMs.  A further potential pharmaceutical use of CORMs stems from their 
multiple modes of biological activity that are being progressively identified with the 
burgeoning scientific interest in CORMs672 732.   
3.3.6 Beneficial effects of CORMs 
Carbon monoxide releasing molecules (CORMs) have the potential for therapeutic benefit 
in the prevention and cure of diseases involving inflammatory, infectious, thrombotic and 
apoptotic processes.  Experimental data from in vivo animal models demonstrate the 
effectiveness of CORM therapy in various conditions including acute liver failure, multiple 
sclerosis, rheumatoid arthritis, stroke, NSAID-induced gastric ulcers, hypertension and 
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infection by antibiotic-resistant strains of bacteria802 803.  Protective anti-inflammatory 
effects of CORMs reported in the literature to date include attenuation of the acute 
inflammatory response both in vitro and in vivo and mitigation of neuronal inflammatory 
responses in microglia292 804-807, reduction of immunological histamine release from 
guinea pig mast cells and human neutrophils808 809 and moderation of hepatic leucocyte 
sequestration and the systemic inflammatory response during severe burn injury810.  In 
studies of the cardiovascular system there is published evidence that CORM treatment 
provides cardioprotection against both ischaemia and myocardial infarction238 721 732 782, 
reduction of cardiac graft rejection and positive inotropic effects on the heart782 811, anti-
hypertensive effects and inhibition of platelet aggregation694 788 and vasodilatation and 
anti-apoptotic effects in the cerebral circulation812-814.  Organ-specific effects 
demonstrated include the improvement of graft function in kidney transplantation when 
CORMs are used in the organ preservation fluid during cold ischaemia, and renal 
protection against cisplatin-induced nephrotoxicity720 784.  CORM exposure has recently 
been shown to decrease photocarcinogenesis in the skin of hairless mice815.   
Recent in vitro studies have observed that CORMs are capable of potent anti-proliferative 
effects in a model of pancreatic fibrosis with inhibition of pancreatic stellate cell 
proliferation714 816.   
Methylene chloride, a compound developed as a cytochrome P450-dependent CO-donor, 
reduced post-transplant atherosclerosis in rat aorta allografts.  Methylene chloride also 
protected mice against lipopolysaccharide-induced liver injury and prevented 
experimentally induced autoimmune encephalitis and arthritis in experimental rats.  
Recent interest in the development of CORMs has provided a useful tool to investigate 
the intracellular signalling pathways involved in CO activity and its mechanisms of 
action671 722 817.  CO release from CO donors affects the function and activity of several 
heme-dependent proteins that have a central role in cellular homeostatic processes671 
including cell proliferation, angiogenesis, the production of reactive oxygen species and 
mitochondrial respiration371 718 719 722.  The activity of NADPH-oxidase in human 
neutrophils and airway smooth muscle cells is inhibited by CO release from CORM 
treatment, thereby attenuating the oxidative stress response.  The heme-dependent 
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NADPH-oxidase enzyme is a major player in triggering and propagating oxidative stress 
via the production of superoxide anion722 808.  Future studies are required to identify 
metal-containing intracellular proteins with a preferential affinity for CO that represent 
signal transduction targets for the beneficial effects of CO activity.   
3.3.7 CORMs and inflammation 
Experimental murine models of sepsis have demonstrated important anti-inflammatory 
effects elicited by CORM treatment.  Intravenous administration of CORM-2 at 8 mg per 
kg immediately after caecal ligation and perforation reduced the consequent induction of 
microbial sepsis.  Accumulation of polymorphonuclear leucocytes, activation of 
transcription factor, up regulation of NF-κB and expression of adhesion molecule ICAM-1 
were all reduced in mouse liver tissue 24 hours after induction of sepsis with CORM 
treatment818.  In a rat model of acute hepatic ischaemia-reperfusion injury a single 
systemic infusion with CORM-2 at 8 mg per kg protected the liver from ischaemia-
reperfusion injury with reduced levels of serum aspartate transaminase enzyme and an 
improved liver histology score.  Rat livers that were re-perfused with CORM-2 after portal 
vein clamping demonstrated reduced levels of apoptosis with down-regulation of 
caspase-3 activation and increased expression of the anti-apoptotic protein Bcl-2819.   
Recent work has aimed to identify CORM candidates that specifically target acute liver 
injury with evaluation of dose-dependent efficacy in a murine model of acetaminophen 
(paracetamol)-induced severe liver damage.  A suitable molybdenum carbonyl CORM 
(ALF-794) was developed to preferentially distribute to the liver where CO release occurs 
through liver metabolism and enables delivery of a highly specific therapeutic dose of CO 
with low systemic toxicity820.  Additional recent studies used a murine model of ulcerative 
colitis in TCR-α deficient mice.  Mice treated with the CO-releasing molecule-186 (ALF186) 
demonstrated an improvement of active colitis with alterations of interleukin expression.  
Exposure to CO suppressed colonic IL-1β, IL-4 and tumour necrosis factor production 
while increasing secretion of IL-10 protein.  Induction of IL-10 expression was mediated 
via pathway dependent upon HO-1 activity821.   
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3.3.8 CORM experiments in lung physiology and sepsis  
The beneficial effects of CORMs in models of sepsis are well-documented.  Moderation of 
the inflammatory response is achieved using CORM treatment with a reduction in 
cytokine release and oxidative stress demonstrated in macrophages and endothelial cells 
stimulated by lipopolysaccharide endotoxin822.  Changes in endothelial cell properties 
have been elicited by CORM treatment in septic and thermally-injured mice with 
decreases in nuclear factor-κB activation, expression of ICAM-1 adhesion protein and 
tissue granulocyte infiltration.  These experiments demonstrate attenuation of the 
systemic inflammatory response and prolonged survival mediated by CO released from 
CORMs in vivo.798 810 818  Studies by Mizuguchi and colleagues used a murine model of lung 
sepsis.  CORM-3 at 3 mg per kg was given to treatment subjects 15 minutes after sepsis 
was induced by caecal ligation and puncture.  Bronchoalveolar lavage (BAL) fluid was 
obtained following a 6-hour period to measure accumulation of PMNs by 
myeloperoxidase assay and protein content of BAL fluid to assess increases in lung 
vascular permeability.  Results demonstrated a reduction in the accumulation of 
polymorphonuclear leucocytes (PMN) and preservation of vascular permeability in the 
septic lung associated with systemic administration of CORM-3823.   
Reported studies collectively show that the CORM-dependent release of CO reduces 
mortality in septic mice and suggest a therapeutic potential of CORMs to prevent organ 
failure and death in severe sepsis824.   
3.3.9 Mitochondrial dynamics 
Recent investigations have addressed the concept that mitochondria have an important 
role in signal transduction pathways mediated by CO activity825.  Studies reported by 
Lancel et al. looked at the potential of CORMs to preserve mitochondrial function in a 
murine model of peritonitis induced by caecal ligation and perforation (CLP).  Functional 
mitochondrial studies were performed and plasma nitrite/nitrate levels, tumour necrosis 
factor and interleukin-10 levels were measured to evaluate the systemic inflammatory 
response.  CORM-3 treatment in CLP-induced mice prevented the adverse effects of 
sepsis on mitochondrial membrane potential, respiratory control ratio and cellular redox 
status.  Administration of CORM-3 during sepsis also elicited a mild oxidative stress 
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response that stimulated mitochondrial biogenesis with corresponding increases in 
(PPAR-γ-) coactivator-1α protein expression and mitochondrial DNA copy number826. 
Recent studies indicate that increased mitochondrial biogenesis is an important 
mechanism by which CORMs and their derived CO gas exert beneficial protective effects 
against cardiomyopathy and cardiac dysfunction in sepsis461 826.  Water-soluble CORM-3 
has been shown to affect the function and bioenergetic parameters of isolated heart 
mitochondria by the delivery of low micro molar concentrations of CO gas.  CORM-3 
treatment regulated the production of reactive oxygen species via uncoupling of 
mitochondrial respiration and decreased mitochondrial membrane potential at 
concentrations that did not inhibit cytochrome c oxidase827 828.  The CO-mediated effects 
observed were diminished by pharmacological agents known to inhibit mitochondrial 
uncoupling827.  
Strategies attempting to modulate mitochondrial uncoupling and metabolism are 
exploited in the development of therapeutic applications for certain pathological 
conditions.  Thyroid hormones, steroid hormones and fatty acids could play a vital role in 
control of mitochondrial respiration.  Current work suggests that CORM treatment and 
exposure to liberated CO gas provides a significant novel regulator of mitochondrial 
function.   
3.3.10 Metal carbonyl chemistry 
Organometallic carbonyl complexes are an established chemical class of metal 
compounds primarily used as precursors to other organometallic compounds or 
catalysts829 830.  Carbon monoxide is well known to bind as a ligand to most transition 
metals in low oxidation states.  The majority of organometallic carbonyl complexes are 
sensitive to water reactions and oxidation by oxygen and are consequently not stable 
under ambient atmospheric conditions of humid air.  Traditional organometallic carbonyl 
chemistry reactions proceed largely in dry solvents and under inert atmospheres and are 
essentially incompatible with biological systems.  Notable exceptions include technetium 
(Tc) and rhenium (Re) transition metal complexes designed to be used as pharmaceuticals 
during radiological imaging831.  These are stable complexes that are excreted in essentially 
their intact form without releasing CO832.  
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If the CORM principle is to be successfully applied to pharmaceutical development then 
the limitations of organometallic complex chemistry need to be overcome.  CORM drugs 
need to demonstrate sufficient stability in formulations appropriate for clinical 
administration such as pill form, liquid suspension or solution for intravenous injection.  
The ancillary non-CO ligands that stabilise the metal carbonyl complex need to be of 
sufficiently small molecular size to ensure that the corresponding CORMs have a size 
reasonable for drug use with a molecular weight (MW) less than 500 – 600 g per mol833.  
Central requirements of CORM therapeutic candidates are stability under ambient 
conditions, solubility in aqueous solutions and the ability of the compound to release its 
CO ligand under controlled conditions.  Targeted CO release can be achieved by selecting 
appropriate chemical structures for the stabilising ancillary non-CO ligands of the 
complexes.  Specific ligands can be used that enable common mechanisms for the 
activation of pro-drugs to be employed.   
CORM-3 has demonstrated encouraging biological activity in several in vitro and in vivo 
biological systems732 781 834.  However the chemical instability of CORM-3 in aqueous 
solutions represents a major limitation for pharmaceutical applications835-837.  
3.3.11 Molybdenum and other transition metals 
There are various reported attempts to evaluate appropriate CO-binding transition metals 
with corresponding ancillary ligands for CORM development.  Metals including 
manganese, cobalt and chromium were quickly discounted for known toxicities or specific 
chemical limitations of compound stability.  CORMS have been developed using 
complexes with iron, ruthenium and rhenium and a variety of ancillary ligands with 
equivocal success838.  A consistent difficulty with CORM synthesis is attaining adequate 
profiles of stability and CO release in air or in aqueous solutions required for acceptable 
pharmaceutical use732 834.  Formation of molybdenum tricarbonyl complexes with lithium 
isocyanoacetate ligands has recently been described by Beck and co-workers.  These 
complexes have a small molecular size and appear to be soluble and stable in water under 
ambient conditions839.   
Molybdenum-based CORMs formed with derivatives of isocyanoacetate ligands have 
recently been synthesised and shown to benefit from certain appropriate pharmaceutical 
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properties.  Molybdenum carbonyl CORMs developed for the treatment of liver diseases 
have demonstrated preferential distribution to the liver after systemic administration 
where bioactivation of the drug enables specific CO delivery to the diseased tissue 
target820.   
A novel approach reported recently by Zobi et al. promotes the use of cyanocobalamine 
(vitamin B12) as a biocompatible scaffold for CORMs containing rhenium (Re) transition 
metal.  The authors synthesised Rhenium-vitamin B12 bioconjugates (B12-ReBr2(CO)2H2O) 
that afforded myocardial protection against experimental ischaemia-reperfusion injury786.  
These organometallic complexes have favourable half-lives for biological and therapeutic 
applications and the resulting oxidised product after CO release (rhenium pertechnetate, 
ReO4
−) is one of the least toxic of the rarest inorganic compounds786.  The Re-
bioconjugates developed have improved biocompatible characteristics as compared to 
their parent complexes.  They have improved solubility in water and are more stable in 
aqueous aerobic media840.   
The therapeutic possibilities of rhenium bioconjugates could apply particularly to the liver 
where vitamin B12 is stored and metabolised.  Potential applications include the 
prevention and treatment of inflammatory liver disorders, treatment of liver injury and 
suppression of graft rejection in liver transplantation732 775 781.   
3.3.12 Challenges of CORM clinical therapeutics 
A central question in approaches to CO therapy is whether CORMs can directly deliver 
gaseous CO to living cells or organisms in a safe, accurate and measurable fashion.  The 
physiological properties and toxicity profile of the CORM chemical scaffold and transition 
metal components as well as the released CO gas must all be carefully considered.   
The principal advantages of CORMs over CO inhalation as a therapeutic approach include 
the precise controlled delivery of CO liberated from CORMs at desired concentrations via 
all possible routes of administration.  Gaseous CO can only be administered effectively by 
inhalation and CO toxicity is a limiting factor.  CORMs can utilize specific chemical 
engineering to trigger targeted delivery of small doses of CO gas to diseased tissue 
without significantly raising CO levels in other tissues.  This should mitigate the overall 
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systemic adverse effects of CO inhalation.  Administration of CORMs directly bypasses the 
pulmonary system and effectively avoids the biological trap of deoxyhemoglobin which is 
inevitably and rapidly converted to HbCO in the lung following CO gas inhalation.  
Formation of HbCO (carboxyhemoglobin) reduces the availability of deoxyhemoglobin 
and compromises tissue oxygen delivery.  CO has an affinity for hemoglobin 240 times 
that of O2
632.  CO delivery to selected target tissue achieved with CORMs results in only 
slight increases in HbCO levels similar to endogenous CO production in disease states670.   
Published data are available on adverse systemic CO effects using pharmacologically 
effective doses of CORM-3 to reduce myocardial infarction and CORM-A1 to improve 
renal haemodynamics after acute renal failure in vivo695 841.  Using CORMs in these 
experiments did not increase measured HbCO levels to a threshold considered to be 
dangerous (10%).   
Working with organometallic complexes in medicinal chemistry offers unique advantages 
due to their marked adaptability and reliable methods of synthesis.  The kinetics of CO 
release can be finely tuned by modifying the ancillary ligand coordinated to the transition 
metal centre or by altering the chemical behaviour according to ambient pH or 
temperature694 717.  Significant progress in the development of CORM pharmaceuticals 
relies upon formulating compounds that are stable in ambient conditions and in vivo and 
can be specifically tailored to achieve precise delivery of CO gas to target tissue sites.  The 
remaining product after CO release should ideally have biologically relevant properties.  
The end-product should be non-toxic or have an acceptable and well-characterised 
toxicity profile.  Pharmacokinetics, efficacy profiles and manufacturing considerations are 
some of the issues to be addressed in ongoing work842-844.   
  
202 
 
  
203 
 
3.4 The Role of Bilirubin 
3.4.1 Bilirubin biochemistry and physiological properties 
The breakdown of heme by heme oxygenase enzyme produces equimolar amounts of 
free iron, carbon monoxide and biliverdin.  Biliverdin is a green linear tetrapyrrole bile 
pigment that is rapidly reduced to bilirubin by the action of biliverdin reductase.  Bilirubin 
is excreted in bile and urine and is responsible for the yellow colour of urine as urobilin 
and the brown colour of faeces via its conversion to stercobilin.  Bilirubin consists of an 
open chain of four pyrrole-like rings to form a tetrapyrrole molecule.  When bilirubin is 
oxidised it reverts to become biliverdin once again in a cycle that suggests a physiological 
role for bilirubin as a cellular antioxidant150 228.  Landmark studies reported by Stocker and 
colleagues provided evidence for the important antioxidant activities of bilirubin and 
changed the traditional view of bilirubin as a potentially cytotoxic lipid-soluble waste 
product simply requiring excretion144.   
At a low concentration bilirubin scavenges reactive oxygen species in vitro thereby 
reducing oxidant-mediated cellular damage and attenuating oxidant stress221.  These 
findings suggested that bilirubin was one of the most important endogenous antioxidants 
present in serum, displaying more effective peroxyl radical scavenging than α-tocopherol 
that was considered to be the most powerful antioxidant molecule available145.  Further 
in vitro studies demonstrated that bilirubin was more effective at protecting lipids from 
peroxidative damage than other endogenous antioxidants, protected human low density 
lipoprotein against oxidation by radicals and directly suppressed hydroxyl radicals 
generated by L-DOPA-mediated DNA cleavage231 845 846.  Bilirubin has been shown to 
partially prevent the effects of potent oxidant agents in human erythrocytes, protect 
neuronal cells against hydrogen peroxide-induced damage and protect vascular smooth 
muscle cells against oxidative stress210 847 848.   
Biliverdin and bilirubin are reducing molecules and hence potential antioxidants.  At 
physiological concentrations in mammalian serum unconjugated bilirubin is an efficient 
scavenger of singlet oxygen and acts as a reducing agent for certain peroxidases including 
horseradish peroxidase and prostaglandin H synthase in the presence of hydrogen 
peroxide and organic hydroperoxides109 849.  Bilirubin has beneficial effects in pulmonary 
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and vascular diseases, improves renal haemodynamics and reduces blood pressure in an 
animal model of hypertension850 851.  Recent studies have demonstrated antiviral activity 
of HO-1-derived bilirubin in vitro852 853.   
The physiological activity of bilirubin and biliverdin may be especially relevant to the 
prevention of cell death mediated by oxidative and nitrosative stress189 748 854.  Bilirubin at 
high concentration can be demonstrated to be toxic to the central nervous system in 
neonates.  The syndrome of kernicterus is a severe irreversible form of bilirubin 
neurotoxicity that has become extremely rare with the advent of phototherapy to treat 
neonatal jaundice855.  In microvascular endothelial cells, lower physiological bilirubin 
concentrations can induce apoptosis and this situation is exacerbated under 
hyperglycaemic conditions.  Endothelial cells of the blood-brain barrier are particularly 
sensitive to these effects of bilirubin and may contribute to its relative neurotoxicity856. 
Exposure to both bilirubin and biliverdin was shown to repress the pro-inflammatory 
effect of zinc protoporphyrin-mediated HO inhibition in rodent models of ischaemia-
reperfusion injury.  The anti-inflammatory effect of HO induction was thereby restored to 
the system234.  Further studies have reported protective effects of biliverdin therapy on 
ischemia and reperfusion injury in rat livers463.  A recent study using a rodent model of 
lipopolysaccharide endotoxin-induced acute lung injury and caecal ligation and puncture 
indicated that biliverdin administration provided a systematic defence against lethal 
endotoxaemia and effectively abrogated the inflammatory response.  Exposure to the 
end-products of HO activity once again substituted for the effects observed with 
induction of HO-1 enzyme857.  
Heme oxygenase protects the intracellular environment from the toxic effects of heme.  
The other major enzyme in the heme degradation pathway is biliverdin reductase that 
has an important role in glucose uptake and the stress response.  The activity of biliverdin 
reductase can produce multiple effects in cell signal transduction and the regulation of 
gene expression.  The first suggestion that biliverdin affords intrinsic cytoprotection 
independent of heme degradation was provided by the use of short-interfering RNA to 
silence human biliverdin reductase and HO-1 enzyme.  Knockdown of biliverdin reductase 
in cultured human embryonic kidney cells increased the sensitivity of the cells to 
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apoptotic cell death mediated by arsenite treatment whereas cells transfected with HO-1 
siRNA were unaffected858.  It should be remembered that biliverdin is rapidly converted to 
bilirubin by biliverdin reductase in mammals and is therefore short-lived in vivo.  
Nevertheless recent evidence supports the role of human biliverdin reductase in cellular 
signalling, cytoprotection and cytotoxicity and as a transcription factor in the regulation of 
gene expression859 860.  Human biliverdin reductase has been identified as an upstream 
activator of the insulin growth factor-1 (IGF-1) and mitogen-activated protein kinase 
(MAPK) signalling pathways and is essential for MAPK–extracellular signal-regulated 
kinase (ERK)1/2 signalling.  The enzyme is recognised to be a heme transporter of ERK1/2 
and hematin as a pivotal component of gene expression during the cellular stress 
response861 862.   
Bilirubin can exert either cytotoxic or cytoprotective effects depending on the 
concentration of its free fraction in serum or tissue, the nature of the target cell or tissue, 
and the cellular redox state.  The central nervous system is particularly sensitive to the 
neurotoxic effects of bilirubin849 863.  Studies in the cardiovascular system have supported 
a cytoprotective role for HO-1-derived bilirubin864 865.  The cardioprotective effect 
observed in humans with moderate hyperbilirubinaemia such as that which occurs in 
Gilbert’s syndrome may result from the antioxidant activity of bilirubin.  Biliverdin and 
bilirubin have been demonstrated to preserve endothelial cell integrity, prevent 
endothelial cell death and sloughing, enhance vascular reactivity, and prevent vascular 
restenosis696 866-870.   
In experimental diabetes, bilirubin is implicated in reducing oxidative stress by increasing 
the bioavailability of nitric oxide needed for endothelial cell integrity and the inhibition of 
NADPH oxidase to reduce the diabetes-mediated generation of oxidants and uncoupling 
of endothelial nitric oxide synthase684 871.  Increased levels of bilirubin can provide 
antiproliferative effect in smooth muscle cells and protect experimental rats from the 
development of atherosclerosis222.  Studies have shown that vascular smooth muscle cell 
proliferation and consequent neointima formation was reduced in hyperbilirubinaemic 
subjects.  This experimental finding is supported by epidemiological reports that describe 
a lower incidence of atherosclerosis in humans with a higher normal endogenous serum 
bilirubin level compared to individuals with low normal bilirubin levels686.   
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Bilirubin can inhibit the proliferation of medial smooth muscle cells following arterial 
injury leading to reduced neointima formation.  The prevention of neointimal thickening 
mediated by bilirubin is associated with alterations in the expression of cell cycle 
regulatory proteins with a significant decrease in cyclin D1 and cyclin A expression and up 
regulation of p53 protein causing an increase in the percentage of cells in the G0/G1 phase 
of the cell cycle.  Bilirubin causes a marked decrease in ERK 1/2 activity and an increase in 
p21 expression that blocks proliferation and migration of human arterial smooth muscle 
cells in a concentration-dependent manner without affecting cell viability872.   
There is a lower incidence of atherosclerosis associated with individuals with Gilbert’s 
syndrome who have a congenital deficiency of glucuronyl transferase and elevated serum 
bilirubin levels.  Glucuronyl transferase enzyme facilitates bilirubin metabolism by 
catalysing its conjugation with glucuronic acid in the liver and making it water-soluble for 
excretion in secreted bile873-875.  Several recent human studies have suggested a 
protective role of bilirubin against coronary artery disease with a reported inverse 
relationship between serum bilirubin level and the incidence of ischaemic stroke257 859 876.  
Retrospective and prospective human studies have indicated serum bilirubin to be 
associated with important cardiovascular risk factors including diabetes mellitus, 
metabolic syndrome, arterial hypertension and body mass index877.  There is a lack of 
consensus in the therapeutic potential of manipulating serum bilirubin levels for the 
prevention or treatment of cardiovascular and related diseases258 876.  Studies assessing 
surrogate markers of atherosclerosis such as measuring the thickness of carotid intima-
media and determining endothelial dysfunction by flow-mediated dilatation have shown 
beneficial effects of increased bilirubin concentrations259.  A greater risk of ischaemic 
heart disease has been reported to be associated with longer GT-repeat HO-1 gene 
promoter polymorphisms via a reduction in serum bilirubin concentration878.   
Bilirubin has been shown to regulate cellular redox status and reactive oxygen species 
and influence the activity of NADPH oxidase enzyme.  In the respiratory system increased 
levels of pulmonary HO-1 protein can be a potential biomarker of chronic silicosis.  
Induction of HO-1 enzyme by hemin treatment attenuates silicosis-induced lung injury 
and disease progression via a reduced production of reactive oxygen species and 
associated oxidative damage879.  Bilirubin can increase tolerance to islet cell allografts by 
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a mechanism that includes its anti-inflammatory and antioxidative properties with 
reduced neutrophil adhesion and down-regulation of adhesion molecule expression880 881.   
The potential role of bilirubin in cancer is not clearly understood, with available evidence 
often contradictory.  It has been suggested that biliverdin acts as a pro-mutagenic agent 
with promotion of neoplastic cell formation in liver epithelial cell cultures exposed to 
aflatoxin B1
882.  More recently a cohort study of a Belgian population demonstrated that 
high serum bilirubin concentrations were associated with low cancer mortality.  Study 
authors propose that this observation could be due to the antioxidant effects of bilirubin 
preventing oxidative damage-induced mutagenesis883.  A novel anti-cancer effect of 
bilirubin was documented by Rao and colleagues in 2006.  Studies using the human 
gastric adenocarcinoma cell line TMK-1 demonstrated both antioxidant and pro-oxidant 
activity of bilirubin.  Cell viability assays by Trypan blue exclusion showed almost a 50% 
reduction in cell proliferation after 48 hours incubation with bilirubin.  Treating cell lines 
with bilirubin caused an increase in intracellular radicals and cell cycle arrest at the G0/G1 
phase of the cell cycle.  There was evidence of impaired mitochondrial function with DNA 
damage characteristic of apoptosis induced by bilirubin exposure884.   
Additional in vitro studies showed a cytostatic and pro-apoptotic activity of bilirubin in a 
variety of cell lines including colonic, pancreatic and hepatocellular carcinoma and 
malignant melanoma885.  Bilirubin inhibited tumour cell proliferation by causing cell cycle 
arrest the G0/G1 phase after 24 hours of incubation and a significant increase in apoptosis 
after 72 hours of bilirubin treatment as compared to controls.  These effects were 
dependent upon phosphorylation of ERK 1/2 by upstream activated kinase pathways.  
Using a specific MEK inhibitor to effectively suppress ERK 1/2 activation abolished the 
anti-proliferative effects of bilirubin on colonic adenocarcinoma cells.  The same study 
describes an in vivo model using mice that were injected subcutaneously with human 
colorectal carcinoma cell line and observation of tumour growth after treatment with 
either phosphate-buffered saline control or 25 mgkg-1 body weight bilirubin.  Dramatically 
slower tumour growth was observed in mice treated with intraperitoneal bilirubin when 
compared to controls885.   
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These recent novel findings and lack of consensus on cytoprotective roles of bilirubin 
provide a study hypothesis to investigate the activity of bilirubin in oesophagogastric 
cancer cells.  Studies were designed to determine the effect of bilirubin on the 
proliferation of gastric and oesophageal cancer cell lines.  
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CHAPTER 4: RESULTS 
Investigating Oxidative Stress and Altered Heme Oxygenase Activity 
4.1 Oxidative stress and the role of heme oxygenase 
4.1.1 Cell proliferation 24 hour experiments – Figure 4.1.1 
The combined results of the MTT assay for the gastric cell lines demonstrate no obvious 
reduction in cell proliferation after 24-hour treatment with H2O2.  There was a reduction 
in MTT activity at higher H2O2 concentrations that was not statistically significant for 
either AGS (p = 0.081) or HGC-27 (p = 0.075) cell lines. 
In contrast to the gastric cell lines 24-hour treatment with H2O2 caused a significant 
increase in OE-33 cell proliferation at concentrations of 10, 20 and 200 µM (p < 0.05).  
There was an observed decrease in proliferation of normal squamous epithelial cell line 
HET-1A after 24-hour exposure to H2O2 at a dose of 200 µM that was not statistically 
significant (p = 0.062).   
Treatment with NAC had a significant effect on AGS cell proliferation after 24 hours with 
convincing effects at doses of 5 mM, 10 mM and 20 mM (p ≤ 0.001).  Although there was 
an observed reduction in the average MTT assay for AGS cells exposed to NAC at doses of 
0.5 mM and 1 mM this effect was not statistically significant (p > 0.05).  Similar results 
were observed with HGC-27 cell lines with significant reduction in cell growth after 24-
hour treatment with NAC at doses of 1 – 20 mM (p ≤ 0.003).   
Morphological cell changes after 48 hours included rounding of cells and a reduction in 
cell confluence with visible necrotic cells detached from the cell monolayer.   
Treatment of OE-33 cells with increasing doses of NAC from 0.1 – 20mM demonstrated a 
statistically significant reduction in cell proliferation at a dose of 10 – 20 mM (p = 0.015).  
Higher concentrations of NAC (10, 20 mM) caused cellular morphological changes with 
cells becoming refractile and losing cell-cell contact.  
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For HET-1A cell lines there was a less marked reduction in cell proliferation after 24 hour 
treatment with NAC at increasing doses with no statistically significant effect observed (p 
= 0.062).   
4.1.2 Cell proliferation time course experiments – Figure 4.1.2 
Extended exposure of AGS cells to NAC at doses of 1, 5, 10 and 20 mM demonstrated a 
persistent reduction in cell proliferation that was significant at doses of 10 and 20 mM up 
to 72 hours incubation (Figure 4.1.2a).  Extending the experiments to 168 hours showed a 
peak in exponential cell growth of control cells at 72 hours with cell numbers levelling out 
at 96 hours and falling at 120 hours and beyond.  This observed effect was due to cells 
becoming confluent and subsequently overcrowded on the growth surface with resulting 
detachment from monolayer.  Consistent effects of significantly reduced cell proliferation 
were seen with prolonged NAC treatment particularly at doses of 10 and 20 mM (p ≤ 
0.017, Figure 4.1.2a).   
Extended treatment with NAC at doses of 1, 5, 10 and 20 mM produced quite different 
effects on cell growth in benign HET-1A cells compared to malignant OE-33 epithelial cells 
(Figures 4.1.2b – c).  The malignant cells showed a clear reduction in cell growth over 24 – 
72 hours with NAC doses of 10 and 20 mM with statistically significant effects over all 
time points with NAC at 20 mM.  By contrast the benign epithelial cell growth was similar 
to control cells across all time points and doses of NAC except for a reduction in MTT 
assay after 72 hours of exposure to NAC at 20 mM concentration (p = 0.047).  Extending 
the experiments to 168 hours in OE-33 cell lines demonstrated a plateau of cell growth in 
untreated controls after 72 hours with a reduction in cell counts by 144 hours as cells 
became detached.  Consistent effects of reducing OE-33 cell proliferation were seen with 
NAC treatment at all concentrations beyond 72 hours (p = 0.008).   
Chemotherapy studies demonstrated the ability of NAC to improve the anti-proliferative 
effects of chemotherapy in malignant OE-33 cells.  The combination of 10mM NAC with 
cisplatin and 5-FU enabled a significant reduction in the IC10 and IC50 doses for both 
reagents (0.1 μgmL-1 and 2.875 μgmL-1 respectively for cisplatin and 0.07 μgmL-1 and 6.5 
μgmL-1 respectively for 5-FU, p < 0.05, Figures 4.1.2d – e).   
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Figure 4.1.1 Cell proliferation experiments: 24-hour data 
Figure 4.1.1a: Effect of H2O2 on AGS & HGC-27 growth at 24 hours 
 
p = 0.081 Kruskal-Wallis Independent Samples test 
 
p = 0.075 Kruskal-Wallis Independent Samples test 
Figure 4.1.1a: Cells were treated with H2O2 0.2 – 200 µM for 24h in 24-well plates and cell viability assessed 
with MTT assay.  Results are expressed as a percentage of vehicle control; values represented as means ± 
SEM; n = 12. Cell growth was not significantly affected by H2O2 treatment.   
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Figure 4.1.1b: Effect of H2O2 on OE-33 & HET-1A growth at 24 hours 
  
*p < 0.05 Kruskal-Wallis Independent Samples test 
 
p = 0.062 Kruskal-Wallis Independent Samples test 
Figure 4.1.1b: Cells were treated with H2O2 0.2 – 200 µM for 24h in 24-well plates and cell viability assessed 
with MTT assay.  Results are expressed as a percentage of vehicle control; values represented as means ± 
SEM; n = 12. HET-1A cell growth was not significantly affected by H2O2 treatment whereas OE-33 growth 
increased with H2O2 exposure.   
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Figure 4.1.1c: Effect of NAC on AGS & HGC-27 growth at 24 hours 
  
  
*p<0.0005, + p = 0.001, ‡ p = 0.003 Kruskal-Wallis Independent Samples test 
Figure 4.1.1c: Cells were treated with NAC 0.1 – 20 mM for 24h in 24-well plates and cell viability assessed 
with MTT assay.  Results are expressed as a percentage of vehicle control; values represented as means ± 
SEM; n = 12. Growth of AGS and HGC-27 cells was significantly inhibited by NAC 5 – 20 mM. 
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Figure 4.1.1d: Effect of NAC on OE-33 & HET-1A growth at 24 hours 
  
+ p = 0.015 Kruskal Wallis Independent Samples test 
 
p = 0.062 Kruskal-Wallis Independent Samples test 
Figure 4.1.1d: Cells were treated with NAC 0.1 – 20 mM for 24h in 24-well plates and cell viability assessed 
with MTT assay.  Results are expressed as a percentage of vehicle control; values represented as means ± 
SEM; n = 12. Growth of OE-33 but not HGC-27 cells was significantly inhibited by NAC 10 – 20 mM. 
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Figure 4.1.2 Cell proliferation experiments: Time-course data  
Figure 4.1.2a: Effect of NAC on AGS growth curve 
 
p ≤ 0.017 Kruskal-Wallis Independent Samples test 
 
‡ p < 0.05 Kruskal-Wallis Independent Samples test  
Figure 4.1.2a: AGS cells were treated with NAC 1 – 20 mM for 24 – 168h in 24-well plates and cell viability 
assessed with MTT assay and cell counts.  Values represented as means ± SEM; n = 12. Growth of AGS cells 
was significantly reduced by NAC 10 and 20 mM over 24 – 72 hours.  Effective inhibition of cell proliferation 
is observed up to 96 hours. 
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Figure 4.1.2b: Effect of NAC on OE-33 growth curves 
 
p = 0.008 Kruskal-Wallis Independent Samples test 
 
+ p = 0.035, ‡ p = 0.0005, † p = 0.047 Kruskal-Wallis Independent Samples test 
Figure 4.1.2b: OE-33 cells were treated with NAC 1 – 20 mM for 24 – 168h in 24-well plates and cell viability 
assessed with MTT assay and cell counts.  Values represented as means ± SEM; n = 12. Growth of OE-33 
cells was significantly reduced by NAC 10 and 20 mM over 24 – 72 hours.  Effective inhibition of cell 
proliferation is observed up to 120 hours.   
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Figure 4.1.2c: Effect of NAC on HET-1A growth time course 
 
p = NS except where stated 
† p = 0.047 Kruskal-Wallis Independent Samples test 
Figure 4.1.2c: HET-1A cells were treated with NAC 1 – 20 mM for 24 – 72h in 24-well plates and cell viability 
assessed with MTT assay.  Results are expressed as a percentage of vehicle control and values represented 
as means ± SEM; n = 12. Growth of HET-1A cells was significantly inhibited only by NAC 20 mM at the 72 h 
time point.   
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Figure 4.1.2d: Effect of NAC on OE-33 response to Cisplatin 
 
p < 0.05 Kruskal-Wallis Independent Samples test 
Figure 4.1.2d: OE-33 cells were treated with cisplatin ± NAC 10 mM in 24-well plates for 48h and cell 
viability assessed with MTT assay over an extended time course.  Values represented as means ± SEM; n = 
12.  The IC10 and IC50 doses of cisplatin were significantly reduced by concomitant NAC treatment. 
Figure 4.1.2e: Effect of NAC on OE-33 response to 5-FU 
 
p < 0.05 Kruskal-Wallis Independent Samples test 
Figure 4.1.2e: OE-33 cells were treated with 5-FU ± NAC 10 mM in 24-well plates for 48h and cell viability 
assessed with MTT assay over an extended time course.  Values represented as means ± SEM; n = 12.  The 
IC10 and IC50 doses of 5-FU were significantly reduced by concomitant NAC treatment. 
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4.1.3 Heme oxygenase protein expression  
NAC and H2O2 treatment did not influence constitutive expression of HO-2 protein in 
malignant gastric epithelial cells.  Western blot analysis (western blots 4.1.3.1) showed no 
evidence of induction of HO-1 expression by NAC or H2O2 in either AGS or HGC-27 gastric 
cell line.  Constitutive HO-2 protein was expressed equally in both cell lines and was 
unchanged by experimental conditions.  HO protein blots correlated well with tubulin 
controls. 
NAC and H2O2 exposure did not cause up-regulation of HO-1 protein in either of the 
oesophageal cell lines studied (western blots 4.1.3.2).  There was equal expression of 
constitutive HO-2 protein in both OE-33 and HET-1A cell lines under basal and 
experimental conditions.  There appears to be reduced expression of HO-2 protein in OE-
33 cells treated with NAC at 1 and 20 mM concentration.  This can be explained by the 
tubulin blots demonstrating a proportional reduced expression in the corresponding 
bands and is most likely to represent a relative lack of protein for this lysate sample and 
unequal loading onto the gel for electrophoresis.   
Western blot analyses were performed in triplicate for each cell line studied.  HO-1 
protein has molecular weight of 32 kDa, HO-2 protein 36 kDa and β-Tubulin 55 kDa.  
Representative blots are shown with additional Western blots included in Appendix IV. 
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Figure 4.1.3 Western Blots  
Western Blots 4.1.3.1: H2O2 and NAC Gastric cell lines 
AGS H2O2 and NAC protein expression 
 
 
 
HGC-27 H2O2 and NAC protein expression 
 
 
 
Figure 4.1.3.1: Protein expression after treatment with H2O2 and NAC in gastric cell lines.  Cells were seeded 
into 24-well plates and protein lysates harvested at 24h.  Gel electrophoresis and Western blotting were 
performed as described.  Blots demonstrate unchanged expression of HO-2 with no induction of HO-1 
protein in AGS or HGC-27 cells.  M = marker, Con = control 
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Western Blots 4.1.3.2: H2O2 and NAC Oesophageal cell lines 
OE-33 H2O2 and NAC protein expression 
 
 
 
HET-1A H2O2 and NAC protein expression 
 
 
 
Figure 4.1.3.2: Protein expression after treatment with H2O2 and NAC in oesophageal cell lines.  Cells were 
seeded into 24-well plates and protein lysates harvested at 24h.  Gel electrophoresis and Western blotting 
were performed as described.  Blots demonstrate unchanged expression of HO-2 with no induction of HO-1 
protein in OE-33 or HET-1A cells with unequal loading of OE-33 lysate samples in the NAC 1 mM and 20 mM 
lanes.  M = marker, Con = control 
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4.1.4 Effect of NAC on heme oxygenase enzyme activity 
Assays of total heme oxygenase enzyme activity were performed on AGS lysate samples 
after 24 and 48 hours of treatment with NAC at 5 and 10 mM concentrations.  The results 
show a statistically significant reduction in total HO activity measured in cells treated with 
NAC at 10 mM concentration for 24 and 48 hours (p < 0.05, Figure 4.1.4).   
Figure 4.1.4: Effect of NAC on HO enzyme activity time course 
 
Figure 4.1.4: Effect of NAC treatment on total HO enzyme activity.  AGS cells were seeded into 175 cm
3
 
flasks and lysates harvested after 24 and 48h NAC treatment as described.  Specific colorimetric assay 
demonstrated a significant reduction in HO activity expressed as pmoles per bilirubin formed per mg of 
protein pellet per 60 min (p < 0.05).  Values are represented as means ± SD; n = 3.    
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4.2 Oxidative stress and HO activity: Apoptosis studies 
4.2.1 Apoptosis Studies: Annexin V and Propidium Iodide staining 
Apoptosis experiments were performed in quadruplicate using cells seeded into 6-well 
plates with 3 wells per sample.  Cell staining with Annexin V-FITC identified cells with 
exposed phosphatidylserine translocated to the external cell membrane at the onset of 
apoptosis.  Propidium iodide (PI) staining identified necrotic and damaged cells with 
permeable plasma cell membranes with exclusion of PI by viable cells.   
Controls were set up with unstained cells, ethanol-treated cells to permeabilise the cell 
membrane for PI staining and with staurosporine-treated cells to induce apoptosis for 
annexin V positive control staining.  These samples were used to set the gates and 
quadrant regions for flow cytometry data analysis (see Appendix V).  All experiment cell 
samples were then stained with both annexin V and PI at 24 hours and 48 hours to 
evaluate a possible process of apoptosis.  Representative flow results from one 
experiment are shown for each sample investigated together with the combined data for 
AGS gastric carcinoma cells (Figure 4.2.1).   
Cells treated with NAC at 10 mM concentration demonstrated a significantly increased 
affinity for annexin V binding after 24 hours as compared to untreated control cells over 
the same time period (40.28% versus 0.05%, p = 0.013, Figure 4.2.1).  At 48 hours the 
treated cells become permeable to PI as membrane integrity is lost (41.07% versus 0.02%, 
p = 0.013).  At 48 hours there were significantly fewer viable cells and significantly 
increased late apoptotic or necrotic cells in samples treated with NAC.  The observed 
movement of treated cells over time through annexin V positive and PI negative to 
annexin V and PI positive suggests a process of early apoptosis progressing to late 
apoptosis and eventual cell death. 
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Figure 4.2.1: Annexin V binding and NAC treatment 
 
 
 
Figure 4.2.1: AGS cells were treated with NAC 10 mM for 24 and 48h in 6-well plates and stained with 
Annexin V-FITC and PI for flow cytometry analysis.  The rate of apoptosis (R6) and late apoptosis / necrosis 
(R4) is expressed relative to vehicle controls with values represented as means ± SD; n = 4; logarithmic 
scale.  The percentage of cells counted in the apoptosis phase after 24h was 0.05% (+/- 0.006) in control 
cells versus 40.28% (+/-3.575) in NAC-treated samples and the percentage in the late apoptotic / necrotic 
phase after 48h was 0.02% (+/- 0.01) in controls versus 41.07% (+/- 3.89) in NAC-treated cells (p = 0.013). 
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Table 4.2.1: Summary of Annexin V binding and NAC treatment 
  
REGION Apoptosis 
Cell sample Measurement R3 R4 R5 R6 p 
Control 24h Cell Count 689 12 30556 15 
  
  % Histogram 2.2 0.04 97.71 0.05 
NAC 10mM 24h Cell Count 18 72 18280 12401 
0.013 
  % Histogram 0.06 0.24 59.43 40.28 
Control 48h Cell Count 671 6 29394 54 
  
  % Histogram 2.23 0.02 97.57 0.18 
NAC 10mM 48h Cell Count 34 12407 11911 5893 
0.013 
  % Histogram 0.11 41.07 39.36 19.46 
 
Table 4.2.1: Apoptosis studies in AGS cells treated with NAC 10 mM for 24 and 48h in 6-well plates.  
Summary data from quadruplicate experiments is displayed (means, n = 4).  Quadrantic regions include: R3 
– necrotic cell debris; R4 – late apoptosis or necrosis; R5 – viable cells; R6 – apoptosis.  At 24h there is a 
significantly higher number of apoptotic cells and at 48h a significantly higher proportion of late apoptosis 
or necrosis in cells treated with NAC as compared to control samples.   
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4.2.2 Apoptosis Studies: Cell cycle analysis 
Analysis of cellular DNA content using PI staining provided information about the position 
of analysed cells on the cell cycle.  Experiments were performed in triplicate using cells 
seeded into 6-well plates.  Representative flow results from one experiment are shown 
for each sample investigated together with the combined data for AGS gastric carcinoma 
cells (Figure 4.2.2).   
Untreated control cell samples demonstrated the majority of cells in the G0/G1 phase 
(52.06%) with 2.41% of cells measured in the sub-G0 region.  There was no sub-G0 peak 
demonstrated with the control cell samples (Figure 4.2.2).  The coefficient of variation 
(CV) of the G0/G1 peak was 7.42 and the ratio of G0/G1 to G2/M cells was 2.02, indicating 
good doublet discrimination. 
Cells treated with NAC at 5 mM concentration for 24 hours showed a reduction in the 
proportion of cells in G0/G1 phase (36.85%) and an increase in cell population in the G2/M 
phase (31.74%) with 7.4% of cells measured in the sub-G0 region.  The CV of the G0/G1 
peak was 7.83 again indicating good quality DNA measurements.   
Cells treated with NAC at 10 mM concentration for 24 hours showed a significant 
reduction in the proportion of cells in G0/G1 phase (23.44%) and significantly increased 
numbers of cells in the G2/M phase (44.7%) and sub-G0 region (11.49%).  There was a sub-
G0 peak population of cells visible (Figure 4.2.2).  The CV of the G0/G1 peak was 8.08 
indicating acceptable doublet discrimination and accuracy of DNA measurement.   
Cells in the sub-G0 region are undergoing the process of apoptosis and the appearance of 
cells in this region was clearly demonstrated after 24-hour treatment with NAC at 10 mM 
concentration (p = 0.02).  There was a significant increase in the proportion of cells 
measured in the G2/M phase to indicate G2/M cell cycle arrest after 24h treatment with 
NAC 10 mM (p = 0.02).   
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Figure 4.2.2: Cell cycle analysis with NAC treatment  
 
 
 
Figure 4.2.2: AGS cells were treated with NAC 5 and 10 mM for 24h in 6-well plates, stained with PI and 
analysed using flow cytometry.  An increase in cells counted at G2/M arrest and sub G0 phase is seen with 
NAC treatment.  Values are the percentage of total cell count per sample represented as means ± SD; n = 3. 
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4.2.3 Apoptosis Studies: Apo-BrdU DNA fragmentation assay 
The Apo-BrdU assay measures the incorporation of brominated deoxyuridine 
triphosphate nucleotides into DNA strand breaks.  DNA fragmentation is a hallmark of 
apoptosis in mammalian cells that is recognised as one of the later stages of the process. 
Positive and negative control cells provided with the Apo-BrdU assay kit were used to set 
the gating regions and reliably identify positive and negative-stained cells.  Apoptotic cells 
show an increased fluorescence with increased FITC staining as the incorporated BrdU 
nucleotide sites are detected by FITC-labelled anti-BrdU antibody.  The positive control 
sample cells demonstrated increased FITC fluorescence compared to negative control 
cells (33.84% versus 0.82%, Appendix VI).  
DNA fragmentation assay experiments were performed in triplicate using cells seeded 
into 6-well plates.  Representative flow results from one experiment are shown for each 
sample investigated together with the combined data for AGS gastric carcinoma cells 
(Figure 4.2.3).   
Control cell samples demonstrated minimal FITC staining after 24 hours with 0.5% in the 
positive R8 region (Figure 4.2.3).  Cells treated with NAC at 10 mM concentration for 24 
hours showed a clear increase in fluorescence with 27.39% positive for FITC staining (p = 
0.05, Figure 4.2.3).  Extended exposure to NAC at 10 mM concentration caused a further 
significant increase in fluorescence when compared to untreated cells over the same time 
period (64.1% versus 0.57% respectively, p = 0.05).  These results indicate that one of the 
hallmarks of apoptosis occurs in AGS cell lines after treatment with NAC at 10 mM 
concentration for 24 and 48 hours.   
  
229 
 
Figure 4.2.3 Apoptosis Studies: Apo-BrdU labelling of DNA fragments 
 
 
 
Figure 4.2.3: ApoBrdU assay performed on AGS cells 24 and 48h after treatment with NAC 10 mM.  DNA 
fragmentation is measured by increased fluorescence in the FITC channel (R8).  The rate of apoptosis is 
expressed as percentage of controls with values represented as means ± SD; n = 3; logarithmic scale. 
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Table 4.2.3: Summary of ApoBrdU DNA fragmentation assays AGS cells 
  
REGION Apoptosis 
Cell sample Measurement R8 R9 p 
Control 24h Cell Count 97 19192 
  
  % Histogram 0.5 99.02 
NAC 10mM 24h Cell Count 5502 14464 
0.05 
  % Histogram 27.39 72.01 
Control 48h Cell Count 119 20662 
  
  % Histogram 0.57 98.98 
NAC 10mM 48h Cell Count 13689 6738 
0.05 
  % Histogram 64.1 31.55 
 
Table 4.2.3: ApoBrdU assay performed on AGS cells 24 and 48 h after treatment with NAC 10 mM.  DNA 
fragmentation is measured by increased fluorescence in the FITC channel (R8).  There is a significant time-
dependent increase in the proportion of cells counted with DNA fragmentation in samples treated with NAC 
10 mM (p = 0.05).  Summary data from triplicate experiments is displayed (means, n = 3).   
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4.2.4 Apoptosis Studies: Caspase 3/7 activity assay 
The Apo-ONE Homogenous Caspase-3/7 assay (Promega) was performed after 24 hour 
treatment with NAC at doses of 5 mM and 10 mM.  Experiments were performed in 
triplicate using cells seeded into 96-well opaque black plates.  The X-Y scatter of 
absorbance data were analysed to identify a linear portion of the graph indicating a steep 
part of the signal curve between particular cycle numbers for each assay.  Values within 
these time points were normalised to MTT assay to obtain the relative caspase activity 
per 1000 cells.   
Cell proliferation experiments were performed concurrently in 96-well plates with an 
identical experiment design to provide cell numbers per well derived from MTT assay as 
described above.  The relative caspase activity per 1000 cells for experiment samples was 
obtained after normalisation to cell number for each experiment well.   
The signal curve generated by absorbance data over 60 minutes from one experiment is 
shown in Figure 4.2.4a.  Combined results of relative caspase activity from triplicate 
experiments demonstrate an increase in fold caspase-3/7 induction after 24 hours 
exposure to NAC with statistical significance at a dose of 10 mM (p = 0.022, Figure 4.2.4b).   
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Figure 4.2.4 Apoptosis Studies: Caspase 3/7 activity assay 
Figure 4.2.4a: Caspase activity at 24 hours AGS cells  
 
Figure 4.2.4a: Evolution of kinetic absorbance data over 60 minutes during caspase 3/7 assay.  AGS cells 
were seeded into black 96-well plates and treated with NAC 5 – 10 mM for 24h.  Apo-ONE® Caspase-3/7 
Reagent was added to each well and fluorescence measured after 1h incubation, collecting data over 250 
plate reading cycles to generate complete signal curves. 
Figure 4.2.4b: Relative caspase activity in AGS cells  
 
Figure 4.2.4b: Effect of NAC treatment on caspase-3/7 activity.  AGS cells were seeded into 96-well plates 
and Apo-ONE® Caspase-3/7 assay performed after 24h.  Results demonstrate a significant increase in 
relative caspase-3/7 activity per 1000 cells with NAC 10 mM (p = 0.022).  Values are represented as means ± 
SD; n = 12.   
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4.3 The role of heme oxygenase activity on cancer cell growth  
Study aims 
The aim of these experiments was to investigate the influence of HO enzyme isoforms 
HO-1 and HO-2 on the regulation of cancer cell growth in cultured cell lines. 
Methods 
Experiments were designed to evaluate the influence of pharmacological modulation of 
HO enzyme activity on cell proliferation.  Cells were treated with the HO enzyme 
substrate Hemin at a dose range between 2 – 200 µM to cause induction of HO-1 
isoenzyme.  Cells were also treated with the competitive HO enzyme inhibitor Zinc 
Protoporphyrin (Zinc PP) at a dose range of 0.1 – 40 µM.  The cell response to treatment 
with vehicle agent sodium hydroxide (NaOH) was evaluated prior to reagent experiments.   
MTT assay was performed at 24 hours and at time points of 24, 48 and 72 hours.  Cell 
counts were also performed during the time course experiments.  Experiments were 
extended to 168 hours (7 days) with AGS and OE-33 cell lines to further assess observed 
effects with selected reagents.  Cell lysates from experiment wells were collected for 
protein, and expression of heme oxygenase 1 and 2 isoforms assessed by western blot 
analysis.  Heme oxygenase activity assay was performed on representative experiment 
samples.  Apoptosis studies were performed to evaluate mechanisms of reduced cell 
growth using caspase activity assay. 
Results are expressed as percentage of control for each individual experiment.  Statistical 
analysis used the non-parametric Kruskal-Wallis Independent samples test or Mann-
Whitney U test for 2 independent samples to look for significant differences between 
average percent of control values.  When histograms of continuous variable data 
demonstrated a normal distribution, one-way ANOVA or the Students t test for 2 
independent samples were used to compare means. 
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4.3.1 Effect of treatment with reagent vehicle NaOH – Figure 4.3.1 
Treatment of AGS, HGC-27, OE-33 and HET-1A cells seeded into 24-well plates with 1 mM 
of NaOH had no significant effect on cell proliferation as measured by MTT assay after 24, 
48 and 72 hours.  This was in contrast to the observed effects of treatment with hemin 
100 µM and zinc protoporphyrin 20 µM over the same time course (Figure 4.3.1).  These 
findings supported the use of NaOH as a vehicle for hemin and zinc reagents.  NaOH was 
used to dissolve hemin and zinc reagents.  The maximal final concentration of NaOH in 
experiment wells was 1 mM.   
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Figure 4.3.1 Cell proliferation experiments: Effect of vehicle on cell growth 
Figure 4.3.1a: Effect of NaOH vehicle on AGS growth 
 
Figure 4.3.1b: Effect of NaOH vehicle on HGC-27 growth 
 
Figure 4.3.1a – b: Cells were seeded into 24-well plates and treated with NaOH, hemin and zinc PP for 24 – 
72h with cell proliferation assessed by MTT assay.  NaOH vehicle had no observed effect on cell 
proliferation for AGS and HGC-27 cells in contrast to significant growth reductions seen with zinc 20 µM.  
Results are expressed as a percentage of untreated control; values represented as means ± SEM; n = 12. 
  
0
20
40
60
80
100
Control NaOH Hemin 100uM ZincPP 20uM
M
T
T 
A
b
so
rb
an
ce
 %
 c
o
n
tr
o
l 
Effect of vehicle on AGS cell growth 
24hrs
48hrs
72hrs
0
20
40
60
80
100
Control NaOH Hemin 100uM ZincPP 20uM
M
T
T 
A
b
so
rb
an
ce
 %
 c
o
n
tr
o
l 
Effect of vehicle on HGC-27 cell growth 
24 hrs
48 hrs
72 hrs
† 
† † 
* 
†p < 0.05 
†p = 0.01 *p = 0.02 
† 
† 
236 
 
Figure 4.3.1c: Effect of NaOH vehicle on OE-33 growth 
 
Figure 4.3.1d: Effect of NaOH vehicle on HET-1A growth 
 
Figure 4.3.1c – d: Cells were seeded into 24-well plates and treated with NaOH, hemin and zinc PP for 24 – 
72h with cell proliferation assessed by MTT assay.  NaOH vehicle had no observed effect on cell 
proliferation for OE-33 and HET-1A cells in contrast to significant growth reductions seen with high-dose 
hemin (100µM) and zinc 20µM.  Results are expressed as a percentage of untreated control; values 
represented as means ± SEM; n = 12. 
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4.3.2 Influence of pharmacological induction of HO by Hemin: 24-hour data 
Treating AGS cells with increasing concentrations of hemin for 24 hours in 5 separate 
experiments with a total of 18 wells per reagent produced no significant overall 
difference in cell growth (p = 0.457).  For HGC-27 cells, hemin treatment had a variable 
effect on cell growth.  At a low concentration of 2 µM there was an increase in MTT assay 
at 24 hours.  Treatment with hemin at 150 µM concentration caused a significant 
reduction in MTT assay after 24 hours (p = 0.029).  No other hemin concentrations 
produced a significant effect in HGC-27 cells.  
Treating OE-33 cells with increasing concentrations of hemin for 24 hours in 5 separate 
experiments with a total of 27 wells per reagent produced no significant difference in cell 
growth (p = 0.417).  For the normal oesophageal squamous epithelial cell line HET-1A, 
hemin caused a significant reduction in MTT assay at doses of 50 µM and above under the 
same experimental conditions (p ≤ 0.003).   
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Figure 4.3.2 Cell proliferation experiments: 24-hour data Hemin 
Figure 4.3.2a: Effect of Hemin on AGS cell growth at 24h – Summary of 5 experiments total 18 
wells per reagent 
 
Figure 4.3.2b: Effect of Hemin on HGC-27 cell growth at 24h – Summary of 5 experiments total 
18 wells per reagent 
  
Figure 4.3.2a – b: Cells were seeded into 24-well plates, treated with Hemin 2 – 200 µM for 24h and cell 
proliferation assessed by MTT assay.  Hemin had no consistent significant effect on cell proliferation for AGS 
and HGC-27 cells with the exception of high-dose hemin at 150 µM causing reduced MTT assay in HGC-27 
cells.  Results are expressed as a percentage of vehicle control; values represented as means ± SEM; n = 18. 
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Figure 4.3.2c: Effect of Hemin on OE-33 cell growth at 24h – Summary of 5 experiments total 27 
wells per reagent 
 
Figure 4.3.2d: Effect of Hemin on HET-1A cell growth at 24h – Summary of 5 experiments total 
27 wells per reagent 
 
Figure 4.3.2c – d: Cells were seeded into 24-well plates, treated with Hemin 2 – 200 µM for 24h and cell 
proliferation assessed by MTT assay.  Hemin had no significant effect on cell proliferation for OE-33 cells but 
caused significant reductions in HET-1A cell growth at doses 50 – 200 µM.  Results are expressed as a 
percentage of vehicle control; values represented as means ± SEM; n = 18. 
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4.3.3 Hemin time course data 
Treatment with hemin at 20, 50 and 100 µM concentrations for 24, 48 and 72 hours 
caused no significant reduction in AGS cell growth measured by MTT assay at any time 
point observed.  Exposing HGC-27 cells to hemin at 20, 50 and 100 µM for 24, 48 and 72 
hours caused a significant reduction in MTT assay only with a hemin concentration of 100 
µM and a treatment period of 48 hours (p = 0.028).  These data represent four 
independent experiments with a total of 15 wells per reagent.   
Identical experiments with oesophageal cell lines demonstrated no significant changes in 
OE-33 cell growth at any time point but significantly reduced HET-1A proliferation at a 
hemin concentration of 100 µM (p = 0.03).   
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Figure 4.3.3 Cell proliferation experiments: Time-course data Hemin 
Figure 4.3.3a: Effect of Hemin on AGS cell growth – time course 
 
  Figure 4.3.3b: Effect of Hemin on HGC-27 cell growth – time course  
  
Figure 4.3.3a – b: Cells were seeded into 24-well plates and treated with Hemin 20 – 100 µM for 24 – 72h 
with cell proliferation assessed by MTT assay.  Hemin had no significant effects on AGS cell proliferation.  
High-dose hemin at 100 µM caused reduced MTT assay in HGC-27 cells at 48h.  Results are expressed as a 
percentage of vehicle control; values represented as means ± SEM; n = 15. 
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Figure 4.3.3c: Effect of Hemin on OE-33 cell growth – time course  
 
Figure 4.3.3d: Effect of Hemin on HET-1A cell growth – time course 
 
Figure 4.3.3c – d: Cells were seeded into 24-well plates and treated with Hemin 20 – 100 µM for 24 – 72h 
with cell proliferation assessed by MTT assay.  Hemin had no significant effects on OE-33 cell proliferation.  
High-dose hemin at 100 µM caused reduced MTT assay in HET-1A cells at all time points.  Results are 
expressed as a percentage of vehicle control; values represented as means ± SEM; n = 15. 
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4.3.4 Influence of competitive inhibition of HO by Zinc Protoporphyrin: 24-hour data 
Incubating AGS cells for 24 hours with increasing concentrations of zinc protoporphyrin in 
5 individual experiments with a total of 18 wells per reagent resulted in cell growth 
inhibition.  MTT assay was significantly reduced at zinc concentrations of 10, 20 and 40 
µM (p < 0.0005).  Adding zinc to HGC-27 cells for 24 hours had no significant effect at 
concentrations of 0.1, 0.5 and 1 µM.  Treatment with higher zinc doses of 10, 20 and 40 
µM caused a significant reduction in cell proliferation as measured by MTT assay (p ≤ 
0.001).   
Oesophageal OE-33 and HET-1A cell lines were treated with zinc at concentrations of 0.1 
– 40 µM in 3 independent experiments with a total of 18 wells per reagent.  There was no 
significant effect on cell growth at lower zinc concentrations.  MTT assay was significantly 
reduced for OE-33 cells after 24 hours of treatment with zinc at concentrations of 10, 20 
and 40 µM (p < 0.0005).  Significant reductions in MTT assay for HET-1A cells were only 
seen at a zinc concentration of 40 µM (p = 0.012).  Treatment with zinc protoporphyrin 10 
µM or 20 µM produced consistent reductions in cell proliferation with statistical 
significance only in malignant gastric and oesophageal adenocarcinoma cells and not in 
control oesophageal squamous epithelium.   
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Figure 4.3.4 Cell proliferation experiments: 24-hour data Zinc 
Figure 4.3.4a: Effect of Zinc on AGS cell growth at 24 hours – Summary of 5 experiments total 18 
wells per reagent 
 
Figure 4.3.4b: Effect of Zinc on HGC-27 cell growth at 24 hours – Summary of 5 experiments total 
18 wells per reagent 
 
Figure 4.3.4a – b: Cells were seeded into 24-well plates, treated with zinc PP 0.1 – 40 µM for 24h and cell 
proliferation assessed by MTT assay.  Zinc PP caused significant cell growth inhibition in AGS and HGC-27 
cells at doses 10 – 40 µM (p ≤ 0.001).  Results are expressed as a percentage of vehicle control; values 
represented as means ± SEM; n = 18. 
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Figure 4.3.4c: Effect of Zinc on OE-33 cell growth at 24 hours – Summary of 4 experiments total 
18 wells per reagent 
 
Figure 4.3.4d: Effect of Zinc on HET-1A cell growth at 24 hours – Summary of 4 experiments total 
18 wells per reagent 
 
Figure 4.3.4c – d: Cells were seeded into 24-well plates, treated with zinc PP 0.1 – 40 µM for 24h and cell 
proliferation assessed by MTT assay.  Zinc PP caused significant cell growth inhibition in OE-33 cells at doses 
10 – 40 µM (p < 0.0005) and in HET-1A cells only at 40 µM concentration (p = 0.012).  Results are expressed 
as a percentage of vehicle control; values represented as means ± SEM; n = 18. 
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4.3.5 Zinc time course data 
Treatment with zinc PP at 10, 20 and 40 µM concentrations for 24, 48 and 72 hours in 4 
independent experiments caused significant decreases in AGS cell growth at zinc PP 
concentrations of 20 and 40 µM (p < 0.03).  Exposing HGC-27 cells to zinc under the same 
experimental conditions produced similar significant reductions in cell proliferation as 
measured by MTT assay for various time points (Figure 4.3.5).   
Identical independent time-course experiments performed in oesophageal cell lines 
demonstrated contrasting results between benign and malignant cells.  Cell proliferation 
measured by MTT assay was significantly reduced in HET-1A cells only with a zinc PP 
concentration of 40 µM.  Growth of OE-33 cells was significantly reduced at all observed 
time points with all experimental concentrations of zinc protoporphyrin (p ≤ 0.038).   
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Figure 4.3.5 Cell proliferation experiments: Time-course data Zinc 
Figure 4.3.5a: Effect of Zinc on AGS cell growth over time – Summary of 4 experiments total 12 
wells per reagent 
 
Figure 4.3.5b: Effect of Zinc on HGC-27 cell growth over time – Summary of 4 experiments total 
12 wells per reagent 
 
Figure 4.3.5a – b: Cells were seeded into 24-well plates and treated with zinc PP 10 – 40 µM for 24 – 72h 
with cell proliferation assessed by MTT assay.  Zinc PP caused significant cell growth inhibition in AGS and 
HGC-27 cell lines at concentrations of 20 and 40 µM at various time points.  Results are expressed as a 
percentage of vehicle control; values represented as means ± SEM; n = 12. 
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Figure 4.3.5c: Effect of Zinc on OE-33 cell growth over time – Summary of 4 experiments total 12 
wells per reagent 
 
Figure 4.3.5d: Effect of Zinc on HET-1A cell growth over time – Summary of 4 experiments total 
12 wells per reagent  
 
Figure 4.3.5c – d: Cells were seeded into 24-well plates and treated with zinc PP 10 – 40 µM for 24 – 72h 
with cell proliferation assessed by MTT assay.  Zinc PP caused significant cell growth inhibition in OE-33 cells 
at all time points with all concentrations.  MTT assay was significantly reduced in HET-1A cells only with a 
zinc PP concentration of 40 µM.  Results are expressed as a percentage of vehicle control; values 
represented as means ± SEM; n = 12. 
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4.3.6 Cell count data 
Cell count data for AGS cells demonstrate a non-significant decrease in cell numbers after 
treatment with hemin at 20, 50 and 100 µM concentrations for 24 hours (p = 0.099).  
There was no real change in HGC-27 cell numbers under the same conditions (p = 0.598).  
Cell counts for both AGS and HGC-27 cells showed a decrease in cell number after 
exposure to zinc at concentrations of 5, 10 and 20 µM for 24 hours (p ≤ 0.014).  
4.3.7 Extended growth curves 
Prolonged exposure of epithelial cells to zinc at concentrations of 20 and 40 µM produced 
similar results in AGS and OE-33 cell lines.  Extending the experiments to 168 hours 
showed a peak in exponential cell growth of control cells at 96 hours with cell numbers 
levelling out and falling beyond 120 hours.  This observed effect was due to cells 
becoming over-confluent and crowded on the growth surface with resulting detachment 
from monolayer.  Consistent effects of significantly reduced cell proliferation in both AGS 
(p < 0.0002) and OE-33 (p < 0.001) cells were seen with zinc treatment at 20 and 40 µM at 
all time points beyond 24 hours (Figure 4.3.7).  
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Figure 4.3.6 Cell Count Data 
Figure 4.3.6a: Effect of Hemin on AGS & HGC-27 cell counts at 24 hours 
 
p = 0.099 Independent Samples Kruskal-Wallis test AGS cells 
p = 0.598 Independent Samples Kruskal-Wallis test HGC-27 cells 
 
Figure 4.3.6b: Effect of Zinc on AGS & HGC-27 cell counts at 24 hours 
 
p = 0.004 Independent Samples Kruskal-Wallis test AGS cells 
p = 0.014 Independent Samples Kruskal-Wallis test HGC-27 cells 
Figure 4.3.6: Gastric cell lines were seeded into 24-well plates and treated with hemin [20, 50, 100 µM] and 
zinc PP [5, 10, 20 µM] for 24h.  Cell growth was assessed by cell counting using Trypan blue exclusion.  
Significantly fewer cells were counted after exposure to zinc PP at concentrations of 5, 10 and 20 µM for 24 
hours (p ≤ 0.014). 
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Figure 4.3.7 Extended Growth Curves: Zinc experiments 
Figure 4.3.7a: Extended growth curves with AGS cells exposed to Zinc 
 
p < 0.0002 all time points Independent Samples Kruskal-Wallis test 
Figure 4.3.7b: Extended growth curves with OE-33 cells exposed to Zinc 
 
p < 0.001 all time points Independent Samples Kruskal-Wallis test 
Figure 4.3.7a – b: AGS and OE-33 cells were treated with zinc PP 20 and 40 µM for 24 – 168h in 24-well 
plates and cell viability assessed with MTT assay and cell counts.  Significant inhibition of cell proliferation is 
observed throughout the period of exponential cell growth in both cell lines (up to 96h AGS cells and 120h 
OE-33 cells).  Values represented as means ± SEM; n = 9. 
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4.3.8 Effect of Hemin and ZnPP on HO protein expression 
Western blot protein analysis showed an increase in HO-1 isoform expression with 
increasing doses of hemin (20, 50 and 100 µM) in all cell lines investigated.  Hemin 
treatment had no effect on HO-2 protein expression in any of the cell lines (western blots 
4.3.8).  This demonstrates the response of the inducible HO-1 isoform to hemin, while 
constitutive HO-2 expression is unchanged.  Tubulin expression was equivalent in 
experimental cell lysates demonstrating adequate protein loading onto electrophoresis 
gels. 
Addition of zinc PP at 5 and 10 µM concentrations caused up-regulation of HO-1 protein 
in AGS and HGC-27 cells after 24 hours (western blots 4.3.8.1).  Expression of HO-2 
protein was equal in gastric cell lines and unchanged with zinc treatment.  Exposure of 
OE-33 and HET-1A cells to zinc protoporphyrin caused a mild decrease in HO-2 isoform 
expression after 24 hours of cell treatment with zinc at 100 µM concentrations (western 
blots 4.3.8.2).  There is slightly decreased β-tubulin expression in the HET-1A sample 
loaded into the zinc 100 µM lane that may account for the apparent reduction in HO-2 
expression.  Probing the blots for tubulin otherwise demonstrated equal protein loading 
of cell lysates.   
In OE-33 cells HO-1 protein expression was less marked and only in response to the 
highest dose of zinc protoporphyrin at 100 µM.  HO-1 protein expression was readily 
induced in HET-1A cells by treatment with zinc at 20, 40 and 100 µM.   
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←HO-2 
←HO-1 
 
←β-Tubulin 
←β-Tubulin 
Figure 4.3.8 Western Blots 
Western Blots 4.3.8.1: Hemin and Zinc PP Gastric Cancer cell lines 
AGS Hemin and Zinc PP protein expression 
 
 
 
HGC-27 Hemin and Zinc PP protein expression 
 
 
 
Figure 4.3.8.1: Protein expression in gastric cell lines after treatment with hemin and zinc PP.  
Cells were seeded into 24-well plates and protein lysates harvested at 24h.  Gel electrophoresis 
and Western blotting were performed as described.  Blots demonstrate unchanged expression of 
HO-2 and increased induction of HO-1 protein with increasing doses of hemin and zinc PP.  M = 
marker, Con = control 
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Western Blots 4.3.8.2: Hemin and Zinc Oesophageal Cancer cell lines 
OE-33 Hemin and Zinc PP protein expression 
 
 
 
 
HET-1A Hemin and Zinc PP protein expression 
 
 
 
 
Figure 4.3.8.2: Protein expression in oesophageal cell lines after treatment with hemin and zinc 
PP.  Cells were seeded into 24-well plates and protein lysates harvested at 24h.  Gel 
electrophoresis and Western blotting were performed as described.  Blots demonstrate slightly 
reduced expression of HO-2 in response to zinc PP 100 µM.  HO-1 protein expression was readily 
induced by hemin and by zinc PP treatment in HET-1A cells.  M = marker, Con = control 
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4.3.9 Heme Oxygenase Enzyme Activity Assay 
Cellular HO activity was measured by performing a specific colorimetric assay.  The results 
demonstrate an increase in total HO enzyme activity after treatment with hemin 40 µM 
for 6, 12 and 24 hours consistent with the demonstrable up regulation of HO-1 protein.  
The results show a significant decrease in total HO enzyme activity after treatment with 
zinc 40 µM for 6 and 12 hours when compared to untreated control cells (Figure 4.3.9).  
These findings are consistent with competitive inhibition of heme oxygenase enzyme by 
zinc protoporphyrin.   
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Figure 4.3.9 Heme Oxygenase Enzyme Activity Assay 
Figure 4.3.9a: Effect of Hemin and Zinc on HO enzyme activity time course  
 
Figure 4.3.9b: Effect of Hemin and Zinc on HO enzyme activity time course 
 
†p ≤ 0.05 Independent Samples Kruskal-Wallis test compared to control 
*p < 0.002 Independent Samples Kruskal-Wallis test all samples 
 
Figure 4.3.9: Effect of hemin and zinc PP on total HO enzyme activity.  AGS cells were seeded into 175 cm
3
 
flasks and lysates harvested after 6, 12 and 24h treatment as described.  Specific colorimetric assay 
demonstrated a significant increase in HO activity with HO-1 induction associated with hemin and a 
significant reduction in HO activity after brief exposure to zinc 40 µM.  Values are represented as means ± 
SD; n = 3.   
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4.3.10 Apoptosis Studies: Caspase 3/7 activity assay 
The Apo-ONE Homogenous Caspase-3/7 assay (Promega) was performed after 12 hour 
treatment with hemin 20 µM and zinc 20 µM and 40 µM.  Evolution of the assay data over 
100 minutes is shown in Figure 4.3.10a. 
Cell proliferation assay was performed concurrently in 96-well plates with an identical 
experiment design to provide cell numbers per well derived from MTT assay performed as 
described above.  The relative caspase activity per 1000 cells for experiment samples was 
obtained after normalisation to MTT assay and untreated control cells.  Results 
demonstrate an increase in fold caspase-3/7 induction after 12 hours treatment with zinc 
protoporphyrin with statistical significance at a dose of 20 µM (p = 0.035, Figure 4.3.10b).  
There was no increase in caspase-3/7 induction after 12 hours exposure to hemin.   
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Figure 4.3.10 Apoptosis Studies: Caspase 3/7 activity assay 
Figure 4.3.10a: Caspase activity at 12 hours AGS cells 
 
Figure 4.3.10a: Evolution of kinetic absorbance data over 100 minutes during caspase 3/7 assay.  AGS cells 
were seeded into black 96-well plates and treated with hemin or zinc PP for 12h.  Apo-ONE® Caspase-3/7 
Reagent was added to each well and fluorescence measured after 1h incubation, collecting data over 250 
plate reading cycles to generate complete signal curves. 
Figure 4.3.10b: Relative caspase activity in AGS cells 
 
Figure 4.3.10b: Effect of hemin and zinc treatment on caspase-3/7 activity.  AGS cells were seeded into 96-
well plates and Apo-ONE® Caspase-3/7 assay performed after 12h.  Results demonstrate a significant 
increase in relative caspase-3/7 activity per 1000 cells with zinc 40 µM (p = 0.035).  Values are represented 
as means ± SD; n = 12.   
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4.4 Investigating a Specific Role for HO-2 Enzyme in Cell Growth 
To investigate a specific effect of the HO-2 isoform protein short interfering RNA (siRNA)-
mediated HO-2 gene knockdown experiments were performed.   
4.4.1 Establishing protocols for adequate transfection of siRNA complex 
4.4.1.1 Toxicity 
Although the manufacturer claims that the transfection reagent has a mild cytotoxicity 
profile, initial experiments were designed to establish the effects of different 
concentrations of Lipofectamine on cellular proliferation.   
4.4.1.2 Lipofectamine protocol  
Lipofectamine experiments were set up in 24-well plates for AGS cells at concentrations 
of 0.5, 1.0 and 1.5 µl.  Cells in culture were diluted with fresh medium without antibiotics 
and seeded at 1.25 x 104 cells per well in 24-well plates, such that cells were 30-40% 
confluent at the time of adding transfection reagent.  Lipofectamine was added diluted in 
Opti-MEM medium at concentrations of 0.5, 1.0 and 1.5 µl per well.  After 10 hours the 
reagent medium was washed out and replaced with fresh serum-complete medium.  MTT 
assay was performed at 72 hours to determine the effect of the transfection reagent on 
cell proliferation. 
4.4.1.3 Lipofectamine results 
MTT assay was not significantly different for AGS cells at concentrations of 0.5, 1.0 and 
1.5µl per well.  There did not appear to be a toxic effect on AGS cells with the 
recommended concentrations of Lipofectamine at 72 hours (Figure 4.4.1a). 
4.4.1.4 Transfection efficiency 
The next stage was to assess the efficacy of oligonucleotide transfection using the chosen 
Lipofectamine transfection reagent.  In order to assess uptake of double stranded nucleic 
acid into the cells, a fluorescently tagged oligonucleotide was transfected with the 
Lipofectamine.  The labelled RNAi duplex recommended for use with Lipofectamine 
RNAiMAX was BLOCK-iT™ AlexaFluor Red Fluorescent Control obtained from Invitrogen.  
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This is a double-stranded RNA molecule with the same length, charge and configuration 
as standard siRNA, whose sequence is not homologous to any known gene to avoid non-
specific cellular events caused by its introduction into the cytoplasm.  
Cells were seeded into a 24-well plate at 1.25 x 104 cells per well.  Lipofectamine and 
AlexaFluor duplexes were first diluted in Opti-MEM medium then combined and left to 
incubate for 20 minutes at room temperature.  This allows the RNAi duplex-Lipofectamine 
transfection complex to form.  The complexes were added to the wells to give a range of 
final concentrations as shown: 
Control Control Control Control Control 
Optimem Lipofectamine 
0.5µl 
Lipofect 0.5µl + 
AlexaFluor10nM 
Lipofect 0.5µl + 
AlexaFluor20nM 
Lipofect 0.5µl + 
AlexaFluor40nM 
Optimem Lipofectamine 
1.0µl 
Lipofect 1.0µl + 
AlexaFluor10nM 
Lipofect 1.0µl + 
AlexaFluor20nM 
Lipofect 1.0µl + 
AlexaFluor40nM 
Optimem Lipofectamine 
1.5µl 
Lipofect 1.5µl + 
AlexaFluor10nM 
Lipofect 1.5µl +  
AlexaFluor20nM 
Lipofect 1.5µl +  
AlexaFluor40nM 
 
After 10 hours the medium in the wells was replaced with fresh serum-complete medium.  
MTT assay was performed at 72 hours to determine any effects on cell growth.  To assess 
the RNA uptake, wells were examined under inverted fluorescent microscopy after 
replacing the culture medium with warm PBS. 
A separate 6-well experiment plate was set up with AlexaFluor oligo at concentrations of 
1, 5, 10, 20 and 40nM.  Lipofectamine was used at 4.2µl per well, equivalent to 1µl per 
well in a 24-well plate.  Microscopy slide coverslips were placed in the base of the well 
and coating medium applied prior to cell seeding.  This enabled subsequent removal of 
the coverslip onto a slide with the cell monolayer intact and facilitated fluorescent 
microscopy examination. 
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4.4.1.5 AlexaFluor results 
Although there was a trend towards reduced cell growth in cells treated with higher 
concentrations of AlexaFluor oligo with a higher concentration of Lipofectamine, there 
were no significant differences between MTT assay results in any of the experimental 
combinations (Figure 4.4.1b). 
AlexaFluor Red-labelled oligo uptake on fluorescent microscopy was assessed comparing 
one concentration of Lipofectamine (1µl) and various oligonucleotide concentrations.  
There was a distinct improvement in uptake with AlexaFluor 10nM as opposed to 1nM or 
5nM, with intracellular red staining clearly visible at x20 and x40 magnifications (Figure 
4.4.1c). 
These results demonstrate effective transfection of the labelled siRNA using 
Lipofectamine reagent at 1µl per well and oligo at 10nM concentration.   
4.4.1.6 siRNA and Negative Universal Control 
In order to assess potential effects of the negative universal control (NUC) on the cell lines 
of interest, experiments were set up using AGS and HGC-27 cells exposed to various 
concentrations of NUC for a 72 hour period.   
4.4.1.7 NUC Oligonucleotide protocol 
Cells were suspended in fresh medium without antibiotics and seeded at 1.25 x 104 cells 
per well in 24-well plates, such that cells were 30-40% confluent at the time of adding 
transfection reagent.  Lipofectamine was used at 1 µl per well, and NUC oligo was added 
to give a final concentrations of 1, 2, 5, 10, 20 and 40 nM per well.  The NUC was supplied 
as a stock solution at 20 µM concentration.  A calculated volume of stock NUC solution 
was added to 50 µl of Opti-MEM reduced serum medium and mixed gently.  
Lipofectamine reagent was mixed before use, and then 1 µl added to 50 µl Opti-MEM 
medium.  The diluted NUC duplex and transfection reagent were combined and allowed 
to incubate for up to 20 minutes at room temperature to allow complexes to form.  The 
total volume of 100 µl was added to 500 µl of antibiotic-free medium in the wells to give a 
total final volume of 600 µl.  Medium was changed after 8 – 10 hours in all wells.  MTT 
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assay and cell counts were performed at 72 hours to assess any effects on cell 
proliferation. 
4.4.1.8 Negative Universal Control results 
For AGS cells there was a reduction in cell growth 72 hours after transfection with 
negative universal control at a concentration of 40 nM.  MTT assay was reduced (p = 
0.069) and cell counts significantly reduced at 72 hours (p = 0.024).  There was no effect 
with NUC 10 nM and no significant effects with NUC 5 nM or 20 nM (Figures 4.4.1d & 
4.4.1e).  
Identical experiments using HGC-27 cells demonstrated similar results with a significantly 
reduced cell growth at 72 hours after transfection with NUC at 40 nM (p = 0.021).  HGC-27 
cells appeared to be more sensitive to transfection with the control oligonucleotide, with 
all concentrations above 1 nM causing a reduction in MTT assay at 72 hours (average % 
control < 90) but these observed effects only reached significance at a concentration of 
NUC 40 nM.  There were no significant differences in MTT assay outcomes for HGC-27 
cells between NUC concentrations of 5, 10 or 20 nM (Figure 4.4.1f). 
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Figure 4.4.1 Establishing protocols for adequate transfection of siRNA complex  
Figure 4.4.1a: Effect of Lipofectamine on AGS cell growth at 72 hours 
 
p = 0.151 Independent samples Kruskal-Wallis test  
Figure 4.4.1a: AGS cells were treated with 0.5 – 1.5 µL lipofectamine transfection reagent in 24-well plates 
for 10h.  MTT assay performed at 72h showed no significant effect on cell proliferation.  Results are 
expressed as a percentage of vehicle control; values represented as means ± SEM; n = 12. 
Figure 4.4.1b: Effect of siRNA controls on AGS cell growth at 72 hours 
 
p = 0.058 Independent samples Kruskal-Wallis test 
Figure 4.4.1b: AGS cells were treated with lipofectamine transfection reagent ± AlexaFluor RNAi duplex at 
various concentration combinations.  MTT assay performed at 72h showed no significant effect on cell 
proliferation despite a trend toward reduced cell growth with high-dose combinations.  Results are 
expressed as a percentage of vehicle control; values represented as means ± SEM; n = 3. 
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Figure 4.4.1c Fluorescent microscopy of siRNA transfection controls 
Lipofectamine 1µl + AlexaFluor 1nM x20 Lipofectamine 1µl + AlexaFluor 5nM x20 
  
Lipofectamine 1µl + AlexaFluor 10nM x20  Lipofectamine 1µl + AlexaFluor 10nM x40 
  
Figure 4.4.1c: Fluorescent microscopy to assess transfection efficiency at various oligonucleotide 
concentrations.  Intracellular red staining is displayed at x20 and x40 magnifications.  Transfection of 
labelled AlexaFluor duplex is effective at 10 nM concentration with 1 µL lipofectamine reagent per well.   
Figure 4.4.1d: Effect of siRNA NUC on AGS cell counts 
 
Figure 4.4.1d: AGS cells seeded into 24-well plates were treated with lipofectamine reagent plus scrambled 
negative universal control duplex (NUC).  Cell counts performed at 72h showed no significant effect on cell 
proliferation except for high dose NUC 40 nM.  Values represented as means ± SEM; n = 12. 
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Figure 4.4.1e: Effect of siRNA NUC on AGS cell growth 
 
p = 0.069 Independent Samples Kruskal-Wallis test 
Figure 4.4.1e: AGS cells seeded into 24-well plates were treated with lipofectamine transfection reagent 
plus NUC.  MTT assay performed at 72h showed no significant effect on cell proliferation.  Results are 
expressed as a percentage of vehicle control; values represented as means ± SEM; n = 12. 
 
Figure 4.4.1f: Effect of siRNA NUC on HGC-27 cell growth 
 
Figure 4.4.1f: HGC-27 cells seeded into 24-well plates were treated with lipofectamine transfection reagent 
plus NUC.  MTT assay performed at 72h showed no significant effect on cell proliferation except for high 
dose NUC 40 nM.  Results are expressed as a percentage of vehicle control; values represented as means ± 
SEM; n = 12. 
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4.4.2 Efficacy of supplied siRNA and HO-2 knockdown 
4.4.2.1 siRNA Oligonucleotide protocol  
The siRNA targeted to the HO-2 gene was supplied as three individual non-overlapping 
sequences (Invitrogen).  The next stage was to determine which individual siRNA resulted 
in effective knockdown of the HO-2 gene transcript.   
The Stealth™ Select siRNA targeted to the HO-2 gene (HMOX2) were delivered freeze-
dried and desalted by normal phase chromatography with a total amount of 20 nmole.  
This amount was resuspended in 1 ml RNase-free water previously treated with 
diethylpyrocarbonate that inactivates RNase enzymes.  This gave 0.02 µmole in 1 ml, a 
solution of 20 µM concentration.  From the stock solution 0.3 µl was added to 50 µl Opti-
MEM medium and mixed gently.  A volume of 1 µl Lipofectamine RNAiMAX was added to 
50 µl Opti-MEM medium and mixed gently, then added to the diluted siRNA 
oligonucleotide.  This mixture was left to incubate for 20 minutes at room temperature to 
enable transfection complexes to form.  The total volume of 100 µl was added to 500 µl 
of antibiotic-free medium in the wells to give a final siRNA concentration of 10 nM in each 
experimental well of a 24-well plate.  The amount of siRNA duplex used in each well was 6 
pmole.  Because transfection complexes were added to more than one well in each 
experiment, a working stock of siRNA with lipofectamine was prepared at x6 
concentration by serial dilution, with 100 µl of the stock added to each siRNA experiment 
well. 
The medium in every well was replaced with fresh serum-complete medium 8 – 10 hours 
after transfection.  Samples were collected for RNA isolation and analysis 24, 48 and 72 
hours after transfection.  Purified RNA was obtained from collected samples and reverse 
transcriptase polymerase chain reaction performed for qualitative and quantitative 
assessment of mRNA knockdown achieved.  Cell lysates were collected for protein assay 
and subsequent Western blotting to assess HO-2 and HO-1 protein expression.   
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4.4.2.2 RNA purification results 
Quality control with PCR using GAPDH primers demonstrated that without using the 
Turbo DNase enzyme (Ambion) there were clear PCR products visible on ethidium 
bromide gels.  There were no bands visible for samples treated with DNase enzyme 
(Figure 4.4.2a).  This process was repeated for every sample of total RNA isolated and 
purified to ensure no contaminating DNA was present prior to making complementary 
DNA. 
4.4.2.3 Reverse transcriptase polymerase chain reaction results 
Analysis of the RT-PCR products demonstrated effective HO-2 gene knockdown after 
transfection with two out of the three supplied siRNA duplexes.  The most effective was 
siRNA 02, with a complete absence of product band identifiable from PCR with the 
HMOX2 primers.  By contrast there were equal bands visible from each RNA sample after 
RT-PCR with GAPDH primers (Figure 4.4.2b).  For all subsequent siRNA experiments the 
siRNA 02 duplex was used for HO-2 gene knockdown.   
Agarose gel analysis of RT-PCR products demonstrated effective knockdown of HO-2 
mRNA after transfecting cells with targeted siRNA for 24, 48 and 72 hours.  There were no 
visible bands after PCR with HMOX2 primers at 24 and 72 hours, and a markedly reduced 
band at 48 hours when compared to PCR products with GAPDH primers.  The quality of 
the results is compromised by the appearance of reduced HO-2 mRNA after 72 hours of 
lipofectamine treatment, although this may reflect a reduction of total RNA in this sample 
(Figure 4.4.2c).  Experiments were repeated and PCR products evaluated using agarose 
gel electrophoresis for both AGS and HGC-27 cell lines.  Although analysis demonstrated 
effective knockdown of HO-2 mRNA after transfecting cells with siRNA duplexes there 
was inconsistent findings with PCR products using GAPDH primers (see Appendix VII).  
These results suggested a compromise in RNA quality with possible DNA contamination in 
the eluted RNA samples.  Treatment with Turbo DNase enzyme was repeated and any 
samples with visible DNA contamination were discarded along with any corresponding 
complementary DNA stored.  Effective knockdown of HO-2 mRNA using the selected 
siRNA duplex was demonstrated in both AGS and HGC-27 cells with relative preservation 
of GAPDH mRNA (Figures 4.4.2d & 4.4.2e). 
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Figure 4.4.2 RNA sample preparation and PCR Products  
Figure 4.4.2a: DNA contamination & DNase treatment 
 
Figure 4.4.2a: PCR products using GAPDH primers demonstrated effective removal of DNA in samples 
treated with DNase enzyme.  Clear bands are visible from samples not treated with DNase.  Isolated RNA 
was therefore treated with DNase prior to making complementary DNA.  LANES: 1=Control, 
2=Lipofectamine, 3=NUC 10nM, 4=siRNA 01 10nM, 5=siRNA 02 10nM, 6=siRNA 03 10nM ALL WITH DNase 
treatment; 7=Lipofectamine, 8=NUC 10nM, 9=siRNA 01 10nM, 10=siRNA 02 10nM, 11=siRNA 03 10nM ALL 
WITHOUT DNase treatment. 
Figure 4.4.2b: siRNA select duplexes 
 
 
Figure 4.4.2b: PCR products demonstrate effective HO-2 gene knockdown after transfection with two out of 
the three supplied siRNA duplexes with the most effective siRNA 02 (lane 5).  LANES: 1=NUC 10nM, 2=NUC 
10nM, 3=NUC 10nM, 4=siRNA duplex 01 10nM, 5=siRNA duplex 02 10nM, 6=siRNA duplex 03 10nM. 
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Figure 4.4.2c: PCR products siRNA knockdown HMOX2 and GAPDH AGS cells 
 
Lanes  
1 = Lipofectamine 24hrs   4 = Lipofectamine 48hrs   7 = Lipofectamine 72hrs 
2 = NUC 10nM 24hrs  5 = NUC 10nM 48hrs  8 = NUC 10nM 72hrs 
3 = siRNA 10nM 24hrs  6 = siRNA 10nM 48hrs  9 = siRNA 10nM 72hrs 
 
Figure 4.4.2c: All subsequent siRNA experiments used the siRNA 02 duplex for HO-2 gene knockdown.  
Analysis of RT-PCR products demonstrated effective knockdown of HO-2 mRNA after 24, 48 and 72 hours.  
The appearance of reduced HO-2 mRNA after 72 hours of lipofectamine treatment may reflect a reduction 
of total RNA in this sample with a visible reduction in GAPDH band for this sample.   
 
 
 
  
 1     2    3     4     5    6     7     8    9  GAPDH primer 
 HMOX2 primer  1     2    3     4     5    6     7     8     9 
DNA 
ladder 
 
PCR 
–ve  
 
270 
 
Figure 4.4.2d: PCR products HMOX2 and GAPDH primers AGS cell samples 
 
 
Lanes 
1 = Lipofectamine 24hrs   4 = Lipofectamine 48hrs   7 = Lipofectamine 72hrs 
2 = NUC 10nM 24hrs  5 = NUC 10nM 48hrs  8 = NUC 10nM 72hrs 
3 = siRNA 02 10nM 24hrs  6 = siRNA 02 10nM 48hrs  9 = siRNA 02 10nM 72hrs 
 
Figure 4.4.2d: Repeated analysis of RT-PCR products demonstrated effective knockdown of HO-2 mRNA 
using the selected siRNA duplex in AGS cells.  HO-2 knockdown appears to be most effective at 48 – 72h 
with relative preservation of GAPDH mRNA.   
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Figure 4.4.2e: PCR products HMOX2 and GAPDH primers HGC-27 cell samples 
 
 
Lanes 
1 = Lipofectamine 24 hrs 
2 = NUC 10nM 24hrs  3 = NUC 10nM 48hrs  4 = NUC 10nM 72hrs 
5 = siRNA 02 10nM 24hrs  6 = siRNA 02 10nM 48hrs  7 = siRNA 02 10nM 72hrs 
Figure 4.4.2e: Repeated analysis of RT-PCR products demonstrated effective knockdown of HO-2 mRNA 
using the selected siRNA duplex in HGC-27 cells.  HO-2 mRNA is reduced even after 24h in HGC-27 cells with 
relative preservation of GAPDH mRNA.   
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4.4.3 Real-time Quantitative PCR 
In order to clarify siRNA-mediated knockdown of the heme oxygenase target mRNA, real-
time quantitative PCR analysis was performed using pre-optimised TaqMan® assays for 
human heme oxygenase 1 (Hs00157965_m1) and heme oxygenase 2 (Hs00157969_m1).   
The purity and concentration of all RNA samples eluted for real-time PCR analysis was 
estimated UV absorbance measurement with a spectrophotometer.  The measured 
A260:A280 ratio value was between 1.8 and 2.1 for all samples, indicating a pure RNA 
sample for experimental purposes (Table 4.4.3).   
To provide accurate RNA quantification prior to reverse transcriptase PCR a sensitive 
RNA-binding stain was used called Quant-iT™ RiboGreen® RNA assay (Invitrogen) with 
construction of standard curves against a ribosomal standard (Figure 4.4.3a).  A total of 
40 ng RNA was used for cDNA synthesis for each sample.  The cDNA samples were diluted 
to 1 ngmL-1 with pure water and a total of 10 ng used in each PCR amplification reaction.   
The comparative CT method was used to calculate the expression of target HO-1 and HO-2 
mRNA in AGS and OE-33 cell samples from siRNA experiments.  The expression level of 
the HO-1 and HO-2 genes of interest were normalised to an endogenous 18S ribosomal 
RNA gene to normalise for variation in the amount and quality of RNA between samples.   
In AGS experiments siRNA-mediated knockdown of HO-2 using two separate 
oligonucleotides (siRNA duplex 01 and siRNA duplex 02) produced a clear reduction in 
relative HO-2 mRNA expression and a significant effect with siRNA duplex 02 (p = 0.004, 
Figure 4.4.3b).  There was a significant corresponding increase in relative expression of 
HO-1 mRNA (Figure 4.4.3c).  Very similar results were seen for the OE-33 cells with 
significantly reduced HO-2 expression and significantly increased HO-1 expression after 
transfection with targeted siRNA oligonucleotides (Figures 4.4.3d & 4.4.3e).  Relative RNA 
expression results are a summary of 3 experiments with total of 9 RNA samples used per 
reagent.  The results confirm efficient knockdown of HO-2 mRNA from the siRNA 
experiment protocols used and indicate a concurrent up regulation of HO-1 mRNA.   
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4.4.3 Real-time Quantitative PCR Results 
Table 4.4.3: RNA quantification by Ultraviolet Absorbance – A260:A280 ratio 
Sample OD 280 nm OD 260 nm Purity RNA [ngµL-1] 
AGS cells 
Control 0.33 0.671 2.033333 402.6 
NUC 0.35 0.709 2.025714 425.4 
siRNA 01 0.205 0.411 2.004878 246.6 
siRNA 02 0.203 0.401 1.975369 240.6 
Control 0.496 1.029 2.074597 617.4 
NUC 0.411 0.848 2.06326 508.8 
siRNA 01 0.273 0.557 2.040293 334.2 
siRNA 02 0.248 0.514 2.072581 308.4 
OE33 cells 
Control 0.333 0.689 2.069069 413.4 
NUC 0.32 0.654 2.04375 392.4 
siRNA 01 0.174 0.357 2.051724 214.2 
siRNA 02 0.215 0.425 1.976744 255 
Control 0.535 1.07 2 642 
NUC 0.41 0.845 2.060976 507 
siRNA 01 0.284 0.587 2.066901 352.2 
siRNA 02 0.275 0.498 1.810909 298.8 
 
Table 4.4.3: UV absorbance measurement of all RNA samples eluted for real-time PCR analysis estimated 
the A260:A280 ratio value between 1.8 and 2.1 indicating a pure RNA sample.   
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Figure 4.4.3a: RNA quantification by RiboGreen Assay 
Standard Curve 
 
RNA concentrations 
Sample SYBR - Blank RNA [ngµL-1]  Mean % CV 
Control 
20563.789 595.488 
565.275 4.645 18922.654 548.004 
19072.285 552.334 
NUC 
21343.844 618.057 
680.308 8.162 24111.793 698.142 
25030.52 724.724 
siRNA 
01 
15685.704 454.349 
421.004 7.065 13710.581 397.203 
14203.291 411.459 
siRNA 
02 
16264.158 471.086 
491.3 4.514 17782.775 515.024 
16841.518 487.791 
CV = coefficient of variation 
Figure 4.4.3a: Accurate RNA quantification was provided by RiboGreen® RNA assay standard curves prior to 
reverse transcriptase PCR.  A total of 40 ng RNA was used for cDNA synthesis for each sample calculated 
from derived RNA concentrations.   
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Figure 4.4.3b: Relative HO-2 mRNA expression after 48 hrs AGS cells 
 
Figure 4.4.3c: Relative HO-1 mRNA expression after 48 hrs AGS cells 
 
Figure 4.4.3b – c: Expression of HO-1 and HO-2 mRNA normalised to endogenous 18S ribosomal RNA using 
the comparative CT method.  Knockdown of HO-2 in AGS cells using two separate oligonucleotides (siRNA 01 
and siRNA 02) produced a significant reduction in relative HO-2 mRNA expression with a corresponding 
increase in relative expression of HO-1 mRNA.  Values represented as means ± SEM; n = 9. 
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Figure 4.4.3d: Relative HO-2 mRNA expression after 48 hrs OE33 cells 
 
Figure 4.4.3e: Relative HO-1 mRNA expression after 48 hrs OE33 cells 
 
Figure 4.4.3d – e: Expression of HO-1 and HO-2 mRNA normalised to endogenous 18S ribosomal RNA using 
the comparative CT method.  Knockdown of HO-2 in OE-33 cells using two separate oligonucleotides (siRNA 
01 and siRNA 02) produced a significant reduction in relative HO-2 mRNA expression with a corresponding 
increase in relative expression of HO-1 mRNA.  Values represented as means ± SEM; n = 9. 
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4.4.4 Effect of siRNA knockdown on heme oxygenase protein expression 
Western blot analysis of protein expression demonstrates a reduction in HO-2 protein in 
AGS cells treated with HMOX2 siRNA 10nM after 24 and 48 hours.  Probing the blots for 
HO-1 protein demonstrates that the protein is up-regulated in cells treated with siRNA 
targeted toward the HO-2 isoform.  HO-1 expression increases with time from 24 hours to 
48 hours.  Differential HO protein expression in experiment wells was supported by 
assessment of β-tubulin that demonstrated relatively equal expression and adequate 
protein loading of gel lanes (western blots 4.4.4.1).  The siRNA oligonucleotides 01 and 02 
are most effective at reducing HO-2 protein bands at 24 hours and all 3 siRNA duplexes 
reduced the expression of HO-2 protein with marked HO-1 up-regulation at 48 hours.  
There is a faint HO-1 band appearing 48 hours after transfection with the scrambled 
oligonucleotide (NUC, negative universal control).  This may represent a non-specific 
induction of HO-1 protein due to off-target effects of the transfection process that did not 
have an observed effect on cell phenotype. 
Further western blot analysis confirms effective reduction in HO-2 protein at 24, 48 and 
72 hours using siRNA duplex 02 with accompanying up-regulation of HO-1 protein at each 
time point.  Expression of HO-1 protein is slightly increased at 24 hours with further time-
dependent increases over 48 and 72 hours (western blots 4.4.4.2).  Adequate protein 
loading is demonstrated across samples with equal expression of β-tubulin protein.   
Western blots from siRNA experiments with OE-33 cells demonstrate reduced expression 
of HO-2 protein 24 and 48 hours after transfection with siRNA duplex at 10 nM 
concentration.  Increased expression of HO-1 protein is seen after 24 and 48 hours using 
siRNA oligonucleotides 01 and 02.  The siRNA duplex 02 appears to be more effective 
than duplex 01 in achieving HO-2 knockdown and consequent HO-1 induction.  Expression 
of β-tubulin protein is slightly reduced in the lysate sample from cells treated with siRNA 
10 nM for 24 hours and otherwise demonstrates equal protein loading (western blots 
4.4.4.3).   
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Figure 4.4.4 Western Blots  
Western Blots 4.4.4.1: siRNA HO-2 knockdown in AGS cells 
AGS siRNA mediated HO-2 knockdown – anti-HO1 & anti-HO-2 
 
 
 
 
Lanes  
1 = Control 48h  2 = NUC 10nM 24h  3 = NUC 10nM 48h  
4 = siRNA 01 10nM 24h 5 = siRNA 01 10nM 48h   
6 = siRNA 02 10nM 24h 7 = siRNA 02 10nM 48h 
8 = siRNA 03 10nM 24h 9 = siRNA 03 10nM 48h 
 
Figure 4.4.4.1: Protein expression in gastric cell lines after siRNA transfection with 3 anti-HO-2 
siRNA duplexes.  Cells were seeded into 6-well plates, protein lysates harvested at 24 – 48h and 
Western blotting performed as described.  Blots demonstrate effective reduction of HO-2 
expression with increased induction of HO-1 protein after 48h transfection.  M = marker, NUC = 
negative universal control 
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Western Blots 4.4.4.2: siRNA HO-2 knockdown in AGS cells  
AGS siRNA mediated HO-2 knockdown – selected siRNA duplex 02 
 
 
 
Lanes  
1 = siRNA 02 10nM 24h 2 = siRNA 02 10nM 48h 3 = siRNA 02 10nM 72h 
4 = NUC 10nM 24h 5 = NUC 10nM 48h 6 = NUC 10nM 72h 
7 = Control 24h  8 = Control 48h  9 = Control 72h 
 
Figure 4.4.4.2: Protein expression in gastric cell lines after siRNA transfection with anti-HO-2 
siRNA 02 duplex.  Cells were seeded into 6-well plates, protein lysates harvested at 24 – 48h and 
Western blotting performed as described.  Blots demonstrate effective knockdown of HO-2 
protein and selective induction of HO-1 protein after 24 – 72h transfection.  M = marker, NUC = 
negative universal control 
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Western Blots 4.4.4.3: siRNA HO-2 knockdown in OE-33 cells 
OE-33 siRNA mediated HO-2 knockdown and HO-1 upregulation 
 
 
 
 
 
Lanes  
1 = Control 24h   2 = Control 48h   
3 = NUC 10nM 24h 4 = siRNA 01 10nM 24h 5 = siRNA 01 10nM 24h 
6 = NUC 10nM 48h 5 = siRNA 02 10nM 48h 6 = siRNA 02 10nM 48h 
 
Figure 4.4.4.3: Protein expression in oesophageal cell lines after siRNA transfection with anti-HO-2 
siRNA duplex.  Cells were seeded into 6-well plates, protein lysates harvested at 24 – 48h and 
Western blotting performed as described.  Blots demonstrate reduced HO-2 expression and 
selective up-regulation of HO-1 protein after 24 – 48h transfection.  M = marker, NUC = negative 
universal control 
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4.4.5 The effect of siRNA HO-2 knockdown on heme oxygenase enzyme activity 
A specific colorimetric HO enzyme assay was performed on AGS cell lysate samples after 
12, 24 and 48 hours treatment with siRNA targeted toward HO-2 protein.  Results from 
triplicate experiments demonstrate a significant reduction in total heme oxygenase 
activity after 24 and 48 hours.  However the combined activity of HO-2 and HO-1 enzyme 
proteins was significantly increased after 12 hours.  This may be due to an increased HO-1 
expression in response to siRNA-mediated HO-2 knockdown (Figure 4.4.5). 
Figure 4.4.5 Heme Oxygenase Enzyme Activity Assay 
Figure 4.4.5: Effect of HO-2 knockdown on HO enzyme activity time course  
 
Figure 4.4.5: Effect of siRNA-mediated HO-2 knockdown on total HO enzyme activity.  AGS cells were 
seeded into 175 cm
3
 flasks and lysates harvested 12, 24 and 48h after transfection as described.  Specific 
colorimetric assay demonstrated a significant reduction in HO activity associated with HO-2 knockdown at 
24 and 48h but a marked increase in combined activity of HO enzymes after 12h.  Values represented are 
means ± SD; n = 3.   
 
  
0
100
200
300
400
500
Control NUC 10nM siRNA 10nM
p
m
o
le
s 
B
ili
 /
 m
g 
p
ro
t 
/ 
6
0
 m
in
 
Effect of siRNA on HO enzyme activity 
12 hrs
24 hrs
48 hrs
†p < 0.02 
† 
† 
† 
282 
 
4.4.6 The effect of siRNA-mediated HO-2 knockdown on cell growth 
4.4.6.1 Cell proliferation protocol 
Experiments were set up to assess the effect of HO-2 gene knockdown on cell 
proliferation in the cultured cell lines.  Cells were seeded at 1.25 x 104 cells per well in 24-
well plates 24 hours prior to adding transfection complexes, at which time the cells were 
30 – 40% confluent.  Lipofectamine was used at a concentration of 1 µL per well.  Six 
pmole of the selected siRNA duplex and negative universal control duplex were used to 
give a final concentration of 10 nM per well.  The medium in every well was replaced with 
fresh serum-complete medium 8 – 10 hours after transfection.  MTT assay and cell counts 
were performed at 24, 48 and 72-hour time points after transfection. 
4.4.6.2 Cell proliferation results – MTT assay 
A total of 3 independent experiments were performed on AGS cells.  The results 
demonstrate a significantly reduced MTT assay at 48 and 72 hours in cells transfected 
with HMOX2 siRNA as compared to negative universal control (Figure 4.4.6.1).  There was 
no effect observed at the 24 hour time point but significantly reduced cell proliferation at 
48 and 72 hours in siRNA-transfected cells as compared to cells treated with NUC at 10 
nM concentration (% of control 63.9% vs. 92.0% at 48 hours and 59.7% vs. 90.5% at 72 
hours, respectively; p < 0.0005).  There was no advantage in treating the cells with 
oligonucleotide complexes at a higher dose of 20 nM. 
Three separate experiments were performed on the HGC-27 cell line with transfection 
performed using HMOX2 siRNA at concentrations of 10 nM and at a lower dose of 5 nM.  
MTT assay results show significant reduction of cell proliferation at 48 and 72 hours in 
cells treated with HMOX2 siRNA (Figure 4.4.6.2).  Cells transfected with HMOX2 siRNA 10 
nM compared to those transfected with NUC 10 nM had significantly reduced cell growth 
at 48 hours (92.5% control vs. 73.6% control, p = 0.007) and at 72 hours (87.5% control vs. 
40.8% control, p = 0.01).  The lower dose of 5 nM was equally as effective in reducing cell 
growth, with no significant differences between the two concentrations in MTT assay 
performed at 48 (p = 0.82) and 72 hours (p = 0.42). 
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Cell growth experiments were also performed to assess the effects of HO-2 knockdown in 
oesophageal cell lines HET-1A and OE-33.  There was a significant reduction in MTT assay 
for OE-33 cells 48 and 72 hours after transfection with HMOX2 siRNA 10 nM compared to 
corresponding controls (Figure 4.4.6.3).  There were similar effects seen in HET-1A cells at 
24 and 48 hours, although cell proliferation measured by MTT assay appeared to recover 
in these cells by 72 hours (Figure 4.4.6.4). 
4.4.6.3 Cell proliferation results – cell counts 
Cell counts performed for siRNA experiments supported the finding of a clear effect on 
cell proliferation (see Appendix VIII).  There were significantly fewer live AGS cells 
counted at 24, 48 and 72 hours from wells treated with siRNA 10 nM as compared to 
those transfected with NUC 10 nM (p < 0.05).  In HGC-27 experiments there were 
significant reductions in cell counts with HO-2 gene knockdown at 48 and 72 hours when 
compared to negative universal control (p < 0.004).  In two cell counts performed from 
OE-33 cell experiments, there was a marked reduction in live cells treated with siRNA at 
48 hours and 72 hours.  OE-33 siRNA experiment cell count data are insufficient for 
statistical significance.  HO-2 knockdown in AGS, HGC-27 and OE-33 cells produced effects 
on cell counts that are more dramatic than those seen with MTT.  The discrepancy 
between cell count numbers and the equivalent MTT results is likely to be explained by 
the technical aspects and relatively cumbersome nature of cell counting with the major 
factor being fewer experiments performed leading to greater variability and an increased 
likelihood of observer error. 
During all cell counts for the siRNA set of experiments there were very few dead cells 
counted in every well, so few that any suggestive comparison from the counting 
technique was inappropriate.   
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Figure 4.4.6 MTT Cell Proliferation Assay – Time course experiments 
Figure 4.4.6.1: Effect of HO-2 knockdown on AGS cell growth  
 
 
Figure 4.4.6.1: Effect of siRNA-mediated HO-2 knockdown on AGS cell growth.  Cells were seeded into 24-
well plates and MTT assay performed 24, 48 and 72h after transfection as described.  HO-2 knockdown 
caused significantly reduced cell proliferation at 48 and 72 hours as compared to cells treated with NUC 
(negative universal control) oligonucleotide.  Results are expressed as a percentage of vehicle control; 
values represented as means ± SEM; n = 15. 
   
95 95 95 92 
64 
75 
91 
60 
71 
0
20
40
60
80
100
NUC 10nM siRNA 10nM siRNA 20nM
M
T
T 
A
b
so
rb
an
ce
 %
 c
o
n
tr
o
l 
Effect of HO-2 knockdown on AGS growth 
24 hrs
48 hrs
72 hrs‡ 
* 
‡p < 0.005 †p = 0.002 *p = 0.006 Independent Samples Kruskal-Wallis test 
† 
285 
 
Figure 4.4.6.2: Effect of HO-2 knockdown on HGC-27 cell growth 
 
 
Figure 4.4.6.2: Effect of siRNA-mediated HO-2 knockdown on HGC-27 cell growth.  Cells were seeded into 
24-well plates and MTT assay performed 24, 48 and 72h after transfection as described.  HO-2 knockdown 
caused significantly reduced cell proliferation at 48 and 72 h.  Results are expressed as a percentage of 
vehicle control; values represented as means ± SEM; n = 15. 
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Figure 4.4.6.3: Effect of HO-2 knockdown on OE-33 cell growth 
 
 
Figure 4.4.6.3: Effect of siRNA-mediated HO-2 knockdown on OE-33 cell growth.  Cells were seeded into 24-
well plates and MTT assay performed 24, 48 and 72h after transfection as described.  HO-2 knockdown 
caused significant reductions in MTT assay at 48 and 72h in OE-33 cells.  Results are expressed as a 
percentage of vehicle control; values represented as means ± SEM; n = 12. 
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Figure 4.4.6.4: Effect of HO-2 knockdown on HET-1A cell growth 
 
 
Figure 4.4.6.4: Effect of siRNA-mediated HO-2 knockdown on HET-1A cell growth.  Cells were seeded into 
24-well plates and MTT assay performed 24, 48 and 72h after transfection as described.  HO-2 knockdown 
caused less dramatic effects on cell growth although statistically significant reductions in MTT assay at 24 
and 48h.  Cell proliferation measured appeared to recover in HET-1A cells by 72h.  Results are expressed as 
a percentage of vehicle control; values represented as means ± SEM; n = 12. 
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4.4.7 Cell Morphology after siRNA-mediated HO-2 knockdown 
Cell phase photographs taken in the same field at x20 magnification demonstrate reduced 
cell confluence in HMOX2 siRNA-treated cells in 24-well plates after 48 hours.   
Figure 4.4.7 Cell Morphology after siRNA-mediated HO-2 knockdown 
Figure 4.4.7.1 Control cells at 48 hours x20 
 
Figure 4.4.7.2 NUC 10nM treated cells at 48 hours x20 
 
Figure 4.4.7.3 siRNA 10nM treated cells at 48 hours x20 
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4.4.8 Apoptosis studies: Annexin V and Propidium Iodide Staining 
Apoptosis experiments were performed in quadruplicate using AGS gastric carcinoma 
cells.  Representative results from one experiment are shown for each sample 
investigated together with the combined data for AGS gastric carcinoma cells (Figure 
4.4.8).   
Controls were set up to set gating parameters with unstained cells, ethanol-treated cells 
to permeabilise the cell membrane for PI staining and with staurosporine-treated cells to 
induce apoptosis for annexin V positive control staining (see Appendix V).   
All experiment cell samples were then stained with both annexin V and PI at 24, 48 and 72 
hours to evaluate a possible process of apoptosis.   
Cells treated with HMOX2 siRNA at 10 nM concentration demonstrated a significantly 
increased affinity for annexin V binding after 24 hours as compared to cells transfected 
with NUC 10 nM over the same time period (28.82% versus 0.01%, p = 0.004, Figures 
4.4.8a – b).  At 48 hours the siRNA treated cells become permeable to PI as membrane 
integrity is lost (51.87% versus 0.03%, p = 0.015).  At 72 hours there were significantly 
fewer viable cells (1.42% versus 99.12%, p = 0.001) and significantly increased late 
apoptotic or necrotic cells (96.97% versus 0.02%, p = 0.003) in samples transfected with 
HMOX2 siRNA compared to NUC.  The observed movement of siRNA-treated cells over 
time through annexin V positive and PI negative to annexin V and PI positive suggests a 
process of early apoptosis progressing to late apoptosis and eventual cell death. 
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Figure 4.4.8a: Annexin V binding and siRNA-mediated HO-2 knockdown 
  
 
 
Figure 4.4.8a: AGS cells were transfected with anti-HO-2 siRNA in 6-well plates and stained with Annexin V-
FITC and PI for flow cytometry analysis at 24, 48 and 72h.  The percentage of cells counted in the apoptosis 
phase after 24h was 0.01% (+/- 0.009) in NUC-transfected cells versus 28.82% (+/- 6.425) in cells with HO-2 
knockdown.  There is progression over time toward late apoptosis or necrosis at 72h in siRNA-treated cells.  
Values are represented as means ± SD; n = 4. 
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Figure 4.4.8b: Annexin V binding and siRNA-mediated HO-2 knockdown 
 
Figure 4.4.8b: AGS cells were transfected with anti-HO-2 siRNA in 6-well plates and stained with Annexin V-
FITC and PI for flow cytometry analysis at 24, 48 and 72h.  The rate of apoptosis (R6) and late apoptosis / 
necrosis (R4) is expressed relative to negative universal control (NUC) with values represented as means ± 
SD; n = 4.  There is a significant increase in the proportion of apoptotic cells counted at 24h progressing to 
late apoptosis or necrosis at 72h. 
Table 4.4.8: Summary of Annexin V binding and siRNA-mediated HO-2 knockdown 
  
REGION Apoptosis 
Cell sample Measurement R3 R4 R5 R6 p 
NUC 10nM 24h Cell Count 641 12 31026 3 
  
  % Histogram 2.02 0.04 97.93 0.01 
siRNA 10nM 24h Cell Count 96 667 19876 8351 
0.004 
  % Histogram 0.33 2.3 68.56 28.81 
NUC 10nM 48h Cell Count 506 10 34359 3 
  
  % Histogram 1.45 0.03 98.51 0.01 
siRNA 10nM 48h Cell Count 34 12521 10304 1281 
0.017 
  % Histogram 0.14 51.87 42.68 5.31 
NUC 10nM 72h Cell Count 152 4 25060 67 
  
  % Histogram 0.6 0.02 99.12 0.27 
siRNA 10nM 72h Cell Count 156 20230 297 179 
0.003* 
  % Histogram 0.75 96.97 1.42 0.86 
 
Table 4.4.8: Apoptosis studies in AGS cells treated with anti-HO-2 siRNA for 24 – 72h in 6-well plates.  
Summary data from 4 experiments is displayed (means, n = 4).  Quadrantic regions: R3 – necrotic cell debris; 
R4 – late apoptosis or necrosis; R5 – viable cells; R6 – apoptosis.  (*) = late apoptosis or necrosis. 
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4.4.9 Apoptosis studies: Cell Cycle Analysis 
Analysis of cellular DNA content using PI staining provided information about the position 
of analysed cells on the cell cycle.  Representative results and combined data from 2 
independent experiments are presented below.   
Forty-eight hours after transfection with NUC oligonucleotide at 10 nM the majority of 
cells were in the G0/G1 phase (55.08%) or the G2/M phase (27.65%) with 17.27% of cells 
measured outside the respective R4 and R5 regions representing cellular debris or late 
apoptotic cells.  There was no sub-G0 peak demonstrated with the NUC treated cell 
samples (Figure 4.4.9a).  The coefficient of variation (CV) of the G0/G1 peak was 6.85 and 
the ratio of G0/G1 to G2/M cells was 1.99, indicating good doublet discrimination. 
Cell samples transfected with HMOX2 siRNA duplex at 10 nM concentration for 24 hours 
demonstrated a reduction in the proportion of cells in G0/G1 phase (42.06%) or G2/M 
phase (10.62%) with 47.32% of cells measured outside the respective R4 and R5 regions.  
There was a sub-G0 population of cells visible (Figure 4.4.9b).  The CV of the G0/G1 peak 
was 3.53 and the ratio of G0/G1 to G2/M cells was 3.96 indicating reduced quality of DNA 
measurement and interference by increased cellular debris.  After 48 hours the siRNA-
treated sample showed a further reduction in the proportion of cells in G0/G1 phase 
(25.59%) or G2/M phase (16.47%) with an increase in cellular debris or apoptotic cells to 
57.94% (Figure 4.4.9c).  The CV of the G0/G1 peak was 4.17 and the ratio of G0/G1 to G2/M 
cells was 1.55 with a broad G0/G1 peak indicating reduced accuracy in DNA measurement.   
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Figure 4.4.9 Apoptosis studies: Cell Cycle Analysis 
Figure 4.4.9a: NUC 10nM treated cells 48 hours DNA analysis  
 
Region Cell Count % Histogram Median  CV Skew 
R4 3059 55.08 67 6.85 0.17 
R5 1536 27.65 126 3.7 -0.03 
Total 5555 100 75 6.85 0.32 
 
Figure 4.4.9b: siRNA 10nM treated cells 24 hours DNA analysis  
 
Region Cell Count % Histogram Median  CV Skew 
R4 895 42.06 51 3.53 0.01 
R5 226 10.62 104 0.83 0.08 
Total 2128 100 48 16.95 0.61 
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Figure 4.4.9c: siRNA 10nM treated cells 48 hours DNA analysis  
 
Region Cell Count % Histogram Median  CV Skew 
R4 889 25.59 60 4.17 0.13 
R5 572 16.47 105 0.92 0.24 
Total 3474 100 54 15.89 0.54 
 
Figure 4.4.9a – c: AGS cells were stained with PI and analysed using flow cytometry 24 and 48h after 
transfection for siRNA-mediated HO-2 knockdown.  A reduction of cells counted in the G0/G1 phase and the 
sub-G0 phase is observed with HO-2 knockdown.  Quality control parameters indicate reduced quality of 
DNA measurement and interference by increased cellular debris.  Values are the percentage of total cell 
count per sample and total cell counts represented as means; n = 3. 
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4.4.10 Apoptosis studies: Apo-BrdU labelling of DNA fragments 
Incorporation of brominated deoxyuridine triphosphate nucleotides into DNA strand 
breaks was measured by the Apo-BrdU assay technique to assess DNA fragmentation as a 
late hallmark of apoptosis in cell samples studied.  Positive and negative control cells 
provided with the Apo-BrdU assay kit were used to set the gating regions and reliably 
identify positive and negative-stained cells as described above.  The positive control 
sample cells demonstrated DNA fragmentation with increased FITC fluorescence 
compared to negative control cells (34.06% versus 1.03%, see Appendix VI).  
Representative results and combined data from triplicate experiments are displayed in 
Figure 4.4.10 and Table 4.4.10.  Cells treated with negative universal control 
oligonucleotide at 10 nM showed minimal FITC staining after 24 hours with 1.08% in the 
positive R8 region.  Cells transfected with HMOX2 siRNA at 10 nM concentration 
demonstrated a clear increase in fluorescence after 24 hours with 29.63% positive for 
FITC staining and a significant reduction in the proportion of non-apoptotic cells (p = 
0.047, Figure 4.4.10).  After 48 hours there is little evidence of DNA fragmentation in 
NUC-treated cells but a significant increase in FITC staining in HMOX2 siRNA-treated cells 
(2.47% versus 39.54%, p = 0.038) and a further reduction in the proportion of non-
apoptotic cells in samples treated with HO-2 knockdown.   
These results indicate that one of the hallmarks of apoptosis is detectable in AGS cell lines 
24 hours after siRNA-mediated knockdown of HO-2 mRNA and that this process 
progresses up to 48 hours after transfection.   
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Figure 4.4.10: Apoptosis Studies: Apo-BrdU labelling of DNA fragments 
   
   
 
Figure 4.4.10: ApoBrdU assay was performed on AGS cells 24 and 48h after transfection for HO-2 
knockdown.  DNA fragmentation is measured by increased fluorescence in the FITC channel (R8).  The rate 
of apoptosis is expressed as percentage of controls with values represented as means ± SD; n = 3; 
logarithmic scale. †p = 0.047, ‡p = 0.038, Independent Samples Kruskal-Wallis test 
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Table 4.4.10: Summary of ApoBrdU DNA fragmentation assays AGS cells 
  
REGION Apoptosis 
Cell sample Measurement R8 R9 p 
NUC 10nM 24h Cell Count 215 19622 
  
  % Histogram 1.08 98.72 
siRNA 10nM 24h Cell Count 5772 13598 
0.047 
  % Histogram 29.63 69.8 
NUC 10nM 48h Cell Count 542 21011 
  
  % Histogram 2.47 95.79 
siRNA 10nM 48h Cell Count 8254 11883 
0.038 
  % Histogram 39.54 56.92 
 
Table 4.4.10: Apoptosis studies with DNA fragmentation assay in AGS cells treated with anti-HO-2 siRNA for 
24 – 48h in 6-well plates.  Summary data from triplicate experiments is displayed (means, n = 3).  DNA 
fragmentation is measured by increased fluorescence in the FITC channel (R8) with no FITC binding in viable 
cells with intact DNA (R9).   
 
4.4.11 Apoptosis Studies: Caspase 3/7 activity assay 
The Apo-ONE Homogenous Caspase-3/7 assay (Promega) was performed 24 hours after 
transfection of AGS cells with HMOX2 siRNA at 10 nM concentration and appropriate 
controls.  Assay reagent was added to each well and fluorescence measured after 1h 
incubation, collecting data over 250 plate reading cycles to generate complete signal 
curves.  Evolution of the assay data over 180 minutes is shown in Figure 4.4.11a.   
Cell proliferation assay was performed concurrently in 96-well plates with an identical 
experiment design to provide cell numbers per well derived from MTT assay performed as 
described above.  The relative caspase activity per 1000 cells for experiment samples was 
obtained after normalisation to MTT assay.  Results demonstrate a statistically significant 
increase in fold caspase-3/7 induction 24 hours after siRNA-mediated HO-2 knockdown 
when compared to controls (p = 0.005, Figure 4.4.11b). 
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Figure 4.4.11 Apoptosis Studies: Caspase 3/7 activity assay 
Figure 4.4.11a: Caspase activity at 24 hours AGS cells 
 
Figure 4.4.11a: Evolution of kinetic absorbance data over 180 minutes during Apo-ONE® Caspase-3/7 assay.  
AGS cells were seeded into black 96-well plates and transfected with anti-HO-2 siRNA for 24h.   
Figure 4.4.11b: Relative caspase activity in AGS cells 
 
Figure 4.4.11b: Effect of HO-2 knockdown on caspase-3/7 activity.  AGS cells were seeded into 96-well 
plates and Apo-ONE® Caspase-3/7 assay performed 24h after transfection with anti-HO-2 siRNA.  Results 
demonstrate a significant increase in relative caspase-3/7 activity per 1000 cells with anti-HO-2 siRNA 10 
nM (p = 0.005).  Values are represented as means ± SD; n = 12.   
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4.5 Downstream Effectors of Heme Oxygenase Activity: Bilirubin 
4.5.1 Cell Proliferation Assay – Time course experiments 
Experiments to evaluate the effect of bilirubin on the proliferation of AGS cells produced 
consistent results.  There was no significant effect on cell proliferation as measured by 
MTT assay with 24 hours of treatment with bilirubin at various doses (p = 0.505, Figure 
4.5.1a).  However, extending cell exposure to bilirubin at doses of 10 µM and 20 µM 
produced a significant reduction in MTT assay after 48 hours (p = 0.001, Figure 4.5.1b) 
and at 72 hours (p = 0.002, Figure 4.5.1c).  These effects were reproducible even after 
replacement of bilirubin reagent medium with fresh serum-complete medium after 24 
hours.  Significant reductions in cell proliferation were observed at 48 hours after bilirubin 
treatment for 24 hours at 10 µM concentration (p = 0.02, Figure 4.5.1d) and at 72 hours 
after cells were exposed to bilirubin at 20 µM concentration for 24 hours (p = 0.001, 
Figure 4.5.1d). 
Cell count data demonstrate a similar trend with reductions in viable cell counts 72 hours 
after treatment with bilirubin at 10 and 20 µM that did not reach statistical significance 
(Figure 4.5.1e). 
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Figure 4.5.1 Cell Proliferation Assay – Time course experiments 
Figure 4.5.1a: Effect of Bilirubin on AGS cell growth at 24 hours 
 
Figure 4.5.1a: Cells were treated with bilirubin 0.1 – 30 µM for 24h in 24-well plates and cell viability 
assessed with MTT assay.  Results are expressed as a percentage of untreated control; values represented 
as means ± SEM; n = 12. Cell growth at 24h was not significantly affected by bilirubin treatment (p = 0.505).  
Figure 4.5.1b: Effect of Bilirubin on AGS cell growth at 48 hours 
 
Figure 4.5.1b: Cells were treated with bilirubin 0.1 – 30 µM for 48h in 24-well plates and cell viability 
assessed with MTT assay.  Results are expressed as a percentage of untreated control; values represented 
as means ± SEM; n = 12. Cell growth at 48h was significantly reduced by bilirubin treatment at doses of 10 
µM and 20 µM (p = 0.001).  
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Figure 4.5.1c: Effect of Bilirubin on AGS cell growth at 72 hours 
 
Figure 4.5.1c: Cells were treated with bilirubin 0.1 – 30 µM for 72h in 24-well plates and cell viability 
assessed with MTT assay.  Results are expressed as a percentage of untreated control; values represented 
as means ± SEM; n = 12. Cell growth at 72h was significantly reduced by bilirubin treatment at doses of 10 
µM and 20 µM (p = 0.002).  
Figure 4.5.1d: Effect of 24 hour Bilirubin exposure – time course data  
 
Figure 4.5.1d: Cells were treated with bilirubin 5, 10 and 20 µM for 24h in 24-well plates before 
replacement of bilirubin reagent medium with fresh serum-complete medium.  MTT assay was performed 
at 24, 48 and 72h.  Results are expressed as a percentage of untreated control; values represented as 
means ± SEM; n = 12. Cell growth at 48h was significantly reduced by bilirubin treatment at 10 µM (p = 0.02) 
and at 72h by bilirubin 20 µM (p = 0.001). 
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Figure 4.5.1e: Cell count AGS cells time course experiments 
 
p = 0.081 Independent Samples Kruskal-Wallis test 
Figure 4.5.1e: Cells were treated with bilirubin 5, 10 and 20 µM for 24h in 24-well plates before 
replacement of bilirubin reagent medium with fresh serum-complete medium.  Cell growth was assessed by 
cell counting using Trypan blue exclusion with reductions in viable cell counts demonstrated 72h after 
bilirubin treatment.  Values are represented as means ± SEM; n = 12. 
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4.5.2 Effect of Bilirubin after HO enzyme inhibition – MTT Assay 
Experiments were performed to investigate the impact of bilirubin treatment for 24 hours 
at a concentration of 5 µM and 10 µM on the reversal or prevention of effects mediated 
by heme oxygenase inhibition or gene knockdown in AGS cells. 
Results demonstrate a significant reduction in cell proliferation after treatment with zinc 
protoporphyrin 10 µM for 48 hours that was observed up to 72 hours.  These effects were 
not reversed or prevented by treatment with bilirubin at 5 or 10 µM concentrations for 
24 hours (Figure 4.5.2a). 
Similar findings were obtained from experiments with specific siRNA-mediated 
knockdown of the HO-2 gene.  Treatment with bilirubin at 5 and 10 µM concentrations for 
24 hours did not prevent significant reductions in cell proliferation observed at 72 hours 
after siRNA transfection (Figure 4.5.2b).   
Figure 4.5.2a: AGS cell proliferation with Zinc and Bilirubin – Time Course  
 
Figure 4.5.2a: Cells seeded into 24-well plates were treated with zinc 10 µM for 48h before replacement of 
reagent medium with fresh serum-complete medium ± bilirubin 5 and 10 µM.  MTT assay was performed at 
24, 48 and 72h.  Zinc effects on cell growth were not prevented by bilirubin treatment.  Values are 
represented as means ± SEM; n = 15.   
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Figure 4.5.2b: AGS cell proliferation after HO-2 knockdown – Time Course  
 
Figure 4.5.2b: Cells seeded into 24-well plates were transfected with anti-HO-2 siRNA and incubated for 48h 
prior to replacement of culture medium with fresh serum-complete medium ± bilirubin 5 and 10 µM.  MTT 
assay was performed at 24, 48 and 72h.  Significant reductions in cell growth at 72h (p = 0.008) were not 
prevented by bilirubin treatment.  Values are represented as means ± SEM; n = 15.   
 
4.5.3 siRNA-mediated HO-2 knockdown – PCR products 
Cells were seeded into 24-well plates and siRNA transfection protocol followed as 
described previously.  After 48h incubation culture medium was replaced with fresh 
serum-complete medium ± bilirubin 5 µM and RNA samples eluted after a further 24h. 
Agarose gel analysis of PCR products demonstrate a clear reduction in HMOX2 mRNA in 
samples eluted from cells after transfection with HMOX2 siRNA duplex 02 at 10 nM 
concentration.  The reduction in HMOX2 mRNA is not prevented by treatment with 
bilirubin at 5 µM concentration for 24 hours.  The HMOX2 siRNA duplex 03 does not 
appear to be effective in reducing HO-2 mRNA in these experiments.  Quality and quantity 
of eluted RNA from experiment samples is indicated by equal expression of GAPDH 
control RNA (Figure 4.5.3). 
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Figure 4.5.3: PCR products siRNA knockdown HMOX2 and GAPDH AGS cells 
 
Lanes 
siRNA duplex 02:  
1 = Control 2 = Vehicle  3 = Bilirubin 5uM   
4 = NUC 10nM  5 = siRNA 10nM  6 = siRNA 10nM + Bilirubin 5uM 24h 
siRNA duplex 03:  
7 = Control  8 = Vehicle 9 = Bilirubin 5uM  
10 = NUC 10nM 11 = siRNA 10nM 12 = siRNA 10nM + Bilirubin 5uM 24h 
Figure 4.5.3: RT-PCR products of RNA samples eluted 72h after anti-HO-2 siRNA transfection ± 24h bilirubin 
treatment.  Effective reduction of HO-2 mRNA is not prevented by treatment with bilirubin 5 µM.   
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4.5.4 Protein expression after siRNA HO-2 knockdown and Zinc PP treatment 
Western blot analyses of protein expression show a clear reduction in HO-2 protein 
expression in cells transfected with HMOX2 siRNA after 24, 48 and 72 hours.  HO-2 
protein expression is not significantly reduced by treatment with bilirubin alone at 5 µM 
concentration for 24 hours.  There is a reduction in control protein β-actin expression at 
48 hours that is not proportional to the reduction in HO-2 protein expression at the same 
time point and represents unequal protein loading onto the gel (western blots 4.5.4). 
Western Blots 4.5.4: Bilirubin and siRNA HO-2 knockdown in AGS cells 
AGS Bilirubin and siRNA mediated HO-2 knockdown  
 
 
 
 
 
 
Lanes: 
1 = Control 72h 2 = NUC 10nM 72h 3 = siRNA 10nM 24h  
4 = siRNA 10nM 24h + Bilirubin 5µM 24h 5 = siRNA 10nM 48h  
6 = siRNA 10nM 48h + Bilirubin 5µM 24h 7 = siRNA 10nM 72h  
8 = siRNA 10nM 72h + Bilirubin 5µM 24h 9 = Bilirubin 5µM 24h 
 
Figure 4.5.4: Protein expression in gastric cell lines after siRNA transfection with anti-HO-2 siRNA ± 24h 
treatment with bilirubin 5µM.  Cells were seeded into 6-well plates, protein lysates harvested at 24 – 72h 
and Western blotting performed as described.  Blots demonstrate effective knockdown of HO-2 protein that 
was not prevented by bilirubin treatment.  Expression of control β-actin demonstrates reduced protein 
loading at 48h.  M = marker, NUC = negative universal control  
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4.5.5 Apoptosis studies: Annexin V and Propidium Iodide Staining 
Apoptosis experiments were performed in triplicate using AGS gastric adenocarcinoma 
cells.  Representative results from one experiment are shown for each sample 
investigated together with combined data from 3 individual experiments.  Controls were 
set up with unstained cells, ethanol-treated cells and with staurosporine-treated cells for 
positive controls as described above.  All experiment cell samples were then stained with 
both annexin V and PI at 36 hours and 48 hours to evaluate potential apoptosis.   
Cells treated with bilirubin at 10 µM concentration demonstrated a significantly increased 
affinity for annexin V binding after 36 hours as compared to vehicle control cells over the 
same time period (19.72% versus 0.01%, p = 0.017, Figure 4.5.5 and Table 4.5.5).  At 48 
hours the bilirubin-treated cells become permeable to PI as membrane integrity is lost 
(32.86% versus 0.02%, p = 0.008).  At 48 hours there were significantly fewer viable cells 
(25.26% versus 97.68%, p = 0.024) and significantly increased late apoptotic or necrotic 
cells in samples treated with bilirubin as compared to vehicle-treated cells.  There is a 
demonstrable shift in the proportion of cells staining annexin V positive 36 hours after 
bilirubin exposure to staining both annexin V and PI after 48 hours (Figure 4.5.5).   
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Figure 4.5.5 Apoptosis studies: Annexin V and Propidium Iodide Staining 
  
  
Figure 4.5.5: AGS cells were treated with bilirubin 10 µM in 6-well plates and stained with Annexin V-FITC 
and PI for flow cytometry analysis at 36 and 48h.  The percentage of cells counted in the apoptosis phase 
(R6) after 24h was 0.01% (±0.01) in vehicle-treated cells versus 19.72% (±4.01) in cells treated with bilirubin 
10 µM with progression over time toward late apoptosis or necrosis at 48h.  Values represented as means ± 
SD; n = 3.   
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Table 4.5.5: Summary of Annexin V binding and Bilirubin 10 µM treatment 
  
REGION Apoptosis 
Cell sample Measurement R3 R4 R5 R6 p 
Vehicle 36h Cell Count 505 12 29556 3 
  
  % Histogram 1.68 0.04 98.27 0.01 
Bilirubin 36h Cell Count 29 92 24504 4399 
0.017 
  % Histogram 0.1 0.32 79.86 19.72 
Vehicle 48h Cell Count 595 7 28382 72 
  
  % Histogram 2.05 0.02 97.68 0.25 
Bilirubin 48h Cell Count 8066 9673 7436 4262 
0.024* 
  % Histogram 27.4 32.86 25.26 14.48 
 
 
Table 4.5.5: Apoptosis studies in AGS cells treated with bilirubin 10 µM in 6-well plates and stained with 
Annexin V-FITC and PI at 36 and 48h.  Summary data from triplicate experiments is displayed (means, n = 3).  
Quadrantic regions include: R3 – necrotic cell debris; R4 – late apoptosis or necrosis; R5 – viable cells; R6 – 
apoptosis.  (*) = late apoptosis or necrosis. 
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4.5.6 Apoptosis studies: Cell Cycle Analysis 
Cell cycle DNA analysis of vehicle control cells demonstrates the majority of cells were in 
the G0/G1 phase (54.34%) or the G2/M phase (22.26%) after 36 hours, with 23.4% of cells 
measured outside the respective R4 and R5 regions representing cellular debris or late 
apoptotic cells.  There was no sub-G0 peak seen with vehicle-treated cell samples at 36 
hours (Figure 4.5.6a).  The coefficient of variation (CV) of the G0/G1 peak was 5.56 and the 
ratio of G0/G1 to G2/M cells was 2.44, indicating good doublet discrimination. 
Cell samples treated with bilirubin at 10 µM concentration for 36 hours demonstrate a 
reduction in the proportion of cells in G0/G1 phase (38.46%) or G2/M phase (17.6%) with 
43.94% of cells measured outside the respective R4 and R5 regions.  There was a 
population of cells undergoing apoptosis visible in the sub-G0 region at 36 hours (Figure 
4.5.6b).  The CV of the G0/G1 peak was 5.65 and the ratio of G0/G1 to G2/M cells 2.19 
indicating good quality of DNA measurement and accurate doublet discrimination.   
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Figure 4.5.6 Apoptosis studies: Cell Cycle Analysis 
Figure 4.5.6a: Vehicle control cells 36 hours DNA analysis 01.05.2010 
 
Phase Region Cell Count % Histogram Median  CV Skew 
G0/G1 R4 1140 54.34 62 5.56 0.19 
G2/M R5 467 22.26 116 4.38 0.05 
 Total 2098 100 65 5.56 0.66 
Apoptosis  491 23.4    
 
Figure 4.5.6b: Bilirubin 10µM treated cells 36 hours DNA analysis 01.05.2010 
 
Phase Region Cell Count % Histogram Median  CV Skew 
G0/G1 R4 638 38.46 60 5.65 0.13 
G2/M R5 292 17.6 108 1.8 -0.01 
 Total 1659 100 64 5.65 0.6 
Apoptosis  729 43.94    
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4.5.7 Apoptosis studies: Apo-BrdU labelling of DNA fragments 
The Apo-BrdU assay was performed to measure DNA fragmentation and indicate a late 
hallmark of apoptosis in cell samples studied.  Positive and negative control cells provided 
with the Apo-BrdU assay kit were used to set the gating regions and identify positive and 
negative-stained cells as described above.  The positive control sample cells 
demonstrated DNA fragmentation with increased FITC fluorescence compared to 
negative control cells (35.81% versus 0.84%, Appendix VI).  There was no significant 
difference observed in FITC staining between cells treated with vehicle control for 36 
hours and untreated control cells (0.64% versus 1.6% respectively, Appendix VI).   
Cells treated with bilirubin 10 µM demonstrated a significant increase in DNA 
fragmentation with positive FITC staining and a significant reduction in the proportion of 
non-apoptotic cells when compared to vehicle control cells after 36 hours (34.7% versus 
0.64%, p = 0.047, Figure 4.5.7). 
After 48 hours there is little evidence of DNA fragmentation in vehicle-treated cells but a 
significant increase in FITC staining in bilirubin-treated cells (0.78% versus 86.63%, p = 
0.047).  There is an observed reduction in the proportion of non-apoptotic cells in 
populations treated with bilirubin compared to controls (12.49% versus 98.63%, p = 
0.104, Figure 4.5.7 and Table 4.5.7).  
These results indicate that one of the hallmarks of apoptosis is specifically detectable in 
AGS cell lines 36 hours after treatment with bilirubin 10 µM and that this process 
progresses up to 48 hours after bilirubin treatment.   
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Figure 4.5.7 Apoptosis Studies: Apo-BrdU labelling of DNA fragments 
 
  
Figure 4.5.7: ApoBrdU assay was performed on AGS cells 36 and 48h after treatment with bilirubin 10 µM in 
6-well plates.  DNA fragmentation is measured by increased fluorescence in the FITC channel (R8) with a 
significant increase at 36h in cells treated with bilirubin compared to vehicle controls (34.69% ±1.42 versus 
0.64% ±0.09, p = 0.047).  The proportion of cells with DNA fragmentation increases by 48h in cells treated 
with bilirubin as compared to those treated with vehicle control (86.63% ±2.46 versus 0.78% ±0.12, p = 
0.047).  Values are represented as means ± SD; n = 3.   
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Table 4.5.7: Summary of ApoBrdU DNA fragmentation assays AGS cells bilirubin treatment 
  
REGION Apoptosis 
Cell sample Measurement R8 R9 p 
Vehicle 36h Cell Count 137 21206 
  
  % Histogram 0.64 99.3 
Bilirubin 36h Cell Count 7130 13320 
0.047 
  % Histogram 34.69 64.81 
Vehicle 48h Cell Count 154 19478 
  
  % Histogram 0.78 98.63 
Bilirubin 48h Cell Count 18764 2705 
0.047 
  % Histogram 86.63 12.49 
 
 
Table 4.5.7: Apoptosis studies with DNA fragmentation assay in AGS cells treated with bilirubin 10 µM for 
36 – 48h in 6-well plates.  Summary data from triplicate experiments is displayed (means, n = 3).  DNA 
fragmentation is measured by increased fluorescence in the FITC channel (R8) with no FITC binding in viable 
cells with intact DNA (R9).   
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4.6 Downstream Effectors of Heme Oxygenase Activity: Carbon Monoxide 
4.6.1 MTT Cell Proliferation Assay – 24-hour experiments CORMS 
The influence of carbon monoxide on the proliferation of oesophagogastric cancer cells 
and their expression of heme oxygenase isoenzymes was investigated. 
Treatment for 24 hours with carbon monoxide-releasing molecules (CORM3) and their 
inactive controls (iCORM) produced consistent results with a specific effect on malignant 
cell lines.  For the normal squamous epithelial cell line HET-1A there was no significant 
effect on cell proliferation measured by MTT assay after 24-hour treatment with iCORM 
or CORM3 at doses of 10, 20, 40 and 60 µM (Figure 4.6.1a).  However the malignant 
adenocarcinoma cell lines behaved very differently after carbon monoxide exposure.  
Treatment with CORM3 for 24 hours caused a significant reduction in MTT assay in AGS 
cells compared to untreated control cells whereas treatment with equivalent doses of 
inactive iCORM had no significant effect (p < 0.0005 versus p = 0.458 respectively, Figure 
4.6.1b).  Cell proliferation in OE-33 cells was similarly reduced after 24 hour exposure to 
CORM3 but not iCORM as compared to untreated controls (p < 0.005 versus p = 0.41 
respectively, Figure 4.6.1c).   
4.6.2 MTT Cell Proliferation Assay – Time course experiments CORMS 
Extending cell proliferation experiments to 72 hours demonstrated persistent reductions 
in cell growth for malignant cells after CORM3 treatment.  There were no significant 
effects on MTT assay for HET-1A cells treated with CORM3 for either 24 hours (p = 0.346), 
48 hours (p = 0.712) or 72 hours (p = 0.979) as compared to equivalent treatment with 
iCORM controls (Figure 4.6.2a).  For malignant OE-33 cells there was a significant 
reduction in cell growth at each time point with CORM3 as compared to the same doses 
of iCORM (Figure 4.6.2b).  Proliferation of the gastric adenocarcinoma AGS cells as 
measured by MTT assay was significantly reduced 24, 48 and 72 hours after treatment 
with CORM3 at doses of 20 and 40 µM when compared to equivalent doses of iCORM.  
Treatment with iCORM at a higher dose of 60 µM caused a reduction in MTT assay at 48 
and 72 hours.  The effects of inactive iCORM treatment at 60 µM were not significantly 
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different to the observed effects of active CORM3 treatment at the same dose after 24 
and 48 hours (Figure 4.6.2c).   
4.6.3 MTT Cell Proliferation Assay – Growth curves CORMS 
Growth curves for the three cell lines investigated display the effects of CORM3 
treatment versus untreated controls in reducing malignant cell growth as compared to 
unaffected benign oesophageal epithelial cells.  There is no significant effect on the HET-
1A cells but marked effects on OE-33 cells at all doses and on AGS cells at doses of 40 and 
60 µM (Figures 4.6.3a – c). 
Figure 4.6.1 MTT Cell Proliferation Assay – 24-hour experiments CORMS 
Figure 4.6.1a: Effect of CORMS on HET-1A cell growth at 24 hours 
 
 
 
 
 
iCORM p = 0.325 all concentrations compared to control 
CORM3 p = 0.258 all concentrations compared to control 
Figure 4.6.1a: HET-1A cells were treated with CORMS 10 – 60 µM for 24h in 24-well plates and cell viability 
assessed with MTT assay.  Results are expressed as a percentage of untreated control; values represented 
as means ± SEM; n = 12. Growth of HET-1A cells was not significantly affected by 24h CORM treatment.   
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Figure 4.6.1b: Effect of CORMS on AGS cell growth at 24 hours 
 
iCORM p = 0.458 all concentrations compared to control 
CORM3 p < 0.0005 all concentrations compared to control 
Figure 4.6.1b: AGS cells were treated with CORMS 10 – 60 µM for 24h in 24-well plates and cell viability 
assessed with MTT assay.  Results are expressed as a percentage of untreated control; values represented 
as means ± SEM; n = 12.  Treatment with active CORM3 caused a significant reduction in AGS cell growth at 
24h.   
Figure 4.6.1c: Effect of CORMS on OE-33 cell growth at 24 hours 
 
iCORM p = 0.410 all concentrations compared to control 
CORM3 compared to control: †p < 0.005, ‡p = 0.032  
Figure 4.6.1c: OE-33 cells were treated with CORMS 10 – 60 µM for 24h in 24-well plates and cell viability 
assessed with MTT assay.  Results are expressed as a percentage of untreated control; values represented 
as means ± SEM; n = 12.  CORM3 caused a significant reduction in OE-33 cell growth at 24h.   
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Figure 4.6.2 MTT Cell Proliferation Assay – Time course experiments CORMS 
Figure 4.6.2a: Effect of CORMS on HET-1A cell growth time course 
 
 
Data 24 hours p = 0.346 Data 48 hours p = 0.712 Data 72 hours p = 0.979 
Figure 4.6.2a: HET-1A cells were seeded into 24-well plates and treated with CORMS 10 – 60 µM for 24 – 
72h with cell proliferation assessed by MTT assay.  Results are expressed as a percentage of untreated 
control; values represented as means ± SEM; n = 15. Growth of HET-1A cells was not significantly affected 
by extended CORM treatment. 
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Figure 4.6.2b: Effect of CORMS on OE-33 cell growth time course 
 
 
iCORM versus CORM3* 
[CORM] 24 hrs 48 hrs 72 hrs 
20 µM p = 0.003 p = 0.009 p = 0.004 
40 µM p < 0.0005 p = 0.001 p < 0.0005 
60 µM p = 0.011 p < 0.0005 p = 0.011 
*Independent Samples Kruskal-Wallis test 
 
Figure 4.6.2b: OE-33 cells were seeded into 24-well plates and treated with CORMS 10 – 60 µM for 24 – 72h 
with cell proliferation assessed by MTT assay.  Results are expressed as a percentage of untreated control; 
values represented as means ± SEM; n = 15.  CORM3 caused significant cell growth inhibition compared to 
inactive CORM treatment in OE-33 cells at concentrations of 20 – 60 µM at all time points studied.  
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Figure 4.6.2c: Effect of CORMS on AGS cell growth time course 
 
 
iCORM versus CORM3* 
[CORM] 24 hrs 48 hrs 72 hrs 
20 µM p < 0.0005 p = 0.02 p = 0.007 
40 µM p = 0.002 p = 0.001 p = 0.004 
60 µM p = NS p = NS p = 0.037 
*Independent Samples Kruskal-Wallis test; NS = not significant at level 0.05 
Figure 4.6.2c: AGS cells were seeded into 24-well plates and treated with CORMS 10 – 60 µM for 24 – 72h 
with cell proliferation assessed by MTT assay.  Results are expressed as a percentage of untreated control; 
values represented as means ± SEM; n = 15.  CORM3 caused significant cell growth inhibition compared to 
inactive CORM treatment in AGS cells at concentrations of 20 and 40 µM at all time points studied as 
shown.  Treatment with iCORM at a higher dose of 60 µM caused a reduction in MTT assay at 48 and 72h.   
 
  
0
20
40
60
80
100
Control 20 40 60
M
TT
 A
b
so
rb
an
ce
 %
 c
o
n
tr
o
l 
iCORM [uM] 
AGS time course iCORM 
24 hrs
48 hrs
72 hrs
0
20
40
60
80
100
Control 20 40 60
M
TT
 A
b
so
rb
an
ce
 %
 c
o
n
tr
o
l 
CORM 3 [uM] 
AGS time course CORM3 
24 hrs
48 hrs
72 hrs
321 
 
Figure 4.6.3 MTT Cell Proliferation Assay – CORM3 Growth Curves  
Figure 4.6.3a: HET-1A growth curves with CORM3 treatment  
 
Figure 4.6.3b: OE-33 growth curves with CORM3 treatment 
 
Figure 4.6.3a – b: Growth curves for HET-1A and OE-33 cell lines demonstrate the effects of CORM3 
treatment in reducing malignant cell proliferation as compared to unaffected benign oesophageal epithelial 
cells.  There is no significant effect on the HET-1A cells but marked effects on OE-33 cells at all doses at 24 – 
72h.   
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Figure 4.6.3c: AGS growth curves with CORM3 treatment 
 
Figure 4.6.3c: Growth curves for AGS cells demonstrate significant effects of CORM3 treatment on AGS cell 
proliferation at doses of 40 and 60 µM at 48 – 72h.   
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4.6.4 Protein expression after CORM and bilirubin treatment 
Western blot analyses of protein expression show no clear changes in constitutive HO-2 
protein expression after 24h treatment with inactive CORMs.  Up-regulation of inducible 
HO-1 protein occurs after 24 hours of treatment with active CORM3 at both 20 and 40 
µM but no visible HO-1 induction with equivalent inactive iCORM treatment (western 
blots 4.6.4.1).  Blots at 48 hours demonstrate induced expression of HO-1 protein after 
48h treatment with active CORM3 but not inactive CORM 20 – 60 µM.  There is a small 
reduction of HO-2 protein after 48h treatment with active CORM3 40 – 60 µM.   
There are no marked changes in HO-2 protein expression after 24 hours treatment with 
bilirubin at 10 µM and 20 µM concentration and no effect from treatment with vehicle 
control.  There is a slight reduction in HO-2 protein demonstrated after 48 hour treatment 
with bilirubin at 20 µM concentration.  Exposure of AGS cells to bilirubin at 10 or 20 µM 
doses for 24 – 48 hours did not cause induction of HO-1 isoform (western blots 4.6.4.2).   
Expression of control protein β-tubulin is unchanged across experimental samples 
analysed indicating adequate equal loading of lysate samples for gel electrophoresis. 
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←β-Tubulin 
 
 
 
Western Blots 4.6.4.1: CORMS and Bilirubin HO protein expression in AGS cells 
CORM and Bilirubin treatment after 24 hours AGS cells 
 
 
Lanes: 
1 = Control   2 = Vehicle  3 = Bilirubin 10 µM 4 = Bilirubin 20 µM 
5 = iCORM 20 µM 6 = iCORM 40 µM 5 = CORM3 20 µM 6 = CORM3 40 µM 
Figure 4.6.4.1: Protein expression in gastric cell lines after 24h treatment with bilirubin and CORMS.  Cells 
were seeded into 6-well plates, protein lysates harvested at 24h and Western blotting performed as 
described.  Blots demonstrate up-regulation of inducible HO-1 protein after 24h treatment with active 
CORM3 at both 20 and 40 µM but no visible HO-1 induction with equivalent inactive iCORM treatment.  HO 
protein expression was unaffected by bilirubin treatment at 24h.  Expression of β-tubulin is unchanged 
indicating equal loading of lysate samples for gel electrophoresis (M = marker).  
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Western Blots 4.6.4.2: CORMS and Bilirubin HO protein expression in AGS cells 
CORM and Bilirubin treatment after 48 hours AGS cells 
 
 
Lanes: 
1 = Vehicle  2 = iCORM 20 µM 3 = iCORM 40 µM 4 = iCORM 60 µM 
5 = Bilirubin 20 µM 6 = CORM3 20 µM 7 = CORM3 40 µM 8 = CORM3 60 µM 
Figure 4.6.4.2: Protein expression in gastric cell lines after 48h treatment with bilirubin and CORMS.  Cells 
were seeded into 6-well plates, protein lysates harvested at 48h and Western blotting performed as 
described.  Blots demonstrate induced expression of HO-1 protein after 48h treatment with active CORM3 
but not inactive CORM 20 – 60 µM.  There is possible reduction of HO-2 protein after 48h treatment with 
bilirubin 20 µM and active CORM3 40 – 60 µM.  Expression of β-tubulin indicates adequate loading of lysate 
samples for gel electrophoresis (M = marker).  
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4.6.5 Apoptosis studies with CORM treatment 
4.6.6 Apoptosis studies: Annexin V and Propidium Iodide Staining 
Apoptosis experiments were performed in triplicate using AGS gastric carcinoma cells.  
Representative results from one experiment are shown for each sample investigated 
together with combined data from 3 individual experiments.  Staining with Annexin V-
FITC identified cells with exposed phosphatidylserine translocated to the external cell 
membrane at the onset of apoptosis.  Propidium iodide (PI) staining identified necrotic 
and damaged cells with permeable plasma cell membranes with exclusion of PI by viable 
cells.   
Controls were set up with unstained cells, ethanol-treated cells and staurosporine-treated 
cells to induce apoptosis for annexin V positive control staining as described above.  
Experiment cell samples were treated with inactive iCORM or active CORM3 at 20 µM 
concentration and stained with both annexin V and PI at 24, 48 and 72 hours to evaluate 
potential apoptosis.   
Cells treated with active CORM3 molecule at 20 µM demonstrated a significantly 
increased affinity for annexin V binding after 24 hours as compared to those treated with 
equivalent inactive iCORM (33.57% versus 0.02%, p = 0.001, Figures 4.6.6a – b).  At 48 
hours a significantly higher proportion of CORM3-treated cells lost plasma membrane 
integrity and became permeable to PI as compared to iCORM-treated cells (54.3% versus 
0.02%, p = 0.028).  There was further progression of CORM3-treated cells with 
significantly fewer viable cells and significantly increased late apoptotic or necrotic cells 
measured at the 72-hour time point (Figures 4.6.6a – b and Table 4.6.6).  This observed 
movement of CORM3-treated cells over time through annexin V positive and PI negative 
to annexin V and PI positive suggests a process of early apoptosis progressing to late 
apoptosis and eventual necrosis. 
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Figure 4.6.6a Apoptosis studies: Annexin V and Propidium Iodide Staining 
   
  
 
Figure 4.6.6a: AGS cells were treated with CORMS 20 µM in 6-well plates and stained with Annexin V-FITC 
and PI for flow cytometry analysis at 24 – 72h.  The percentage of cells counted in the apoptosis phase (R6) 
after 24h was 0.02% (±0.03) in cells treated with inactive CORM 20 µM versus 33.57% (±5.1) in CORM3-
treated cells.  Active CORM3 treatment caused time-dependent progression toward late apoptosis or 
necrosis at 72h.  Values represented as means ± SD; n = 3.   
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Table 4.6.6 Summary of Annexin V binding and CORM treatment 
  
REGION Apoptosis 
Cell sample Measurement R3 R4 R5 R6 p 
iCORM 24 hrs Cell Count 738 17 27266 7 
  
  % Histogram 2.63 0.06 97.28 0.02 
CORM3 24 hrs Cell Count 18 174 19755 10080 
0.001 
  % Histogram 0.06 0.58 65.79 33.57 
iCORM 48 hrs Cell Count 703 9 37460 89 
  
  % Histogram 1.84 0.02 97.91 0.23 
CORM3 48 hrs Cell Count 58 15917 11689 1647 
0.028 
  % Histogram 0.2 54.3 39.88 5.62 
iCORM 72 hrs Cell Count 729 5 29812 61 
  
  % Histogram 2.38 0.02 97.4 0.2 
CORM3 72 hrs Cell Count 230 19149 786 373 
0.002* 
  % Histogram 1.12 93.24 3.83 1.82 
 
Table 4.6.6: Apoptosis studies in AGS cells treated with CORMS 20 µM and stained with Annexin V-FITC and 
PI at 24 – 72h.  Summary data from triplicate experiments is displayed (means, n = 3).  Quadrantic regions 
include: R3 – necrotic cell debris; R4 – late apoptosis or necrosis; R5 – viable cells; R6 – apoptosis.  (*) = late 
apoptosis or necrosis. 
Figure 4.6.6b Apoptosis studies: Annexin V and Propidium Iodide Staining 
 
Figure 4.6.6b: AGS cells were treated with CORMS 20 µM in 6-well plates and stained with Annexin V-FITC 
and PI at 24 – 72h.  The rate of apoptosis (R6) and late apoptosis / necrosis (R4) is expressed relative to 
inactive CORM controls with values represented as means ± SD; n = 3; logarithmic scale. 
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4.6.7 Apoptosis studies: Apo-BrdU labelling of DNA fragments  
Incorporation of bromodeoxyuridine triphosphate nucleotides into DNA strand breaks 
was measured by the Apo-BrdU assay to assess DNA fragmentation as one of the later 
hallmarks of apoptosis in mammalian cells.   
Positive and negative control cells provided with the Apo-BrdU assay kit were used to set 
the gating regions and validate data collection protocols to reliably identify positive and 
negative-stained cells.  Apoptotic cells are characterised by an increased FITC staining as 
the incorporated BrdU nucleotide sites are detected by FITC-labelled anti-BrdU antibody.  
The positive control sample cells demonstrated increased FITC fluorescence compared to 
negative control cells as described above (33.84% versus 0.82%, Appendix VI).  
Untreated experiment control cell samples demonstrated minimal FITC staining after 48 
hours with 0.82% in the positive R8 region (Appendix VI).  Cells treated with inactive 
iCORM had similarly little positive FITC staining at 48 hours (0.95%, Figure 4.6.7).  
Treatment with active CORM3 molecule caused a significant increase in fluorescence 
when compared to control cells over 48 hours indicating a significant increase in the 
detection of apoptotic cells (38.02% versus 0.95%, p = 0.011).  Exposure to carbon 
monoxide from active CORM3 produced a significant increase in the proportion of 
apoptotic cells and a significant decrease in the proportion of non-apoptotic cells 
measured by the Apo-BrdU assay as compared to both untreated cells and those treated 
with inactive iCORM (Figure 4.6.7 and Table 4.6.7).  These finding indicate that one of the 
hallmarks of apoptosis occurs in AGS cell lines after treatment with CORM3 at 20 µM 
concentration for 48 hours.   
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Figure 4.6.7 Apoptosis Studies: Apo-BrdU labelling of DNA fragments 
   
 
 
Figure 4.6.7: ApoBrdU assay was performed on AGS cells 48h after treatment with CORMS in 6-well plates.  
DNA fragmentation is measured by increased fluorescence in the FITC channel (R8) with a significant 
increase at 48h in cells treated with CORM3 compared to those treated with inactive iCORM (38.02% ±0.87 
versus 0.95% ±0.3, p = 0.011).  Values are represented as means ± SD; n = 3.   
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Table 4.6.7: Summary of ApoBrdU DNA fragmentation assays AGS cells CORM treatment 
  
REGION Apoptosis 
Cell sample Measurement R8 R9 p 
Control 48h Cell Count 169 19274 
  
  % Histogram 0.86 98.21 
iCORM 20µM 48h Cell Count 201 20684 
NS 
  % Histogram 0.95 97.83 
CORM3 20µM 48h Cell Count 7994 12679 
0.011 
  % Histogram 38.02 60.3 
 
Table 4.6.7: Apoptosis studies with DNA fragmentation assay in AGS cells treated with CORM3 and inactive 
iCORM at 20 µM concentration for 48h.  Summary data from triplicate experiments is displayed (means, n = 
3).  DNA fragmentation is measured by increased fluorescence in the FITC channel (R8) with no FITC binding 
in viable cells with intact DNA (R9).  There were no significant differences observed between control cells 
and iCORM-treated cells but significantly increased apoptosis and a reduction in viable cells associated with 
active CORM3 treatment.   
4.6.8 Apoptosis Studies: Mitochondrial staining using JC-1 reagent 
Activation of the mitochondrial permeability transition pore is an important step in the 
induction of apoptosis causing a loss of mitochondrial membrane potential (Δψm) that can 
be measured using the JC-1 assay.  The cationic JC-1 dye accumulates in the mitochondrial 
matrix of healthy cells and forms aggregates that emit red fluorescence.  When the 
mitochondrial membrane potential collapses in apoptotic cells the JC-1 monomers remain 
in the cell cytoplasm and emit green as opposed to red fluorescence.   
AGS cells treated with active CORM3 20 µM for 48 hours demonstrated a significant 
increase in green fluorescence as compared to iCORM-treated control cells after both 
samples were labelled with JC-1 (43.35% versus 8.19%, p = 0.031, Figure 4.6.8).  
Treatment with CORM3 for 48 hours produced a significant loss of red fluorescence after 
JC-1 labelling compared to equivalent treatment with iCORM (32.7% versus 78.7%, p = 
0.05, Figure 4.6.8).  These results indicate the induction of apoptosis in a significantly 
higher proportion of cells treated with active CORM3 for 48 hours as compared to cells 
treated with inactive iCORM.   
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Figure 4.6.8 Apoptosis Studies: Mitochondrial staining using JC-1 reagent 
Figure 4.6.8: CORM-treated cells 48 hours JC-1 labelled 
 
Region Cell Count % Histogram Median X Median Y 
R1 3612 78.69 619.67 536.31 
R3 376 8.19 1027.46 76.27 
Total 4590 100 642.46 464.16 
 
 
Region Cell Count % Histogram Median X Median Y 
R1 10587 32.71 576.48 498.93 
R3 14033 43.35 251.19 47.69 
Total 32368 100 387.47 70.95 
 
Figure 4.6.8: JC-1 labelling of cell samples treated with CORMS for 48h in 6-well plates.  There is a significant 
increase in the proportion of cells counted with a lost Δψm (R3) in cells treated with active CORM3 as 
compared to those treated with inactive iCORM (43.4% ±2.46 versus 8.2% ±1.15,  p = 0.031).   
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4.6.9 Apoptosis Studies: Caspase 3/7 activity assay 
The Apo-ONE Homogenous Caspase-3/7 assay (Promega) was performed after 48 hours 
of treatment with CORMs at 20 µM and bilirubin at 20 µM concentration.  Evolution of 
the assay data over 60 minutes is shown in Figure 4.6.9a.  Cell proliferation assay was 
performed concurrently in 96-well plates with an identical experiment design to provide 
cell numbers per well derived from MTT assay performed as described above.  The 
relative caspase activity per 1000 cells for experiment samples was obtained after 
normalisation to untreated control cells. 
Results demonstrate a significant increase in fold caspase-3/7 induction after 48 hours 
exposure to active CORM3 as compared to inactive iCORM (p < 0.05, Figure 4.6.9b).  
Treatment with bilirubin produced a significant increase in caspase-3/7 activity after 48 
hours as compared to vehicle control (p < 0.05, Figure 4.6.9b).  These findings support the 
notion that the observed cell proliferation effects of both bilirubin and carbon monoxide 
are mediated by a process of apoptosis.   
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Figure 4.6.9 Apoptosis Studies: Caspase 3/7 activity assay 
Figure 4.6.9a: Caspase activity at 48 hours in AGS cells 
 
Figure 4.6.9a: Evolution of kinetic absorbance data over 1h Apo-ONE® Caspase-3/7 assay.  AGS cells were 
seeded into black 96-well plates and treated with bilirubin, inactive iCORM and active CORM3 all at 20 µM 
concentration.   
Figure 4.6.9b: Relative caspase activity in AGS cells 
 
Figure 4.6.9b: Effect of HO downstream effectors on caspase-3/7 activity.  AGS cells were seeded into 96-
well plates and Apo-ONE® Caspase-3/7 assay performed 48h after addition of reagents.  Results 
demonstrate a significant increase in relative caspase-3/7 activity per 1000 cells with bilirubin 20 µM and 
CORM3 20 µM after 48h (p < 0.05).  Values are represented as means ± SD; n = 12.   
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4.6.10 Heme Oxygenase Enzyme Activity Assay 
Cellular HO activity was measured by performing a specific colorimetric assay as 
described above.  The results demonstrate an increase in total HO enzyme activity after 
treatment with hemin 40 µM for 24 and 48 hours consistent with up regulation of HO-1 
protein.   
A decrease in total HO enzyme activity was observed after treatment with CORM3 
molecule for 24 and 48 hours as compared to untreated control cells and cells treated 
with inactive iCORM.  There was no difference between iCORM-treated cells and 
untreated controls.  Although there was an observed reduction in measured HO activity 
after CORM3 treatment the data did not reach statistical significance (p = 0.07, Figures 
4.6.10a – b).   
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Figure 4.6.10 Heme Oxygenase Enzyme Activity Assay 
Figure 4.6.10a: Effect of CORMS on HO enzyme activity in AGS cells 
 
Figure 4.6.10b: Effect of CORMS on HO enzyme activity logarithmic scale 
 
Figure 4.6.10a – b: Effect of CORM treatment on total HO enzyme activity.  AGS cells were seeded into 175 
cm
3
 flasks and lysates harvested after 24 and 48h treatment with CORMS.  Specific colorimetric assay 
demonstrated a significant increase in HO activity with HO-1 induction associated with hemin controls.  A 
reduction in total HO enzyme activity was observed after CORM3 treatment that did not reach statistical 
significance (p = 0.07).  HO activity is expressed as pmoles per bilirubin formed per mg of protein pellet per 
60 min, values represented as means ± SD; n = 3.   
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CHAPTER 5: DISCUSSION 
5.1 Oxidative stress and the role of heme oxygenase 
5.1.1 Oxidative stress and cell proliferation 
Gastric cell lines exposed to oxidative stress as simulated by H2O2 treatment show no 
significant reduction in cell proliferation after 24 hours.  There was a reduction in MTT 
activity at higher H2O2 concentrations that was not statistically significant.  By contrast, 
treating oesophageal OE-33 cells with the same reagent caused an increase in cell growth, 
while there were variable non-significant effects in the epithelial HET-1A cells.  The 
findings suggest that malignant gastric cells are more susceptible than malignant 
oesophageal cells to inhibition of cell growth induced by oxidative stress.  Growth 
inhibition may be mediated by an alternative pathway to the heme oxygenase system as 
the observed effects of experimental oxidative stress occurred independently of HO-1 
protein expression.  Oesophageal adenocarcinoma cells in culture appeared to be 
protected from adverse proliferation effects caused by oxidative stress simulated by H2O2, 
indeed the malignant cell line thrived under these conditions.  The consistent levels of 
HO-1 and HO-2 expression do not indicate a protective role of HO in response to H2O2 
exposure.  Up-regulation of inducible HO-1 protein did not occur in response to 
experimental oxidative stress in any of the cell lines studied.  This finding challenges the 
expectation that HO-1 enzyme plays an important role in the oxidative stress response for 
the cells investigated.  However the lack of significant proliferation effects in AGS and OE-
33 cells treated with H2O2 suggest that a cytoprotective response is not required, 
indicating that the cell biology specific to these malignant cells has adapted and has 
become robust enough to maintain healthy growth in conditions of oxidative stress. 
Proliferation of AGS and HGC-27 cells was significantly affected by antioxidant treatment 
with N-acetylcysteine with morphological changes observed after 24 hour NAC treatment 
at 10 mM concentration.  Consistent effects of significantly reduced cell proliferation 
were seen in prolonged NAC treatment of AGS cells with extended growth curves to 
seven days.   
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Treatment with NAC over 24 – 72 hours produced a marked contrast in growth effects in 
benign HET-1A cells compared to malignant OE-33 epithelial cells.  The malignant cells 
showed statistically significant reductions in cell growth over 24 – 72 hours with NAC 
doses of 10 mM.  By contrast growth of treated HET-1A cells was similar to untreated 
control cells except for an observed reduction in MTT assay after 72 hours of exposure to 
NAC at 20 mM concentration.  Consistent effects of a significant reduction in OE-33 cell 
proliferation were seen with NAC treatment at all concentrations beyond 72 hours.  The 
combination of 10mM NAC with cisplatin and 5-FU enabled a significant reduction in the 
IC10 and IC50 doses for both reagents (0.1 μgmL
-1 and 2.875 μgmL-1 respectively for 
cisplatin and 0.07 μgmL-1 and 6.5 μgmL-1 respectively for 5-FU, p < 0.05).   
This is an important cancer-specific finding with anti-oxidant treatment causing significant 
effects on the growth of malignant cells without adverse effects in benign cells.  This 
finding is in keeping with similar findings from a published study of NAC treatment in 
human signet ring gastric carcinoma cells886.  These results provide further evidence to 
support the idea that malignant cells thrive under conditions of oxidative stress as the 
anti-oxidant treatment proves detrimental to cell proliferation.  Furthermore a link 
between chronic inflammation, oxidative stress and cancer can be demonstrated to be 
relevant for oesophagogastric cancer under experimental conditions: the oesophageal 
adenocarcinoma cell lines were susceptible to antioxidant treatment but not simulated 
conditions of oxidative stress.  As discussed previously there is evidence for genomic 
instability associated with persistent acid reflux-induced inflammation in patients with 
Barrett’s that predisposes to the progression to invasive carcinoma490 887.  These 
experiments support this concept by demonstrating that the transformed malignant 
oesophageal adenocarcinoma cells are resistant to oxidative stress and susceptible to 
antioxidant treatment472 480.   
5.1.2 Oxidative stress and heme oxygenase protein expression 
Western blot analysis of protein expression demonstrate that under basal conditions, all 
of the investigated cell lines express the constitutive heme oxygenase isoform HO-2 but 
do not express the inducible HO-1 isoform.  Up-regulation of HO-1 protein was not caused 
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by treatment with either hydrogen peroxide or N-acetylcysteine in any of the cell lines 
investigated. 
NAC and H2O2 treatment did not influence constitutive expression of HO-2 protein in AGS 
or HGC-27 gastric cell lines.  There was comparable expression of constitutive HO-2 
protein in both OE-33 and HET-1A cell lines under basal and experimental conditions but 
an apparent reduction in HO-2 protein in OE-33 cells treated with NAC at 10 mM 
concentration.  However this finding may represent a relative lack of protein for this 
lysate sample as there is a reduction in the corresponding expression of control β-tubulin.  
The proportional reduced expression in corresponding bands represents a relative lack of 
protein for this lysate sample and unequal loading onto the gel for electrophoresis.    
Results suggest that oxidative stress may have an important role in the growth of gastric 
and oesophageal epithelial cancer cells.  This effect could be cancer cell-specific and 
related to a malignant cell phenotype as the effects were not observed in normal 
oesophageal epithelial cells.  Further experiments were designed to define the cellular 
proliferation response to antioxidant treatment. 
5.1.3 The effect of NAC on heme oxygenase enzyme activity 
Assays of total heme oxygenase enzyme activity after NAC treatment demonstrated very 
interesting results with a statistically significant reduction in total HO activity measured in 
AGS cells treated with NAC at 10 mM concentration for 24 and 48 hours.  This means that 
despite no demonstrable reduction in HO-2 protein expression there is a clear reduction 
in measurable total HO enzyme activity.  This suggests that HO-2 enzyme activity is 
important for maintaining exponential cell proliferation in malignant AGS cells.   
5.1.4 The effect of NAC on cellular apoptosis 
Cell populations treated with NAC at 10 mM concentration demonstrated significantly 
increased evidence of early apoptosis after 24 hours when compared to untreated control 
cells over the same time period.  At 48 hours there were significantly fewer viable cells 
and significantly increased late apoptotic or necrotic cells in samples treated with NAC.  
The observed movement of treated cells over time suggests a process of early apoptosis 
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progressing to late apoptosis and eventual cell death as a cancer-specific cellular 
response to NAC treatment.   
Cell cycle studies demonstrated cells undergoing a process of apoptosis with a sub-G0 
peak population of cells visible after 24-hour treatment with NAC at 5 and 10 mM 
concentrations.  There was a significant increase in the proportion of cells measured in 
the G2/M phase to indicate G2/M cell cycle arrest after 24h treatment with NAC 10 mM (p 
= 0.02).  The measured coefficient of variation of the G0/G1 peak and the ratio of G0/G1 to 
G2/M cells indicated good quality doublet discrimination and accuracy of DNA 
measurement.   
Studies show significantly increased DNA fragmentation in cells treated with NAC at 10 
mM concentration for 24 hours.  Extended exposure to NAC at 10 mM concentration for 
48 hours caused a further significant increase in DNA fragmentation compared to 
untreated cells over the same time period.  The findings indicate that one of the 
hallmarks of apoptosis occurs in AGS cell lines after treatment with NAC at 10 mM 
concentration for 24 and 48 hours.  Caspase-3/7 assays demonstrate a significant increase 
in relative caspase activity after 24 hours in cells treated with NAC 10 mM compared to 
untreated control cells and provide additional supporting evidence for a process of 
apoptosis.   
5.1.5 Oxidative stress and the role of heme oxygenase: Conclusions 
Experiments performed to investigate oxidative stress provide evidence of a cancer-
specific effect of antioxidant NAC treatment in reducing the proliferation of 
oesophagogastric cancer cells.  This effect is independent of HO-1 induction and is 
associated with a reduction in HO-2 protein activity.  Studies of apoptosis provide 
evidence for an increased induction and maintenance of the apoptotic process in cells 
treated with N-acetylcysteine.   
There was no significant effect on the proliferation of gastric and oesophageal 
adenocarcinoma cells with oxidative stress simulated by H2O2 exposure.  There were 
variable non-significant effects observed with normal squamous epithelial cells.  There 
was no up-regulation of HO-1 protein in response to H2O2 exposure in any of the cell lines 
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investigated indicating that HO-1 does not have a protective role in response to oxidative 
stress in these cells.  Collectively the experiment findings suggest that the malignant cells 
studied have adapted to thrive under conditions of oxidative stress and indeed 
demonstrate adverse responses with antioxidant treatment.  Consistent cancer-specific 
effects of significantly reduced cell proliferation were seen with NAC treatments that 
were independent of HO-1 up-regulation.  Hallmark features of apoptosis including 
increased relative caspase-3/7 activity and DNA fragmentation are demonstrable after 
NAC treatment in malignant adenocarcinoma cells.  NAC administration caused G2/M cell 
cycle arrest in cancer cell lines studied.   
There is no associated induction of HO-1 protein so these events are mediated by an 
alternative pathway.  Induction of HO-1 enzyme has been demonstrated to occur as a 
response to various conditions and stimuli including oxidative stress, endotoxin, 
inflammatory cytokines and hyperthermia.  Increased enzyme activity is a positive cellular 
response to stressful conditions and has been demonstrated to confer cytoprotection 
through anti-oxidative, anti-apoptotic and anti-inflammatory actions326 888-890.  
Constitutive over-expression of HO-1 enzyme is not a characteristic feature of the 
oesophagogastric cancer cells studied.   
Inducible HO-1 expression is relatively low in most tissues and it has functional 
significance only in response to stressful stimuli.  Constitutive HO-2 is believed to be 
responsible for basal HO activity contributing to cell homeostasis and normal cellular 
function both in maintaining intracellular heme levels and in the tonic production of 
biliverdin and CO that contribute to regulation of signalling pathways. 
A salient finding from these studies is a clear reduction in measurable total HO enzyme 
activity after antioxidant treatment despite no demonstrable reduction in HO-2 protein 
expression or HO-1 protein induction.  These results indicate that HO-2 enzyme activity is 
important for maintaining exponential cell proliferation in malignant AGS cells. 
The anti-cancer effects of N-acetyl cysteine in vitro have been demonstrated by two 
recent studies.  Treatment with NAC was able to selectively inhibit the growth of human 
signet ring gastric cancer cells in a time-dependent and dose-dependent manner by 
inducing apoptosis and DNA synthesis arrest within 48 hours of treatment886.  More 
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recent studies on a hepatocellular carcinoma cell line demonstrate the ability of NAC to 
reduce cell viability and to enhance the cytotoxic effect of the chemotherapeutic agent 
Interferon alpha891.   
The implications of these published studies and the findings of experiments performed 
for this thesis relate to the potential of N-acetyl cysteine as a useful adjunct for the 
treatment of oesophagogastric cancer. 
Results from oxidative stress experiments provide further evidence to support the idea 
that malignant cells thrive under conditions of oxidative stress with anti-oxidant 
treatment detrimental to cell proliferation.  The role of reactive oxygen species (ROS) and 
redox regulation in the promotion and survival of cancer cells is only partially understood 
with both pro-tumourigenic and anti-cancer effects described.  Production of reactive 
oxygen species have been demonstrated to enhance carcinogenesis in fibroblasts and 
promote survival of epithelial tumour cells892-894.  Conversely, an increase in ROS levels 
has been shown to lower the threshold for cellular apoptosis and increase the cytotoxicity 
of therapeutic agents895 896.  Chemosensitivity toward platinum-based drugs may be 
enhanced by co-treatment with agents that increase ROS production897 898.  A recent 
paper describes how the relative levels of ROS in malignant and benign cells can be 
exploited to design therapies that can preferentially target the increased stress response 
in cancer cells899.   
N-acetylcysteine (NAC) is a precursor of L-cysteine that can enter the glutathione 
synthesis pathway to augment physiological glutathione reserves.  NAC binds directly to 
toxic metabolites together with glutathione and is a scavenger of free radicals via 
interaction of reactive thiol groups with ROS900.  The antioxidant activity of NAC has been 
investigated in clinical studies to prevent contrast-induced nephropathy with variable 
success901.   
NAC may also directly bind to and inactivate platinum-based chemotherapy agents 
including cisplatin902.  NAC is able to form a complex with platinum that modulates the 
metabolism of cisplatin and enables a reduction in cisplatin adverse side effects with 
concomitant administration of NAC903.  Published studies have demonstrated that NAC 
reduces bone marrow toxicity and prevents ototoxicity associated with chemotherapy in 
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murine models as well as reducing the cytotoxicity of alkylating chemotherapeutic agents 
in vitro904-907.  The toxicity of chemotherapeutic agents has been shown to be prevented 
or reduced by antioxidant treatment without compromising their anti-cancer effects906 
908.   
Cellular resistance to cisplatin is often associated with elevated levels of intracellular 
glutathione.  The role of glutathione activity and metabolism in the mechanism of cellular 
resistance to cisplatin is a subject of some debate909 910.   
Studies for this thesis demonstrate consistent effects of a significant cancer-specific 
reduction in OE-33 cell proliferation with NAC antioxidant treatment without adverse 
effects in benign cells.  The combination of 10mM NAC with cisplatin and 5-FU enabled a 
significant reduction in the IC10 and IC50 doses for both reagents (0.1 μgmL
-1 and 2.875 
μgmL-1 respectively for cisplatin and 0.07 μgmL-1 and 6.5 μgmL-1 respectively for 5-FU, p < 
0.05).  These findings appear to be somewhat at odds with existing studies of NAC and 
cisplatin activity.  Recent published data describe a reduction in cisplatin-induced 
apoptosis in vitro if NAC was present in the culture medium.  Washout of NAC prior to 
cisplatin addition prevented the NAC chemoprotective effects, suggesting a direct effect 
on cisplatin by NAC binding as opposed to a downstream metabolite or increased 
glutathione.  Concurrent administration of NAC prevented apoptosis and impaired 
cisplatin cytotoxicity but these effects were diminished if NAC was added more than 2 
hours after cisplatin treatment and minimal by 8 hours post-chemotherapy treatment911.  
Timing appears to be a crucial factor and the effects of adding NAC after the 
chemotherapy agents may well contribute to the continued activity of cisplatin observed 
in our thesis studies.  Irreversible protein changes may already be set in motion within a 
short space of time after cisplatin administration.  Cisplatin is able to rapidly enter target 
cells and interact irreversibly with nuclear DNA911.   
Furthermore, an important finding is the selective inhibition of heme oxygenase 
enzymatic activity demonstrated with NAC administration.  The reduction in HO activity 
may be solely responsible for the cell proliferation effects observed without influence 
from cisplatin activity.  In addition there may be effects on downstream cell signalling 
pathways mediated by HO activity that demand further investigation.  It has been 
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suggested that NAC chemoprotection observed in vitro may be dependent upon p53 
tumour suppressor activity911, and this requires clarification in the oesophagogastric 
cancer cell model studied here.   
Resistance to cisplatin has been shown to be associated with high levels of basal p38 
mitogen activated protein kinase (MAPK) activity in cancer cell line experiments912.  
Recent studies attempting to clarify the influence of p38 MAPK signalling on cisplatin 
sensitivity or resistance demonstrate an enhanced sensitivity to cisplatin chemotherapy 
associated with p38 MAPK inhibition in human cancer cells913.  Investigators found that 
inhibition of p38 MAPK resulted in upregulation of ROS and activation of the JNK pathway 
to increase the sensitivity of malignant cells to cisplatin-induced apoptosis.  Published 
evidence suggests that NAC causes inhibition of p38 MAPK signalling.  NAC interacts with 
cell signalling molecules to inhibit the activation of p38 MAP kinase and JNK pathways 
and reduce nuclear factor κB transcription factor activities914 915.  This suggests a potential 
mechanism by which NAC treatment is able to maintain or enhance cisplatin activity.   
The mechanisms that control the effect of NAC on the anticancer activity of agents such 
as cisplatin have not been fully established.  The interaction between NAC and p53, p21 
and apoptotic signalling are incompletely understood.  The additional influence of HO 
activity needs further investigation with particular interest in p38 MAPK signalling 
pathways.  Further studies are required in animal models to investigate whether the 
cancer-specific anti-proliferative effects of NAC described here can be reproduced in vivo 
and whether NAC treatment can enable administration of lower doses of 
chemotherapeutic agents whilst maintaining their anti-tumour activity.  NAC will only be a 
useful adjunct for the treatment of oesophagogastric cancer if a rational delivery regimen 
can be determined to maximise chemoprotective effects while minimising any impact on 
chemotherapeutic efficacy.  The timing and route of NAC administration may provide a 
mechanism by which the toxic side effect profile of cisplatin is reduced without any 
therapeutic compromise in vivo.   
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5.3 Pharmacological modulation of heme oxygenase activity 
5.3.1 The effect of pharmacological induction of HO by Hemin 
Treating AGS cells with increasing concentrations of hemin for 24 – 72 hours produced no 
significant difference in cell proliferation measured by MTT assay at any time point 
observed.  Identical experiments in HGC-27 cells caused significant reductions in MTT 
assay only after 24 or 48 hour treatment with higher doses of hemin at 100 and 150 µM.   
Experiments with oesophageal cell lines demonstrated no significant changes in OE-33 
cell growth at any time point but significantly reduced HET-1A proliferation at hemin 
concentrations of 50 µM and above after 24 hours and at 100 µM over 24 – 72 hours.  
These findings reflect the relative toxicity of hemin at higher concentrations.  Comparing 
the normal oesophageal squamous cells to the adenocarcinoma cells suggests an 
increased resistance to the effects of hemin on cell proliferation in malignant cell lines.   
5.3.2 The effect of competitive inhibition of HO by Zinc Protoporphyrin 
Treatment of AGS and HGC-27 gastric adenocarcinoma cells with zinc protoporphyrin at 
concentrations of 10, 20 and 40 µM caused significant reductions in cell proliferation at 
24, 48 and 72 hours as measured by MTT assay.   
Experiments in oesophageal cell lines demonstrate a differential response to zinc 
treatment in cell proliferation between malignant and benign cells.  MTT assay was 
significantly reduced for OE-33 cells after 24 hours of treatment with zinc at 
concentrations of 10, 20 and 40 µM whereas significant reductions in MTT assay for HET-
1A cells were only seen at a zinc concentration of 40 µM.  These effects were replicated in 
time-course experiments with a significant reduction in OE-33 cell growth at all observed 
time points with all experimental concentrations of zinc.  Cell proliferation measured by 
MTT assay was significantly reduced in HET-1A cells after 24 – 72 hours only with a zinc 
concentration of 40 µM.   
Extending the growth curve experiments to 7 days showed consistent effects of 
significantly reduced cell proliferation in AGS and OE-33 cells with zinc treatment at 20 
and 40 µM at all time points beyond 24 hours.   
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5.3.3 The effect of Hemin and Zinc Protoporphyrin on HO protein expression 
Expression of constitutive HO-2 protein was equal in all cell lines and essentially 
unchanged by treatment with either hemin or zinc protoporphyrin.  Exposure of OE-33 
cells to zinc protoporphyrin at 20 and 40µM concentration caused a mild decrease in HO-
2 isoform expression after 24 hours.  There was a demonstrable up-regulation of 
inducible HO-1 protein in response to both hemin treatment and zinc treatment in all cell 
lines investigated.  In OE-33 cells HO-1 protein expression was less marked and only in 
response to the highest dose of zinc protoporphyrin at 100 µM.   
Western blot analysis demonstrates absent basal expression of HO-1 protein in the entire 
panel of cell lines investigated with readily inducible HO-1 expression in response to 
pharmacological agents.  In an attempt to gain a broader picture of HO-1 expression in 
oesophagogastric cancer a further study was performed to assess HO-1 expression in ex-
vivo samples.  This study was part of a separate study comparing the histopathological 
expression of various cell proteins before neoadjuvant chemotherapy to the pathological 
response after chemotherapy according to Mandard criteria916.  Samples were identified 
from patients with oesophagogastric cancer who had undergone neoadjuvant 
chemotherapy as part of their treatment pathway.  A total of 72 samples taken at index 
diagnostic endoscopy were retrieved from paraffin-embedded blocks.  The tissue samples 
were then cut and slides prepared for a panel of immunohistochemistry including staining 
for HO-1.  Samples from human spleen were used as a positive control to ensure an 
adequate staining protocol for HO-1 protein.  Review of the slides with an independent 
consultant revealed that none of the retrieved ex-vivo samples stained positive for HO-1 
protein.  However, review of the cut slides also highlighted inconsistencies with the 
quality of prepared tissue.  In some of the slides there was no malignant tissue visible.  
Due to these inconsistencies the findings of the study were deemed to be highly 
questionable and essentially unreliable and were therefore discarded.  The inherent 
difficulties of the study relate to the robust retrieval and preparation of retrospectively 
identified tissue samples from paraffin blocks.  A relatively small amount of tissue is 
routinely taken at index endoscopy for histological diagnosis and the amount of tissue 
available in paraffin blocks for future studies is limited.  After processing the tissue for the 
panel study of cellular proteins any tissue left over proved to be inadequate for any 
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meaningful subsequent analysis of HO-1 protein expression.  Therefore this study is 
planned to be repeated with prospective collection, preparation and staining of 
oesophagogastric cancer tissue samples.   
5.3.4 Heme Oxygenase Enzyme Activity Assay 
Enzyme assay results demonstrate an increase in total HO enzyme activity after treatment 
with hemin consistent with up-regulation of HO-1 protein.  There was a significant 
decrease in total HO enzyme activity after treatment with zinc 40 µM compared to 
untreated control cells despite expression of inducible HO-1 protein.  These findings are 
consistent with competitive inhibition of heme oxygenase enzyme by zinc 
protoporphyrin.   
The collective evidence indicates that the observed reductions in cell proliferation after 
zinc treatment are accompanied by a reduction in total HO enzyme activity despite 
induction of HO-1 protein.  It cannot be deduced that basal HO-2 enzyme activity is 
therefore more important to maintain malignant cell proliferation as the zinc 
protoporphyrin inhibits both constitutively expressed and induced HO enzyme isoforms.  
The up-regulation of HO-1 protein is not sufficient to overcome the inhibition by zinc and 
cannot rectify the reduction in total HO enzyme activity.   
5.3.5 Apoptosis Studies: Caspase 3/7 activity assay 
Caspase-3/7 assay demonstrates a significant increase in relative caspase activity after 12 
hours treatment with zinc protoporphyrin 20 µM and no increase in fold caspase-3/7 
induction after 12 hours exposure to hemin 20 µM.  These data suggest a process of 
apoptosis induced by the reduction in HO enzyme activity caused by zinc treatment.   
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5.3.6 Pharmacological modulation of heme oxygenase activity: Conclusions 
The collective data indicate that inhibition of heme oxygenase enzyme activity causes a 
reduction in cell growth of all cultured cell lines under investigation.  HO-1 isoform is not 
expressed under basal conditions, but is inducible by treatment with hemin and zinc 
protoporphyrin.  Hemin treatment and consequent increased HO-1 expression does not 
cause an increase in cell growth, with results showing either no significant effect or a 
decrease in MTT assay.   
Treatment with hemin caused up-regulation of inducible HO-1 protein and a consequent 
increase in total cellular HO enzymatic activity without adverse effects on cell 
proliferation, notwithstanding the relative toxicity of heme at higher concentrations.  
Therefore an increase in HO activity is not detrimental to cancer cell proliferation.  This 
means that cellular antioxidant or anti-inflammatory mechanisms mediated by heme 
oxygenase activity do not prevent or hinder exponential proliferation in malignant cells.  
Heme oxygenase products may confer anti-apoptotic properties to cells with increased 
HO activity, or these effects may be mediated by alternative pathways activated by HO-1 
protein. 
Pharmacological competitive inhibition of HO enzyme by zinc protoporphyrin causes a 
significant reduction of cell proliferation in all malignant cell lines at all time points 
studied.  Treatment with zinc protoporphyrin 10 µM or 20 µM produced consistent 
reductions in cell proliferation with statistical significance only in malignant gastric and 
oesophageal adenocarcinoma cells and not in control oesophageal squamous epithelium.  
Zinc treatments at doses of 10 – 20 µM provide a cancer-specific effect to cause reduced 
cell growth.  Growth curves up to seven days were significantly reduced in studies using 
AGS and OE-33 cells.  There was a clear reduction in total HO activity mediated by zinc 
treatment despite induction of HO-1 enzyme.  Results indicate that inhibition of HO-2 
enzyme under basal conditions and inhibition of the up-regulated HO-1 enzyme causes a 
reduction in overall enzymatic activity that is detrimental to cancer cell proliferation.  
Treatment with zinc protoporphyrin caused a concentration-dependent increase in 
relative caspase-3/7 activity following 12 hours of incubation compared to untreated 
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controls.  The observed effects on cell growth can be observed to be mediated by an 
increase in apoptosis when HO activity is inhibited.   
Inhibition of the HO-2 enzyme present will cause intracellular heme substrate 
accumulation and consequent up-regulation of HO-1 isoform.  This is clearly 
demonstrated for zinc concentrations of 5 and 10 µM in gastric cancer cells.  In 
oesophageal cancer cells there is less obvious HO-1 expression, and only then at higher 
zinc doses of 40 and 100 µM.  Despite up-regulation of HO-1 to augment basal HO-2 
activity, it is likely that enzyme levels do not overcome the potent competitive inhibition 
of the zinc protoporphyrin.  In gastric cancer cell lines the anti-proliferative outcomes of 
both HO-1 induction by hemin at higher doses and HO activity inhibition by zinc may 
seem to be contradictory.  However this may correspond to cellular responses to enzyme 
products or substrate accumulation causing cellular toxicity.  The effects of CO, biliverdin, 
Fe2+ and intracellular heme are not mutually exclusive, and the overall proliferative 
response in cancer cells is difficult to predict.  There may be a fine balance between 
oxidative and antioxidant and inflammatory and anti-inflammatory cellular states that 
govern cell phenotype and cell growth.   
Collectively these data suggest a novel role for the constitutive (HO-2) rather than 
inducible (HO-1) isoform in the tonic regulation of gastro-oesophageal adenocarcinoma 
cell growth.  The zinc protoporphyrin inhibited proliferation by acting on the 
constitutively expressed HO-2 enzyme as the cells did not express HO-1 under basal 
conditions. 
The potential anti-cancer activity of pharmacological heme oxygenase enzyme inhibition 
by metalloporphyrins has been previously investigated356 358 360 361 431 917 918.  Zinc 
protoporphyrin has been demonstrated to inhibit lung cancer tumour growth in a mouse 
model in a dose-dependent fashion361.  Additional rat models have indicated a significant 
reduction of tumour growth with inhibition of HO activity by zinc PP358.  Potent anti-
tumour effects in vivo have been reported with a water-soluble conjugated zinc 
protoporphyrin used in a murine model with demonstrable induction of apoptosis in solid 
sarcoma tumours356.  Pegylated zinc PP treatment also significantly reduced the growth of 
sarcoma 180 tumours in a mouse model357.   
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One recently published report investigated the ability of zinc protoporphyrin to 
potentiate chemotherapeutic activity431.  This study found that zinc PP caused significant 
accumulation of reactive oxygen species in tumour cells and exhibited potent cytotoxic 
effects against human and murine tumour cell lines with evidence for the induction of 
apoptosis.  In a murine model, however, transplanted melanoma cells over-expressing 
HO-1 did not respond to zinc treatment.  Zinc PP was unable to sensitise tumour cells to 
the chemotherapeutic activity of 5-fluorouracil, cisplatin or doxorubicin in three different 
tumour models431.   
Treatment with pegylated zinc protoporphyrin has been demonstrated to reduce the 
required lethal doses of doxorubicin and hydrogen peroxide in cultured human colonic 
carcinoma cells357.  More recent studies have focused on the potential for selective 
tumour targeting by heme oxygenase inhibitors360 917.  Fang and colleagues report studies 
using a water-soluble micelle containing zinc protoporphyrin for tumour-targeted 
inhibition of HO activity919 920.  They report a profound in vitro cytotoxic effect of the 
water-soluble zinc micelle specific to various tumour cells from studies using eleven 
cultured tumour cell lines and six normal cell lines.  A potent anti-tumour effect was also 
observed in murine melanoma and fibrosarcoma xenograft in vivo models.  The zinc 
micelle was found to predominantly accumulate in the liver tissue after intravenous 
injection facilitating an impressive anti-cancer effect seen in a rabbit liver tumour 
model919.  
The findings from the current studies demonstrate an important role of heme oxygenase 
enzyme activity in maintaining cell growth.  The inhibition of heme oxygenase enzyme 
produces anti-cancer effects even though over-expression of HO-1 enzyme is not a 
feature of these cancer cells investigated.  The results provide evidence for a crucial role 
of the HO-2 isoform in this context, with inhibition of the constitutively expressed protein 
causing anti-proliferative and pro-apoptotic sequelae that cannot be prevented by up-
regulation of HO-1 protein.  Reduction of the total cellular heme oxygenase enzymatic 
activity by pharmacological inhibition provokes a reduction in cancer cell growth that is 
consistent with published reports.   
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The limitations of these studies relate to potential non-specific pharmacological effects of 
zinc protoporphyrin.  It is possible that inhibition of cell growth is achieved through non-
specific zinc effects as opposed to inhibition of HO-2 isoform enzyme.  Zinc 
protoporphyrin (zinc PP) is a potent selective inhibitor of heme oxygenase enzyme that 
inhibits the oxidative catalytic cleavage of the α-meso carbon bridge of the heme 
porphyrin ring by heme oxygenase.  Zinc PP however also inhibits other intracellular 
enzymes and signalling molecules including interleukin-1 and nitric oxide synthase.  It 
exhibits inactivation of all three isoforms of nitric oxide synthase in a time-dependent and 
concentration-dependent manner109 356 921-923.   
The diverse effects of zinc protoporphyrin may be responsible for the proliferation effects 
observed in these cell lines investigated.  The effect of zinc PP may be cell-specific as it 
has been demonstrated to promote the proliferation of growth factor-stimulated vascular 
smooth muscle cells but inhibit endothelial cell proliferation during angiogenesis.  The 
problem arises when considering possible non-specific and HO-independent effects of 
zinc PP as a pharmacological agent922 924 925.   
Metalloporphyrins (MP) have been used to inhibit heme oxygenase activity both in vitro 
and in vivo for several decades.  It has recently been suggested that not all commonly-
used MPs are specific to HO enzyme.  A recent study comparing metalloporphyrins 
reported that zinc protoporphyrin was neither the most selective nor the most effective 
inhibitor of HO.  The majority of tested MPs (four out of five) also inhibited the activity of 
other enzymes including nitric oxide synthase (NOS).  This raises doubt about whether the 
observed zinc PP-mediated effects on cell proliferation are indeed related to the HO 
pathway, particularly as the NOS system is closely related to the cellular oxidative stress 
response.  The use of a more specific and effective agent would be beneficial but every 
pharmacological agent comes with its own profile of adverse and off-target effects359 921 
926. 
Subsequent experiments were therefore designed to investigate a specific role of HO-2 
enzyme in cell proliferation using siRNA-mediated knockdown of the HO-2 gene.  This 
methodological approach attempts to minimise the potential diverse effects that are a 
common concern with pharmacological agents.   
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5.4 Investigating a Specific Role for HO-2 Enzyme in Cell Growth 
5.4.1 Establishing protocols for adequate transfection of siRNA complex 
Short interfering RNA-mediated HO-2 gene knockdown experiments were carefully 
designed with the aim of investigating a specific role for the HO-2 isoform protein.  
Experiment protocols were developed to minimise adverse effects of various reagents 
used on the proliferation of cells investigated.  The transfection reagent Lipofectamine 
did not significantly affect MTT assay for AGS cells up to 72 hours at concentration 
between 0.5 and 1.5 µL.  The efficacy of oligonucleotide transfection was assessed with 
experiments using a fluorescently tagged oligonucleotide (AlexaFluor) that demonstrated 
improved oligo uptake into cell cytoplasm on fluorescent microscopy at 10 nM 
concentration with no significant effects on MTT proliferation assay.  These results 
demonstrate effective transfection of the labelled siRNA using Lipofectamine reagent at 1 
µL per well and oligonucleotide at 10nM concentration.  Using a negative universal 
control oligonucleotide at concentrations of 5, 10 or 20 nM resulted in no significant 
differences in MTT assay outcomes for AGS and HGC-27 cells up to 72 hours.   
Therefore the experiment protocol derived from the experiment described above 
included final concentration of Lipofectamine reagent at 1 µL and siRNA oligonucleotide 
at 5 – 20 nM in experiment wells to facilitate efficient siRNA transfection with minimal 
adverse effects.  Given the findings from the labelled RNAi duplex and NUC experiments it 
was decided to start siRNA experiments using oligonucleotide at 10 – 20 nM 
concentration.  Although this does not rule out the possibility of mild cellular phenotype 
effects as a direct result of oligonucleotide transfection in HGC-27 cell lines, it does 
ensure uptake of the siRNA into the cell.  Experiments were designed to include the 
negative universal control siRNA duplex at the same concentrations as the gene-targeted 
siRNA duplex to allow for direct comparison between the two.  This would give further 
confidence in any observed results being due to effects mediated by knockdown of the 
targeted gene as opposed to the transfection process.   
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5.4.2 Efficacy of supplied siRNA and HO-2 mRNA knockdown 
Agarose gel analysis of RT-PCR products demonstrated effective knockdown of HO-2 
mRNA after transfecting cells with targeted siRNA for 24, 48 and 72 hours.  The most 
effective knockdown of HO-2 RNA was achieved after transfection with supplied siRNA 
duplex 02.  Experiments were repeated in an attempt to further validate effective HMOX2 
mRNA knockdown but inconsistent results were obtained with PCR products using GAPDH 
primer controls.  These findings suggested a compromise in RNA quality such that every 
stage of the PCR process had to be interrogated for possible contamination of samples.  
All eluted RNA samples were therefore treated repeatedly with DNase enzyme and 
examined for DNA contamination with agarose gel electrophoresis.  All samples with 
visible evidence of DNA contamination were discarded along with any corresponding 
complementary DNA stored.  Repeat steps of RNA elution and RT-PCR were performed 
and the PCR products analysed on agarose gels to demonstrate effective knockdown of 
HMOX2 mRNA after transfection with the selected 02 siRNA duplex.   
Real-time quantitative PCR analysis was performed to further clarify siRNA-mediated 
knockdown of the heme oxygenase target mRNA.  The quality of experimental RNA 
samples was confirmed with an accepted experimental standard level of purity obtained. 
Quantitative RT-PCR results indicate a significant reduction in relative HO-2 mRNA 
expression in both AGS and OE-33 cells after transfection with the selected siRNA duplex 
02 oligonucleotide.  For all subsequent siRNA experiments the siRNA 02 duplex was 
therefore used for effective HO-2 gene knockdown.  There was a significant 
corresponding increase in the relative expression of HO-1 mRNA in both cell lines after 
transfection with HMOX2-targeted siRNA.   
Real-time quantitative PCR results confirm efficient knockdown of HO-2 mRNA from the 
siRNA experiment protocols used and indicate a concurrent up regulation of HO-1 mRNA.  
These findings are in keeping with previous published studies of the interaction between 
HO-1 and HO-2 proteins399.     
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5.4.3 Effect of siRNA-mediated HO-2 knockdown on heme oxygenase expression & total 
heme oxygenase enzyme activity 
Western blot analyses of protein expression demonstrate effective reduction of HO-2 
protein 24, 48 and 72 hours after transfection of AGS cells using siRNA duplex 02 for HO-2 
gene knockdown.  Probing the blots for HO-1 protein indicates HO-1 up-regulation in cells 
treated with HMOX2-targeted siRNA with a time-dependent increase in HO-1 expression 
over 24 – 72 hours demonstrated in AGS cells.  Experiments using OE-33 cells 
demonstrate similar patterns of reduced HO-2 protein expression and increased HO-1 
protein expression up to 48 hours after transfection with HMOX2-targeted siRNA duplex.  
Induction of HO-1 protein may represent a cellular response to various elements of 
siRNA-mediated HO-2 mRNA knockdown as well as the potential build-up of heme 
substrate as a consequence of reduced functional HO-2 protein.   
Specific colorimetric HO enzyme assays demonstrate a significant reduction in total heme 
oxygenase activity 24 and 48 hours after treatment with siRNA targeted toward HO-2 
protein.  The combined activity of HO-2 and HO-1 enzyme proteins was however 
significantly increased after 12 hours.  This represents a short-lived increase in total 
enzyme activity that may be due to an increased HO-1 expression in response to siRNA-
mediated HO-2 knockdown.  Although HO-1 protein expression increases over 24 – 72 
hours after HO-2 knockdown the effect on overall HO enzyme activity is only seen within 
the initial 12 hours.  This suggests that basal activity of constitutively expressed HO-2 
enzyme provides the major contribution to overall HO enzyme activity.  It is possible that 
the induced HO-1 protein is sensitive to cellular feedback mechanisms or that activity of 
the HO-1 enzyme is specifically regulated by downstream enzyme products.  The 
collective data indicate that in siRNA-treated cells measurable total HO enzyme activity is 
not maintained despite up-regulation of HO-1 protein in response to knockdown of HO-2 
mRNA.  This has important implications for the cell proliferation effects observed with 
HO-2 protein knockdown.   
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5.4.4 The effect of siRNA-mediated HO-2 knockdown on cell growth 
Experiments to assess cell proliferation demonstrate a significantly reduced MTT assay at 
48 and 72 hours in cells transfected with HMOX2 siRNA at 10 nM concentration as 
compared to an equivalent treatment with negative universal control siRNA.  Consistently 
significant results were obtained in repeated experiments using AGS, HGC-27 and OE-33 
cell lines.  There were no significant effects on cell growth observed at the 24 hour time 
point.   
Results from cell counts using trypan blue exclusion suggest that the observed reductions 
in MTT assay are not due to increased numbers of necrotic cells.  The very limited number 
of dead cells counted in all experiment wells suggests an anti-proliferative or pro-
apoptotic response to reduced HO-2 activity.  HO-2 knockdown in AGS, HGC-27 and OE-33 
cells produced effects on cell counts that are more dramatic than those seen with MTT.  
The discrepancy between cell count numbers and the equivalent MTT results is likely to 
be explained by the technical aspects and relatively cumbersome nature of cell counting 
with the major factor being fewer experiments performed leading to greater variability 
and an increased likelihood of observer error. 
Further experiments were designed to assess cell cycle kinetics with flow cytometry and 
to investigate apoptosis after specific HO-2 knockdown.   
5.4.5 The effect of siRNA-mediated HO-2 knockdown on cellular apoptosis 
Cells treated with HMOX2 siRNA at 10 nM concentration demonstrated a significantly 
increased affinity for annexin V binding as evidence for early apoptosis after 24 hours as 
compared to cells transfected with NUC 10 nM over the same time period.  At 72 hours 
there were significantly fewer viable cells and significantly increased late apoptotic or 
necrotic cells in samples transfected with HMOX2 siRNA compared to NUC.  The observed 
movement of siRNA-treated cells over time through annexin V positive and PI negative to 
annexin V and PI positive suggests a process of early apoptosis progressing to late 
apoptosis and eventual cell death. 
Cell cycle studies demonstrated cells undergoing a process of apoptosis with a sub-G0 
peak population of cells visible 24 and 48 hours after transfection with HMOX2 siRNA 
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duplex at 10 nM concentration.  After 48 hours the siRNA-treated sample showed a 
further reduction in the proportion of cells in G0/G1 or G2/M phase with an increase in the 
proportion of cellular debris or apoptotic cells.   
The measured coefficient of variation of the G0/G1 peak and the ratio of G0/G1 to G2/M 
cells indicated reduced accuracy of DNA measurement and interference of doublet 
discrimination by increased cellular debris.  The ratio between G1 and G2 peaks should be 
between 1.95 and 2.05 and the cell debris measured should be up to a maximum of 30%.  
The linearity of the plot should produce a tight and short distance G1 peak with a CV of 
less than 8% to indicate good quality DNA measurement.   
Cytometry studies show a significant increase in DNA fragmentation 24 hours after 
transfecting cells with HMOX2 siRNA at 10 nM concentration and a significant reduction 
in the proportion of non-apoptotic cells present.  After 48 hours there is a further 
significant increase in DNA fragmentation and fewer non-apoptotic cells in samples 
treated with HMOX2 siRNA as compared to cells transfected with negative universal 
control siRNA.  These results indicate that one of the hallmarks of apoptosis is detectable 
in AGS cell lines 24 hours after siRNA-mediated knockdown of HO-2 mRNA and that this 
process progresses up to 48 hours after transfection.   
Caspase-3/7 assays performed in AGS cells demonstrate a statistically significant increase 
in relative caspase activity 24 hours after siRNA-mediated HO-2 knockdown when 
compared to appropriate controls and provide additional supporting evidence for a 
process of apoptosis.   
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5.4.6 Investigating a Specific Role for HO-2 Enzyme in Cell Growth: Conclusions 
There are several limiting technical factors in the siRNA experiments.  In oesophageal cell 
lines transfection with the negative universal control caused non-significant reductions in 
cell growth when compared to non-transfected control cells.  Despite the careful design 
of control oligonucleotides from specialist manufacturers, there must be off-target effects 
either related to RNA interference or non-specific cellular stress responses.  However 
subtle these effects are, there is a detectable change in cell phenotype with the outcome 
under investigation.  Comparison between the negative universal control and the HO-2 
targeted siRNA remains a valid approach to elicit phenotypic changes that are a 
consequence of specific gene knockdown.   
These preliminary experiments demonstrated cellular uptake of transfected siRNA and 
efficient knock down of targeted HO-2 mRNA.  A reduction in HO-2 protein expression 
and reduction in total HO enzyme activity has been achieved by this approach.  Cells with 
reduced HO activity despite increased HO-1 expression demonstrate an altered 
phenotype with a reduction in cell proliferation and increase in apoptosis.  Together with 
the experiments using zinc protoporphyrin, the different approaches of modulation of 
HO-2 expression by mRNA knockdown and HO-2 activity by competitive pharmacological 
inhibition result in the same biological outcome, i.e. inhibition of cancer cell growth. 
Targeted knockdown of HO-2 protein had a clear effect on the proliferation of AGS and 
HGC-27 gastric cancer cells and OE-33 oesophageal cancer cells with significant growth 
inhibition at 48 and 72 hours.  The time-dependent effect does not appear to be 
correlated to the presence of HO-1 protein, as HO-1 protein is induced within 48 hours of 
HO-2 knockdown. As demonstrated with assays of HO enzyme activity the contribution of 
induced HO-1 enzyme is short-lived.  It is noteworthy that the cellular phenotype effects 
of reduced proliferation are observed after a measurable reduction in total HO enzyme 
activity.  Furthermore the continued expression of HO-1 protein cannot compensate for 
the lack of HO-2 protein.  Residual activity of HO-2 enzyme following mRNA knockdown or 
short-lived activity of up-regulated HO-1 isoform does not restore total HO enzyme 
activity to the same level as untreated control cells.  The reduction in overall HO enzyme 
activity appears to be sufficient to cause an anti-proliferative and pro-apoptotic effect.   
359 
 
These findings support the idea of tonic HO-2 activity having a vital role in 
oesophagogastric cancer cell biology.  Tonic HO activity provided by the HO-2 isoform 
may be required to maintain redox balance in the cell, and reduction of this activity could 
lead to intracellular oxidative stress which may affect proliferative pathways.  The cellular 
biology of HO-1 and HO-2 enzyme isoforms is clearly closely linked: HO-1 induction was 
clearly demonstrated in response to HO-2 mRNA knockdown.  Although HO-1 protein 
expression increases over 24 – 72 hours after HO-2 knockdown the effect on overall HO 
enzyme activity is only seen within the initial 12 hours.  This suggests that basal activity of 
constitutively expressed HO-2 enzyme provides the major contribution to overall HO 
enzyme activity.  Induced HO-1 protein may be sensitive to specific cellular feedback 
mechanisms or regulated by downstream enzyme products.  The relative contribution of 
HO-1 and HO-2 isoforms toward overall HO enzyme activity require further investigation.  
The specific interaction of HO-1 and HO-2 proteins with cell signalling pathways may 
influence the resulting phenotype.  The experiments detailed above demonstrate that the 
specific phenotypic effects of increased apoptosis caused by HO-2 knockdown are not 
prevented by induction of HO-1 expression.  This may be due to either a reduction in 
enzyme activity or a differential interaction of HO-1 and HO-2 isoforms with cell signalling 
and apoptotic pathways.  Total enzyme activity is not maintained beyond the initial 
significant increase at 12 hours, so the activity of the up-regulated HO-1 protein is either 
compromised or not relevant to the cell outcomes measured.  It is possible that tonic or 
residual HO activity from specifically the HO-2 isoform is responsible for maintenance of 
exponential proliferation in oesophagogastric cancer cells.  It is possible that the 
constitutive HO-2 isoform and not the inducible HO-1 isoform is responsible for 
interaction with pathways to apoptosis, or indeed that the balance between the relative 
expression of HO isoforms maintains cellular homeostasis. 
Published studies provide supporting evidence for the role of HO-2 protein in cellular 
homeostasis.  Recent reports have established the important antioxidative functions of 
HO-2 protein.  The HO-2 protein molecule contains heme-binding heme regulatory motifs 
(HRMs) that function as heme – oxygen sensors in bacteria, yeast and mammals109 117 211 
212.  The presence of HRMs in the HO-2 enzyme suggests the further unique function of 
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binding and regulating the heme gaseous ligands nitric oxide (NO), carbon monoxide (CO) 
and oxygen (O2)
116 224.  
Recent studies have shown that the expression levels of HO-1 and HO-2 proteins are 
reduced under hypoxia.  Certain features suggest separate physiologic roles of HO-1 and 
HO-2 and support the proposed function of HO-2 as a potential oxygen sensor206.  HO-2 
has recently been demonstrated to interact with nitric oxide synthase enzyme, binding 
the vasodilator NO with high affinity and the potential vasodilator CO with less affinity214.  
Calcium-sensitive potassium channels are stimulated by the interaction of HO-2 with CO 
to mediate the excitatory responses of the carotid body to hypoxia215. 
Recent studies provide evidence for a critical role of HO-2 protein in acute inflammation 
with specific roles in repair responses of the cornea to injury927 928.  Halilovic and co-
workers demonstrate that the highly-expressed HO-2 protein in the corneal epithelium is 
critical for corneal wound healing.  Specific knockdown of HO-2 expression significantly 
impaired wound healing whereas knockdown of HO-1 protein had no significant effect928.  
Specific HO-2 knockdown has been shown to impair the acute inflammatory and 
reparative response after epithelial injury and recent in vivo studies demonstrate an 
exaggerated inflammatory response in HO-2 -/- models of antigen-induced peritonitis174.  
Cerebral vascular endothelial cells from HO-2 knockout mice have been reported to show 
a greater sensitivity to oxidative stress and apoptosis caused by serum deprivation and 
TNF-α treatment than cells from wild-type mice.  Studies suggest that HO-2 plays an 
important anti-apoptotic role in the protection of cerebrovascular endothelium against 
oxidative stress and acute cytokine-mediated inflammation209.  
Published studies suggest a role for HO-1 enzyme activity in cancers with constitutive 
over-expression of HO-1 protein.  Berberat and colleagues found a 6-fold up-regulation of 
HO-1 mRNA in human pancreatic cancer cells when compared to normal human 
pancreas.  Significant inhibition of cancer cell proliferation was effected by siRNA-
mediated knockdown of HO-1 protein with enhanced cancer cell sensitivity to 
gemcitabine chemotherapy and radiotherapy334.   
The current study demonstrates an interaction between constitutive HO-2 and inducible 
HO-1 proteins.  Specific siRNA-mediated HMOX2 knockdown caused up-regulation of 
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inducible HO-1 protein.  This finding is consistent with published studies from Ding and 
colleagues who demonstrated induction of HO-1 expression at both mRNA and protein 
levels with siRNA-mediated HO-2 knockdown in cultured cell lines399.  It is noteworthy 
that in cells that over-expressed HO-1 protein, specific knockdown of HO-1 expression did 
not affect HO-2 expression.  Reduction of HO-2 protein expression caused heme 
accumulation only when the affected cells were exposed to exogenous hemin.  This 
means that the induction of HO-1 protein in response to HO-2 knockdown is not due to a 
reduced total HO enzymatic activity causing heme substrate build-up.  These results 
suggest that HO-2 protein may directly down-regulate the expression of HO-1 to facilitate 
the co-ordinated expression of both cellular isoforms.  Alternative findings suggest that 
HO-2 protein is critical for HO-1 expression with deletion of HO-2 associated with 
impaired induction of HO-1 and subsequent development of chronic inflammation174.  
The current study provides further supportive evidence for interaction between HO-1 and 
HO-2 isoforms and presents a novel finding of the importance of tonic HO-2 activity for 
the regulation of cancer cell growth.   
Products of enzyme activity such as bilirubin or carbon monoxide may directly reduce HO-
1 enzyme activity by negative feedback.  Inhibition of heme oxygenase activity or specific 
knockdown of HO-2 enzyme might be detrimental to cells both due to the accumulation 
of pro-oxidant substrate heme and due to reduced production of beneficial anti-oxidant 
downstream products.   
Further studies were designed to assess the influence of downstream enzyme products 
bilirubin and carbon monoxide on HO enzyme activity and on cellular proliferation 
outcomes.   
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5.5 Downstream Effectors of Heme Oxygenase Activity: Bilirubin 
5.5.1 The effect of Bilirubin on cell proliferation 
Experiments to investigate the effects of bilirubin on cell growth yielded some surprising 
results.  There was no significant effect on cell proliferation as measured by MTT assay 
performed after 24 hours of treatment with bilirubin at various doses.  However, 
extending cell exposure to bilirubin at doses of 10 µM and 20 µM produced a significant 
reduction in MTT assay after 48 hours and at 72 hours.  Interestingly these effects were 
reproduced when the bilirubin reagent medium was replaced with fresh serum-complete 
medium after 24 hours.  Treatment of cells with bilirubin at 10 or 20 µM for 24 hours 
produced significant reductions in cell proliferation measured at 48 or 72 hours 
respectively.  Cell count data demonstrated a similar trend with increases in viable cell 
counts at 24 hours and reductions in viable cell counts 72 hours after bilirubin treatment. 
These findings indicate a direct effect of bilirubin treatment on cell proliferation that is 
not apparent within the first 24 hours of bilirubin exposure.  A possible explanation for 
the increase in cell numbers at 24 hours lies in the well-established antioxidant properties 
of bilirubin210 847 929-931.  Bilirubin may exert a cytoprotective effect on the cells by 
providing protection against oxidative damage and thus facilitating survival and 
exponential proliferation within the first 24 hours.  In addition, bilirubin has recently been 
found to possess anti-nitrosative properties.  Peroxynitrite is a highly reactive molecule 
formed when the gaseous mediator nitric oxide reacts with superoxide anions.  Bilirubin 
has been shown to effectively scavenge peroxynitrite and thus reduce nitrosative damage 
to cells932 933.  
The current experiments consistently demonstrate a decrease in viable cell number and 
reduced cell proliferation 48 – 72 hours after addition of bilirubin.  These findings are 
consistent with previous findings of cytotoxic activity of bilirubin via pro-oxidant 
mechanisms884.  
The cytoxicity of bilirubin at high concentrations has been established in physiological 
studies.  When serum bilirubin concentrations reach 300 µM neurotoxicity becomes a 
problem causing cell death.  In the infantile condition of kernicterus brain damage ensues 
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as a result of high serum bilirubin levels934.  One proposed mechanism of bilirubin 
cytotoxicity is damage to mitochondrial membranes with consequent impairment of 
cellular metabolism935.  Anti-proliferative effects of bilirubin may be mediated by 
apoptotic pathways.  Bilirubin has been shown to cause cell cycle arrest at the G0/G1 
phase934.  The effects of bilirubin have been proposed to be dependent upon various 
factors including the differential susceptibility of cells to bilirubin toxicity, variation in the 
expression of membrane transporter proteins, the extent of conjugation and oxidation of 
the bilirubin pigment and the prevailing milieu of cytosolic binding proteins936 937.  
Replacement of the bilirubin with fresh media does not prevent the anti-proliferative 
effects observed in the current experiments.  This suggests possible interaction with 
intracellular signalling pathways that once activated no longer require continued stimulus 
from the presence of bilirubin.   
5.5.2 The effect of Bilirubin after HO enzyme inhibition or HO-2 knockdown 
Experiment results demonstrate that although cell proliferation is maintained with 
bilirubin treatment alone for 24 hours the effects mediated by heme oxygenase inhibition 
or HO-2 gene knockdown cannot be reversed or prevented by treatment with bilirubin at 
5 or 10 µM concentrations for 24 hours.  There was a significant reduction in cell 
proliferation after treatment with zinc protoporphyrin 10 µM for 48 hours observed up to 
72 hours and significant reductions in cell proliferation observed at 72 hours after siRNA 
transfection that bilirubin treatment did not affect.  One possible explanation for these 
observations is the inhibition of HO enzyme activity via a bilirubin negative feedback 
mechanism.  It could be that the anti-oxidant and cytoprotective mechanisms of bilirubin 
are mediated by or dependent upon activity of heme oxygenase and more specifically the 
HO-2 isoform.  This may explain the apparent lack of cell protection with bilirubin 
treatment that is observed in the setting of HO-2 gene knockdown or HO-2 enzyme 
inhibition.   
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5.5.3 RNA and Protein expression after siRNA HO-2 knockdown and Zinc PP 
Agarose gel analysis of PCR products demonstrate a clear reduction in HMOX2 mRNA 
from cells treated with HMOX2 siRNA that is not mitigated by treatment with bilirubin 5 
µM for 24 hours.  Western blot analyses show a clear reduction in HO-2 protein 
expression in cells transfected with HMOX2 siRNA after 24, 48 and 72 hours.  HO-2 
protein expression is not affected when cells are incubated with bilirubin at 5 µM for 24 
hours.  There is a reduction in control protein β-actin expression at 48 hours that is not 
proportional to the reduction in HO-2 protein expression at the same time point and 
represents unequal protein loading.  The return of HO-2 protein expression beyond 72 
hours was not investigated in these studies.  The transient nature of siRNA-mediated 
knockdown of HO-2 mRNA may allow restoration of protein expression without 
preventing the phenotypic cellular effects of reduced proliferation.  A possible strategy to 
avoid the transient action of transfected siRNA oligonucleotides would be to use viral 
vectors engineered to continuously produce the required siRNA. 
Expression of HO-2 protein is reduced by treatment with zinc protoporphyrin (zinc PP) for 
24 – 72 hours as described above.  Zinc protoporphyrin is a potent competitive inhibitor 
of heme oxygenase enzyme.  Treating cells with zinc PP is demonstrated to reduce total 
HO enzyme activity in enzyme assays detailed above.  This will cause heme substrate 
build-up and thus provide a direct stimulus for induction of HO-1 protein.  The up-
regulation of HO-1 protein may lead to a compensatory down-regulation in HO-2 
expression.  This idea is supported by published reports suggesting that the interaction 
between HO-1 and HO-2 isoforms serves to limit total HO activity and promote non-
enzymatic functions of heme oxygenase938.  
5.5.4 The effect of Bilirubin on cellular apoptosis  
Cell populations treated with bilirubin 10 µM demonstrated a significantly increased 
affinity for annexin V binding as evidence for early apoptosis after 36 hours when 
compared to vehicle-treated control cells over the same time period.  At 48 hours there 
were significantly fewer viable cells and significantly increased late apoptotic or necrotic 
cells in samples treated with bilirubin as compared to vehicle-treated cells.  The 
demonstrable shift in the proportion of cells staining annexin V positive 36 hours after 
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bilirubin exposure to staining both annexin V and PI after 48 hours suggests a process of 
apoptosis in cells treated with bilirubin. 
Cell cycle studies demonstrate a reduction in the proportion of cells in G0/G1 phase or 
G2/M phase with a sub-G0 peak population of cells visible 36 hours after treatment with 
bilirubin at 10 µM concentration.  The measured coefficient of variation of the G0/G1 peak 
was 5.65 and the ratio of G0/G1 to G2/M cells 2.19 indicating good quality of DNA 
measurement and accurate doublet discrimination.   
Studies of DNA fragmentation show no observable difference between cells treated with 
vehicle control for 36 hours and untreated control cells.  Cells treated with bilirubin 10 
µM demonstrate a significant increase in DNA fragmentation with a significant reduction 
in the proportion of non-apoptotic cells when compared to control cells after 36 hours.  
There is a further significant increase in DNA fragmentation observed 48 hours after 
bilirubin treatment.  Results indicate that a hallmark feature of apoptosis is detectable in 
AGS cell lines 36 and 48 hours after treatment with bilirubin 10 µM. 
Collectively the studies of apoptosis contribute persuasive evidence for a process of 
apoptosis that occurs in response to treatment with bilirubin.  This process is 
demonstrable 36 hours after treatment with bilirubin.  The effects on cell proliferation 
are measurable at 48 hours and at 72 hours by MTT assay.  The timing of apoptosis assays 
was informed by the observed effects on cell growth, given that no reductions in cell 
proliferation were recorded within 24 hours of bilirubin treatment.  Initial apoptosis 
studies were able to identify a process of early apoptosis as demonstrated by increased 
affinity for annexin V at 36 hours.  This supports the idea that the process of apoptosis is 
not significantly increased in bilirubin-treated cells until at least 24 hours of reagent 
exposure, further promoting the suggested interaction of bilirubin with intracellular 
signalling pathways.   
An important feature of these bilirubin experiments relates to the duration of bilirubin 
exposure and the observed effects at various time points.  No difference in cell 
proliferative effects was observed between cells exposed to bilirubin for 24 hours and 
cells treated with bilirubin for up to 72 hours when these effects were measured at the 
same time points of 24, 48 and 72 hours.  Replacing the reagent medium with fresh 
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serum-complete media after 24 hours made no difference to the cell phenotype.  Studies 
of apoptosis were therefore designed to elucidate a process of apoptosis in cells treated 
with bilirubin for only 24 hours: reagent media was replaced with serum-complete media 
at 24 hours as described above and the apoptosis assays performed at 36 or 48 hours.  
These data indicate that the bilirubin-mediated effects on apoptosis and cell growth are 
not dependent on continued exposure to bilirubin beyond 24 hours.  This provides 
additional supporting evidence for the activation of downstream signalling pathways by 
cellular interaction with bilirubin.   
5.5.5 The effect of treatment with Bilirubin: Conclusions 
The heme oxygenase pathway and its downstream products are widely regarded to 
possess cytoprotective and antioxidant properties, both in physiological and pathological 
states.  However little is known about the mechanisms by which these effects are 
conferred, particularly in the field of cancer research.  Previous studies suggest that the 
actions of the HO pathway may depend on the activity of its downstream products.  
Administration of bilirubin and carbon monoxide to cells has been demonstrated to 
produce the same effects mediated by induction of the HO-2 pathway209.  The observed 
neuroprotective activity of HO-2 enzyme has been reported to be due to accumulation of 
bilirubin177 210 233.  Bilirubin can no longer be considered simply a toxic waste product of 
heme catabolism.  There is persuasive evidence for an important role of heme oxygenase 
as an endogenous cytoprotective compound at physiological concentrations.   
The activity of biliverdin reductase enzyme is recognised as a critical component in the 
role of heme oxygenase in protecting cells from the toxic effects of heme.  The 
antioxidative and anti-inflammatory effects of bile pigments and their regulatory 
functions can be mediated by the activity of biliverdin reductase939 940.  Published 
evidence supports the diverse functions of biliverdin reductase and its peptide fragments 
in the regulation of gene expression and activation of cell signalling pathways941.  
Bilirubin can exhibit either cytotoxic or cytoprotective activity depending on the tissue 
concentration of its unbound fraction and the cellular redox state of the target tissue.  
Bilirubin has been established to exert antioxidant effects at low to moderate 
concentrations while possessing pro-oxidant activity at high concentrations144 931.  In vitro 
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studies demonstrate that both free and albumin-bound bilirubins are able to scavenge 
peroxylradicals and protect low-density lipoprotein against peroxidation221 846.  
Subsequent studies have indicated a cytoprotective role for bilirubin in response to 
various oxidative insults210 929 942.  Bilirubin reacts with various reactive oxygen and 
nitrogen species including singlet oxygen, hydroxylradical, nitric oxide and peroxynitrite931 
to reduce oxidative stress. 
The antioxidant, anti-mutagenic and anti-carcinogenic activities of bilirubin are well 
established in published reports of in vitro experiments144 930 943 944.  Bilirubin has 
demonstrable in vitro effects against inflammation and fibrosis with published reports of 
activity in immune-mediated inflammatory diseases and pathophysiological processes 
including atherosclerosis457 945 946.  Bilirubin exerts critical anti-inflammatory actions in the 
vascular system.  The protective effects of bilirubin in the vasculature include inhibition of 
neointima formation and the reduction of vascular smooth muscle cell proliferation and 
migration947.  Bilirubin treatment inhibits the expression of leucocyte adhesion molecules 
in endothelial cells and prevents the adhesion and infiltration of leucocytes into the 
vessel wall255.  Low bilirubin concentrations induce apoptosis in microvascular endothelial 
cells that is more pronounced under conditions of hyperglycaemia and particularly 
relevant in the endothelial cells of the blood-brain barrier856.   
Bilirubin has beneficial effects in pulmonary and vascular diseases851, improves renal 
blood flow and renal haemodynamics in an animal model of hypertension850 and displays 
antiviral activity852 853.  A mildly elevated level of circulating bilirubin has been shown to 
prevent disease in human subjects by antioxidant mechanisms876 948-950.  Unconjugated 
bilirubin may have an important protective physiological role in the prevention of 
gastrointestinal and colorectal cancers951.   
The current thesis studies indicate that bilirubin plays a role in reducing oesophagogastric 
cancer cell growth.  This role involves activation of cellular apoptosis most likely by time-
dependent intracellular pathways that are effective after removal of the bilirubin reagent.  
Addition of bilirubin after HO inhibition or HO-2 gene knockdown does not ameliorate the 
anti-proliferative effects of reduced HO enzymatic activity.   
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The effects of bilirubin on heme oxygenase protein expression and enzymatic activity are 
less clear.  There is no change in HO-2 protein expression 24 hours after treatment with 
bilirubin.  There is a slight reduction in HO-2 protein demonstrated after 48 hour 
treatment with bilirubin at 20 µM concentration.  The HO-1 isoform is not up-regulated in 
response to bilirubin treatment despite changes in the cellular phenotype observed at 48 
hours and beyond.  Bilirubin may well exert a negative-feedback effect on HO-2 protein 
expression and activity and indeed on the induction of HO-1 enzyme.  A limitation of 
these experiments is the lack of data explaining the effects of bilirubin on overall HO 
enzymatic activity.  The methodology of the specific HO enzyme activity assay involves 
colorimetry to measure the production of bilirubin pigment.  The problem comes when 
treating cells with bilirubin pigment for 24 hours.  Despite best attempts to washout the 
reagent with fresh media there are inevitably bilirubin salts remaining in the adherent cell 
monolayer.  It was decided that there was sufficient residual bilirubin pigment in bilirubin-
treated cells to render the colorimetric HO activity assay invalid for these experiments.   
Two published studies to date have demonstrated a direct effect of bilirubin on cancer 
cell growth in vitro.  Bilirubin treatment inhibited cell proliferation in multiple cell lines 
with induction of apoptosis and cell cycle arrest.  Activation of cell signalling pathways 
was demonstrated with induction of p53 and p27885.  Bilirubin has been shown to 
decrease the viability of colonic adenocarcinoma cell monolayers in a dose-dependent 
manner with induction of apoptosis and caspase activation952.  Bilirubin was capable of 
activating the intrinsic apoptotic pathway by inducing loss of mitochondrial membrane 
potential in cultured cell lines952.  In addition, the presence of bilirubin has been 
associated with inhibition of tumour cell growth in a murine colon cancer xenograft 
model885.  A more recent study demonstrated critical damage to human colorectal 
adenocarcinoma (Caco2) and hepatocellular carcinoma (HepG2) cells with DNA strand 
breaks caused by treatment with unconjugated bilirubin and other structurally related 
tetrapyrroles953.  
The concentration of free unbound bilirubin depends upon the ratio of bilirubin to 
albumin.  This ratio dictates the degree to which unbound bilirubin can diffuse across 
plasma cell membranes and interact with cell mitochondrial membrane936 952 954.  In the 
methodology of the current studies bilirubin was added to cell culture medium at a final 
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concentration of 10 – 20 µM per experiment well.  The culture medium included 10% 
foetal bovine serum that would reduce the free unbound fraction of bilirubin.  A recent 
meta-analysis of in vitro neurotoxicity mediated by unconjugated bilirubin found evidence 
of adverse cellular effects when the free unbound bilirubin concentration was close to the 
aqueous saturation limit of 70 nM937.   
The anti-proliferative in vitro activity of relatively higher levels of bilirubin demonstrated 
in the current study is supported by at least 2 previous studies as described above, and is 
the first demonstration in oesophagogastric cancer cells.   
One of the most important practical problems encountered in conducting these studies 
was the accurate preparation of bilirubin solutions.  The lack of an accepted standard 
protocol meant that bilirubin preparation became largely a trial and error exercise.  
Bilirubin is not readily soluble, is sensitive to light and is particularly susceptible to 
oxidization that can change its chemical and biological properties.  Careful design of a 
reproducible and reliable bilirubin preparation protocol was of paramount importance. 
A further limitation of these studies is the relative lack of experimental data for cell 
proliferation outcomes and apoptosis assays measured at further time points.  Further 
studies are indicated to assess the effects of bilirubin treatment at 6, 12 and 36 hours and 
extended growth curves to seven days. 
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5.6 Downstream Effectors of Heme Oxygenase Activity: Carbon Monoxide 
5.6.1 The effect of CORMS on cell proliferation 
Cell treatment with carbon monoxide-releasing molecules (CORM3) and their inactive 
controls (iCORM) produced consistent cancer-specific results.  There were no significant 
effects on cell proliferation for normal squamous epithelial HET-1A cells treated with 
iCORM controls or CORM3 at doses of 10 – 60 µM for 24 – 72 hours.  Cell proliferation 
measured by MTT assay was significantly reduced in malignant adenocarcinoma OE-33 
cells treated with CORM3 at doses of 10 – 60 µM at each time point measured over 24, 48 
and 72 hours as compared to equivalent treatment with iCORM.  Gastric adenocarcinoma 
AGS cell growth was significantly reduced 24, 48 and 72 hours after treatment with 
CORM3 at doses of 20 and 40 µM when compared to equivalent treatment with iCORM.  
Morphological changes are demonstrated after 48 hours of CORM3 treatment with cells 
becoming more rounded and an increase in cellular debris.  These findings represent a 
novel cancer-specific in vitro anti-proliferative effect of carbon monoxide on 
oesophagogastric cancer cells.   
5.6.2 Protein expression after CORM and bilirubin treatment 
Western blot analyses of protein expression in AGS cells show a marked up-regulation of 
HO-1 protein after 24 and 48 hours of treatment with active CORM3 but no HO-1 
induction with equivalent iCORM treatment.  There is a small reduction of HO-2 protein 
after 48h treatment with active CORM3 molecule.   
There are no marked changes in HO-2 protein expression after 24 hours treatment with 
bilirubin and a slight reduction in HO-2 protein demonstrated after 48 hour treatment 
with bilirubin 20 µM.  Expression of HO-1 protein was not induced by up to 48 hours of 
bilirubin treatment.   
  
372 
 
5.6.3 The effect of carbon monoxide on cellular apoptosis 
Experiment cell samples treated with CORM3 molecule at 20 µM demonstrated a 
significantly increased affinity for annexin V binding after 24 hours as compared to those 
treated with equivalent inactive iCORM to indicate a process of early apoptosis.  Over 48 
– 72 hours there was further progression of CORM3-treated cells with significantly fewer 
viable cells and significantly increased late apoptotic or necrotic cells measurable over 
time as compared to iCORM-treated cells.   
DNA fragmentation was detectable 48 hours after treatment with CORM3 with a 
significant increase in the proportion of apoptotic cells measured by Apo-BrdU assay as 
compared to both untreated control cells and those treated with inactive iCORM.  Studies 
using JC-1 labelling demonstrate a significant loss of mitochondrial membrane potential 
after 48 hours in cells treated with CORM3 20 µM compared to equivalent treatment with 
iCORM.  There is a significantly reduced proportion of viable cells measured at 48 hours in 
CORM3-treated cells compared to iCORM controls.  These findings indicate that two 
hallmark features of apoptosis occur in AGS cell lines specifically after treatment with 
CORM3 20 µM for 48 hours.   
Caspase activity assay results demonstrate a significant increase in fold caspase-3/7 
induction after 48 hours exposure to active CORM3 as compared to inactive iCORM.  
Treatment with bilirubin produced a significant increase in caspase-3/7 activity after 48 
hours as compared to vehicle control.   
These findings provide collective supportive evidence for the concept of a process of 
apoptosis.  Results indicate that the observed cell proliferation effects of both bilirubin 
and carbon monoxide are mediated by a process of apoptosis.   
5.6.4 Heme Oxygenase Enzyme Activity Assay 
Specific colorimetric assay demonstrates a decrease in total cellular HO enzyme activity 
after treatment with CORM3 molecule for 24 and 48 hours as compared to untreated 
control cells and cells treated with inactive iCORM.  These results were consistent despite 
the induced expression of HO-1 protein in response to CORM3 treatment.  This finding is 
important because it implies the inhibition of heme oxygenase activity by carbon 
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monoxide via direct or indirect mechanisms.  Both bilirubin and CORM3 treatment reduce 
HO-2 protein expression at 48 hours but only CORM3 causes induction of HO-1.  This 
suggests that carbon monoxide and bilirubin interact with specific and distinctive 
intracellular signalling pathways.  Carbon monoxide inhibits the activity of HO enzyme: it 
may achieve this via a direct negative feedback mechanism and this action may apply to 
both constitutive HO-2 and inducible HO-1 isoforms.  Bilirubin meanwhile also inhibits the 
HO system by causing reduced expression of HO-2 protein.  The specific effects of 
bilirubin on HO-1 protein and on HO enzymatic activity require further investigation.  In 
the studies performed within the scope of this thesis, induction of HO-1 enzyme did not 
occur in response to bilirubin treatment.  The fact that HO-1 protein was induced by 
carbon monoxide suggests a more pivotal role played by CO in the regulation of the HO 
pathway.  This regulation includes up-regulation of HO-1 protein and inhibition of total 
HO enzyme activity.  One interesting question is whether or not the induction of HO-1 
isoform occurs simply as a response to inhibition of HO enzymatic activity by carbon 
monoxide and the consequent build-up of heme substrate.  Alternatively HO-1 induction 
could occur as a direct response to CO exposure.   
The mechanisms and signalling pathways involved in the CO-mediated regulation of HO 
activity demand further study and are beyond the scope of this thesis.   
5.6.5 The effect of treatment with carbon monoxide: Conclusions 
The protective effects of HO activity may largely depend upon the activity of 
endogenously produced carbon monoxide (CO).  Treatment with CO has been 
demonstrated to reverse or reduce the adverse effects of treatment with inhibitors of 
heme oxygenase enzyme.  Induction of HO-1 enzyme and administration of CO have been 
shown to interfere with liver ischaemia and reperfusion injury and to improve transplant 
recipient and graft survival695 955.   
As discussed previously constitutive over-expression of HO-1 is a feature of various 
tumours including hepatocellular carcinoma (HCC)955.  The anti-apoptotic properties of 
HO enzyme are predominantly mediated by CO and confer a risk of tumour growth 
promotion when activity is increased in relevant tumours.  Whereas the biliverdin and 
bilirubin products have direct capability to scavenge oxidants and prevent damage, the 
374 
 
CO product has additional unique activity in cell signalling pathways.  The mechanisms 
and signal transduction pathways implicated in the anti-apoptotic and anti-inflammatory 
activity mediated by carbon monoxide include the mitogen-activated protein kinase 
cascade (MAPK), particularly the p38 protein MAP kinases, phosphatidylinositol 3-kinases 
(PI3-K) and NF-κB signalling pathways201 237 249.   
One of the most important effects of CO is its ability to influence cellular proliferation.  
CO blocks the proliferation of smooth muscle cells of hyperplastic intima following vessel 
trauma, as well as chronic vascular remodelling in transplant vascular stenosis or 
pulmonary hypertension271 732.  CO has been demonstrated to inhibit apoptosis of 
endothelial and epithelial cells and to reduce proliferation of smooth muscle cells and 
fibroblasts via cell cycle arrest775 955.  CO inhibits the proliferation of pancreatic stellate 
cells by activating p38 MAPK714 whereas CO produces a similar reduction in proliferation 
of human airway smooth muscle cells by inhibiting ERK activation715.  
CO-releasing compounds have been shown to be effective in delivering CO and to cause 
induction of HO-1 protein670 695.  There is the distinct possibility that CO delivery can be 
achieved with negligible elevations in HbCO, as has been shown with CORM3956.  
Compounds such as CORMA1 or CORM3 are pharmacologically stable, water soluble and 
exhibit protective effects.  CORMs allow for the design of tissue-selective agents for 
disease-specific targeting; a clear advantage over inhaled CO.  For example, control of CO 
in the stomach may well be modulated by a CORM sensitive to pH672.  CORMs have been 
demonstrated to mediate cytoprotection in cultured lung cells via activation of p38 
MAPK957.  
Recent in vitro studies have observed that CORMs are capable of potent anti-proliferative 
effects in a model of pancreatic fibrosis with inhibition of pancreatic stellate cell 
proliferation.  In vivo, CO confers tissue protection in animal models of pancreatic 
disease, including those with hyperglycaemia and inflammatory injury of the gland816 958.  
Recent studies with CORMS have demonstrated the ability of CO delivery to attenuate 
paracetamol-induced liver failure in mice820.  Studies of the therapeutic potential of 
carbon monoxide published to date have focused on the cytoprotective and antioxidant 
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properties of CO in the context of inflammatory conditions or acute bacterial infection775 
802 803 834 842.   
The current study provides the first evidence for the benefit of CORM treatment that 
relates to a specific anti-cancer effect.  This is an important novel finding that warrants 
further investigation to evaluate the possible benefits of CO administration in therapy 
regimens for oesophagogastric cancer.   
The presence of transition metals may affect the overall activity of CO released by 
CORMs.  However, it is also true that in most cases the effect of CORMs have been 
corroborated to be essentially mediated by CO through the use of proper negative 
controls (i.e. the inactive prepared CORM) such as those employed in the current studies.   
CORM3 exhibits a rapid CO release (half-life < 1 min)732 and the anti-proliferative and HO 
enzyme effects observed after CORM3 treatment are likely to involve activation of 
downstream intracellular pathways that are activated by a relatively brief exposure to 
CO775.   
Cell treatment with carbon monoxide-releasing molecules (CORM3) produced consistent 
cancer-specific results with a significant reduction in the proliferation of malignant gastric 
AGS and oesophageal OE-33 adenocarcinoma cells and morphological changes after 48 
hours of CORM3 treatment.  These findings represent a novel cancer-specific in vitro anti-
proliferative effect of carbon monoxide on oesophagogastric cancer cells.  Results 
indicate that the observed cell proliferation effects of both bilirubin and carbon monoxide 
are mediated by a process of apoptosis with two hallmark features of apoptosis and 
increased caspase activity demonstrated in AGS cell lines after treatment with CORM3 20 
µM for 48 hours.   
CORM3 treatment caused a reduction in HO-2 protein expression after 48 hours with up-
regulation of inducible HO-1 protein.  Carbon monoxide exposure inhibited total HO 
enzymatic activity despite induced expression of HO-1 protein in response to CORM3 
treatment.  Both bilirubin and CORM3 treatment reduce HO-2 protein expression at 48 
hours but only CORM3 causes induction of HO-1 suggesting that carbon monoxide and 
bilirubin interact with specific and distinctive signalling pathways to regulate HO enzyme 
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activity.  The specific mechanisms and signalling pathways involved in the CO-mediated 
regulation of HO activity require further investigation. 
The cancer-specific effect of apoptosis induction by CORM3 treatment has important 
implications for potential clinical applications that demand further in vivo studies.  The 
potential anti-cancer activity of CO therapy adds another aspect to the diverse 
therapeutic possibilities of CO described above.  The development of CORMS and specific 
tissue delivery mechanisms are particularly relevant to the current findings.  The 
environment of the stomach is characterised by a distinctive pH range and this fact could 
be exploited by design of a CORM agent whose release of CO is governed by a specific pH.  
In this way tissue-specific delivery of therapeutic CO could be achieved with the release of 
CO from orally-administered water-soluble CORMS only occurring in the acidic pH 
environment of the stomach. 
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5.7 The role of the heme oxygenase pathway: Summary 
5.7.1 Thesis conclusions 
The main conclusions from the studies performed for this thesis include the finding that 
the prevailing cellular redox state has an important influence on the in vitro cell biology of 
oesophagogastric cancer cells.  Oesophageal adenocarcinoma cells appeared to thrive 
under conditions of oxidative stress and the exponential growth of gastric 
adenocarcinoma cells was not affected by oxidative stress simulated by treatment with 
hydrogen peroxide.  Treatment with N-acetyl cysteine antioxidant, by contrast, had a 
cancer-specific effect with a significant reduction in cell proliferation and increased 
apoptosis in oesophageal and gastric cancer cells.   
Constitutive over-expression of heme oxygenase-1 protein was not a feature of the 
oesophagogastric adenocarcinoma cell lines studied.  Tonic activity of HO-2 enzyme was 
essential for the maintenance of in vitro exponential cell growth in the cell lines studied.  
Up-regulation of HO-1 isoform protein was readily induced by treatment with HO 
substrate hemin.  Hemin caused a demonstrable increase in enzymatic activity of total HO 
enzyme that was not accompanied by any observed effects on cell proliferation.  This 
means that any antioxidant activity mediated by an increase in HO enzymatic activity may 
not affect cell proliferation and may not be detrimental to continued exponential growth 
of cancer cells.  Treatment with NAC antioxidant however caused a cancer-specific 
reduction in cell proliferation in these studies that was associated with a significant 
reduction in overall HO enzymatic activity.  These findings suggest that N-acetyl cysteine 
antioxidant and HO-1 enzyme activate distinct and diverse signalling pathways involved in 
the oxidative stress response. 
Although increased HO enzymatic activity mediated by HO-1 induction did not adversely 
affect cell growth there was a significant reduction in the proliferation of cells with an 
increase in apoptosis caused by a reduction in total HO enzymatic activity.  Treatment 
with zinc protoporphyrin caused a clear reduction in total cellular HO activity despite up-
regulation of inducible HO-1 protein.  The findings indicate that heme oxygenase activity 
from either HO-1 or HO-2 isoforms is essential for the maintenance of growth in the 
oesophageal and gastric cell lines studied and that increasing the activity of HO-1 enzyme 
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in cancer cell phenotypes that do not constitutively over-express the protein is not 
unfavourable for continued tumour cell growth. 
Notable findings from specific siRNA-mediated knockdown of HO-2 protein include a 
significant reduction in measurable total HO enzyme activity despite the up-regulation of 
HO-1 protein in response to knockdown of HO-2 mRNA.  These experiments confirm 
published reports of the interaction between HO-1 and HO-2 isoforms and suggest an 
intrinsic regulation pathway to maintain a co-ordinated expression of heme oxygenase 
proteins and resulting enzymatic activity.  These experiments represent a novel role for 
the HO-2 protein and its tonic activity in sustaining the growth of cancer cells in vitro.  
Furthermore the findings suggest that induced HO-1 protein may be sensitive to cellular 
feedback mechanisms or regulated by downstream enzyme products in the cell lines 
investigated.   
Studies of possible downstream effectors of HO activity demonstrate that neither 
bilirubin nor carbon monoxide are beneficial to oesophagogastric cancer cells with 
reduced cell growth effects that are not reproduced by an increase in HO activity in the 
same cells.  An increase in the activity of HO-1 enzyme does not lead to comparable 
reductions in cell proliferation and apoptosis induction as those caused by bilirubin or 
carbon monoxide treatment. 
The current studies indicate that bilirubin plays a role in reducing oesophagogastric 
cancer cell growth.  This role involves activation of cellular apoptosis most likely by time-
dependent intracellular pathways that maintain an effect after washout of the bilirubin 
reagent.  Addition of bilirubin after HO inhibition or HO-2 gene knockdown does not 
ameliorate the anti-proliferative effects of reduced HO enzymatic activity.  Bilirubin 
appears to exert a negative-feedback activity on HO protein expression pathways with a 
demonstrable reduction in HO-2 protein expression without HO-1 induction 48 hours 
after bilirubin treatment.  The effects of bilirubin treatment on overall total HO enzymatic 
activity are unknown.  The anti-proliferative in vitro activity of relatively higher levels of 
bilirubin demonstrated in the current study is the first demonstration of these effects in 
oesophagogastric cancer cells.   
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Cell treatment with carbon monoxide-releasing molecules (CORM3) produced consistent 
and profound cancer-specific reductions in cell proliferation with increased apoptotic 
activity.  CORM3 treatment inhibited total HO enzymatic activity with a reduction in HO-2 
protein expression and despite up-regulation of HO-1 protein.  The findings support 
future potential clinical applications of CO therapy that demand further experimental 
animal model and clinical studies wherever appropriate.   
These studies of HO enzyme products suggest that carbon monoxide and bilirubin interact 
with specific and distinctive signalling pathways to regulate HO enzyme activity given that 
CO but not bilirubin caused up-regulation of HO-1 protein.   
The findings challenge any assumptions that the recognised cellular consequences of HO 
activity such as cytoprotective and antioxidant effects are as a result of the downstream 
effectors bilirubin and CO.  Both CO and bilirubin have clear anti-proliferative effects in 
cells with disordered growth, i.e. malignant oesophagogastric cancer cells.   
These conclusions do not preclude the possibility that CO and bilirubin have potent and 
significant antioxidant and cytoprotective roles in the context of damaged healthy cells.  
Only in a situation of altered cell biology and disordered exponential growth do the 
effects of bilirubin and carbon monoxide result in induction of apoptosis and reduced 
proliferation.  These effects could still be mediated via the same cell signalling pathways 
that in healthy cells have cytoprotective and antioxidant effects.  This idea is supported by 
studies of N-acetyl cysteine treatment that also produce reduced proliferation in 
malignant cells that may be related to reduced HO activity and involve MAP kinase 
signalling pathways.  The specific mechanisms and signalling pathways involved with NAC, 
bilirubin and CO treatment warrant further investigation that is beyond the scope of this 
thesis. 
5.7.2 Limitations of the cultured cell line model  
A widely accepted limitation of in vitro cell culture work is the fact that the cell phenotype 
may not accurately reflect that of the cellular phenotype in vivo.  By the time cells are 
obtained from in vivo tumours, immortalised and made ready for commercial use, the 
phenotype of the cell lines may change to the extent that it is no longer an accurate 
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representation of the primary tumour from which it is derived.  In addition, in vivo 
tumour cell growth is often influenced by surrounding tissue particularly the extracellular 
matrix that is not usually accounted for in cell culture models.  Consequently, trends and 
effects demonstrable from in vitro studies require further validation from in vivo studies.   
A further consideration is whether or not normal epithelial cell lines can reliably be used 
for comparative purposes.  The normal cells are not genuinely resting cells but proliferate 
in response to serum stimulation when grown under recommended culture medium 
conditions.   
These limitations notwithstanding, exponential growth was demonstrated in the 
malignant cell lines under basal conditions and not in the comparative normal epithelial 
cell line.  The experiments produced statistically significant and reproducible proliferation 
effects that were specific to cancer cell lines in certain cases as described above.  The cell 
culture experiments provide further important information about the mechanisms of 
growth effects with assays of apoptosis and the possible regulatory pathways involved.  
The cell line model is also a very useful methodology for investigating the effects of 
siRNA-mediated knockdown of HO-2 mRNA and novel information about the importance 
of HO-2 protein in cancer cell growth was gained from these studies.   
HO-1 gene expression is readily induced by a variety of stimuli and it is recognised that 
simply describing a process of increased HO protein expression or demonstrating an 
increased level of HO protein does not directly equate to overall HO enzymatic activity.  
Previous studies have reported that increased HO-1 protein expression in Zucker rats did 
not result in increased total HO activity.   
Specific colorimetric assays indicate the effects of variations in cellular heme oxygenase 
activity that provides additional valuable information about the role of the enzyme 
system in cancer cell proliferation.   
5.7.3 Future work  
The main findings that warrant further specific investigation include the cell signalling 
pathways involved in the proliferation effects observed after treatment with N-acetyl 
cysteine, bilirubin and carbon monoxide-releasing molecules.  Further work is also 
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required to determine whether the cancer-specific cell proliferation effects observed in 
vitro can be reproduced in vivo.   
The pathways of interest include the p21-activated kinases as part of the p53/p21 DNA 
damage-signalling pathway and the mitogen-activated protein kinase pathways, 
specifically the extracellular signal-related kinases (ERK1/2 MAP kinase pathway) and the 
p38 MAP kinase pathway.  Further in vitro experiments are planned to elicit expression of 
p38 and ERK1/2 protein using western blotting and probing of blots with anti-
phosphorylated and anti-total p38 and ERK1/2 antibodies (Cell Signaling Technology, 
Danvers, MA) as well as p21 expression using monoclonal mouse anti-p21 antibody (Santa 
Cruz, CA).  Studies will aim to elucidate how activation of these pathways is associated 
with NAC activity and heme oxygenase enzyme activity with its downstream products.  
Co-treatment of cells with the specific p38 MAPK inhibitor SB203580 (Calbiochem, Bad 
Soden, Germany) is planned to determine whether the observed proliferation effects are 
mediated via p38 MAPK activity.   
As mentioned above the novel findings in preliminary in vitro studies require further in 
vivo clarification.  The experiments with the most relevant therapeutic potential are the 
cancer-specific effects observed with N-acetyl cysteine treatment and CORM3 treatment.  
In collaboration with colleagues at the Northwick Park Institute for Medical Research 
(NPIMR) further work is planned to investigate the therapeutic and adverse effects of 
CORM treatment in a xenograft rodent model of oesophagogastric cancer.  This work will 
aim to answer outstanding questions about the optimal delivery methods of carbon 
monoxide from CORM constructs to facilitate therapeutic levels of CO to target tissues as 
well as to clarify whether cancer-specific anti-proliferative effects of CO can be 
reproduced in an animal model.  
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APPENDICES 
Appendix I: Cell seeding protocol 
PLATES   Wells  Growth Area (cm
2
) volume  
SARSTEDT  24W  2.0   max 3.6mL 
   6W  9.5   max 17.2mL 
 
NUNC   24W  1.9   1mL recommended 
   12W  3.5   2mL recommended 
   6W  9.6   3mL recommended 
 
24W plates seed at 500,000 – 600,000 cells per plate = 25,000 cells per well AGS 
6W plates seed at 750,000 cells per plate = 125,000 cells per well AGS 
NUMBERS REFLECT THE DIFFERENTIAL SEEDING SUCCESS OF CELL LINES  
OE-33 & HET-1A seeding for Flow Cytometry 
6W 165,000 cells per well in 2.5mls  1 x 10
6
 cells in 15mls 
24W 33,000 cells per well in 0.5mls  800,000 cells in 12mls 
96W 7000 cells per well in 100μl  672,000 cells in 9.6mls 
OE-33 & HET-1A seeding for siRNA transfection 
6W 125,000 cells per well in 2.5mls  750,000 cells per plate in 15mls 
24W 25,000 cells per well in 0.5mls  600,000 cells per plate in 12mls 
96W 5,000 cells per well in 100μl  480,000 cells per plate in 9.6mls 
AGS & HGC-27 seeding for Flow Cytometry 
6W 125,000 cells per well in 2.5mls  750,000 cells per plate in 15mls 
24W 25,000 cells per well in 0.5mls  600,000 cells per plate in 12mls 
96W 5000 cells per well in 100μl  480,000 cells per plate in 9.6mls 
AGS & HGC-27 seeding for siRNA transfection 
6W 75,000 cells per well in 2.5mls  450,000 cells per plate in 15mls 
24W 15,000 cells per well in 0.5mls  360,000 cells per plate in 12mls 
96W 3,000 cells per well in 100μl  288,000 cells per plate in 9.6mls 
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Appendix II: Assessment of cell proliferation 
Figure II.1a: 24-hour cell counts from HGC-27 cell seeding 
 
 
 
Pearson correlation  0.992145 
Sig. (2-tailed)  1.2 x10
-6
 
 
Figure II.1b: MTT assay for HGC-27 cells seeded in 24-well plate  
  
Pearson correlation  0.966893 
Sig. (2-tailed)  8.85 x10
-5
 
 
Figure II.1: HGC-27 cells were seeded into 24-well plates at known density per well.  Cell counts & MTT were 
performed at 24h.  Results demonstrate a close correlation between cell counting using Trypan blue 
exclusion and MTT assay to assess cell proliferation. 
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Figure II.2a: 24-hour cell counts from AGS cell seeding 
 
Pearson correlation  0.947167 
Sig. (2-tailed)  0.00354 
 
Figure II.2b: MTT assay for AGS cells seeded in 24-well plate 
 
Pearson correlation  0.988064 
Sig. (2-tailed)  4.21 x10
-6
 
 
Figure II.2c: MTT assay for AGS cells seeded in 96-well plate 
 
Pearson correlation  0.969 
Sig. (2-tailed)  7.0 x10
-5
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Figure II.2d: MTT standard curve AGS cells 24 hours 
 
Figure II.2: AGS cells were seeded into 24 and 96-well plates at known density per well.  Cell counts & MTT 
were performed at 24h.  Results demonstrate a close correlation between cell counting using Trypan blue 
exclusion and MTT assay to assess cell proliferation.  Standard curves were constructed to enable 
estimation of cell number using MTT data.   
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Appendix III: Growth curves for all cell lines studied 
Figure III.1a: Viable cell counts time course AGS cells 
 
Figure III.1b: MTT assay time course AGS cells: Growth curve 
 
Figure III.1c: AGS MTT assay: Growth curve 
 
Figure III.1: AGS growth curves using MTT and cell counts to assess cell proliferation.  Cells were seeded into 
24-well plates and maintained in serum-complete Ham F12 medium under humidified 5% CO2 at 37°C.  
Results demonstrate exponential growth of AGS cells under recommended culture conditions.   
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Figure III.2a: Viable cell counts time course HGC-27 cells 
 
Figure III.2b: MTT assay time course HGC-27 cells: Growth Curve 
 
Figure III.2c: HGC-27 MTT assay: Growth Curve 
 
 
Figure III.2: HGC-27 growth curves using MTT and cell counts to assess cell proliferation.  Cells were seeded 
into 24-well plates and maintained in serum-complete DMEM medium under humidified 5% CO2 at 37°C.  
Results demonstrate exponential growth of HGC-27 cells under recommended culture conditions.    
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Figure III.3a: MTT standard curve OE-33 cells 24 hours 
 
Figure III.3b: MTT assay time course OE-33 cells: Growth Curve 
 
Figure III.3c: OE-33 MTT assay: Growth Curve 
 
Figure III.3: OE-33 growth curves using MTT to assess cell proliferation.  Cells were seeded into 24-well 
plates and maintained in serum-complete RPMI medium under humidified 5% CO2 at 37°C.  Results 
demonstrate exponential growth of OE-33 cells under recommended culture conditions.   
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Figure III.4a: MTT assay time course HET-1A cells 
 
Figure III.4b: Growth Curve HET-1A cells  
 
Figure III.4: HET-1A growth curves using MTT to assess cell proliferation.  Cells were seeded into 24-well 
plates and maintained in supplemented BEGM medium under humidified 5% CO2 at 37°C.  Results 
demonstrate exponential growth of HET-1A cells under recommended culture conditions.   
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Figure III.5: All cells different media Growth at 36 hours 
 
Figure III.5: Cell growth using MTT to assess cell proliferation at 36h.  Cells were seeded into 24-well plates 
and maintained in various culture media under humidified 5% CO2 at 37°C.  Results demonstrate 
significantly increased exponential growth of malignant cells under recommended culture conditions as 
compared to HET-1A cell growth.  Significantly increased* cell growth in malignant cell lines compared to 
benign oesophageal epithelial cell line HET-1A in all media studied: HET-1A compared to OE-33 p = 
0.000174; HET-1A compared to AGS cells p = 3.23 x10
-5
; HET-1A compared to HGC-27 cells p = 3.23 x10
-5
 
*Mann Whitney U test 
Assessment of cell proliferation 
To evaluate the relationship between MTT optical density and number of viable cells, cell seeding 
experiments were performed with all cell lines seeded in 24-well and 96-well plates at a specific number.  
Cell counts using trypan blue exclusion and MTT assay were performed at 24, 48 and 72 hours.  Experiment 
results demonstrate that both the cell counts and the MTT assay results correlated well with the original 
cell seeding number.  The results support the MTT and cell counting technique as a valid measure of cell 
proliferation in cell lines studied for cells seeded in a 24-well or a 96-well plate.   
To investigate cell proliferation of the four available cell lines, cells were seeded at the same number and 
grown under conditions recommended by the cell suppliers.  Growth curves obtained for each cell line 
provide a comparison of growth patterns for each of the cell lines under investigation.  Exponential cell 
growth was demonstrated up to 72 hours with significantly higher proliferation in malignant cell lines as 
compared to benign.  Cell seeding protocols for all experiments were devised according to the differential 
growth pattern and the success of cell types in adhering to the growth surface in monolayer at a particular 
seeding density.  This approach provided the optimal seeding density for each individual experiment, e.g. 
seeding OE-33 and HET-1A cells at 33,000 cells per well in a 24-well plate and seeding AGS and HGC-27 cells 
at 25,000 cells per well in a 24-well plate produced the same degree of cell confluence after 24 hours for 
the addition of experimental reagents.   
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Appendix IV: WESTERN BLOTS: Additional representative protein blots 
Figure IV.1 Representative Blots: AGS cells anti-HO-1 blots 
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Figure IV.2 Representative Blots: AGS cells anti-HO-2 blots 
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←HO-2 
←HO-1 
 
 ←Tubulin 
Figure IV.3 Representative Blots: AGS cells anti-Tubulin blots 
 
Figure IV.4 WESTERN BLOTS: Additional Protein Blots 
OE-33 H2O2 and NAC protein expression 
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Appendix V: Annexin V & Propidium Iodide staining – controls to set gating and quadrant regions 
Figure V.1: Unstained cells control – to set gating and quadrant regions 
 
Region R3 R4 R5 R6 
Cell Count 403 14 24233 4 
% Histogram 1.63 0.06 98.29 0.02 
Median X,Y 1.07, 16.73 27.74, 20.04 2.38, 1.29 26.76, 10.46 
 
Figure V.2: Control cells Ethanol treated – PI positive control staining 
 
Region R3 R4 R5 R6 
Cell Count 10201 3 1913 2 
% Histogram 84.17 0.02 15.79 0.02 
Median X,Y 1.49, 35.72 42.79, 17.35 1, 5.66 24.89, 10.09 
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Figure V.3: Control cells Staurosporine treated – Annexin V positive control 
 
Region R3 R4 R5 R6 
Cell Count 0 21 2419 1470 
% Histogram 0 0.54 61.87 37.6 
Median X,Y  0, 0 85, 16.14 9.39, 1 53.15, 3.06 
 
Figure V.1 – V.3: AGS control cells were seeded into 6-well plates, samples harvested at 24 – 72h and 
prepared for staining with Annexin V-FITC and PI for flow cytometry analysis.  Controls were prepared to set 
gating parameters with unstained cells, ethanol-treated cells to permeabilise the cell membrane for PI 
staining and with staurosporine-treated cells to induce apoptosis for annexin V positive control staining.  
Staurosporine-treated cells demonstrate a significant increase in the proportion of cells counted in the 
apoptotic phase (R6) as compared to untreated control cells.   
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Appendix VI: ApoBrdU DNA Fragmentation assay – controls to set gating and quadrant regions 
Figure VI.1a: Positive control cells Apo-BrdU assay NAC experiments 
 
Region Cell Count % Histogram Median X Median Y 
R8 3612 33.84 81 98.21 
R9 6858 64.25 52 7.56 
Total 10674 100 55 8.73 
 
Figure VI.1b: Negative control cells Apo-BrdU assay NAC experiments 
 
Region Cell Count % Histogram Median X Median Y 
R8 103 0.82 64 101.82 
R9 12419 98.85 58 7.29 
Total 12563 100 58 7.29 
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Figure VI.2a: Positive control cells Apo-BrdU assay siRNA experiments 
 
Region Cell Count % Histogram Median X  Median Y 
R8 2860 34.06 176 172.83 
R9 5329 63.46 136 19.33 
Total 8398 100 142 21.16 
 
Figure VI.2b: Negative control cells Apo-BrdU assay siRNA experiments 
 
Region Cell Count % Histogram Median X  Median Y 
R8 112 1.03 66 128.65 
R9 10353 95.49 60 8.22 
Total 10842 100 60 8.22 
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Figure VI.3a: Negative control cells Apo-BrdU assay Bilirubin & CORM experiments 
 
Region Cell Count % Histogram Median X  Median Y 
R8 98 0.84 64 101.82 
R9 11617 99 58 7.29 
Total 11734 100 58 7.29 
 
Figure VI.3b: Positive control cells Apo-BrdU assay Bilirubin & CORM experiments 
 
Region Cell Count % Histogram Median X  Median Y 
R8 2225 35.81 79 101.82 
R9 3903 62.81 52 7.56 
Total 6214 100 55 8.73 
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Figure VI.3c: Untreated control cells Apo-BrdU assay 36 hours Bilirubin experiments 
 
Region Cell Count % Histogram Median X  Median Y 
R8 149 1.6 94 323.45 
R9 9119 97.93 82 21.54 
Total 9312 100 82 21.54 
 
Figure VI.3d: Untreated control cells sample Apo-BrdU assay 48 hours CORM experiments 
 
Region Cell Count % Histogram Median X  Median Y 
R8 41 0.82 125 233.68 
R9 4903 97.55 103 8.12 
Total 5026 100 103 8.12 
 
Figures VI.1 – VI.3: Incorporation of brominated deoxyuridine triphosphate nucleotides into DNA strand 
breaks was measured by the Apo-BrdU assay to assess DNA fragmentation.  Positive and negative control 
cells provided with the Apo-BrdU assay kit were used to set gating regions and reliably identify positive and 
negative-stained cells for each assay performed as described above.  Positive control sample cells 
demonstrated DNA fragmentation with increased FITC fluorescence compared to negative control cells and 
untreated controls.   
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Appendix VII: PCR Products – additional results 
Figure VII.1: PCR products siRNA knockdown AGS cells additional samples 
 
 
Lanes 
1 = NUC 10nM 24hrs  4 = NUC 10nM 48hrs  7 = NUC 10nM 72hrs 
2 = siRNA 01 10nM 24hrs  5 = siRNA 01 10nM 48hrs  8 = siRNA 01 10nM 72hrs 
3 = siRNA 02 10nM 24hrs  6 = siRNA 02 10nM 48hrs  9 = siRNA 02 10nM 72hrs 
10 = cDNA negative control 
11 = RNA plus H2O negative control 
 
Experiments were repeated and PCR products evaluated using agarose gel electrophoresis for both AGS and 
HGC-27 cell lines.  Although analysis demonstrated effective knockdown of HO-2 mRNA after transfecting 
cells with siRNA duplexes there was inconsistent findings with PCR products using GAPDH primers (Figures 
VII.1 & VII.2).  These results suggested a compromise in RNA quality with possible DNA contamination in the 
eluted RNA samples.  Treatment with Turbo DNase enzyme was repeated and any samples with visible DNA 
contamination were discarded along with any corresponding complementary DNA stored (Figures VII.3 & 
VII.4).   
Representative blots of ethidium bromide gel electrophoresis for PCR products are shown in Figures VII.5 – 
VII.6.  
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Figure VII.2: PCR products siRNA knockdown HMOX2 and GAPDH HGC-27 cells 
 
 
Lanes 
1 = NUC 10nM 24hrs  2 = NUC 10nM 48hrs  3 = NUC 10nM 72hrs 
4 = siRNA 02 10nM 24hrs  5 = siRNA 02 10nM 48hrs  6 = siRNA 02 10nM 72hrs 
7 = Lipofectamine 24hrs  8 = cDNA negative control  9 = PCR negative control 
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Figure VII.3: RNA samples AGS cell experiments DNase treated 
 
Lanes 
1 = NUC 10nM 24hrs  4 = NUC 10nM 48hrs  7 = NUC 10nM 72hrs 
2 = siRNA 01 10nM 24hrs  5 = siRNA 01 10nM 48hrs  8 = siRNA 01 10nM 72hrs 
3 = siRNA 02 10nM 24hrs  6 = siRNA 02 10nM 48hrs  9 = siRNA 02 10nM 72hrs 
10 = siRNA 03 10nM 24hrs  11 = siRNA 03 10nM 48hrs  12 = siRNA 03 10nM 72hrs 
13 = NUC 10nM 72hrs  14 = Lipofectamine 24hrs  15 = Lipofectamine 72hrs 
 
 
Figure VII.4: RNA samples HGC-27 and AGS cell experiments DNase treated 
 
 
Lanes 
1 = NUC 10nM 24hrs  2 = NUC 10nM 48hrs  3 = NUC 10nM 72hrs 
4 = siRNA 02 10nM 24hrs        5 = siRNA 02 10nM 48hrs  6 = siRNA 02 10nM 72hrs 
7 = Lipofectamine 24hrs  8 = NUC 10nM 24hrs  9 = NUC 10nM 48hrs  
10 = NUC 10nM 72hrs  11 = siRNA 02 10nM 24hrs  12 = siRNA 02 10nM 48hrs  
13 = siRNA 02 10nM 72hrs  14 = AGS cells Lipofectamine 48hrs 15 = AGS cells NUC 10nM 48hrs 
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Representative Gels PCR Products  
Figure VII.5: RNA samples AGS cell experiments HO-2 knockdown 01 
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Figure VII.5: RNA samples AGS cell experiments HO-2 knockdown 02 
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Appendix VIII: Cell Growth after siRNA-mediated HO-2 knockdown – cell counts 
Figure VIII.1: AGS cell counts after HO-2 knockdown 
 
†p < 0.05  Independent Samples Kruskal-Wallis test cf. NUC 
Figure VIII.2: HGC-27 cell counts after HO-2 knockdown 
 
†p < 0.004 Independent Samples Kruskal-Wallis test cf. NUC 
Summary of 3 experiments both AGS and HGC-27 cell lines 
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Figure VIII.3: OE-33 cell counts after HO-2 knockdown 
 
p = 0.406 Independent Samples Kruskal-Wallis test 
Summary of 2 experiments OE-33 cell line 
Cell counts performed for siRNA experiments demonstrated significantly fewer live AGS cells 
counted at 24, 48 and 72 hours from wells treated with siRNA 10 nM as compared to those 
transfected with NUC 10 nM (p < 0.05).  In HGC-27 experiments there were significant reductions 
in cell counts with HO-2 gene knockdown at 48 and 72 hours when compared to negative 
universal control (p < 0.004).  In two cell counts performed from OE-33 cell experiments, there 
was a marked reduction in live cells treated with siRNA at 48 hours and 72 hours.  OE-33 siRNA 
experiment cell count data are insufficient for statistical significance.  HO-2 knockdown in AGS, 
HGC-27 and OE-33 cells produced effects on cell counts that are more dramatic than those seen 
with MTT.  The discrepancy between cell count numbers and the equivalent MTT results is likely 
to be explained by the technical aspects and relatively cumbersome nature of cell counting with 
the major factor being fewer experiments performed leading to greater variability and an 
increased likelihood of observer error. 
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